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The impact of antipsychotic dose and treatment indication on the risk of new-
onset diabetes associated with use of second-generation antipsychotic (SGA) 
monotherapy were assessed using medical data from Texas Medicaid. Eligible 
enrollees aged ≥18 years of age were followed for a maximum of 12 months between 
1997 and 2001. Patients were stratified according to treatment dose (low, medium, 
high) and a hierarchy of mutually exclusive diagnostic categories: schizophrenia; 
bipolar disorder; dementia; psychotic disorder; non-psychotic disorder; and no 
mental health indication. 
The average patient age (N=19,430) was 60.3 years (SD: 21.9); the majority 
of whom were White (55.1%) females (65.7%) aged ≥60 years (50.4%). At 
treatment-onset, the prevalence of diabetes was 16.9%. The mean (SD) dose for the 
most prevalent conditions (schizophrenia, bipolar disorder and dementia, 
 
 vi
respectively) were as follows: olanzapine (12.04mg (6.73); 8.91mg (5.78); 4.87mg 
(3.00)); quetiapine (273.16mg (203.86)); 146.33mg (142.29); 79.59 (82.57)); and 
risperidone (3.55mg (2.37); 2.05 (1.76); 1.12 (0.85)). The incidence of diabetes was 
2.37%. After controlling for demographic, clinical and medication variables, no 
difference (p=0.281) was noted in the incidence of diabetes according to the specific 
SGA used (N=7,842). Compared to risperidone, the odds of new-onset diabetes were 
0.879 (95% CI: 0.653 to 1.184) and 0.683 (95% CI: 0.414 to 1.126) for olanzapine 
and quetiapine, respectively.  Neither treatment indication (p=0.876) nor dose 
(p=0.274) were associated with the development of diabetes. When examined 
according to the individual SGA, the incidence of diabetes did not differ (p≥0.292) 
according to antipsychotic dose or treatment indication for quetiapine and 
risperidone. For olanzapine, while no difference was noted according to the dose 
used (p=0.384), the incidence of diabetes differed according to the treatment 
indication (p=0.034), with a significant increase in the odds of diabetes noted for 
those with a psychotic disorder (OR: 2.911, 95%CI: 1.088 to 7.790) or a non-
psychotic disorder (OR: 2.433, 95%CI: 1.042 to 5.680) compared to schizophrenia. 
Results indicate that the risk of new-onset diabetes does not differ among the 
SGA agents. While the dose of antipsychotic prescribed varied significantly 
according to treatment indication and patient age, neither dose nor treatment 
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Chapter 1: Introduction and Literature Review 
1.1 Problem Statement 
Diabetes mellitus is a chronic disabling disease that is associated with 
significant morbidity and mortality. 1 The estimated prevalence of diabetes in the 
United States (U.S.) was 6.2 percent in 2000 (17 million people) of whom 35 
percent (5.9 million) were undiagnosed. 2 Studies have suggested an increased 
risk of diabetes of two- to three-fold in patients treated with second-generation 
antipsychotic agents. 3;4 This has significant ramifications in terms of both the 
economic cost of treatment and the disease burden for patients treated with these 
agents. Based on information from case studies reported in the literature, there 
appears to be an alarming risk of diabetic ketoacidosis in patients treated with 
second-generation antipsychotic agents. 5-8 This is a medical emergency; the 
evaluation and treatment of which may be complicated if the patient has 
concurrent psychosis. 
While glucose dysregulation appears to be associated with the use of 
second-generation antipsychotic agents, it is difficult to ascertain the extent of 
the problem. Glucose dysregulation appears to be independent of second-
generation antipsychotic dose although the evidence is conflicting.3;9;10 The dose 
of antipsychotic prescribed depends on the indication for which it is 
prescribed.11;12 For example, the dose used to treat schizophrenia differs from 
that used to treat dementia-related behavioral problems.11;12 Differences in dose 
may explain differences in the relative risk of developing diabetes. Alternatively, 
these differences may reflect the differing propensities of patients to develop 
diabetes mellitus as documented by reports of a higher prevalence of diabetes 
mellitus in patients with schizophrenia and bipolar disorder than in the general 
population that is independent of antipsychotic treatment.13-18 Patient age is an 
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important confounding variable. Regardless of treatment indication, older 
patients typically are prescribed lower doses due to decreased metabolism and 
poorer tolerance of these agents.11;12 In addition, patients with serious mental 
illness, including schizophrenia and bipolar disorder, are at significantly higher 
risk for premature death than the overall population.19 Previous studies with a 
preponderance of older patients may have included disproportionate numbers 
with dementia and other psychotic disorders, conditions for which risperidone is 
more frequently prescribed in clinical practice than olanzapine. The combination 
of lower treatment doses in this population, and the fact that older patients may 
lack the diathesis for developing diabetes, may have skewed study findings. As a 
result, studies that do not control for treatment indication and dose may favor one 
second-generation agent over another in terms of the risk of new-onset diabetes. 
In September 2003, the Center for Drug Evaluation and Research 
(CDER) requested that the labeling for second-generation antipsychotic agents be 
changed to acknowledge the perceived association between the use of these 
agents and the development of hyperglycemia.20 In requesting this change, the 
CDER acknowledged the limitations of the available data, particularly in relation 
to the potential impact of confounding variables and the ability to determine the 
relative risk of the different second-generation antipsychotic agents. They 
highlighted the need for additional research to assess this relative risk and to 
identify patient sub-groups that may be more susceptible to this adverse event. 
To this end, the purpose of this study is to examine the impact of antipsychotic 
dose and treatment indication, on the association between second-generation 
antipsychotic use and development of diabetes mellitus. 
By answering these questions, the risks and benefits associated with the 
use of the various agents can be assessed with greater clarity. Research in this 
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area will also impact the future management of psychotic patients in terms of 
screening and surveillance for diabetes mellitus. 
1.2 Literature Review 
To provide context to this study, a general overview of current treatment 
practices regarding the therapeutic use of second-generation antipsychotic agents 
is provided. Specifically, the use of these agents in schizophrenia, bipolar 
disorder, other psychotic disorders, dementia and in other non-psychotic mental 
disorders is examined. A comprehensive review of the metabolic disturbances 
associated with the second-generation antipsychotic agents, including a critical 
review of the studies published in this area is then presented. An overview of 
diabetes mellitus (hereafter referred to as diabetes), with particular emphasis on 
diabetes in patients with mental health disorders is included as additional 
background material. As the focus of this study relates to the potential impact of 
dose and treatment indication on the occurrence of antipsychotic-induced new-
onset diabetes, a comprehensive section on the prescribing patterns of these 
agents is included. The proposed study will use a secondary database; therefore, 
the use of such large claims databases in health outcomes research is discussed, 
with particular emphasis on the Medicaid claims database. This chapter 
concludes with the rationale and objectives for the study together with a detailed 
list of hypotheses. 
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1.3 Section 1 - General Background on Schizophrenia 
The purpose of this section is to provide a brief overview of 
schizophrenia – its characteristics, classification and management. 
1.3.1 Epidemiology 
Schizophrenia affects between 0.5 and one percent of the adult 
population.21 Although the prevalence is similar for men and women, the age of 
onset differs.22 The median age of onset is the early to mid twenties for men and 
the late twenties for women. Schizophrenia rarely presents before adolescence or 
after the age of 40 years.22 
1.3.2 Etiology and Pathogenesis 
The etiology of schizophrenia is unknown. There is evidence of a genetic 
basis to the disease with an increased prevalence of ten percent noted if a first-
degree relative is affected, and three percent if a second-degree relative is 
affected when compared to the general population.23 A greater concordance has 
been documented in monozygotic twins than dizygotic twins.23 Similarly, 
adoption studies indicate an increased risk of illness among adopted children 
whose biological mothers have schizophrenia.23 Environmental factors such as 
prenatal, perinatal and childhood brain injury have also been associated with an 
increased risk of schizophrenia.23 
There are no laboratory findings that are diagnostic of schizophrenia; 
however, research has centered on the hypothesis of increased dopamine activity. 
Evidence for dopamine overactivity includes: the strong correlation between the 
extent of dopamine D2 receptor blockade and antipsychotic drug efficacy; the 
exacerbation of the signs and symptoms of schizophrenia by dopamine agonists; 
and the reports of increased dopamine D2 receptors density seen by positron-
emission tomography, and at autopsy, of patients with schizophrenia.24 
 5
Serotonergic and glutamergic dysfunction have also been hypothesized to be 
etiologic in schizophrenia.24 A variety of anatomic abnormalities have been 
associated with schizophrenia, including enlargement of the lateral and third 
ventricles and reduction in the size of the limbic and prefrontal cortex brain 
areas.25 However, no single neuroanatomic defect has been consistently 
demonstrated in patients with schizophrenia.25 
1.3.3 Classification and Clinical Characteristics 
Schizophrenia is a psychotic disorder. The characteristic symptoms of 
schizophrenia are grouped into three categories: positive symptoms; negative 
symptoms; and cognitive deficits. Positive symptoms typically relate to a 
distortion or excess of normal function and include delusions and 
hallucinations.22 Negative symptoms relate to a diminution of normal process and 
include affective flattening, alogia, anhedonia and avolition.22 Cognitive deficits 
include alterations of attention, working memory, and executive function. To 
confirm a diagnosis of schizophrenia, two or more of these symptoms must 
persist for at least one month, with some of the symptoms persisting for at least 
six months.22 Several subtypes of schizophrenia exist. These are defined 
according to the predominant symptoms at the time of evaluation and may, 
therefore, change over time. The subtypes include: paranoid; disorganized; 
catatonic; undifferentiated; and residual types.22 The disease is further specified 
according to the time course of the illness, with course specifiers including: 
episodic with and without interepisode residual symptoms; continuous; single 
episode in partial or full remission; and other or unspecified pattern.22 
1.3.4 Course 
The onset of the schizophrenia may be abrupt or insidious.26 The clinical 
course is variable with the majority of patients displaying exacerbations, in the 
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form of acute psychotic episodes, and remissions.26 Following remission of an 
acute psychotic episode, residual features typically remain.26 These vary in 
severity but can include: anxiety; suspiciousness; and lack of volition, 
motivation, insight and judgment. As a consequence, the majority of patients 
with schizophrenia experience impairment of occupational and/or social 
function.21 Complete remission is rare and the long-term prognosis for most 
patients is poor.21;27 Epidemiological studies have demonstrated a steep decline 
in survival over the initial two to five years following diagnosis, plateauing 
thereafter.27 Schizophrenia is associated with an increased incidence of 
comorbidities including substance misuse, other mental disorders and general 
medical conditions.27 These, combined with a lifetime prevalence of suicide of 
approximately ten percent, contribute to an increased mortality rate in patients 
with schizophrenia.22 
The American Psychiatric Association describes three phases of 
schizophrenia: an acute psychotic phase; a stabilization phase in which the acute 
psychotic symptoms decrease in severity; and a stable phase in which symptoms 
are stable and typically less severe than in the acute phase.21 As stated, most 
patients alternate between these phases achieving full or partial remission during 
the stable phase. With treatment, approximately 30 percent of patients achieve 
partial but good responses, a further 30 percent achieve partial but inadequate 
responses and the remainder experience chronic deterioration. Approximately 10 
percent of patients experience continuous psychotic symptoms.28 A number of 
factors are predictive of a better prognosis including: being female; married; 
having an abrupt onset of illness with a good premorbid function; and minimal 
comorbidity.26 However, these account for only a small percentage of outcome 
variance. As schizophrenia is a disease characterized by multiple relapses, long-
term treatment is recommended.28 In the absence of continuing prophylaxis, up to 
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75 percent of patients will relapse with an acute psychotic episode within six to 
24 months.28 
1.3.5 Treatment 
Drug therapy, in particular with antipsychotics, forms the mainstay of 
schizophrenia management. The management of schizophrenia was 
revolutionized with the discovery of chlorpromazine in the 1950s.29 Multiple 
antipsychotic agents have since been developed. These agents are broadly 
divided into two classes: ‘typical,’ ‘conventional,’ or ‘first-generation’ agents 
and ‘atypical,’ ‘new,’ or ‘second-generation’ agents, the prototype of which is 
clozapine. The latter is generally accepted to refer to an antipsychotic agent with 
a low propensity to cause extrapyramidal side-effects or a sustained increase in 
prolactin levels.30 Hereafter, the terms ‘first-generation’ and ‘second-generation’ 
will be used to distinguish the classes. Non-drug treatments, such as psychosocial 
rehabilitation programs, are used as adjunctive measures. This section provides 
information on the pharmacotherapy of schizophrenia, with particular emphasis 
on the second-generation or atypical antipsychotic agents. The section concludes 
with a brief overview of the role of non-drug therapy. 
1.3.5.1 First-Generation Antipsychotics 
First-generation antipsychotic agents include: chlorpromazine; 
fluphenazine; haloperidol; perphenzaine; trifluoperazine; thiothixene; and 
thioridazine. These agents are further stratified into low and high-potency agents 
based on the minimum amount of drug in milligrams required to achieve the 
desired antipsychotic effect. High-potency agents include haloperidol and 
fluphenazine, and have a daily dose of a few milligrams, whereas low-potency 
agents include chlorpromazine and thioridazine which have higher daily doses.29  
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1.3.5.1.1 Mechanism of Action 
The exact mechanism of action of the antipsychotic agents has not fully 
been elucidated. These agents inhibit dopamine, specifically dopamine D2 
receptors.24 Relief of positive psychotic symptoms occurs when 60 to 65 percent 
of D2 receptors are occupied while increasing occupation of these receptors to 77 
percent or more, is associated with extrapyramidal side effects.24 The first-
generation antipsychotic agents are characterized by having a high affinity of 
between 70 and 90 percent for dopamine D2 receptors.24 The relative affinities of 
the agents for these, and other receptors, including serotonin 5-HT2A and 5-HT2C, 
dopamine D1 and D4, α1-adrenergic, histaminic and cholinergic receptors, 
appears to differentiate the antipsychotics in terms of adverse effect profiles.24 
1.3.5.1.2 Efficacy 
The efficacy of the first-generation antipsychotics in the acute 
management of schizophrenia is well established.29 These agents have been 
demonstrated to reduce the intensity of positive symptoms, shorten acute 
episodes or exacerbations, and reduce the likelihood of recurrence.29 These 
agents appear to have little effect on affect, cognitive symptoms or negative 
symptoms.30 There is considerable heterogeneity of response to the first-
generation agents, with between 10 and 20 percent having a minimal response to 
treatment and a smaller percentage being considered to be treatment refractory.29 
These agents are considered equally effective when used in equipotent doses; 
therefore, the clinical choice depends on the adverse effects profile.29 
1.3.5.1.3 Adverse Effects 
Although as a class these agents all cause similar adverse effects, they 
differ in their propensity to do so. Adverse effects include: antihistaminic 
(sedation); antidopaminergic D2 (extrapyramidal side-effects and 
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hyperprolactinemia); anticholinergic (dry mouth, blurred vision, constipation, 
urinary retention, sinus tachycardia, cognition and memory effects); and anti- α1-
adrenergic effects (reflex tachycardia and orthostatic hypotension).31 Typically, 
the lower potency agents cause more sedation and hypotension, and the high 
potency agents more extrapyramidal side effects.32 These include: dystonia; 
akathisia; pseudoparkonism; and tardive dyskinesia which can occur at rates of 
up to 64, 36, 59, and 20 percent, respectively.32 It is the extrapyramidal effects, 
particularly tardive dyskinesia, that limit the usefulness of these agents relegating 
them to second-line therapy in clinical practice. Among the first-generation 
antipsychotics, the low-potency agents, in particular chlorpromazine have been 
associated with glucose intolerance.33 
1.3.5.2 Second-Generation Antipsychotics 
The first agent in this class, clozapine, was licensed in the United States 
(U.S.) in 1989.34 Agents currently available in the U.S. in 2006 are: aripiprazole; 
clozapine; olanzapine; quetiapine; risperidone; and ziprasidone. These agents, 
with the exception of clozapine, are now established as first-line therapy for the 
management of schizophrenia. (Table 1.1) 
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Table 1.1: Licensed Doses for the Second-Generation Antipsychotic Agents 
Drug 
(Indication) 
Initial Dose Titration Rate Target Daily Dose Maximum Daily 
Dose (MDD) 




10-15mg qd Not before 2 weeks 10-15mg qd 30mg No ↑ in efficacy noted with doses >15mg 
↑ or ↓ dose when used with inducers or 
inhibitors of cytochrome P450 
Aripiprazole35 
(BIP) 
30mg qd N/R 15-30mg qd 30mg Dose ↓ to 15mg in 15% of patients in 
flexible dose trials based on tolerability 
Clozapine36 
(Resistant SCZ) 
12.5mg qd/bid 25-50mg/qd until 
at TDD, then 
≤100mg qd  
1-2 x week 
300-450mg qd 
(at 2 weeks) 
MDD = 600mg 
100-900mg qd 
No safety data for 
doses >900mg qd* 
Maintenance phase: use lowest possible 




in SCZ/SAD)  
12.5mg qd/bid N/R MDD = 300mg 
(12.5 – 900mg) 
As above As above 
Olanzapine37 
(SCZ) 
5-10mg qd 5mg/qd q week 10-20mg No safety data for 
doses > 20mg qd* 
No ↑ in efficacy noted with doses >10mg 
Debilitated patients / slow metabolism 5mg 
qd starting dose 
Olanzapine37 
(BIP) 
10-15mg qd 5mg/qd q240 5-20mg No safety data for 




25mg bid 25-50mg bid or tid 
q240-480 
300-400mg qd 150-750mg 
No safety data for 
doses > 800mg qd 
No ↑ in efficacy noted with doses >300mg
Elderly / hepatic impairment: ↓dose and 





50mg bid 50mg bid q240  400-800mg qd No safety data for 
doses > 800mg qd* 
As above 
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Table 1.1: Licensed Doses for the Second-Generation Antipsychotic Agents (continued) 
Drug 
(Indication) 
Initial Dose Titration Rate Target Daily Dose Maximum Daily 
Dose (MDD) 




1mg bid 1mg bid/ qd Acute phase: 
3mg bid 
Maintenance phase: 
4mg qd  
4-8mg qd 
No safety data for 
doses > 16mg qd* 
Elderly /debilitated /renal /hepatic 
impairment ↓ dose and titrate slower: 0.5mg 
bid, ↑ 0.5mg bid/qd and then q week when 
reach 1.5mg bid 
No ↑ in efficacy noted with doses >6-8mg 
Risperidone39 
(BIP) 




20mg bid 20mg bid 20-80mg bid >80mg bid usually 
not recommended 
No safety data for 




40mg bid 20-40mg bid on 
day two 
40-80mg bid As above Mean daily dose in clinical trial = 120mg qd 
Abbreviations: SCZ – Schizophrenia; SAD – Schizoaffective Disorder; BIP – Bipolar Disorder; Tx - Treatment; N/R – not reported; MDD – 
Maximum Daily Dose; TDD – Target Daily Dose; qd – once daily; q240 – every 24 hours; q480 – every 48 hours; bid - twice daily; tid - three 
times daily; q week – every week 
* According to the product package insert. 
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1.3.5.2.1 Mechanism of Action 
As noted previously, the exact mechanism of action of the antipsychotic agents 
has not fully been elucidated. The second-generation agents all inhibit dopamine 
D2 receptors, but to a lesser extent than the first-generation agents. For example, 
clozapine occupies only 38 to 63 percent of D2 receptors.24 This is lower that the 
threshold of 77 percent occupancy associated with extrapyramidal side-effects 
thereby explaining the decreased propensity of these agents to cause this 
problem.24 A notable exception is risperidone, which at daily doses greater than 
six milligrams typically exceeds the threshold occupancy rate for extrapyramidal 
side-effects.24 The second-generation agents exhibit a high affinity for serotonin 
5-HT2A receptors although the clinical significance of this is not fully known.30 
Aripiprazole is unique among the second-generation antipsychotics, in that it acts 
as a partial agonist at dopamine D2 and serotonin 5-HT1 receptors.31 The second-
generation agents have varying effects on multiple other neurotransmitters 
including: dopamine D1 and D4 receptors; histamine H1; serotonin 5-HT2C; 
cholinergic; and α1-adrenergic receptors.30 As a result, this group is 
heterogeneous both in terms of efficacy and tolerability. 
1.3.5.2.2 Efficacy 
The second-generation agents are more effective than placebo in treating 
both the positive and negative symptoms of schizophrenia, although the 
magnitude of the effect is deemed only to be moderate (mean effect size = 0.25 
(95% confidence interval (CI): 0.22-0.28)).41;42 When compared to the first-
generation antipsychotics, these agents have been found to have comparable 
efficacy in treating the positive symptoms, and superior efficacy in treating both 
the negative symptoms and cognitive deficits of schizophrenia, although 
heterogeneity of effect has been seen.41-43 The superiority of the second-
generation agents is disputed with assertions that the differences are based on 
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inappropriate comparator doses and that the available studies were short-term in 
nature.44 In clinical practice, the second-generation agents have been deemed 
more effective than the first-generation agents due to a lower propensity to be 
prematurely discontinued.45 
Clozapine, which is reserved as a second-line agent due to its toxicity, has 
been demonstrated to be effective in treatment resistant schizophrenia, with 60 
percent of patients responding within six weeks.46 Clozapine is also indicated for 
reducing suicidal ideation in at-risk patients although a reduction in the rate of 
death by suicide is yet to be confirmed.36;47;48 
1.3.5.2.3 Adverse Effects 
As with the first-generation agents, the second-generation antipsychotics 
can cause a wide range of adverse effects including: antihistaminic; 
antidopaminergic D2; anticholinergic; and anti-α1-adrenergic effects.31 
Comparatively, however, the second-generation agents are more tolerable. In 
particular, the second-generation agents, with the exception of risperidone, have 
a reduced propensity to cause extrapyramidal side effects. When used at doses 
greater than six milligrams a day, risperidone has a similar risk of extrapyramidal 
effects as haloperidol. Agranulocytosis, occurring at a rate of 0.39 percent, 
myocarditis and an increased propensity to lower the seizure threshold, are 
important side effects associated with clozapine and limit its use to that of 
second-line therapy.36 The risk of metabolic side effects with the second-
generation agents, including the potential for: weight gain; glucose 
dysregulation; dyslipidemia; hyperglycemia; pancreatitis; and 
hyperprolactinemia will be discussed in detail in section 6. 
1.3.5.3 Other Drugs Used in the Treatment of Schizophrenia 
Several classes of drugs are used in addition to the antipsychotic agents in 
the management of schizophrenia. These are primarily used as adjunctive therapy 
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to treat either comorbid conditions or to alleviate adverse effects of the 
antipsychotic agents. A brief description of their role in therapy follows. 
1.3.5.3.1 Benzodiazepines 
Benzodiazepines are primarily used as adjunctive therapy to 
antipsychotics in patients experiencing acute exacerbations, particularly with 
severe anxiety, agitation, or irritability.49 They are used for their anxiolytic or 
sedative-hypnotic properties as opposed to having a direct impact on psychotic 
symptoms.49 They have been used acutely in lieu of intramuscular antipsychotics, 
but in combination with maintenance antipsychotic therapy in the management of 
acute agitation and aggression.49 Use of these agents is complicated by their side-
effects including sedation, ataxia and dependence.49 
1.3.5.3.2 Mood Stabilizing Agents 
The use of lithium and anticonvulsants is recommended as adjunctive 
therapy in the management of schizophrenia. These agents are used to improve 
labile affect and agitation.49 Despite their widespread use there is limited 
empirical evidence to support this.50;51 The use of these agents is complicated by 
their adverse effects. These may be additive to those of the antipsychotic agents, 
or complicate their use, and include weight gain, liver toxicity and enzyme 
induction.31;50 
1.3.5.3.3 Antidepressants 
Depression is a significant comorbidity in schizophrenia with an 
estimated prevalence of 25 percent.52 Antidepressants are indicated as adjunctive 
treatment for patients with comorbid depression, obsessive compulsive disorder 
or panic attacks.49 The use of these agents may be complicated by overlapping 
toxicities between the antidepressants and the second-generation 
antipsychotics.31;49 There is also potential for clinically significant drug-drug 
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interactions due to the inhibitory effects of certain antidepressants on the 
cytochrome P450 enzyme system.31 
1.3.5.3.4 Antiparkinson Agents 
Agents such as benztropine, procyclidine and trihexyphenidyl are widely 
used in patients with schizophrenia to prevent or alleviate the extrapyramidal 
side-effects caused by the antipsychotic agents.49 
1.3.5.4 Treatment Algorithms 
A number of treatment algorithms have been developed to aid clinicians 
in selecting a drug.21;53 One that is widely used is the Texas Medication 
Algorithm Project (TMAP). This advocates the use of the second-generation 
antipsychotic agents as first and also as second-line therapy. Following failure of 
two agents, use of either clozapine or another first or second-generation agent is 
recommended as third-line. Combination antipsychotic therapy should only be 
considered after exhaustion of all of these options. 53 
1.3.5.5 Non-Drug Therapy 
Non-pharmacological measures are ancillary to pharmacological 
management and have been documented to be beneficial in preventing relapse, 
improving social and vocational functioning, and increasing coping skills and 
independent function.21 Treatments include psychosocial interventions such as 
individual, family and group therapy.28 Social and community interventions 
focus on coordinating care and providing social support such as in community 
case management programs.28 Non-pharmacological measures also focus on 
patient rehabilitation and include social skills training and vocational 
rehabilitation.28 While the quality of controlled clinical trials is variable, there is 
evidence that these programs are effective in reducing hospitalization rates and 
improving social functioning.21;28 
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1.3.6 Summary 
Second-generation antipsychotics are established treatment for the acute 
and long-term management of schizophrenia. Clozapine aside, there is little 
compelling evidence to discriminate between the agents based on efficacy. These 
agents differ in terms of their tolerability, although differences in the relative 
potential to induce diabetes are yet to be confirmed. Given the apparent 
association between schizophrenia and diabetes, it is imperative that the relative 
potential of these agents to induce diabetes be clarified so that their respective 
roles in therapy can be more clearly delineated.  
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1.4 Section 2: General Background on Bipolar Disorder 
In this section an overview of bipolar disorder, including its 
epidemiology, course and management, is provided. 
1.4.1 Epidemiology 
Bipolar disorder is a common mental disorder that affects between 1.5 
and 3 percent of the population.54 Bipolar I disorder affects both men and women 
equally, with a median age of onset of 20 years and an estimated prevalence of 
0.4 to 1.6 percent.55 Bipolar II disorder occurs in approximately 0.5 percent of 
the population and is thought to be more common in women than men.22;55  
1.4.2 Etiology and Pathogenesis 
The precise etiology of bipolar disorder is unknown.55 There is 
considerable evidence for a genetic basis to the disease although the mode of 
transmission is unknown. First-degree relatives of patients with bipolar disorder 
have a 15 to 35 percent risk of developing a mood disorder.56 Twin studies also 
support this hypothesis, with concordance rates of 78 to 80 percent documented 
in monozygotic twins, compared to 20 percent in dizygotic twins.56 
Dysregulation of the neurotransmitters, specifically a relative excess of 
norepinephrine and dopamine in mania, and a functional deficit of these 
neurotransmitters together with serotonin in depression, have been implicated in 
the pathogenesis of bipolar disorder.56 Disturbances in thyroid activity, calcium 
and sodium homeostasis together with abnormalities in membrane transport and 
secondary messenger systems have also been implicated.56 A biological rhythms 
hypothesis has also been proposed based on observed seasonal trends in episode 
(particularly depressive episode) recurrence. Psychosocial and environmental 
stressors are known to impact both the severity and course of illness, lengthening 
the time of recovery and increasing the risk of relapse.55;56 
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1.4.3 Classification 
Previously referred to as manic-depression, bipolar disorder is a mood 
disorder. It is differentiated from major depressive disorder by a history of mania 
or hypomania.22 Based on the presence of specific mood episodes, bipolar 
disorder has been divided into four subtypes: bipolar I; bipolar II; cyclothymic 
disorder; and bipolar disorder not otherwise specified.22 Further specifiers are 
used to describe the course of recurrent episodes, such as the pattern of episode 
occurrence and the longitudinal course of these episodes.22 Bipolar I disorder is 
characterized by the occurrence of one or more manic or mixed episodes.22 
Bipolar II disorder is characterized by the occurrence of one or more major 
depressive episodes accompanied by at least one hypomanic episode.22 
Cyclothymic disorder is characterized by the occurrence of numerous periods of 
depressive symptoms and of hypomanic symptoms in a two- year period, with no 
symptom-free period greater than two months in duration, and in the absence of a 
past history of a manic, mixed, or major depressive episode.22 
1.4.4 Course 
Bipolar disorder is typically a lifelong disorder with an episodic and 
protean course. In bipolar I disorder, women typically first present with a 
depressive episode, whereas men present with a manic episode.22 Regardless of 
gender, the average age of onset for the first manic episode is 20 years.22 Patients 
rarely present with a first manic episode after the age of 40 years.22 Although a 
history of depression is not necessary to confirm a diagnosis of bipolar I disorder, 
more than 95 percent of patients experience at least one depressive episode.22 
Psychotic symptoms can occur in both bipolar I and bipolar II disorder, although 
they are more common in bipolar I disorder.22 As stated, bipolar I disorder is an 
episodic condition with patients typically experiencing multiple episodes of 
mania and depression.22 Bipolar II disorder is also characterized by multiple 
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relapses or episodes.22;55 The duration and severity of these episodes, as well as 
the interval between episodes, varies by patient. Patients may experience normal 
functioning between episodes, but more than 50 percent experience some 
functional impairment after the onset of illness, with 10 to 15 percent 
experiencing severe impairment of function.55;56 Due to the prevalence of the 
disorder and the pervasiveness of associated symptoms, bipolar disorder is the 
sixth leading cause of disability in developed nations worldwide.57 Bipolar 
disorder is also associated with an increased incidence of comorbidities including 
diabetes, substance misuse, anxiety, panic disorder and other mental 
disorders.18;22;58 These, combined with a lifetime prevalence of suicide of 
approximately 10 to 15 percent, contribute to an increased mortality rate in these 
patients.22 
1.4.5 Treatment 
The goals of treatment include resolution of bipolar symptoms and 
prevention of further relapse while minimizing the risk of adverse effects. The 
management of bipolar disorder includes pharmacological and non-
pharmacological strategies. It is estimated that only one-third of patients with 
bipolar disorder receive appropriate treatment.59 This is due to a combination of 
factors including inadequate rates of diagnosis and high medication 
nonadherence rates due to lack of insight or medication intolerance.59;60 This 
section provides information on the role of pharmacotherapy in the acute and 
maintenance management of mania and depression. Particular emphasis will be 
given to the role of the second-generation antipsychotic agents. 
1.4.5.1 Acute Affective Episodes: Mania 
The American Psychiatric Association advocates the combined use of 
lithium and an antipsychotic, or valproate and an antipsychotic, as first-line 
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therapy for acute manic or mixed episodes.55 In patients who are less ill, 
monotherapy with lithium, valproate or an antipsychotic are considered to be 
possibly sufficient. Alternative treatment options include use of carbamazepine 
or oxcarbazepine in lieu of lithium or valproate. The specific role of the 
aforementioned agents in the management of acute mania will now be presented. 
1.4.5.1.1 Lithium 
Lithium is the gold standard in the management of bipolar disorder and is 
indicated as both acute and prophylactic treatment.55;61 In placebo-controlled 
trials, 70 percent of patients treated with lithium experienced at least a partial 
reduction of acute mania or hypomania.61 In comparison trials, lithium 
monotherapy has been found to be more effective than carbamazepine or 
antipsychotics, but comparable in efficacy to valproate.61 Certain subsets of 
patients are thought to be less responsive to lithium including patients with rapid-
cycling, mania secondary to a medical condition, and those with mania and 
mixed or dysphoric features.61 The use of lithium is complicated by its adverse 
effects profile, and the need for drug serum level monitoring, with up to 75 
percent of patients experiencing some side effects.55;56 Adverse effects include: 
hypothyroidism; polyuria; polydypsia; weight gain; cognitive problems; sedation; 
lethargy; gastrointestinal toxicity; hair loss; and acne.55;56  
1.4.5.1.2 Anticonvulsant Agents 
Also known as mood-stabilizing agents, the efficacy of the two most 
commonly used anticonvulsant agents, divalproex sodium (including its alternate 
formulations: sodium valproate and valproic acid) and carbamazepine, is well 
documented in acute bipolar mania.55;61 Both carbamazepine and divalproex are 
associated with considerable adverse effects burdens. Transient dose-related 
toxicities associated with carbamazepine include: neurological symptoms such as 
diplopia; blurred vision; fatigue; and ataxia.55;56 Less frequently, patients may 
 21
experience skin rashes, hyponatremia and weight gain. Infrequent serious 
toxicities include: blood dyscrasias; Stevens-Johnson syndrome; liver failure; and 
pancreatitis.56 Routine serum drug level monitoring is required with 
carbamazepine because of its narrow therapeutic window.55 Further complicating 
the use of carbamazepine is its action as an inducer of, and substrate for, 
cytochrome P 450, and hence the potential for multiple drug-drug interactions.55 
Adverse effects associated with valproate include: sedation; gastrointestinal 
distress; osteoporosis; polycystic ovarian syndrome; tremor; alopecia, increased 
appetite; and weight gain.55;56 Rare serious adverse effects include blood 
dyscrasias and hepatotoxicty, which can progress to liver failure.55;56 Both 
carbamazepine and divalproex are known teratogens.55 Other possible agents in 
this category include: lamotrigine (for bipolar depression), and oxcarbazepine, 
although the evidence to support their use is limited.55;61  
1.4.5.1.3 Antipsychotics 
The use of antipsychotics in the management of bipolar mania is 
common, and endorsed by several expert consensus series.21;62;63 This is due to a 
combination of factors including: limited efficacy of lithium and the 
anticonvulsant agents as monotherapy in certain subtypes; a prevalence of 
psychosis in 50 to 75 percent of patients with acute mania; and documented 
efficacy of the antipsychotics as mono- or adjunctive therapy.64 Prior to the 
widespread availability of the second-generation agents, the use of the first-
generation antipsychotics was commonplace. In a meta-analysis of 16 studies, 
including 2,738 patients with bipolar disorder, 84.7 percent received a first-
generation antipsychotic, with monotherapy accounting for 53.8 percent of this 
use, and dual therapy with lithium, valproate or carbamazepine accounting for 
47.4 percent of the use.62 In a study of hospitalized patients with bipolar I 
disorder published in 2001, antipsychotic agents were prescribed to 74 to 78 
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percent of patients with psychotic features, and to 33 to 41 percent without, with 
second-generation antipsychotics accounting for two-thirds of this use.65 The role 
of the first- and second-generation antipsychotic agents in the acute management 
of bipolar mania will now be reviewed. 
1.4.5.1.3.1 First-Generation Antipsychotics 
Antipsychotics have been used in the acute management of bipolar mania 
since the 1950s.64 Initially used to control agitation, these agents were 
subsequently noted to have anti-manic properties, and although less efficacious 
than lithium, have the advantage of a more rapid onset of action.62 If an 
antipsychotic agent is required, the second-generation antipsychotics are now 
preferred due to the unfavorable adverse effects profile associated with the first-
generation agents.55;63 These include neuroleptic malignant syndrome, and 
extrapyramidal side-effects.55;64 In particular, patients with bipolar disorder have 
an apparent increased susceptibility to extrapyramidal side-effects and tardive 
dyskinesia. A prevalence of tardive dyskinesia of 19 to 41 percent has been noted 
in bipolar patients treated with the first-generation antipsychotics.66  
1.4.5.1.3.2 Second-Generation Antipsychotics 
The efficacy of aripiprazole, olanzapine, quetiapine, risperidone and 
ziprasidone in the management of acute mania has been documented in a number 
of large double-blind, placebo-controlled trials.67-74 When compared to placebo, 
an incremental response of 20 to 25 percent in the reduction of acute mania was 
typically seen.75 When used as monotherapy, olanzapine, quetiapine and 
risperidone have been demonstrated to have comparable efficacy to lithium or 
haloperidol.75 Similarly, olanzapine has been demonstrated to be comparable 
to,76 or superior to,77 divalproex monotherapy for the remission of acute mania. 
The efficacy of olanzapine, risperidone and quetiapine as adjunctive therapy to 
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lithium or divalproex has also been demonstrated, with an increase in response 
rate of approximately 20 percent seen with the combination therapy.78-81 
Olanzapine was first licensed as monotherapy for acute bipolar mania in 
September 2000.37 It was subsequently licensed for use as adjunctive therapy 
with lithium or divalproex in acute mania in July 2003, and as maintenance 
monotherapy in January 2004.37 Quetiapine and risperidone were newly 
approved in January 2004 and December 2003, respectively, for use as 
monotherapy and as adjunctive therapy with lithium or divalproex in the 
treatment of acute bipolar mania.38;39 Food and Drug Administration (FDA) 
approval for the use of aripiprazole and ziprasidone in acute manic and mixed 
episodes associated with bipolar disorder, with or without psychotic features was 
granted in September 2004 and August 2004, respectively.35;40 
There is evidence that clozapine is effective in bipolar disorder, including 
treatment-resistant cases. The use of clozapine is limited due to its adverse 
effects profile, in particular the risk of potentially fatal agranulocytosis.50 When 
used in bipolar disorder, and consistent with the findings in schizophrenia, there 
are a number of adverse effects commonly associated with the use of the other 
second-generation antipsychotic agents. These include: extrapyramidal side-
effects and tardive dyskinesia; endocrine disturbances such as 
hyperprolactinemia; weight gain; and metabolic disturbances such as 
dyslipidemia and diabetes. To be effective, a drug must be taken as prescribed; 
therefore, tolerability is critical to the success of treatment.  
1.4.5.2 Acute Affective Episodes: Depression 
As noted, the American Psychiatric Association advocates the combined 
use of lithium and an antipsychotic, or valproate and an antipsychotic, as first-
line therapy for acute manic or mixed episodes.55 While new data is emerging on 
the treatment of bipolar depression, historically few randomized clinical trials 
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have been conducted in this area.82;83 Controversy exists as to the risks and 
benefits of using antidepressants due to the potential for treatment-emergent 
mania.83 Recent trials have highlighted the benefits of lamotrigine both as acute 
management, and for prevention of bipolar depressive episodes.82 When 
combined with lithium or divalproex, paroxetine has also been shown to have a 
significant antidepressant effect with limited risk of treatment–emergent mania.82 
The potential for treatment-emergent mania with tricyclic antidepressant therapy 
has, however, been substantiated and would appear to limit the utility of these 
agents for bipolar depression.82 
The first-generation antipsychotics appear to be ineffective as 
antidepressants, and may, in fact, induce depressive symptoms in patients with 
bipolar depression.64 In contrast, consistent with their effects as serotonin 
receptor antagonists, the second-generation antipsychotics appear to alleviate 
symptoms of acute depression in bipolar disorder, although the evidence is 
limited. In a randomized, double-blind clinical trial, olanzapine as monotherapy, 
or in combination with fluoxetine, was demonstrated to be superior to placebo in 
decreasing depressive symptoms in patients with bipolar disorder, while not 
increasing the risk of treatment-emergent mania.68 A combined olanzapine / 
fluoxetine preparation has recently been licensed for this indication.84 In a 
randomized placebo-controlled trial, quetiapine monotherapy was shown to be 
effective in the acute management of bipolar depression (including significantly 
reducing suicidal ideation) and to have a larger effect size compared to that 
recorded in similar placebo-controlled trials for olanzapine, and olanzapine-
fluoxetine combination.85 As with schizophrenia and bipolar mania, a careful 
risk/benefit analysis is warranted for each patient to balance the apparent benefits 
of therapy with the potential for adverse effects including: weight gain; diabetes; 
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hyperlipidemia; hyperprolactinemia; cardiac effects; and extrapyramidal side-
effects. 
1.4.5.3 Summary 
The efficacy of lithium, the anticonvulsant agent’s divalproex and 
carbamazepine, and the first-generation antipsychotics in acute bipolar mania is 
well established. There is also limited evidence to support the efficacy of the 
selective serotonin reuptake inhibitors (SSRIs) for bipolar depression More 
recently, a number of the second-generation antipsychotics have emerged as 
effective treatment for both bipolar mania and depression. Despite these 
successes, up to 50 percent of patients with acute affective episodes do not 
respond to any of these agents. Furthermore, the use of these agents is 
complicated by unwanted side-effects, some of which can be serious. 
1.4.5.4 Maintenance Phase Management 
The goals of maintenance phase management include: relapse prevention; 
reduction of the risk of cycling frequency; mood instability and suicide; and 
improvement in psychosocial functioning.55 Following the remission of an acute 
manic episode, maintenance therapy with a mood stabilizer is recommended 
while adjunctive treatments are tapered and discontinued.55 While there is dispute 
as to what constitutes recovery from an acute episode, the maintenance phase is 
typically defined as the time interval from the recovery from one acute episode to 
the time of onset of a new acute episode.86 Lifetime prophylaxis with a mood 
stabilizer is recommended for patients with bipolar I disorder that have 
experienced two manic episodes, or one severe episode.55 Patients with bipolar II 
disorder are recommended to remain on lifelong therapy if they experience three 
hypomanic attacks, or require an antidepressant but become hypomanic.55 The 
use of lithium, anticonvulsants and antipsychotics in the maintenance phase 
management of bipolar disorder will now be discussed briefly. 
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1.4.5.4.1 Lithium 
Although early studies reported lithium to be more effective than placebo 
in preventing episode recurrence, many of these studies were methodologically 
flawed.55;82;86 More recently, naturalistic studies have indicated that lithium 
decreases the risk of relapse in approximately one-third of patients, although 
these studies were characterized by high drop-out rates.86 Two recent randomized 
controlled trials have confirmed the efficacy of lithium compared to placebo in 
relapse prevention.82 Specifically, lithium reduced the risk of recurrence of 
mania, but not depression, when compared to placebo.82 Lithium has 
demonstrated possibly specific anti-suicide effects, and is the only maintenance 
treatment proven to decrease the risk of suicide in patients with bipolar 
disorder.87 Lithium is less effective in certain patient subsets, including those 
with rapid cycling.55 Whereas lithium appears to be more effective at higher 
serum drug levels, the corollary is poorer tolerability.55 Nonadherence to therapy 
is common, particularly during maintenance therapy. In addition to the risk of 
relapse, abrupt discontinuation of lithium may increase the risk of a treatment-
refractory state thereby limiting the benefit of future treatment. Forty percent of 
acute patients are believed to be resistant to lithium.88 
1.4.5.4.2 Anticonvulsants 
Lamotrigine is the only anticonvulsant agent approved by the FDA for 
maintenance treatment in bipolar disorder.55 It is well-tolerated, with headache 
the most commonly reported side-effect in clinical trials.56 No serum drug level 
monitoring is required and it appears to have no effect on weight or cognition.55 
Limited data with divalproex shows that it appears to be at least comparable in 
efficacy to lithium as a maintenance agent.55 Currently there is no conclusive 
evidence to support the use of oxcarbazepine, carbamazepine, topiramate or 
gabapentin as maintenance therapy.55;89 
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1.4.5.4.3 Antipsychotics 
The first-generation antipsychotics have not been demonstrated to be 
effective in the long-term treatment of bipolar disorder.75 Although effective as 
anti-manic agents, they have not been demonstrated to prevent depression, and 
moreover, may contribute to its development.75 As noted previously, the use of 
these agents in bipolar disorder is complicated by their adverse effects profile, in 
particular the propensity to cause tardive dyskinesia.66 
Limited data support the long-term use of the second-generation 
antipsychotics. Olanzapine, the only agent in this class approved for this 
indication, was licensed as maintenance monotherapy in January 2004.37 When 
used as monotherapy, it has been shown to be significantly more effective than 
placebo in preventing manic and depressive relapses.90 Similarly, when used as 
monotherapy, or in combination with lithium or divalproex, it has also been 
demonstrated to be significantly superior to monotherapy with lithium or 
divalproex in preventing manic, although not depressive relapse.75;91 There is 
preliminary evidence for the efficacy of the other second-generation 
antipsychotics as maintenance therapy; however, the results of long term trials 
are pending.75 
Although olanzapine has demonstrated efficacy as maintenance 
monotherapy for relapse prevention in bipolar disorder, some results from the 
clinical trials highlight key issues relating to the long-term management of 
bipolar disorder. The studies were characterized by high rates of treatment 
discontinuation, with 52-week completion rates of 23.6 to 46.5 percent for 
olanzapine, 9.6 percent for placebo, and 32.7 percent for lithium.75 Although 
patients experienced a significant reduction in the risk of affective relapse, 
relapse rates in patients on monotherapy were still considerable, that is, from 30 
to 46.7 percent with olanzapine compared to 80.1 percent with placebo, and 39 
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percent with lithium.75 Due to its variable course and considerable interpatient 
variability, bipolar disorder is difficult to manage. As seen here, it is 
characterized by high rates of treatment non-adherence and poor persistence with 
therapy, which may reflect limited efficacy or poor tolerance of therapy. In 
tandem with efficacy research, it is important to study the long-term tolerability 
of these agents, so that the optimal agent can be selected for each patient. 
1.4.6 Summary 
Bipolar disorder is a prevalent condition characterized by multiple 
relapses and a variable course. The majority of patients do not respond 
adequately to monotherapy. Long-term maintenance therapy is required to 
ameliorate symptoms and prevent relapse. Antipsychotic agents are now widely 
used in the acute and long-term management of bipolar disorder. In particular, 
the second-generation antipsychotic agents have been endorsed for use as both 
mono- and adjunctive therapy, in patients with and without psychotic symptoms. 
The use of these agents is likely to expand following their recent FDA approval 
for these indications. The acute and long-term risks associated with these agents, 
including the potential for treatment-emergent diabetes, needs to be determined 
so that their role in the management of bipolar disorder can be more fully 
assessed. 
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1.5 Section 3: General Background on other Psychotic Disorders 
In addition to schizophrenia, there are a number of other disorders 
classified as being psychotic disorders. While all include psychotic symptoms as 
a prominent feature, they differ in their etiology, the duration of symptoms and 
the constellation of symptoms encompassed by the term ‘psychotic.’22 Disorders 
for which psychotic symptoms are present as associated, rather than prominent 
features, of the disorder are usually categorized according to the major 
diagnosis.22 The presence of psychosis is then included as a specifier, for 
example, major depressive disorder, with psychotic features.22 In addition to 
defining psychosis, this section will provide background information on the 
various psychotic disorders as well as conditions in which psychotic symptoms 
commonly occur. The role of the second-generation antipsychotics in the 
management of these disorders will then be discussed. 
1.5.1 Definition of Psychosis 
The term psychotic has historically had a number of definitions, the most 
restrictive of which is the occurrence of delusions or prominent hallucinations in 
the absence of insight.22 Although the Diagnostic and Statistical Manual of 
Mental Disorders, 4th edition, (DSM IV) limits the definition of psychosis to the 
presence of certain symptoms, these vary according to the diagnostic category.22 
For example, in schizophrenia, schizoaffective disorder, schizophreniform 
disorder and brief psychotic disorder, the term ‘psychotic’ refers to the presence 
of delusions, prominent hallucinations, disorganized speech, or grossly 
disorganized or catatonic behavior.22 Psychosis in the context of delusional 
disorder, or shared psychotic disorder, refers only to a patient being delusional.22 
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1.5.2 Classification (DSM IV Criteria) 
Included in the DSM IV section entitled ‘Schizophrenia and Other 
Psychotic Disorders’ are the following disorders: schizophreniform disorder; 
schizoaffective disorder; delusional disorder; brief psychotic disorder; shared 
psychotic disorder; psychotic disorder due to a general medical condition; 
substance-induced psychotic disorder; and psychotic disorder not otherwise 
specified.22 As noted, psychotic symptoms may accompany a variety of medical 
conditions. In this case, they are considered to be associated, rather than 
prominent features of the disorder, for example, psychoses associated with major 
depressive disorder. 
1.5.3 Epidemiology and Course 
A brief description of these psychotic disorders will be provided here, 
focusing on their epidemiology and course. In particular, those features that 
differentiate these disorders from schizophrenia are highlighted. 
1.5.3.1 Schizophreniform Disorder 
This disorder is indistinguishable from schizophrenia with the exception 
of two features: duration and impairment of function. Whereas schizophrenia 
must persist in excess of six months, with a minimum of one month of active-
phase (two or more symptoms), schizophreniform disorder is defined as a 
disorder that persists for one month, but no longer than six months.22 In addition, 
schizophrenia is characterized by functional impairment in at least one domain 
whereas no such impairment is required in schizophreniform disorder. 22 The 
prevalence of schizophreniform disorder is estimated to be one-fifth of that of 
schizophrenia. 22 Prospectively, in a clinical setting, a diagnosis of 
schizophreniform disorder is a provisional diagnosis, with approximately one-
third of patients experiencing symptom remission within six months and, 
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therefore, meeting the criteria for the disorder and the remainder proceeding to 
being diagnosed as having schizophrenia or schizoaffective disorder. 22 
1.5.3.2 Schizoaffective Disorder 
This disorder is characterized as a combination of a mood disorder and 
symptoms characteristic of schizophrenia.22 To fulfill the diagnosis, mood 
symptoms must be present for a considerable proportion of the entire duration of 
illness but in addition there must be a minimum two-week period of illness where 
the patient has psychotic symptoms in the absence of prominent mood 
symptoms.22 The prevalence of schizoaffective disorder is unknown, but it is 
apparently less common than schizophrenia. Differentiating between 
schizophrenia, schizoaffective disorder and mood disorders with psychotic 
features can be difficult, and frequently a diagnosis may change according to the 
prominent symptoms within an episode or in subsequent episodes. 22 
1.5.3.3 Brief Psychotic Disorder 
This disorder differs from schizophrenia in two regards: the duration of 
psychosis is shorter, with a minimum duration of at least one day but not 
exceeding one month; and the patient must experience full recovery to premorbid 
functioning.22 The prevalence of this disorder is unknown. 22 Brief episodes of 
psychosis may occur with a wide range of medical conditions and in addition, the 
condition may be difficult to differentiate from schizophreniform disorder if the 
symptoms remit in less than one month in response to antipsychotic treatment.22 
1.5.3.4 Delusional Disorder 
Delusional disorder is distinguished from schizophrenia in that the 
symptoms are generally limited to delusions, and do not include other psychotic 
symptoms.22 It may be difficult to differentiate from other disorders for which 
delusions are a prominent symptom.22 Delusional disorder usually manifests late 
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in life, has a variable course, affects men and women equally, and has an 
estimated population prevalence of 0.03 percent.22 
1.5.3.5 Shared Psychotic Disorder 
This is a delusional disorder characterized by the co-occurrence of 
delusions in an individual under the influence of another who has a pre-existing 
psychotic disorder featuring delusions as a prominent symptom.22 While the 
condition is typically chronic, it remits over time when the patient is separated 
from the primary case.22 The prevalence of this disorder is unknown, with a 
belief that the condition is under-diagnosed.22 
1.5.3.6 Psychotic Disorder Due to a General Medical Condition 
Psychotic symptoms assessed as being a direct physiological consequence 
of a general medical condition are included in this disorder.22 Patients are 
subdivided according to their predominant symptoms: delusions or 
hallucinations.22 The prevalence, course and management of the disorder depend 
on the underlying etiology, with psychotic symptoms generally remitting with 
treatment of the underlying condition.22 
1.5.3.7 Substance-Induced Psychotic Disorder 
In this disorder, psychotic symptoms are judged to be a direct 
physiological consequence of an ingested substance (alcohol, drug of abuse, 
medication or toxin). 22 Patients are subtyped according to their predominant 
symptom: delusions or hallucinations; with additional specifiers used to indicate 
the time of onset of the symptoms, that is, during intoxication or during 
substance withdrawal.22 Psychotic symptoms typically remit on withdrawal of 
the substance, or within weeks in the case of withdrawal syndrome. A differential 
diagnosis may be difficult where there are comorbid medical conditions. 22 
 
 33
1.5.3.8 Psychoses not otherwise Specified 
This diagnosis is assigned when the presenting psychotic symptoms do 
not meet the criteria for any of the specific psychotic disorders, or if there is 
inadequate information to concur or contradict with another diagnosis.22 
1.5.3.9 Major Depressive Disorder with Psychotic Features 
Major depressive disorder is classified according to severity, with severe 
episodes categorized as being with, or without psychotic episodes.22 Psychotic 
symptoms include delusions or hallucinations (which are typically auditory), the 
content of which are usually consistent with the depressed mood (i.e., mood 
congruent).22 The prevalence of psychotic depression is estimated to be 0.6 
percent in the general population, accounting for approximately 20 percent of 
major depressive episodes.92 Psychotic depression is associated with greater 
morbidity and mortality than non-psychotic depression, and is associated with an 
increased risk of relapse and recurrence, although the literature supporting this is 
equivocal.93 Psychotic depression may be difficult to distinguish from other 
conditions where psychoses and depression co-occur including schizophrenia, 
delusional disorder and psychotic disorder not otherwise specified.22 
1.5.4 Role of the Second-Generation Antipsychotics 
With the exception of clozapine, which has a licensed indication for 
reduction of suicidal ideation in patients with schizoaffective disorder, the 
second-generation antipsychotics are not licensed for use in conditions other than 
schizophrenia and bipolar mania. (Table 1.1).35-39 However, there is widespread 
clinical consensus that these medications are appropriate for the management of 
psychoses regardless of the etiology. In an expert consensus guideline series 
entitled ‘Optimizing Pharmacological Treatment of Psychotic Disorders,’ the role 
of these agents was considered for patients with psychotic disorders.94 Psychotic 
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disorders were defined as those included in the DSM IV criteria discussed above, 
that is, schizophrenia; schizoaffective disorder; schizophreniform disorder; 
delusional disorder; and brief psychotic disorder.94 No adjustment to treatment 
was recommended based on the etiology of the psychosis, rather modifications 
were proposed based on the patient experiencing first-episode versus multiple 
recurrent episodes of psychoses, and based on the presence of comorbid disease 
states.94 In a similar guideline examining the use of antipsychotics in older 
patients, the experts concurred that the use of antipsychotics was appropriate in 
patients with psychosis regardless of etiology.11 
Treatment recommendations for psychoses associated with major 
depressive disorder include the use of electroconvulsive therapy (ECT) or a 
combination of antidepressant and an antipsychotic, although monotherapy with 
the second-generation antipsychotics olanzapine and risperidone has also been 
used.95-98 In particular, combined treatment with olanzapine and fluoxetine has 
been compared to olanzapine monotherapy, and placebo in the treatment of 
major depressive disorder with psychotic features.99 Combined therapy was 
associated with a significantly higher response rate than with either olanzapine 
monotherapy (p=0.027) or placebo (p=0.004), although this finding was not 
corroborated in a subsequent trial.99 
The key difference between the use of antipsychotics for schizophrenia 
and non-schizophrenia conditions appear to be the dose and duration of therapy, 
with typically lower doses recommended for conditions other than schizophrenia. 
Schizophrenia is characterized as a life-long chronic relapsing condition.26 It is, 
therefore, recommended that antipsychotics be continued indefinitely at the 
lowest effective dose to prevent relapse.11;94 In fact, the majority of experts in the 
field would not lower the dose of antipsychotic in the maintenance phase from 
that required in the acute treatment phase.94 Those who endorse the strategy of 
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using a lower maintenance phase dose recommend that the patient be stable for a 
period of six months, and preferably one year prior to attempting a dose 
reduction.94 In contrast, a shorter treatment duration is recommended in other 
conditions.11 The duration of treatment recommended before an attempt is made 
to discontinue treatment, ranges from one week to six months. (Table 1.2) 11 
 
Table 1.2: Recommended Duration of Treatment (after a Clinical Response Achieved) with 
an Antipsychotic Prior to Attempting to Discontinue Treatment, Stratified According to 
Treatment Indication11 
Condition Duration and Action 
Delirium 1 week 
Agitated Dementia (with and without 
delusions) 
Begin taper in 3-6 months to determine lowest 
effective maintenance dose 
Schizophrenia Indefinitely at lowest effective dose 
Delusional Disorder 6 months to indefinitely at the lowest effective 
dose 
Psychotic Major Depression 6 months 
Agitated Non-Psychotic Major Depression 2 months 
Non-Psychotic Major Depression with 
Severe Anxiety* 
2 months 
Mania with Psychosis 3 months 
Mania without Psychosis 2 months 
* Approximately 33 percent of experts did not advocate the use of antipsychotics for this 
condition other than for patients that were intolerant or, or unresponsive to first-line treatment. 
 
1.5.5 Summary 
In this section, psychotic disorders other than schizophrenia, as well as 
disorders for which psychotic symptoms may present as associated symptoms 
were outlined. A number of these disorders are clinically very similar to 
schizophrenia and may be considered as ‘schizophrenia spectrum disorders.’22 
Specifically, schizophreniform disorder is indistinguishable from schizophrenia 
with the exception of the duration of the disorder. Schizoaffective disorder also 
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may be difficult to distinguish from schizophrenia and the patient diagnosis may 
change according to the prominent symptoms during a given episode. The use of 
antipsychotics, including the use of the second-generation antipsychotics, is 
considered clinically acceptable for psychotic conditions despite the fact that 
they do not have licensed indications for such use. However, the pattern of 
antipsychotic use in conditions other than schizophrenia appears to vary from 
that in schizophrenia, with typically lower doses or shorter durations of treatment 
advocated.11 
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1.6 Section 4: General Background on Dementia with an Emphasis 
on Behavioral and Psychological Disturbances of Dementia 
The second-generation antipsychotics have been widely used in patients 
with behavioral and psychological symptoms of dementia, in part because of 
their favorable adverse-effects profile compared to the first-generation agents. 
While psychotic symptoms are not synonymous with dementia, there is a high 
life-time prevalence of psychoses in patients with dementia. The use of second-
generation antipsychotics for both psychotic and non-psychotic symptoms of 
dementia is reviewed in this section. 
1.6.1 Classification (DSM IV Criteria) 
According to the DSM IV, patients with psychoses that is considered to 
be “a direct etiological consequence of the pathological process causing the 
dementia” may be classified as having a diagnosis of a psychotic disorder due to 
a general medical condition, in addition to having a diagnosis of dementia. 
1.6.2 Epidemiology and Course 
Dementia, which was previously categorized under the now defunct term 
‘organic mental disorder,’ is considered primarily to be a cognitive disorder 
characterized by multiple cognitive deficits.22 Dementias are categorized 
according to presumed etiology and include: Dementia of Alzheimer’s type; 
Vascular dementia; Dementia due to other general medical conditions (including 
Parkinson’s disease and Huntington’s disease); Substance-induced persisting 
dementia; Dementia due to multiple etiologies; and Dementia not otherwise 
specified.22 The prevalence of dementia increases with age, with a prevalence of 
1.4 to 1.6 percent in those aged between 65 to 69 years, increasing to 16 to 25 
percent in those aged over 85 years.22 Alzheimer’s disease is the most common 
of the dementias accounting for approximately 50 to 75 percent of all cases.100 
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Vascular dementia is the next most common form of dementia, although the 
prevalence of this condition is unknown.100 Behavioral (agitation, physical and 
verbal aggression, noisy vocalizations) and psychological (delusions and 
hallucinations) symptoms are common in elderly patients with dementia and are 
usually grouped under the umbrella term ‘behavioral and psychological 
symptoms of dementia’ (BPSD).101 The lifetime prevalence of these symptoms in 
patients with dementia is estimated to be 50 to 70 percent in those with 
Alzheimer’s disease, and between 70 to 80 percent in those with any type of 
dementia. 101;102 In particular, psychotic symptoms are common in patients with 
dementia secondary to Parkinson’s disease, Lewy body disease, Pick’s disease 
and the other frontal lobe dementias.100 The typically late-life onset of dementia 
facilitates its differential diagnosis from other conditions associated with 
cognitive impairment.22 What can be difficult however is distinguishing between 
delirium (a reversible condition) and dementia, particularly as delirium may often 
be superimposed on a preexisting dementia.22 
1.6.3 Role of the Second-Generation Antipsychotics 
Treatment options for BPSD have traditionally included mechanical 
restraints.100 These are generally no longer favored as an increased level of 
agitation has been documented in restrained patients.100 Similarly, first-
generation antipsychotics which are effective, and previously widely used, are 
now considered second-line due to their unfavorable adverse effects profile, 
particularly the potential for extrapyramidal side-effects.100-102 The second-
generation agents are thought to be more effective in managing psychosis and 
aggression than the first-generation agents and have the additional benefits of a 
decreased potential for extra-pyramidal side-effects and efficacy at relatively low 
doses.101;102 It is generally recommended that elderly patients be started at 
approximately 25 percent of the usual antipsychotic dose due to a possible 
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altered rate of metabolism of these agents, decreased tolerance of adverse effects 
and an increased likelihood of comorbid conditions.102 Gradual titration of the 
dose to effect is also recommended to minimize adverse effects such as 
orthostatic hypotension and sedation.102  
Although not approved by the FDA for this indication, there is a general 
clinical consensus that the use of second-generation antipsychotics for the 
management of psychotic symptoms in patients with dementia is 
appropriate.11;100 Their use for this indication is widespread and well 
documented.101-103 The role of these agents for behavioral disturbances, including 
agitation, is less clear. As noted, symptoms are frequently grouped under the 
umbrella term BPSD, therefore, it may be difficult to ascertain the extent to 
which these agents are being used for psychotic symptoms, as opposed to 
behavioral disturbances.101 Due to the pervasive use of antipsychotics in patients 
with dementia, particularly among nursing-home residents, and a perception that 
these agents were being over-used, the Centers for Medicare and Medicaid 
Services issued guidelines on what was considered appropriate use of 
antipsychotics in nursing homes.103;104 They recommended that antipsychotic 
therapy be limited to the following indications: psychotic disorders, Tourette’s 
syndrome, Huntington’s syndrome, or if hallucinations are currently present.104 
In addition, the use of antipsychotics could be considered in ‘high risk’ patients, 
that is, those with cognitive impairment exhibiting verbally or physically abusive 
behavior, or socially inappropriate /disruptive behavior, provided this was 
currently being monitored.104 Similarly, in an expert consensus guideline series, 
the use of antipsychotics was usually considered to be indicated in dementia 
patients with agitation and delusions, but only sometimes indicated in dementia 
patients with agitation only.11 Of note, however, is a black box warning issued in 
April 2005, by the Center for Drug Evaluation and Research highlighting an 
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increased rate of death in elderly patients with dementia-related psychosis treated 
with a second-generation antipsychotic compared to placebo.  This was based on 
analyses of seventeen placebo-controlled trials in which the rate of death among 
treated patients was 1.6 to 1.7 fold higher than for the placebo group (4.5% vs. 
2.9%, respectively).105 
The majority of the literature supporting the use of the second-generation 
antipsychotics for BPSD relate to the use of risperidone,102 the efficacy of which 
has been demonstrated in a number of randomized, controlled trials.106;107 In a 
controlled study of dementia patients (N=625) residing in a nursing home or 
chronic hospital, a clinically significant improvement in psychotic symptoms was 
documented with risperidone at a dose of one milligram daily (p=0.02), with 
slightly higher efficacy at a dose of two milligrams daily (p=0.002).106 Increased 
adverse effects with the two milligram dose prompted the authors to recommend 
the lower dose in this cohort.106 In a similar trial of 344 nursing home patients 
with dementia, risperidone at a mean dose of 1.1 milligram daily was found to be 
well tolerated and efficacious in decreasing BPSD.107 The efficacy of olanzapine 
in the treatment of BPSD was documented in a randomized, controlled trial of 
206 nursing home residents with Alzheimer’s disease. A significant improvement 
in psychotic symptoms was noted at doses of five to ten milligrams daily, with 
the five milligram dose proving most beneficial.108 There is limited evidence to 
support the use of quetiapine in patients with dementia-related psychoses, 
although preliminary reports from small open-label studies suggest that it is well-
tolerated and associated with an improvement in symptoms at an average dose of 
60 to 100 milligrams daily.109-111 
The use of second-generation antipsychotics is widespread in patients 
with BPSD. In a large, retrospective study of nursing home residents in the U.S. 
in 1999 to 2000, 18.2 percent of patients were receiving an antipsychotic with 
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second-generation antipsychotics accounting for approximately 60 percent of this 
use.103 Likewise, in a study of patients with dementia discharged from psychiatric 
inpatient units, 36.6 percent were receiving antipsychotic therapy.101 The dose of 
antipsychotic used is considerably lower than that seen in conditions such as 
schizophrenia, moreover, the dose required to treat behavioral disturbances of 
dementia may be lower than that required for psychotic symptoms in dementia. 
In a 12-week randomized, controlled trial, risperidone at a dose of 0.5-2.0 
milligrams daily was effective for behavioral symptoms, compared to a dose of 
1.0-2.0 milligrams daily in those with psychotic symptoms.106  
As noted in section three, shorter periods of treatment are advocated 
when antipsychotics are used for conditions other than schizophrenia. Regardless 
of the presence of absence of delusions, it is generally recommended that an 
attempt to taper treatment to the lowest effective dose or to discontinuation be 
made within three to six months in patients with agitated dementia (Table 1.2).11 
1.6.4 Summary 
This section reviewed the use of second-generation antipsychotics in 
patients with dementia. For patients with psychotic symptoms associated with 
dementia, the use of these agents is considered clinically acceptable despite the 
fact that they are not licensed for such use. The role of antipsychotics in the 
management of behavioral symptoms of dementia is less well established. In 
retrospective studies, it may however be difficult to distinguish between 
appropriate and inappropriate use of these medications because symptoms are 
commonly grouped under the term BPSD.101 Likewise, clinical trials in this 
cohort may not distinguish between behavioral and psychological symptoms for 
the purpose of trial inclusion. Similar to the other non-schizophrenia conditions, 
the pattern of antipsychotic use differs from that in schizophrenia, with lower 
doses used and shorter durations of treatment advocated. 
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1.7 Section 5: General Background on Non-Psychotic Mental 
Disorders 
1.7.1 Introduction 
The second-generation antipsychotics have been used in a wide range of 
mental disorders in addition to being used to treat schizophrenia, bipolar disorder 
and other psychotic conditions. The purpose of this section is to provide some 
background material on this diverse range of conditions and to highlight the role 
of the second-generation antipsychotics in their management. 
1.7.1.1 Post Traumatic Stress Disorder 
Post traumatic stress disorder (PTSD) is categorized as an anxiety 
disorder and has an estimated life-time prevalence of 7.8 percent, although a 
prevalence as high as 20 percent has been noted in at-risk populations.22;112 The 
DSM IV defines PTSD as the development of a characteristic set of symptoms 
that persists for more than one month subsequent to a traumatic experience and 
that cause significant distress or functional impairment.113 Cognitive behavioral 
therapy and SSRIs are established effective treatment for PTSD.113 Currently the 
only FDA-approved treatments for PTSD are sertraline and paroxetine.114 
Guidelines on the use of other pharmacological agents depend on specific target 
symptoms that the patient experiences. In particular, the use of second-generation 
antipsychotics has been recommended for psychosis, psychotic depression and 
mania secondary to PTSD as well as refractory PTSD.112 There is preliminary 
evidence to support the use of clozapine, olanzapine, quetiapine and risperidone 
in the management of PTSD.114-117 
In an uncontrolled eight-week study, 48 patients with combat-induced 
PTSD were treated with olanzapine monotherapy (mean dose: 14 milligrams). A 
significant improvement in all symptoms was noted; however, over one-third of 
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patients failed to complete the trial primarily due to intolerable adverse effects.116 
Risperidone at a mean daily dose range of 1-3 milligrams has been noted to be 
effective in reducing target symptoms of combat-induced PTSD in a number of 
small trials.115 Likewise, in a six-week open label add-on trial of 20 combat 
veterans with PTSD who had an inadequate response to antidepressant therapy, 
quetiapine was shown to be effective in ameliorating PTSD symptoms at a mean 
daily dose of 100 milligrams (SD: 70).114 
1.7.1.2 Obsessive-Compulsive Disorder 
As with PTSD, obsessive-compulsive disorder (OCD) is categorized as 
an anxiety disorder.22 Although the exact prevalence is unknown, it is estimated 
to range from 2.5 to 7.9 percent of the general population. 22;118 The condition is 
commonly associated with Tourette’s disorder, with an estimated comorbidity in 
five to seven percent of patients with OCD. 22 The first-line treatment of patients 
is SSRI therapy, however between 40 to 60 percent of patients are poorly 
responsive to such therapy. Although there are few randomized, controlled trials 
to support their use, the second-generation antipsychotics have been widely used 
as augmentation therapy in this population. In a randomized, controlled trial, 36 
patients with OCD refractory to a 12-week course of SSRI therapy were 
randomized to receive augmentation therapy with risperidone or placebo. Using a 
mean daily dose of 2.2 milligrams (SD: 0.7mg), significant reductions in 
obsessive-compulsive behavior (p<0.001), depression (p<0.001) and anxiety 
(p=0.003) were noted compared to placebo therapy. Similar findings were 
documented in a small, open-trial of risperidone augmented SSRI therapy.119 
Likewise, olanzapine has been noted to be efficacious and well-tolerated in a 




1.7.1.3 Borderline Personality Disorder 
Borderline personality disorder (BPD) is a prevalent condition in the 
U.S., with an estimated prevalence of two percent in the general population.22 It 
is a challenging and expensive disorder to treat, with a prevalence of 10 percent 
in out-patient mental health clinics, and 15 to 20 percent in inpatient mental 
health beds.22 The disorder is characterized by marked instability of relationships 
and affect, impulsivity and recurrent suicidal behavior.22 Psychotic-like 
symptoms may occasionally be present.22 A wide range of medications have been 
studied for the management of BPD, but there is no standard approach to the 
management of this disorder.121 The second-generation antipsychotics have 
shown to be promising in the management of BPD, with preliminary evidence 
that they are effective in symptom reduction, particularly in reducing impulse-
aggression.121;122 Support for the use of risperidone comes from two small trials 
using mean doses of 2.2 milligrams and 3.3 milligrams daily where a significant 
reduction in impulse aggression was noted.122 The efficacy of olanzapine has 
similarly been noted in two short-term, randomized, controlled trials using mean 
doses of olanzapine of 5.3 to 6.9 milligrams daily where significant improvement 
in BPD symptoms were noted. 121;122 Likewise quetiapine and clozapine have 
preliminary evidence of efficacy at mean daily doses of 200 to 300 milligrams, 
and 334 milligrams, respectively.122 As long-term trials have yet to be conducted 
in this population, it is not known whether maintenance or intermittent therapy 
will prove superior, nor what the optimal doses for acute treatment and 
maintenance therapy are.122 
1.7.1.4 Autistic Disorder and other Pervasive Developmental Disorders 
Autistic disorder is a neuropsychiatric disorder with an approximate 
prevalence of five cases per 100,000 individuals.22 Autistic disorder is a life-long 
developmental disorder defined by an age of onset less than three years and is the 
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most common of the pervasive developmental disorders.22 Although commonly 
associated with mental retardation, autism is distinct from it.22 Antipsychotic 
therapy has been used to manage some of the specific behavioral disturbances 
associated with autism, including self-injury, aggression and stereotypies.123;124 
The first-generation antipsychotics have been widely used for this indication; 
however, their use is limited by the high incidence of treatment-induced 
dyskinesias in this population.123 
The majority of the literature regarding use of second-generation 
antipsychotics for autism relates to their use in children.123;124 Studies are 
typically small and restricted to case series and open-label non-randomized trials. 
123;124 Risperidone is the most widely studied agent with a median dose of 2.7 
milligrams daily. 123 It has been demonstrated to be effective and well tolerated 
in a short-term, randomized, double-blind placebo-controlled trial of children 
with autism and serious behavioral problems.125 In studies that restricted their 
inclusion to adults, the mean daily dose range was from 2.9 to 7.0 
milligrams.123;124 In a randomized, controlled trial of 31 adults with autistic 
disorder and pervasive developmental disorder, risperidone at a mean daily dose 
of 2.9 milligrams (SD: 1.4mg) was seen to be well tolerated and effective in 
reducing the behavioral symptoms of autism.126 The possible role of olanzapine 
in autism has been reported in a number of small studies, all of which included 
children with autism.123 The median daily dose used was 7.8 milligrams daily 
(range 7.5 to 15mg), it was well tolerated and appeared to be effective although 
these findings need to substantiated in larger, controlled trials.123 There is also 





1.7.1.5 Major Depressive Disorder without Psychoses 
Major depressive disorder is a prevalent condition in the U.S., affecting 
approximately ten percent of the population annually.98 As outlined in section 3, 
severe episodes of major depressive disorder are further specified according to 
the presence or absence of psychotic symptoms.22 While the use of antipsychotic 
therapy for psychotic symptoms is generally accepted, the use for non-psychotic 
conditions is more contentious.11 A number of studies have, however, examined 
the use of these agents for treatment-resistant depression. One definition of 
treatment-resistant depression is a failure to respond to an adequate dose and 
duration of at least two different antidepressant medications.98 It is estimated that 
46 to 50 percent of patients fail to respond, or achieve only partial response to 
conventional antidepressant treatment.98;127 In a 76-week, open-label study of 
adults with major depressive disorder (N=560), including a subset of patients 
with treatment-resistant depression (N=145), a combination of olanzapine and 
fluoxetine was tested.98 The mean modal dose of olanzapine was 7.7 milligrams 
(SD: 3.9mg) daily for patients with treatment-resistant depression and 7.4 
milligrams (SD: 3.3mg) daily for those with non-treatment-resistant depression.98 
Combination therapy was seen to be rapidly effective, tolerable, with a durable 
response in both groups.98 The authors concluded that while effective in patients 
without treatment-resistant depression, it was unlikely to be necessary for the 
majority of such patients.98 However, they concluded that combination therapy 
may represent a reasonable option for treatment-resistant depression, or in 
patients with severe acute major depressive disorder requiring a rapid response.98 
Similar rapid response has been seen in a number of small studies using 
risperidone and ziprasidone augmentation in patients with an inadequate response 
to SSRI therapy.127;128 
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While second-generation antipsychotics are being used to treat non-
psychotic depression, including treatment-resistant depression, it is generally 
advocated that their use be limited to patients that are refractory to other 
treatments including failing multiple different antidepressants and augmentation 
strategies such as lithium and thyroid therapy.96 In an expert consensus guideline 
series examining the use of antipsychotics in older patients, there was limited 
support for the use of a second-generation antipsychotic in treatment-resistant 
depression, with only 36 percent responding that they would consider adding a 
second-generation antipsychotic, and a general recommendation that an attempt 
be made to discontinue treatment two months after a response had been noted 
(Table 1.2).11 
1.7.1.6 Other Conditions 
The second-generation antipsychotics have been used in a wide range of 
conditions in addition to those enumerated above. These include: anorexia 
nervosa; substance abuse; behavioral disturbances associated with intellectual 
disability; delirium; and movement disorder.129 The literature supporting their 
use for such indications is generally limited to anecdotal reports, case series, 
small open-label trials and rarely, controlled trials.129 This does not appear to 
limit the use of antipsychotics for these indications in clinical practice. For 
example, the use of antipsychotics in institutionalized patients with intellectual 
disability is widespread, with reports that approximately 50 percent of patients 
are receiving antipsychotic treatment. 130 Despite this, there are few systematic 
controlled trials in this population and for those trials that have been conducted, 
equivocal findings regarding the efficacy of such treatment. 130  
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1.7.2 Summary 
There are a wide variety of non-psychotic conditions for which the 
second-generation antipsychotics are commonly used in clinical practice. The 
pattern of antipsychotic use in a number of these conditions appears to differ 
from that for schizophrenia, particularly in terms of dose and duration of 
treatment. Moreover, these populations may differ from those with schizophrenia 
or bipolar disorder with respect to demographic variables and the occurrence, and 
treatment of comorbid conditions. This study seeks to examine the occurrence of 
new-onset diabetes associated with the second-generation antipsychotics, and in 
particular the differential rate of new-onset diabetes associated with the various 
agents. As will be discussed in section 8, the incidence of diabetes is known to 
vary according to demographic variables and comorbid clinical conditions. It is 
important to account for these differences, including any possible treatment-
related differences, such as the potential for a dose-related effect, so that the 
association between second-generation antipsychotic use and new-onset diabetes 
can be more accurately described.  
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1.8 Section 6: Metabolic Disturbances Associated with the Second-
Generation Antipsychotic Agents 
The second-generation antipsychotic agents have been associated with a 
variety of metabolic disturbances, the most serious of which is glucose 
dysregulation. This includes the development of new-onset diabetes, diabetic 
ketoacidosis and hyperglycemic nonketonic coma, with infrequent fatalities 
reported. Weight gain is widely reported with a number of the second-generation 
antipsychotic agents. While it is disputed if this is the mechanism by which 
antipsychotics induce diabetes, obesity and weight gain are independently 
associated with an increase in morbidity and mortality. Additional metabolic 
adverse effects described with the second-generation antipsychotics include 
dyslipidemia, pancreatitis, and hyperprolactinemia. In this section, each of these 
metabolic disturbances is reviewed in detail, with particular emphasis on 
antipsychotic-induced glucose dysregulation. 
1.8.1 Antipsychotic Induced Weight Gain 
1.8.1.1 Magnitude of Weight Gain 
A commonly documented adverse effect of the antipsychotic agents is 
weight gain. The extent of this gain appears to vary by drug. Allison et al. 
conducted a meta-analysis of estimated changes in weight, from baseline, after 
ten weeks of treatment with standard doses of second-generation antipsychotic 
agents.131 As illustrated in Table 1.3, the highest weight gain liabilities were 
noted with clozapine and olanzapine, with ziprasidone appearing to be weight 
neutral.131 
 50
Table 1.3: Estimated Weight Change (Kg) from Baseline at 10 Weeks in Patients Treated 
with Standard Doses of Second-Generation Antipsychotic Agents131 
Antipsychotic Estimated Weight Change (Kg) (95% CI) 
Placebo  -0.74 (-1.60-0.12) 
Clozapine 4.45 (3.02-5.88) 
Olanzapine 4.15 (3.82-4.48) 
Quetiapine* 2.18 (1.53-2.83) 
Risperidone 2.10 (1.69-2.51) 
Ziprasidone  0.04 (-0.49-0.57) 
* Effect estimated at six weeks of treatment 
 
The FDA defines a clinically significant weight gain as an increase of seven 
percent or more from baseline body weight, although this definition has not been 
universally adopted. Using this definition, Table 1.4 illustrates the percentage of 
patients experiencing clinically significant weight gain in short-term, 
randomized, placebo controlled trials of four to eight weeks duration.35;37-40 The 
relative ordering of the agents is consistent with the relative ordering reported by 
Allison et al.131 
 
Table 1.4: Percentage of Schizophrenia Patients Experiencing a ≥ 7 Percent Increase in 
Body Weight from Baseline in Randomized Controlled Trials: A Comparison of Second-







Aripiprazole ***   8 3 5 
Olanzapine * 29 3 26 
Quetiapine** 23 6 17 
Risperidone * 18 9 9 
Ziprasidone ** 10 4 6 
Trial Duration: * 6-8 week; ** 4-6 week; *** ‘Short-term.’ 
Net Difference: Percentage experiencing a ≥ 7% increase in body weight on antipsychotic 
therapy minus percentage achieving a ≥ 7% increase in body weight on placebo. 
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Similar findings have been reported in clinical practice. One retrospective 
analysis examined the relative weight gain potential of a number of second-
generation antipsychotics in schizophrenia patients. Clozapine and olanzapine 
were associated with the highest weight gain (mean maximal weight gains of 7.5 
± 6.0Kg and 8.0 ± 6.0Kg, respectively) compared to weight increases of 4.1 ± 
3.4Kg with risperidone, and 3.5 ± 4.1Kg with haloperidol.132 The time course 
over which weight changes occurred is also distinctive. Weight gain associated 
with olanzapine and clozapine tends to plateau after 20 weeks treatment 
compared to ten weeks with risperidone.132 Other studies have suggested that 
weight gain with olanzapine does not plateau until 40 to 52 weeks after 
commencing treatment, with mean weight gains of 12Kg reported for patients 
prescribed between 12.5 to 17.5 milligrams olanzapine daily.133 In a European 
study, weight gain was listed as an adverse effect for 74.5 percent of patients 
treated with olanzapine, compared to 53.4 and 40.0 percent of patients treated 
with risperidone and haloperidol, respectively.134 Using the definition of a seven 
percent increase or greater in body weight from baseline as being clinically 
significant, 45.7 percent of patients treated with olanzapine had clinically 
relevant increases in weight compared to 30.6 treated with risperidone and 22.4 
percent with haloperidol.134 Data for quetiapine were not conclusive due to the 
small sample size and short duration of treatment.134 However, mean weight 
increases of 2 to 5.6Kg have been reported with long-term quetiapine therapy.133 
Ziprasidone, in contrast, appears to be weight neutral, with no, or minimal mean 
weight changes reported over one year of treatment.133 Similarly, aripiprazole 
appears to be weight neutral, with mean weight changes of -1.4Kg and +1Kg 
reported after 26 and 52 weeks of therapy, respectively, in randomized, clinical 
trials.35;135 
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The pattern of weight gain for antipsychotic agents appears to vary 
according to patient baseline weight. When stratified according to baseline body 
mass index (BMI), patients with low BMI (< 23Kg/m2) and normal BMI (23-
27Kg/m2) typically have larger increases in weight compared to those patients 
that are overweight (BMI > 27Kg/m2) when commencing antipsychotic 
therapy.35;37;40 It has been postulated that antipsychotic efficacy may be 
correlated with increases in body weight; however, study findings have been 
inconsistent.133 
1.8.1.2 Mechanism of Antipsychotic-Induced Weight Gain 
The mechanism by which the second-generation antipsychotics induce 
weight gain is uncertain, but is thought to relate to an increased caloric intake.136 
This is possibly mediated thought the antagonistic effects of these agents at 
dopamine, serotonin, histamine and acetylcholine receptors.136 The relative 
weight gain associated with the various second-generation agents does not 
however correlate very well with their relative affinities for these receptors.137 
Proposed mechanisms for weight gain include: antagonism of dopamine D2 and 
serotonin 5-HT2 receptors leading to increased feeding; anticholinergic effects 
causing dry mouth thereby simulating thirst which may be quenched using high 
caloric drinks; and antihistaminic H1 effects leading to sedation and decreased 
activity.137 Additional hypotheses regarding antipsychotic-induced weight gain 
relate to their effects on tumor necrosis factor-alpha (TNF-α) and leptin.136 
Increased serum levels of these cytokines have been documented with clozapine 
and olanzapine treatment.136;138 TNF-α affects glucose, protein and lipid 
metabolism whereas leptin is thought to regulate appetite and weight by acting 
on leptin receptors in the satiety center in the hypothalamus.136;138 Leptin is 
normally synthesized by adipocytes in response to insulin, with increased leptin 
levels also noted in response to insulin resistance and hyperinsulinemia.138 As the 
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second-generation antipsychotics have been noted to cause increased serum 
insulin levels, elevated leptin levels may be secondary to the effect of these 
agents on insulin secretion, although a direct effect on leptin production cannot 
be excluded.138 Weight gain with these agents may alternatively be due to 
insulin, which causes weight gain by a direct effect on adipose tissue and also by 
hypoglycemia-induced increased appetite.138 
1.8.1.3 Weight Gain Associated with Other Psychotropic Medications 
A number of other psychotropic medications have been implicated with 
regard to weight gain. Weight gain associated with antidepressant therapy is 
variable and relates to the dose, duration of therapy and agent use.139 Lithium and 
mood stabilizing agents such as valproic acid and carbamazepine have well 
documented weight gain potential. Lithium-induced weight gain is dose 
dependent and may be considerable with a mean weight gain of 10Kg over six to 
ten years reported, with weight gain occurring in one-third to two-thirds of 
patients.139 Similarly, weight gain is common with valproic acid, with up to 59 
percent of patients gaining between 8 to 14Kg, and is related to the duration of 
treatment.139 Weight gain is a common cause of patient non-adherence and 
premature treatment discontinuation.139 
1.8.1.4 Summary 
In summary, weight gain is commonly reported with the second-
generation antipsychotic agents. The magnitude of weight gain appears to be 
greatest with clozapine and olanzapine, with aripiprazole and ziprasidone 
appearing to be weight neutral. The situation may be further exacerbated for 
patients requiring concomitant treatment with other psychotropic agents known 
to cause weight gain. Obesity and weight gain are important issues for patients 
with serious mental illness. The prevalence of overweight and obesity in patients 
with schizophrenia and bipolar disorder has been documented to exceed that of 
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the general population independent of antipsychotic use.140-144 Aside from the 
immediate implications for treatment adherence, obesity and weight gain are 
associated with an increased risk of morbidity and mortality. The benefits of 
treatment with the various antipsychotic agents must be balanced against their 
relative potential to cause weight gain. 
1.8.2 Glucose Dysregulation 
The use of the second-generation antipsychotics has been associated with 
reports of glucose dysregulation, including new-onset diabetes and cases of acute 
metabolic decompensation including diabetic ketoacidosis. While double-blind, 
randomized, placebo-controlled clinical trials may help to establish a causal 
relationship; these studies are limited in number. Nonetheless, support for 
causality can be derived from the multitude of published reports. These include: 
case reports; adverse drug reaction surveillance reports; clinical studies; 
prevalence studies; case-control studies; and retrospective cohort studies. These 
reports are examined in detail here and the case for a causal association between 
use of second-generation antipsychotics and development of hyperglycemia built. 
1.8.2.1 Case Reports 
In 1994, the first case reports of possible glucose dysregulation secondary 
to the use of second-generation antipsychotics appeared in the literature.145;146 
Since then a total of 99 published cases of glucose dysregulation in adults aged 
18 years or older, have been identified.145-200 (Appendix A) Clozapine (N=30) 
and olanzapine (N=59) were most frequently implicated, with fewer reports 
attributed to risperidone (N=6), quetiapine (N=3)163;169;198 and ziprasidone 
(N=1)188. In 14 cases, patients were receiving dual antipsychotic therapy, nine of 
whom were receiving concomitant first-generation antipsychotic therapy. Other 
combinations used included: clozapine with risperidone (N=1)149; clozapine with 
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ziprasidone (N=1)188; quetiapine with risperidone (N=1);198 and olanzapine with 
quetiapine (N=1).174 One patient was receiving a combination of olanzapine, 
zotepine (a second-generation antipsychotic licensed in Europe and Asia) and a 
first-generation antipsychotic.199 In each case, the authors proposed a single 
causative agent on the basis that the patient had been maintained without adverse 
effect on one agent, that glucose dysregulation commenced subsequent to the 
second agent being added and resolved on its discontinuation. The descriptive 
data on demographic variables, medications, diagnoses and risk factors for 
diabetes are presented in Table 1.5. 
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Table 1.5: Descriptive Analysis of 99 Published Cases of Glucose Dysregulation Associated 
with Second-Generation Antipsychotic Therapy 
Variable N % 1 
Second-Generation Antipsychotic   
   Clozapine 30 2 30.3 
   Olanzapine 59 3 59.6 
   Quetiapine 34 3.0 
   Risperidone 6 6.1 
   Ziprasidone 15 1.0 
Gender   
   Male 74 74.7 
   Female 25 25.3 
Race   
   African American 30 30.3 
   Asian 6 6.1 
   Black 6 5 5.1 
   Caucasian 37 37.4 
   Hispanic 1 1.0 
   Not Reported 20 20.2 
Age Group   
   18-44 58 58.6 
   45-64 36 36.4 
   65-74 2 2.0 
   ≥75 1 1.0 
   Not Reported 2 2.0 
Baseline Body Mass Index Category Kg/m2   
   Normal (18.5-24.9) 8 8.1 
   Overweight (25-29.9) 27 27.3 
   Obese Class I (30-34.9) 18 18.2 
   Obese Class II (35-39.9) 8 8.1 
   Obese Class III (≥ 40) 2 2.0 
   Not Reported 36 36.4 
Family History of Diabetes   
   Yes 28 28.3 
   No 43 43.4 
   Not Reported 28 28.3 
Mental Disorder Diagnosis   
   Schizophrenia 55 55.6 
   Schizoaffective Disorder 17 17.2 
   Bipolar Disorder 8 8.2 
   Psychotic Disorder 4 4.0 
   Depressive Disorder 8 8.1 
   Not Reported 7 7.1 
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Table 1.5: Descriptive Analysis of 99 Published Cases of Glucose Dysregulation Associated 
with Second-Generation Antipsychotic Therapy (continued) 
Variable N % 1 
Event   
   New-Onset Diabetes Mellitus 55 55.6 
   Diabetic Ketoacidosis 27 27.3 
   Decreased Glycemic Control 10 10.1 
   Hyperosmolar, Hyperglycemic, Nonketonic Coma 3 3.0 
   Transient Hyperglycemia 3 3.0 
   Diabetic Coma 1 1.0 
Time to Event (weeks)   
   1-4 25 25.3 
   5-9 14 14.1 
   10-12 14 14.1 
   13-26 16 16.2 
   27-52 12 12.1 
   >52 14 14.1 
   Not reported 4 4.0 
Maximum Blood Glucose Level Reported (mg/dL)   
   <300 22 22.2 
   300-499 27 27.3 
   500-999 31 31.3 
   ≥ 1000 13 13.1 
   Not Reported 6 6.1 
Percentage Hemoglobin A1C (HbA1C) Level at Time of Event   
   6.0-7.0 3 3.0 
   7.1-8.0 0 0.0 
   8.1-12.0 8 8.1 
   12.1-14.0 7 7.1 
   ≥ 14.1 4 4.0 
   Not Reported 77 77.8 
Treatment Associated Weight Gain   
   No Weight Gain 8 8.1 
   < 6.7 Kg 15 15.2 
   6.8 – 13.6 Kg 18 18.2 
   ≥ 13.7 Kg 12 12.1 
   Weight Gain -amount not specified 5 5.1 
   Weight Loss 11 11.1 
   Not Reported 30 30.3 
1. Figures may not sum to 100%, due to rounding. 
2. One patient on dual therapy with risperidone; clozapine presumed to be the causative agent. 
3. Dual therapy (N=1 quetiapine; N=1 ziprasidone); olanzapine presumed to be the causative 
agent. 
4. One patient on dual therapy with risperidone; quetiapine presumed to be the causative agent. 
5. Patient on dual therapy with clozapine; ziprasidone presumed to be the causative agent. 
6. Black race includes: African; Afro-Caribbean and Aboriginal. 
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The majority of cases were men (N=74), with African Americans (N=30) 
and Caucasians (N=37) most frequently affected. Patients ranged in age from 18 
to 79 years, with a mean age of 41.8 years (SD: 10.7). Among the 69 patients for 
whom weight changes were reported, treatment associated weight gain was 
documented in 50 patients, of whom 30 gained in excess of 6.8Kg (15 pounds), 
and 12 gained in excess of 13.7Kg (30 pounds). Data on body mass index 
available for 62 patients indicated that 89 percent of patients were overweight 
(N=27) or obese (N=28) at baseline. Twenty-nine patients (29.3%) had a positive 
family history for diabetes. Three patients had a history of impaired glucose 
tolerance. A mental disorder diagnosis was provided for 92 patients, of whom the 
majority (78%) was being treated for schizophrenia or schizoaffective disorder. 
Mean daily doses of the antipsychotics used were: clozapine 399.0 milligrams 
(SD: 248.7mg); olanzapine 16.9 milligrams (SD: 7.4mg); and risperidone 7.0 
milligrams (SD: 3.0mg). 
Eighty-six patients (86%) were diagnosed with new-onset diabetes. The 
time to onset of diabetes ranged from 4 days to 5 years, with over 50 percent of 
cases occurring within three months, and over two-thirds of cases (69.7%) 
occurring within six months of initiating therapy. Of note, 27 of these patients 
presented directly as diabetic ketoacidosis (DKA) (31%), with one patient 
presenting with a diabetic coma,171 and three with hyperglycemic, hyperosmolar 
nonketonic coma.180;192;200 At the time of diagnosis, 76 percent of patients had a 
blood glucose level greater than 300mg/dL, and 48 percent a value greater than 
500mg/dL. Baseline hemoglobin A1C (HbA1C) levels were infrequently reported 
(N=21) but ranged from 6.1 to 18.6 (mean 12.2, SD: 3.4) in patients without a 
previous diagnosis of diabetes. Ten patients with preexisting diabetes 
experienced loss of glycemic control beginning between four days and 18 weeks 
subsequent to commencing antipsychotic therapy.149;162;179;184;190;200 
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In 50 percent of patients, the hyperglycemia resolved with either 
discontinuation of antipsychotic therapy (N=31); switching to an alternative 
antipsychotic (N=8); dose reduction (N=1); using dietary control (N=2) or 
resolved spontaneously despite continuing antipsychotic therapy (N=5). Five 
patients experienced a recurrence of hyperglycemia when rechallenged with 
therapy.149;154;155;161;191 Forty-one patients maintained on antipsychotic therapy 
(either first or second-generation) required ongoing therapy for their diabetes 
(insulin N=17; oral hypoglycemic therapy N=24). Five patients experienced 
ongoing diabetes mellitus, and one impaired glucose tolerance, despite 
discontinuation of all antipsychotic therapy.148;149;153;171;184;199 Three patients 
died.150;185;192 
In order to identify risk factors that may predispose a patient to the 
development of DKA, a comparison of patients who presented with new onset 
diabetes alone compared to those who presented with DKA was conducted. No 
significant differences were found between the two cohorts based on gender, 
race, being overweight at baseline, having a family history of diabetes, the 
duration of antipsychotic therapy or the HbA1C levels at presentation. (Table 1.6)  
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Table 1.6: Comparison of Patient Characteristics for Patients Treated with Second-
Generation Antipsychotic Agents Developing New Onset Diabetes Mellitus (DM) Only or 
Diabetic Ketoacidosis (DKA) 






t test or χ2 p 
Gender (male) 76.4 77.8 0.02 0.887 
Race (African American) 32.7 48.1 1.83 0.228 
Overweight at baseline (N=53) 91.7 94.1 0.10 0.753 
Treatment associated weight gain (N=56) 72.5 68.8 0.08 0.779 
Family history of diabetes 32.7 29.6 0.08 0.777 
 Mean (SD)   










Maximum blood glucose (mg/dL) (N=75) 441 (253) 789 (297) 5.50 <0.001 
HbA1C at time of event (%) (N=19) 12.2 (3.4) 12.7 (3.3) 0.37 0.711 
Clozapine dose (mg) (N=22) 462 (325) 325 (118) 1.55 0.142 
Olanzapine dose (mg) (N=44) 16.4 (7.7) 17.7 (7.5) 0.52 0.604 
Baseline BMI (Kg/m2) (N=34) 29.6 (5.0) 30.6 (5.6) 0.571 0.572 
Treatment associated weight gain (Kg) 
(N=39) 
11.4 (7.9) 12.0 (9.7) 0.195 0.874 
 
Patients who developed DKA were found to be younger (mean age difference 5.1 
years; t=2.34, df=78, p=0.0218) and as expected, had higher maximum blood 
glucose levels reported (mean difference 351mg/dL; t=5.50; df=74; p<0.001). 
When the dose of the two most frequently implicated agents, clozapine and 
olanzapine was examined, no difference in mean daily dose was found for 
patients who developed diabetes only, compared to those presenting with DKA. 
The markedly different frequency of glucose dysregulation reported for 
the various second-generation antipsychotic agents cannot entirely be explained 
by length of time on the market, or number of prescriptions. Based on published 
case reports, it appears that there is an increased risk of glucose dysregulation for 
patients treated with clozapine or olanzapine compared to risperidone. The 
limited use of quetiapine and ziprasidone during the time frame of these reports 
(1994 to 2004) does not permit comparisons to be made. When compared to a 
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national prevalence of approximately 12 percent, African American patients 
appear to be over-represented in this dataset with a prevalence of 30.3 percent. 
This may reflect a genetic predisposition of this population to diabetes as, of 
note, national figures from 2002 suggest that among diagnosed diabetics, non-
Hispanic blacks were 1.6 times as likely as non-Hispanic whites of a similar age 
to have diabetes.201 At the time of diagnosis, 58.6 percent of patients were aged 
less than 45 years, a trend which is not consistent with national figures for 
patients presenting with diabetes.202 Glucose dysregulation occurred in both the 
presence and absence of weight gain. Nearly 90 percent of patients were 
overweight or obese prior to commencing treatment with a second-generation 
antipsychotic however, suggesting that this may be a potential risk factor for the 
development of glucose dysregulation in these patients. Confusing the issue 
somewhat is the knowledge that in over 50 percent of patients, glucose 
dysregulation resolved quite rapidly on discontinuation or switching of 
antipsychotic therapy and without necessarily being accompanied by any weight 
loss. 
HbA1C, or glycated hemoglobin, is used as a measure of average glycemic 
control over a 120 day period, with each one percent increase in HbA1C 
correlated with a 35mg/dL increase in mean plasma glucose.203 HbA1C levels 
were rarely measured in these patients; however, a mean baseline HbA1C of 12.2 
(SD: 3.4) correlates with a mean plasma glucose level of 352 mg/dL (SD: 119) in 
the preceding 120 days. For patients newly diagnosed with diabetes soon after 
commencing an antipsychotic, a high HbA1C at the time of diagnosis may imply 
that the diabetes pre-dated the use of the antipsychotic. This possibly over-
simplifies the relationship between HbA1C and mean plasma glucose, however, 
as the HbA1C may be viewed as a “weighted” average of plasma glucose 
levels.203 That is, HbA1C levels are influenced most by the plasma glucose levels 
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in the proximate weeks, and can increase rapidly with large changes in plasma 
glucose.203 
Of major concern is the fact that 31 percent of patients presented with 
hyperglycemic crisis (DKA, diabetic coma or hyperosmolar hyperglycemic 
coma). These life-threatening conditions are typically rare in patients with type 2 
diabetes and usually manifest only secondary to a stressor such as an infection.204 
With the exception of younger age, no predictors for the development of DKA 
were found. The preponderance of these cases in this series may reflect a 
publication bias toward serious or unusual cases. Alternatively, it may reflect the 
mechanism by which the second-generation antipsychotics induce glucose 
dysregulation, that is, by both induction of peripheral insulin resistance and the 
impairment of insulin secretion. 
While acknowledging that neither incidence nor prevalence can be 
determined from case reports, there appears to be an association between the use 
of second-generation antipsychotics and the development of new-onset diabetes. 
The findings of this review of published case reports is consistent with an earlier 
report by Jin et al.205 It is unclear from these case reports if the difference in 
report frequency for the five second-generation antipsychotic agents reflects 
differences in their prescribing frequency, or differences in their effect on 
glucose regulation or adiposity or both, or merely a reporting bias. 
1.8.2.2 Case Series and Adverse Event Reports 
As noted, case reports are particularly susceptible to bias as they involve 
a small and highly selective group of patients. To strengthen the case for a causal 
relationship between the use of second-generation antipsychotics and the 
development of glucose dysregulation, case series and adverse event reports may 
be examined. While acknowledging limitations associated with these reports 
(such as the absence of a comparator group, their retrospective nature and the 
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fact that they represent a survival cohort) these reports involve larger numbers of 
patients than case reports and are thereby a useful tool in demarcating the clinical 
problem.206 
Using the Ohio Department of Mental Health database to identify patients 
treated in a state hospital, Wilson et al. conducted a retrospective review of 
patients who were treated with a second-generation antipsychotic and who were 
also evaluated or treated for diabetes mellitus.207 Of a total of 126 patients 
treated, 14 patients had blood glucose levels performed or were evaluated for 
glucose intolerance or diabetes.207 New-onset diabetes was documented in 11 
patients following treatment initiation with clozapine, olanzapine, or quetiapine, 
or addition of risperidone to clozapine.207 Five of these patients developed 
diabetic ketoacidosis, with a median time to onset of 33 days.207 
In a series of reports by Koller et al. summarizing the submissions to the 
voluntary adverse drug reporting scheme (MedWatch), the association between 
the use of clozapine, olanzapine, quetiapine and risperidone and the development 
of hyperglycemia was examined.5-8 A total of 798 cases (clozapine (N=384); 
olanzapine (N=237); quetiapine (N=46); risperidone (N=131)) of new-onset 
hyperglycemia were identified.5-8 These included new-onset diabetes (clozapine 
(N=242); olanzapine (N=188); quetiapine (N=34); and risperidone (N=78)); 
exacerbations of existing diabetes (clozapine (N=54); olanzapine (N=44); 
quetiapine (N=8); risperidone (N=46)); and cases of diabetic ketoacidosis 
(clozapine (N=80); olanzapine (N=80); quetiapine (N=21); risperidone (N=26)).5-
8 A total of 55 fatalities were reported (clozapine (N=25); olanzapine (N=15); 
quetiapine (N=11); risperidone (N=4)).5-8 The majority of cases were reported 
within six months of initiating therapy with the antipsychotic agent (range 60 to 
75%), with approximately 23 percent of cases occurring within one month of 
initiating therapy (range 17 to 31%).5-8 The mean age at presentation was similar 
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for all four drugs (clozapine: 40.0 ± 12.0; olanzapine: 39.8 ± 12.4; quetiapine: 
35.3 ± 16.2; and risperidone 39.8 ± 17.4) with patients presenting with new-onset 
cases consistently younger than those experiencing exacerbation of preexisting-
diabetes.5-8 The majority of cases were men (male: female ratio range: 1.5-2.0).5-8 
No association between time to onset, or severity of hyperglycemia and dose of 
antipsychotic used was established.5-8 The authors suggest a causal relationship 
between the use of these agents and the development of hyperglycemia due to: 
the number of reports; the temporal relationship to treatment initiation; and the 
prompt reversal of hyperglycemia on antipsychotic discontinuation. In addition, 
patients were typically younger than anticipated by national data for patients 
presenting with type 2 diabetes, with a disproportionate number of male cases 
compared to national data.5-8 It is unclear if the disparity in the number of cases 
reported represents a reporting bias, differences in drug utilization rates, or a 
genuine difference in risk between the individual drugs. However, while 
relatively fewer cases of hyperglycemia were reported for risperidone, the 
number of cases for this agent were considerably higher that for the first-
generation antipsychotic, haloperidol (reporting ratio 8.5:1 based on prescription 
sales data).6 Furthermore, for quetiapine, an agent approved by the FDA in 
September 1997, an increase in the number of hyperglycemic events reported 
was documented with increasing patient exposure as measured by the number of 
prescriptions dispensed each year.7 
Similar findings to that of Koller et al. were documented in a study using 
the World Health Organization database for adverse drug reactions.208 In it a 
significant association between the use of clozapine, olanzapine and risperidone 
and the development of glucose intolerance was documented. 208 Furthermore, 
potential risk factors for glucose intolerance in patients taking second-generation 
antipsychotics were identified. Specifically, male gender; an increase in weight; 
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concomitant use of valproic acid, selective serotonin reuptake inhibitors or 
buspirone; or an underlying diabetic condition were significantly associated with 
the development of glucose intolerance.208 
As noted previously, while neither causality nor relative risk can be 
established using case series or adverse event reporting, these reports serve to 
support the hypothesis that the use of second-generation antipsychotics may 
precipitate hyperglycemia, the onset of which may be rapid and severe. 
1.8.2.3 Retrospective Clinical Studies 
To further the hypothesis of a causal relationship between use of the 
second-generation antipsychotics and the development of glucose dysregulation, 
retrospective clinical studies which support the biological plausibility of the 
hypothesis will be presented. Kinon et al. conducted a retrospective chart review 
comparing patients treated with olanzapine (N=573) and haloperidol (N=103) for 
up to three years. Patients treated with olanzapine had significantly higher mean 
weight gains (6.26Kg vs. 0.69Kg, p< .001) and a higher median nonfasting serum 
glucose level (99.1mg/dL vs. 93.7mg/dL, p=0.01).209 In a similar study published 
by Meyer et al. comparing the metabolic outcomes during the first year of 
therapy for patients treated with either olanzapine (N=47) or risperidone (N=47), 
no significant difference was found between the groups in terms of serum 
glucose or weight gained.210 After stratifying the patients according to age, 
olanzapine was associated with significantly greater increases in plasma glucose 
than risperidone (+10.8mg/dL vs. 0.74mg/dL, p=0.03) but a non-significant 
difference in weight gain (+20.4lb vs. +11.9lb, p=0.091) in patients aged less 
than 60 years.210 
Wirshing et al. documented changes in mean plasma glucose levels in 
215 patients treated with antipsychotic therapy (clozapine (N=39); olanzapine 
(N=32); risperidone (N=49); quetiapine (N=13); haloperidol: (N=41) and 
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fluphenazine (N=41)).211 Increases in mean plasma glucose levels from baseline 
were noted for all six agents ranging from a three percent increase for risperidone 
(+4mg/dL) to a 21 percent increase with olanzapine (+22.2mg/dL).211 Increases 
for clozapine, olanzapine and haloperidol were significant at the 0.05 level.211 
New-onset diabetes requiring initiation of a glucose lowering agent was required 
in five patients (13%) treated with clozapine. Two patients with a past history of 
diabetes and stabilized on a glucose-lowering agent required an increased dose to 
control their glucose level following initiation of olanzapine.211 
The impact of clozapine on serum insulin levels was examined in a small 
study which compared patients treated with clozapine (N=13) to those treated 
with first-generation antipsychotics (N=28).212 The clozapine patients had higher 
insulin levels, lower median insulin-like growth factor I (IGF-I) levels, but 
similar BMI and fasting blood glucose levels to patients treated with the first-
generation antipsychotics.212 Serum insulin levels were found to be positively 
correlated with serum clozapine concentrations, but were not correlated to serum 
concentrations of the first-generation antipsychotics. The authors hypothesized 
that clozapine induces peripheral insulin resistance and a secondary increase in 
insulin secretion. Consistent with this, Henderson et al. reported significant 
insulin resistance and impairment of glucose effectiveness with clozapine and 
olanzapine, compared to risperidone in a cross-sectional study of stable, non-
obese schizophrenia patients using a frequently sampled intravenous glucose 
tolerance test.213 Likewise, Newcomer et al. documented significantly abnormal 
glucose tolerance tests in patients treated with clozapine and olanzapine, but not 
risperidone or first-generation antipsychotics.214 
A number of these studies were limited by small sample sizes, absence of 
control groups, and an inability to confirm fasting blood glucose levels. Reports 
conflicted regarding the proposed mechanism by which the second-generation 
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antipsychotics induce glucose dysregulation, specifically regarding the 
development of insulin resistance. Regardless of the mechanism by which the 
second-generation antipsychotic agents induce glucose dysregulation, these 
studies all support the theory that the second-generation antipsychotics, and 
specifically clozapine and olanzapine, induce hyperglycemia and glucose 
dysregulation which may be independent of weight gain or BMI. 
1.8.2.4 Prevalence Studies  
Cross-sectional or prevalence studies provide somewhat more robust 
support of the hypothesis of second-generation antipsychotic induced-glucose 
dysregulation than the information heretofore presented. These studies minimize 
the risk of selection bias, but are still susceptible to the effects of confounding 
and measurement bias.215 Nonetheless, they help to corroborate the hypothesis 
and are, therefore, included here. 
A number of cohort studies have examined the prevalence of diabetes 
among patients taking second-generation antipsychotics.216-223 The prevalence of 
diabetes and impaired glucose tolerance in these studies ranged from nine to 36.6 
percent, and in each instance was significantly greater than that noted in a similar 
age-matched general population. Association between the prevalence of glucose 
dysregulation and the class of antipsychotic (first or second-generation), or 
specific second-generation agent used varied. The results of a number of these 
studies will now be highlighted. 
In a prospective study, Hagg et al. assessed the prevalence of diabetes 
mellitus or impaired glucose tolerance in patients treated with clozapine (N=63) 
compared to patients treated with depot preparations of first-generation 
antipsychotics (N=67).216 Diabetes mellitus or impaired glucose tolerance was 
documented in 22 percent of clozapine patients compared to 10 percent of the 
control group, although the difference was not statistically significant 
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(p=0.06).216 Henderson et al. published a five-year naturalistic study in which 30 
new cases of diabetes were diagnosed among 82 non-diabetic patients (36.6%) 
treated with clozapine.223 The development of diabetes was not found to be 
associated with changes in weight (despite documentation of a significant 
increase in weight equating to 0.5 Kg / month (p < 0.001)), use of valproate or 
total daily dose of clozapine.223 In a similar study, Gupta et al. noted a prevalence 
of diabetes of 17 percent in a cohort of 208 patients (mean age 46 years (SD 
14.5)) with serious mental illness receiving monotherapy with either a first or 
second-generation antipsychotic.221 No difference in the prevalence of diabetes 
was found between the different antipsychotic agents.221 
Using data from the Veterans Health Administration of the Department of 
Veterans Affairs (VA), Sernyak et al. conducted a retrospective review 
comparing the prevalence of diabetes in 38,632 outpatients with schizophrenia 
receiving treatment with first- and second-generation antipsychotics.222 The 
prevalence of diabetes did not differ between patients receiving treatment with 
first- and second-generation antipsychotics with rates of 18.64 percent and 18.84 
percent, respectively.222 After controlling for the effect of age, patients receiving 
second-generation agents were noted to be significantly more likely to have 
diabetes (odds ratio (OR): 1.09; 95% CI: 1.03-1.15, p=0.002) compared to those 
receiving a first-generation antipsychotic.222 Stratifying by age, the effect was 
most pronounced for those aged less than 40 years (OR: 1.63; 95% CI: 1.23-2.16, 
p=0.001) with prevalence rates of 6.2 to 8.7 percent noted.222 In contrast to the 
study by Gupta et al., a significant difference in the prevalence of diabetes was 
found between the different antipsychotic agents.221;223 Specifically, there was a 
significant association between the use of clozapine, olanzapine and quetiapine, 
but not risperidone, and a diagnosis of diabetes.222 
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Clearly prevalence data cannot be used to determine the incidence of 
diabetes associated with the use of second-generation antipsychotics. These data 
merely serve to highlight the high prevalence of diabetes among patients with 
serious mental illness prescribed antipsychotic agents. The prevalence of 
diagnosed diabetes in these studies exceeds that of the general U.S. population at 
approximately 5.4 percent in 2002.224 This may relate to the use of 
antipsychotics, to a more diabetogenic lifestyle, or a genetic predisposition of this 
vulnerable population to the development of diabetes. In any case, the trend is 
worrying given the increased morbidity and mortality associated with diabetes.204 
1.8.2.5 Case-Control and Cohort Studies 
Recent cohort studies have also supported the evidence for a causal 
relationship between the use of second-generation antipsychotics and the 
development of diabetes, by comparing incidence rates in patients exposed to 
second-generation antipsychotics to those exposed either to no therapy, or to 
first-generation antipsychotic agents. These studies will now be reviewed in 
detail. 
1.8.2.5.1 General Findings 
A total of five case-control 3;10;225-227 and 27 retrospective cohort studies 
that used large claims 4;9;228-250 or clinical trials databases251;252 were identified. 
(Appendix B) The majority of the studies were conducted using claims data from 
the U.S., with three studies using claims data from Canada; 230;232;245 four using 
data from the United Kingdom (U.K.); 3;4;10;229 and one using Italian-based 
data.248 Among the U.S. studies, four databases incorporated Medicaid data; 
226;227;239;243 four examined Veterans Affairs databases; 228;231;235;242 eleven used 
databases from private health care plans;9;234;236-238;240;241;244;246;247;250 three used 
data from hospital inpatients or ambulatory care clinics;225;233;249 and two 
conducted post-hoc analyses of data from clinical trials databases.251;252 These 
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studies varied according to the inclusion criteria, that is, inclusion of 
schizophrenia patients only (N=7);3;226;231;242;246;250;251, patients with 
schizophrenia or a mood disorder only (N=2);239;240 any patient with psychosis 
(N=2);236;237 patients with mood disorders (N=1); 238 patients with dementia 
(N=1); 252 patients with a mental health diagnosis (N=2);227;244 and those studies 
that included all patients treated with an antipsychotic agent (N=16).4;9;10;225;228-
230;232-235;241;245;247-249 Studies also varied according to how they classified incident 
diabetes. Classifications included: an International Classification of Diseases, 9th 
Revision (ICD-9) code of 250.xx; a prescription for a diabetic medication (oral 
hypoglycemic agent or insulin); a blood glucose level of 200mg/dL or greater; a 
glycated hemoglobin (HbA1c) greater than nine percent; or a combination 
thereof. Studies also varied according to the level of pre-screening for diabetes in 
determining incident cases, and if they limited, or did not limit enrollees to 
antipsychotic monotherapy. Exclusion periods ranged from zero to twelve 
months prior to study enrollment.  
When compared to untreated patients, variable relative risks (RR) of 
developing diabetes were documented, that is, clozapine (N=5, RR: 0.78-7.44*); 
9;227;234;236;239 olanzapine (N=9, RR: 1.00–5.8*); 3;9;229;234;236-240 risperidone (N=9, 
RR: 0.66-3.7*); 3;9;229;234;236-240 quetiapine (N=5, RR: 0.98-1.9*);9;234;237;239;240 a 
first-generation antipsychotic (N=12, RR: 0.885-4.97); 3;4;9;10;229;232;234;236-240 and 
any second-generation antipsychotic agent (N=7, RR: 0.9-4.7*).4;9;10;229;232;234;239 
Sacchetti et al. also used an untreated population as the comparator group, 
however, the hazard ratios reported were highly inflated by comparison, most 
likely because of the small sample sizes.248 When compared to patients treated 
with first-generation antipsychotic agents, the relative risk of developing diabetes 
again varied according to the study, that is, clozapine (N=8, RR: 1.2-
2.1*);9;226;231;234;242-244;253 olanzapine (N=10, RR: 0.9–4.2*); 
* Statistically significant finding 
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3;9;225;226;231;233;234;241;242;250 quetiapine (N=7, RR: 0.7*-3.3*);9;225;226;231;234;242;244 
risperidone (N=10, RR: 0.7*-4.1*);3;9;225;226;231;233;234;241;242;250 and any second-
generation agent (N=9, RR: 0.9-2.6*).3;4;228;229;234;241;246;247;250 
A number of studies also directly compared the relative propensities of 
the second-generation antipsychotics to induce diabetes. When compared to 
risperidone, patients treated with olanzapine were documented to have an 
increased risk of diabetes in seven studies (RR: 1.2*-4.2*); 229;230;235;236;238;245;247 
and a reduced or comparable risk in five studies (RR: 0.3*-1.0).9;232;241;248;250 
Patients treated with clozapine were documented to have an increased risk of 
diabetes relative to those treated with risperidone (N=2; RR: 1.1-8.4*), 236;247 as 
were those treated with ziprasidone (N=1; RR: 2.64). 247 In contrast, those treated 
with quetiapine were found to have a comparable or lower risk (N=3; RR: 0.7-
1.0) 232;247;248 of diabetes. Relative to olanzapine, no statistical difference in risk 
of diabetes was reported with clozapine (N=2; RR: 0.8-1.5), quetiapine (N=2; 
RR: 1.2 (N=1 reported as ‘non-significant’)) or risperidone (N=3; RR: 0.8-
1.0).246;248;249 Many of these studies documented statistically significant findings; 
however, it is worth remembering that a relative risk of two or greater is 
generally recommended when reporting clinical significance. Of interest, of the 
five studies sponsored by Eli Lilly and Co., the manufacturers of Zyprexa 
(olanzapine), three reported a favorable risk for olanzapine compared to 
risperidone, with two studies reporting an increased, albeit non-statistical 
difference in risk.9;229;241;247;250 Four of the five studies favoring risperidone over 
olanzapine were sponsored and co-authored by Janssen Pharmaceutica, the 
manufacturers of Risperdal (risperidone), 230;235;236;245 with the fifth study 
sponsored by AstraZeneca Pharmaceuticals, the manufacturers of Seroquel 
(quetiapine).245 Studies reporting comparable risk between the two agents did not 
report sponsorship or were independently sponsored.232;246;248;249 
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1.8.2.5.2 Antipsychotic Dose and Diabetes Risk 
The possibility that the association between antipsychotic use and the 
development of diabetes is a dose-related effect is an important issue. This 
association was examined in seven studies.9;226;227;236;238-240 No relationship was 
noted in a study by Wang et al. that compared patients with a mental health 
diagnosis treated with clozapine to those not on antipsychotic treatment.227 
Patients were stratified into four quartiles based on the distribution of mean daily 
dose of clozapine (17-225mg; 226-452mg; 453-572mg; 573-1618mg). Daily 
doses of 300 to 900 milligrams clozapine have been documented to be effective 
in patients with schizophrenia with the mean and median dose reported to be 600 
milligrams daily.36 Using this dose, more than 75 percent of patients received 
low doses of clozapine, possibly due to the older age of patients in the study 
(mean age 61.9-63.6 years).227 This may have limited the power to detect a dose-
response relationship. In addition, there were a limited number of control patients 
relative to cases in this study, thereby limiting the power to detect an effect 
should one have existed.  
A possible dose-response with quetiapine, but not olanzapine or 
risperidone, was documented in a study by Buse et al. This study did not limit 
enrollment to patients with a specific mental health diagnosis, rather it included 
any patient treated with antipsychotic therapy. The mean daily doses of 
antipsychotic reported were low, for example: olanzapine 5.1 milligrams (SD: 
4.2mg); quetiapine 79.9 milligrams (SD: 96.7mg); and risperidone 1.2 milligrams 
(SD: 1mg); a limitation acknowledged by the authors, but refuted by them 
because of the wide range of doses used.9 
Lambert et al. reported a possible dose-response with olanzapine in a 
case-control study of schizophrenia patients enrolled in California Medicaid. 
Patients in this study were stratified as receiving low, medium or high dose 
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second-generation antipsychotic therapy based on the empirical distribution of 
the actual doses and expert clinical knowledge. By this system, 20 percent of 
patients received low-dose therapy (clozapine <300mg; olanzapine < 7.5mg; 
quetiapine <250mg; risperidone <3mg), 43.2 percent received medium-dose 
therapy (clozapine 300-600mg; olanzapine 7.5-12.5mg; quetiapine 250-500mg; 
risperidone 3-6mg) and 36.8 percent high-dose therapy (clozapine >600mg; 
olanzapine > 12.5mg; quetiapine >500mg; risperidone >6mg). Using any dose of 
a first-generation antipsychotic as a comparator, no association between 
antipsychotic dose and risk of diabetes was noted for any agent using 12 or 24-
week exposure windows. Using a 52-week exposure window, a possible dose-
response was seen for olanzapine where the odds ratio for low-dose therapy 
(OR=1.25; 95% CI: 1.00-1.57) was significantly smaller than for medium 
(OR=1.84; 95% CI: 1.53-2.22) or high doses (OR=1.87; 95% CI: 1.58-2.21).226 
Gianfrancesco et al. have published widely in this area. In a study 
published in 2002 involving psychosis patients enrolled in a private managed 
health care plan, a possible dose-response was seen for patients treated with 
olanzapine, but not clozapine or risperidone. Compared to untreated patients, the 
odds of diabetes increased significantly (OR: 1.22, p<0.002) for each 2.6 
milligram increase in olanzapine dose.236 Similarly, in a study published in 2003 
of patients with mood disorders enrolled in private managed care plans, a 
significant dose-response was noted for olanzapine (2.6mg dose-increment OR: 
1.34, p<0.0001), but not risperidone or first-generation antipsychotics.238 The 
mean daily dose of olanzapine used in these studies were 9.4 milligrams (SD: 
5.2mg) and 8.9 milligrams (SD: 4.7mg), respectively. 236;238 Mean daily 
risperidone doses were 2.3 milligrams (SD: 1.8) and 2.1 milligrams (SD: 1.7mg), 
respectively. 236;238 In a study published in 2006 involving Ohio Medicaid 
enrollees with a diagnosis of schizophrenia, bipolar disorder or major depressive 
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disorder, the authors reported a ten to 25 percent increase in risk of diabetes with 
medium or high-dose therapy compared to low-dose or no antipsychotic 
treatment.239 Also published in 2006 by the same authors was a study examining 
antipsychotic-related diabetes in patients with schizophrenia, bipolar disorder or 
major depressive disorder enrolled in a managed care plan. The authors noted 
that the odds of new-onset diabetes generally increased with increasing dose of 
the second-generation antipsychotics. Compared to untreated patients, the odds 
of developing diabetes was significantly increased for patients receiving high 
dose risperidone, medium or high dose olanzapine, and any dose of a first-
generation antipsychotic. 240  
In summary, there are conflicting reports of an association between 
antipsychotic dose and the emergence of new-onset diabetes. A possible 
relationship has been reported for clozapine, olanzapine, and quetiapine with 
medium or high-dose therapy compared to no, or low-dose antipsychotic therapy. 
The discrepancies between the results may result from differences in dose 
calculations and stratifications, as well as differences in treatment duration, 
indication and dose, and the comparator chosen. 
1.8.2.5.3 Treatment Indication and Diabetes Risk 
Treatment indication is an important consideration in any study 
examining the relationship between antipsychotic use and new-onset diabetes. As 
will be discussed in detail in section 1.9.7.4, a diagnosis of schizophrenia and 
affective disorders may predispose patients to diabetes. Failure to control for 
treatment indication could, therefore, confound the study findings. 
The published studies in this area have varied in their inclusion criteria, 
that is, inclusion of schizophrenia patients only (N=7); 3;226;231;242;246;250;251, 
patients with schizophrenia or a mood disorder only (N=1); 239 any patient with 
psychosis (N=3);236;237;240 patients with mood disorders (N=1); 238 patients with 
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dementia (N=1); 252 patients with a mental health diagnosis (N=2);227;244 and 
those studies that included all patients treated with an antipsychotic agent 
(N=16).4;9;10;225;228-230;232-235;241;245;247-249 A number of studies (N=16) have 
attempted to control for differences in treatment indication by including the type 
of mental health diagnosis (either primary diagnosis or comorbid diagnosis) as a 
covariate in the logistic regression analyses. 
The majority of studies reported a non-significant relationship between 
diagnosis and occurrence of new-onset diabetes. 10;228;230;233;236;238-240;242;246;250 
Miller et al. reported that mental health diagnoses associated with an increased 
risk of diabetes were schizophrenia (HR: 1.622, 95% CI: 1.233-2.132), bipolar 
disorder (HR: 1.355; 95%CI: 1.073-1.711), and post-traumatic stress disorder 
(HR: 1.691; 95%CI: 1.019-2.806) whereas ‘other psychosis’ was associated with 
a decreased risk (HR: 0.602; 95%CI: 0.389-0.931) of diabetes. In contrast, in a 
model comparing patients treated with a first or second-generation antipsychotic, 
Lee et al. noted a decreased risk of diabetes for patients with bipolar disorder 
(p=0.425).241 Gianfrancesco et al. noted a significant decrease in risk of new-
onset diabetes associated with a diagnosis of bipolar disorder (OR: 0.444, 
p=0.0100) or major depression (OR: 0.449, p=0.0015), but not schizophrenia 
(OR: 0.445, p=0.1076) compared to other psychoses. 237 In direct contrast, 
Gianfrancesco et al. reported in a later publication that a diagnosis of 
schizophrenia significantly increased the risk of new-onset diabetes. When 
compared to patients with major depression and bipolar disorder, patients with 
schizophrenia had an increased risk of new-onset diabetes of 40 to 100 percent 
and 30 to 70 percent, respectively. 240 
Discrepancies in study findings may relate to differences in the 
demographics of the different study populations and also to differences in the 
dose of antipsychotic used for the different treatment indications. As will be 
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discussed in detail in section 1.10.3, antipsychotic doses used in clinical practice 
vary according to the indication, age and ethnicity of the population. Failure to 
control for these variables may confound a possible relationship between 
antipsychotic use and risk of new-onset diabetes.  
1.8.2.5.4 Summary  
The conflicting results reported from these case-control and cohort 
studies may be a result of differences in the classification of incident or new-
onset diabetes used, the definition of exposure to an antipsychotic, the number 
and type of covariates used, together with differences in study duration and study 
population. The majority of reports appear to indicate an increase in the risk of 
developing diabetes in patients treated with second-generation antipsychotic 
agents compared to those treated with first-generation antipsychotics, and to 
those receiving no treatment. There appears to be an increased risk associated 
with the use of clozapine and olanzapine relative to risperidone. There is limited 
data on the use of quetiapine and ziprasidone, with the result that most studies are 
not adequately powered to detect an effect, should one exist. 
1.8.2.6 Prospective Trials 
Well-conducted prospective double-blind, randomized controlled-trials 
with adequate numbers of patients are considered the best-evidence for a cause 
and effect relationship. The most notable trial in this area is the Clinical 
Antipsychotic Trials of Intervention Effectiveness (CATIE) study, a randomized 
active-control trial sponsored by the National Institute of Mental Health (NIMH), 
published in September 2005. The outcomes from this trial will be discussed in 
depth. While not necessarily meeting all of the above criteria, the remaining 
published prospective studies reviewed in this section still serve to provide strong 
evidence of a causal relationship between use of the second-generation 
antipsychotics and occurrence of glucose dysregulation. 
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1.8.2.6.1 The CATIE Study 
The CATIE study was a double-blind, active-control clinical trial, 
conducted between January 2001 and December 2004, and was designed to 
compare the effectiveness of the first- and second-generation antipsychotic 
agents. Secondary goals of this study included a comparison of treatment-related 
adverse effects and specifically, differences in metabolic effects. The trial was 
limited patients with a diagnosis of schizophrenia aged between 18 and 65 years, 
who did not have a history of treatment-resistance or serious adverse-effects to 
the proposed treatment. A total of 1,493 patients were randomized to receive 
olanzapine (N=330), quetiapine (N=329), risperidone (N=333), ziprasidone 
(N=183), or the first-generation antipsychotic, perphenazine (N=257) for up to 
the 18 months.254 
The majority of patients were male (74%), white (60%), with a mean age 
of 40.6 years (SD: 11.1). Prevalent diagnoses at baseline included: diabetes 
(11%); hyperlipidemia (14%) and hypertension (20%). The mean modal 
treatment doses were as follows: olanzapine 20.1 milligrams; quetiapine 543.4 
milligrams; risperidone 3.9 milligrams; ziprasidone 112.8 milligrams; and 
perphenazine 20.8 milligrams. Consistent with trends in schizophrenia 
management, treatment was frequently discontinued with only 26 percent of 
patients continuing treatment for the planned 18 months. Overall, patients were 
least likely to discontinue olanzapine (64%) and most likely to discontinue 
quetiapine (82%) treatment. Similarly the time to treatment discontinuation was 
longest for olanzapine (median: 9.2 months), compared to quetiapine (4.6 
months), risperidone (4.8 months), ziprasidone (3.5 months) and perphenazine 
(5.6 months). Of note, the agents differed in their rate of discontinuation because 
of treatment intolerance (p=0.04) even after adjusting for duration of exposure. 
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Olanzapine was the most likely (18%), and risperidone the least likely (10%) to 
be discontinued owing to intolerability.254 
The agents differed significantly regarding treatment-related weight gain 
and changes in measures of glucose and lipid metabolism. Regardless of 
treatment duration, olanzapine was associated with the greatest increase in 
weight (p<0.001), glycosylated hemoglobin (HbA1C) (p<0.001), cholesterol 
(p<0.001) and triglycerides (p<0.001) from baseline and was significantly more 
likely to be discontinued because of these effects (p<0.001) than the other agents. 
The magnitude of the changes in these parameters is noteworthy. Exposure-
adjusted increases in mean blood glucose ranged from 2.9mg/dL (standard error 
(SE) 3.4) for ziprasidone to 13.7mg/dL (SE: 2.5) for olanzapine (p=0.59). 
Exposure-adjusted changes in glycated hemoglobin (HbA1c) from baseline 
ranged from 0.04 percent (SE: 0.08) for risperidone to 0.40 percent (SE: 0.07) for 
olanzapine (p=0.01).254 Changes of this scale are only likely to be problematic in 
a patient with a high baseline risk of diabetes, wherein a relatively small change 
in blood glucose could shift the patient from pre-diabetes (fasting blood glucose: 
≥100mg/dL) to diabetes (fasting blood glucose ≥126mg/dL). 
1.8.2.6.2 Glucose Control and Insulin Resistance 
Several prospective trials have examined the association between use of 
second-generation antipsychotics and disruptions in glucose-insulin homeostasis. 
These open-label studies and short-term randomized controlled trials will now be 
briefly reviewed. 
In a placebo-controlled, open-label study examining olanzapine-induced 
glucose dysregulation, patients treated with olanzapine experienced significant 
increases in fasting insulin concentrations and a rapid and significant increase in 
insulin-resistance. This was not associated with a change in beta cell function; 
thereby refuting the hypothesis that olanzapine acts as a direct toxin on beta cells 
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and suggesting instead that the mechanism of glucose dysregulation is due to an 
induction of peripheral insulin resistance. Compared to controls, patients treated 
with olanzapine (medication period 8.1 weeks) experienced significant increases 
in fasting plasma glucose levels (0.7mmol/L versus 0 mmol/L; p=0.009), weight 
(3.3Kg versus 0.6Kg; p=0.005) and as noted, fasting insulin concentrations 
(4.5µU/mL versus -1.0 µU/mL; p=0.008) from baseline. While the association 
between weight gain and insulin resistance is well documented, the authors noted 
that this is unlikely to be the sole factor contributing to the development of 
insulin resistance due to the absence of weight gain in some patients and the 
rapid onset of insulin resistance.255 
In a randomized, controlled, double-blind, six-week trial (N=269) 
comparing olanzapine and ziprasidone, differences in the metabolic profile of the 
two agents were noted. Compared to ziprasidone, olanzapine was associated with 
greater increases in weight (p<0.001), body mass index (p<0.0005), fasting 
serum insulin (p=0.051), C-peptide (p=0.07), and homeostasis model assessment 
insulin resistance logarithm (HOMA-IR[log]) (p=0.08) – a measure which takes 
into account both fasting insulin and fasting glucose measures. Neither agent was 
noted to significantly affect fasting serum glucose levels with a median increase 
from baseline of one milligram per deciliter noted for both agents.256 
In contrast to the study by Simpson et al.,256 Howes et al. documented 
significant glucose dysregulation in 11 of 20 schizophrenia patients treated with 
clozapine that was not associated with significant changes in insulin levels or 
insulin resistance levels.257 Changes in glucose control were also independent of 
changes in BMI. The authors hypothesized that glucose dysregulation may be 
secondary to a direct effect of clozapine in reducing neuronal glucose uptake 
leading to compensatory increases in glucose levels rather than to clozapine-
induced peripheral insulin resistance.257 Moreover, these authors subsequently 
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found that changes in glucose control do not appear to be related to changes in 
growth hormone, insulin-like growth factor-1 or insulin-like growth factor 
binding protein-1 (all important glucoregulatory factors). This supports a theory 
of a possible direct effect of antipsychotics on central glucose regulation.258 
Kingsbury et al. examined the short-term effects of ziprasidone on BMI 
and serum glucose levels in a six-week, open-label, multi-center study (N=37).259 
No significant change in BMI or serum glucose level was documented. Similar 
findings were documented in a fourteen-week, prospective, randomized trial 
where clozapine, olanzapine and haloperidol, but not risperidone, were 
associated with significant increases in plasma glucose levels in 101 patients with 
schizophrenia or schizoaffective disorder.260 
1.8.2.6.2 Summary 
While there are some inconsistencies in the findings of the various 
prospective studies, there nonetheless appears to be a trend towards greater 
dysregulation of glucose and insulin homeostasis with clozapine and olanzapine 
than with quetiapine, risperidone and ziprasidone. Given the magnitude of the 
changes noted, treatment with these agents could precipitate diabetes (fasting 
plasma glucose (FPG) ≥ 126mg/dL) in a patient with pre-diabetes (100mg/dL ≤ 
FPG < 126mg/dL) or cause a non-diabetic (FPG < 100mg/dL) to be re-classified 
as having pre-diabetes. 
1.8.2.6 Proposed Mechanisms of Second-Generation Antipsychotic-Induced 
Glucose Dysregulation 
There are several hypotheses as to how the second-generation 
antipsychotics may induce glucose dysregulation. These include a direct toxic 
effect on pancreatic islet cell receptors, via inhibition of dopamine D2 receptors 
or by antagonism of serotonin 5-HT1A and 5-HT2A/C receptors.153 Alternatively, 
insulin resistance may arise due to treatment-induced weight gain and increases 
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in abdominal adiposity.153 Weight gain is unlikely to be the sole etiology of 
glucose dysregulation induced by the second-generation antipsychotics, as 
glucose dysregulation has occurred in both the presence153;165;171 and absence of 
weight gain.190;193 Likewise, glucose dysregulation has been noted to resolve, in 
some cases rapidly, on discontinuation of the antipsychotic but without 
necessarily an accompanying decrease in weight. Irrespective of the mechanism 
by which glucose dysregulation occurs, it may have significant short and long-
term sequelae for a patient’s health. 
1.8.2.7 Conclusion 
While glucose dysregulation appears to be associated with the use of 
second-generation antipsychotic agents, it is difficult to ascertain the extent of 
the problem. Many of the studies conducted were limited by small sample sizes, 
absence of control groups, and an inability to confirm fasting blood glucose 
levels. Cohort studies have used varied eligibility criteria and methodologies with 
the result that the findings are conflicting. Although there are a limited number of 
well-controlled trials, these typically have restricted their inclusion criteria to 
patients with schizophrenia or schizoaffective disorder, and may have limited 
generalizability to other patients prescribed antipsychotic therapy. Of the second-
generation agents, clozapine and olanzapine have been most frequently 
implicated to date; however, there is insufficient evidence to determine the 
differential propensities of the various agents. Glucose dysregulation appears to 
be independent of dose although the evidence is conflicting. 
Four of the six second-generation antipsychotic agents (clozapine, 
olanzapine, risperidone and quetiapine) have been associated with weight gain. 
The research studies describing weight gain are poorly controlled and often 
reported idiosyncratically. Weight gain is hypothesized as a mechanism by which 
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these agents may induce glucose dysregulation; however, studies suggest it may 
be just one of the factors contributing to glucose dysregulation. 
The correlation between second-generation antipsychotics and diabetes 
remains unknown. The increasing numbers of reports of glucose dysregulation 
following treatment initiation with the second-generation antipsychotic agents 
prompts concerns of a possible casual relationship. A diagnosis of diabetes does 
not preclude the use of second-generation antipsychotics nor does it 
contraindicate their continued use in patients who develop glucose dysregulation 
while on treatment. Judicious management of these patients using standard 
dietary interventions, weight control and the use of glucose regulating agents 
may be applied. In February 2004, an expert consensus panel issued 
recommendations on the management of patients treated with antipsychotics with 
regard to obesity and diabetes.261 Baseline screening and routine follow-up 
monitoring is advocated for all patients commencing antipsychotic therapy. 
(Table 1.7) 
 
Table 1.7: Protocol for Monitoring Patients on Second-Generation Antipsychotic 
Therapy*261 






Quarterly Annually Every  
5 years 
Personal        
 /Family History 
X     X  
Weight (BMI) X X X X X   
Waist  
 Circumference 
X     X  
Blood Pressure X   X  X  
Fasting Blood  
 Glucose 
X   X  X  
Fasting Lipid  
 Profile 
X   X   X 




They recommend that patients with a high risk of diabetes at baseline, those who 
gain five percent or more weight from baseline at any time during therapy, or 
those who develop worsening glycemia while on antipsychotic therapy be treated 
with aripiprazole or ziprasidone, two agents, which to date have not been 
associated with significant weight gain or diabetes.261 In making these 
recommendations, the expert panel acknowledged the deficits in the currently 
available research.261 They emphasize the need for well controlled trials with 
adequate sample sizes to determine if there is a difference in the potential of the 
various second-generation agents to cause diabetes, so that the risks and benefits 
associated with the use of these agents can be more accurately assessed. 
1.8.3 Dyslipidemia 
Hyperlipidemia was first reported with clozapine in the mid-1990s.262;263 
Subsequently, similar reports documented new-onset hypertriglyceridemia in 
patients treated with olanzapine.264;265 Using pooled data from short-term, 
placebo-controlled clinical trial reports, olanzapine, quetiapine and ziprasidone 
have ‘infrequently’ been associated with hypercholesterolemia, and additionally, 
in the case of quetiapine, hypertriglyceridemia.37;38;40 In post-marketing 
evaluation reports, risperidone was ‘rarely’ associated with 
hypertriglyceridemia.39 In contrast, aripiprazole was not associated with 
medically important changes in triglyceride, HDL, LDL or total cholesterol 
levels in a 26-week placebo-controlled trial.35 
The findings from case studies and controlled trials have been confirmed 
in retrospective clinical studies. Using a nested case-control design, Koro et al. 
assessed the effect of olanzapine and risperidone on the risk of hyperlipidemia in 
patients with schizophrenia.266 Treatment with olanzapine was associated with a 
significant increase in odds of developing hyperlipidemia compared to those 
receiving no antipsychotic therapy, and to those treated with a first-generation 
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antipsychotic agent, with odds ratios of 4.65 (95% CI: 2.44-8.85) and 3.36 (1.77-
6.39) reported, respectively.266 In contrast, regardless of comparator group, no 
such increase was noted with risperidone.266 Similarly, in a retrospective chart 
review assessing metabolic changes in patients during their first year of 
treatment, olanzapine was associated with significantly greater increases in 
serum triglycerides compared to risperidone (+88.2mg/dL versus +29.7mg/dL; 
p=0.042).210 Fasting total cholesterol levels were also noted to increase 
significantly in the olanzapine cohort (+23.6mg/dL; p<0.001), but not in those 
treated with risperidone (+7.2mg/dL; p=0.131).210 Increases in lipid parameters 
were not correlated with changes in weight parameters.210 
In a prospective 12-week review, olanzapine-associated increases in 
serum triglycerides (mean +60mg/dL; p<0.04) were found to correlate (r = 0.484; 
p<0.02) with changes in body weight.264 No increase in fasting blood cholesterol 
levels was noted.264 Of concern is the magnitude of increase in triglyceride 
levels, with an average increase of 37 percent from baseline fasting levels noted. 
Likewise, in a 12-month study, average increases of 48 percent and 35 percent in 
fasting triglyceride levels, respectively, were noted for male and female patients 
treated with clozapine.267 When compared to ziprasidone, significant increases in 
total cholesterol (p<0.0001), triglycerides (p<0.003), low-density lipoprotein 
(LDL) cholesterol (p<0.0004) and apoprotein B levels (p<0.0001) were noted 
with olanzapine in a double-blind, randomized controlled trial including patients 
with schizophrenia or schizoaffective disorder. Triglyceride levels increased by a 
median of 28mg/dL in the olanzapine group compared to a median decrease of 
2mg/dL in the ziprasidone group in this brief six-week trial. High density 
lipoprotein (HDL) cholesterol levels were not significantly altered in this 
study.256 
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The exact mechanism by which the second-generation antipsychotics 
influence triglyceride metabolism is unknown. One hypothesis relates to the 
structural similarity between the agents associated with the most significant 
effects on triglyceride levels, clozapine, olanzapine and quetiapine, and the 
phenothiazine derivatives which have also been associated with this adverse 
effect.268 While weight gain is a risk factor for dyslipidemia, it has not been 
found to be consistently correlated with the development of dyslipidemia with 
the second-generation antipsychotics.210;264 
Dyslipidemia is of particular importance in patients with serious mental 
illness as many possess multiple risk factors for the development of coronary 
artery disease including high prevalence rates of smoking. Elevation of 
triglyceride levels to 400 to 500mg/dL or higher increases the risk of acute 
pancreatitis, a condition associated with increased morbidity and mortality. 
Dyslipidemia, specifically low HDL cholesterol or high triglyceride levels, is 
also an independent risk factor for diabetes. 
1.8.4 Pancreatitis 
In a report published by Koller et al., it was suggested that the second-
generation antipsychotic agents clozapine, olanzapine and risperidone may 
precipitate pancreatitis.269 This is an inflammatory condition of the pancreas 
which may be acute or chronic.270 Acute pancreatitis is characterized by 
increased serum concentrations of pancreatic amylase and lipase and severe 
upper abdominal pain.270 The authors examined adverse drug reports for these 
agents in addition to haloperidol. Despite historically more extensive usage of 
haloperidol, it was associated with fewer reported cases of pancreatitis. Forty 
percent, 33 percent, 16 percent and 12 percent of the reports were for patients 
treated with clozapine, olanzapine, risperidone and haloperidol, respectively.269 
Furthermore, 50 percent of patients who developed pancreatitis on haloperidol 
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were receiving concomitant therapy with a second-generation antipsychotic.269 
Pancreatitis was accompanied by hyperglycemia, and less frequently acidosis, in 
some of the patients treated with the second-generation antipsychotics.269 In an 
acute attack of pancreatitis, the occurrence of hyperglycemia in excess of 
200mg/dL is a marker for clinically severe disease.270 In patients with chronic 
pancreatitis, diabetes typically occurs as a late manifestation of the disease 
associated with calcification of the pancreas.270 
Pancreatitis is a significant adverse effect in that it associated with 
considerable morbidity and/or mortality.270 Fifteen to twenty percent of patients 
die as a result of complications from an acute attack, with mortality rates of 50 
percent reported within 20 to 25 years of diagnosis in patients with chronic 
pancreatitis.270 In particular, patients who are obese, or older, appear to be at 
increased risk of complications.269;270 In the series reported by Koller et al., 22 of 
the 192 patients died as a result of pancreatitis, with death most frequently 
associated with clozapine (N=7) and olanzapine (N=9).269 Pancreatitis did not 
appear to be a dose-related effect, and the majority of cases occurred within six 
months of initiating antipsychotic treatment.269 Of note, alcohol abuse is a risk 
factor for pancreatitis and accounts for approximately 40 percent of acute, and 70 
percent of chronic cases in the U.S..270 Substance abuse is commonly reported 
among patients with schizophrenia and bipolar disorder, although it was not 
present as a comorbidity in at least 20 percent of the patients in this case 
series.22;27;58;269 Valproic acid has additionally been associated with pancreatitis, 
and was prescribed as a concomitant medication in 23 percent of the 
patients.269;270 The authors postulated, however, that as many of these patients 
had been treated long-term with valproate without undue effect, that 
antipsychotic therapy had acted to augment the toxicity of valproate to the 
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pancreas.269 In post-marketing surveillance reports, aripiprazole and quetiapine 
have rarely been associated with pancreatitis.35;38 
In summary, although rarely reported with the first-generation 
antipsychotics, there appears to be a surfeit of reports of pancreatitis associated 
with the second-generation agents, with clozapine and olanzapine most 
frequently implicated. This has implications for the selection of antipsychotic 
therapy in the seriously mentally ill, given the prevalence of additional risk 
factors for pancreatitis or its consequences, including alcohol abuse, valproate 
use and obesity in this cohort. 
1.8.5 Hyperprolactinemia 
Elevated plasma prolactin levels are commonly reported in patients 
treated with first-generation antipsychotic agents.24;271;272 It results from the 
action of these agents as dopamine D2 receptor antagonists in the 
tuberinfundibular tract, leading to increased prolactin secretion from the anterior 
pituitary.272 The second-generation agents also inhibit dopamine D2 receptors but 
to a lesser extent that the first-generation agents.24 Among the second-generation 
antipsychotics, prolactin levels may be elevated by variable amounts. 
Risperidone is reported to cause significant increases in prolactin, with increases 
in serum prolactin levels of 45 to 80 ng/mL reported (normal prolactin levels: 
<20ng/mL).272 This effect appears to be dose-related, to affect both men and 
women, and to persist with chronic treatment.272 In contrast, aripiprazole, 
clozapine and ziprasidone have not been associated with sustained increases in 
prolactin levels.35;36;271;272 The effect of olanzapine is equivocal with both 
decreases and moderate increases (1-4ng/mL) in prolactin levels reported.272 Any 
hyperprolactinemia appears to be dose-related, occurring when doses of 
olanzapine in excess of 20 milligrams a day are used.271;272 Switching patients to 
olanzapine has also been reported to reverse risperidone-induced 
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hyperprolactinemia without loss of treatment efficacy.271 Differences in the effect 
of antipsychotic agents on prolactin levels is thought to relate to their differential 
binding properties on pituitary D2 receptors.273 With the exception of risperidone 
and high dose olanzapine, the threshold for achieving sustained D2 inhibition in 
the pituitary, and consequent increased prolactin levels, is not reached by the 
second-generation antipsychotic agents.272;273 
Adverse systemic effects associated with increased prolactin levels 
include: galactorrhea, amenorrhea, infertility, acne and hirsutism in women; 
gynecomastia in men; and sexual dysfunction in both men and women.24;271;272 It 
has been proposed that women experiencing amenorrhea may be at increased risk 
of osteoporosis and cardiovascular events secondary to estrogen deficiency274. 
Hyperprolactinemia has also been associated with an increased risk of breast 
cancer, although the evidence is conflicting.271 
Symptomatic patients may be managed by switching to an agent not 
associated with an appreciable sustained effect on prolactin, such as aripiprazole, 
olanzapine, quetiapine or ziprasidone.24 Alternatively, dopamine receptor agents 
such as bromocriptine or amantadine may be used, although there is a possible 
risk of psychotic relapse.24 Combined oral contraceptives may be effective in 
women with secondary amenorrhea to reverse the symptoms associated with 
estrogen deficiency, including loss of bone mineral density and osteoporosis.271 
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1.9 Section 7: Diabetes Mellitus 
A brief overview of the epidemiology, etiology and classification of 
diabetes mellitus will be provided in this section. The proposed association 
between diabetes mellitus and mental health illnesses will be discussed. In 
addition, some of the difficulties associated with diagnosing and managing a 
chronic health condition, such as diabetes, in patients with serious mental health 
disorders will be highlighted. 
1.9.1 Epidemiology 
Diabetes Mellitus (hereafter referred to as diabetes) has been described as 
a “group of metabolic diseases characterized by hyperglycemia resulting from 
defects in insulin secretion, insulin action, or both.”224 The estimated prevalence 
of diabetes among U.S. adults was 8.7 percent (13 million) in 2002, of whom 
approximately 29 percent (five million) were undiagnosed.224 As illustrated in 
Figure 1.1 (page 91), there has been a worrying increase in the prevalence of 
diabetes in the U.S. in recent years, from an age-adjusted prevalence of 
diagnosed diabetes of 5.3 percent in 1997, to 6.4 percent in 2003.202 The 
prevalence of diabetes is dependent on age, with adults aged 65 years or older 
twice as likely to have diabetes compared to those aged between 45 and 54 years. 
(Figure 1.2, page 92) 202 The prevalence of diabetes also varies by race/ethnicity. 
In 2002, among adults with diagnosed diabetes, non-Hispanic blacks were 1.6 
times as likely, and Hispanic/Latino Americans 1.5 times as likely to have 
diabetes as non-Hispanic white adults of similar age. (Figure 1.3, page 93) 201 
Among the largest Hispanic-Latino subgroup, Mexican Americans, the risk of 
diabetes is two-fold that of non-Hispanic whites of a similar age.201 The highest 
prevalence of diagnosed diabetes occurs in American Indians and Alaskan 
Natives; of those receiving care from the Indian Health Service, 14.9 percent 
 90
have been diagnosed with diabetes.201 The prevalence of pre-diabetes has been 
estimated to be 12 million (22.6%) among overweight adults aged 45 to 74 years. 
This number is expected to be considerably higher if expanded to all overweight 
individuals aged 18 years or older.275. In 2000, over 1 million adults aged 18 to 
79 years in the U.S. were newly diagnosed with diabetes. Consistent with 
prevalence trends, the incidence of diabetes is dependent on age and 
race/ethnicity with a higher incidence noted among older adults, blacks and 
Hispanics. The highest incidence of diagnosed diabetes is among men aged 65-
79 years with 14.5 cases per 1,000 population reported in 2001, compared to 9.4 
cases per 1,000 population among women of the same age.276 
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* Data from January –September 2003202 
1 Prevalence of diabetes is based on self-reported of ever being diagnosed with diabetes. 













Figure 1.1: Age-Adjusted Prevalence1 of Diagnosed Diabetes 




* Data from January –September 2003202 



















Figure 1.2: Prevalence of Diagnosed Diabetes Among Adults Aged 18 







* Data for Hispanic/Latino American, Non-Hispanic black and Non-Hispanic white populations extrapolated from 
National Health Interview Survey (1999-2001) and National Health and Nutrition Examination Survey (1999-2000) 
data. 
** Data for American Indians /Alaska Natives based on prevalence of diabetes in those receiving outpatient care in 2002 





Figure 1.3: Age-Adjusted Prevalence of Diagnosed Diabetes Among 



























The majority of patients are categorized as either Type 1 diabetics (5 to 
10%) or Type 2 diabetics (90 to 95%).204 Type 1 diabetes is caused by an 
absolute deficiency of insulin secretion and Type 2 diabetes by a combination of 
insulin resistance and inadequate insulin secretory response.204 Impaired glucose 
tolerance (IGT) and impaired fasting glucose (IFG) are terms used to describe 
patients with plasma glucose levels that are elevated, but not diagnostic of 
diabetes.204 These patients are, however, classified as ‘pre-diabetes,’ as 
approximately 25 percent of these patients proceed to frank diabetes.204 In 2003, 
the criteria for the diagnosis of diabetes was revised, and are shown below in 
Table 1.8.277 As illustrated, there are three possible ways in which diabetes may 
be diagnosed, each of which requires confirmatory testing on a subsequent day in 
the absence of unequivocal hyperglycemia.277 
 
Table 1.8: Criteria for the Diagnosis of Diabetes Mellitus204 
1. Symptoms of diabetes plus casual plasma glucose concentration ≥ 200mg/dL. Casual is 
defined as any time of day without regard to time since last meal. The classic symptoms of 
diabetes include polyuria; polydypsia; and unexplained weight loss. 
 
Or 
2. FPG ≥ 126mg/dL. Fasting is defined as no caloric intake for at least 8 hours. 
 
Or 
3. 2-hour postload glucose ≥ 200mg/dL during an OGTT. The test should be performed as 
described by WHO, using a glucose load containing the equivalent of 75g anhydrous glucose 
dissolved in water. 
 
In the absence of unequivocal hyperglycemia, these criteria should be confirmed by repeat 
testing on a different day. The third measure is not recommended for routine, clinical use. 
 
Abbreviations: FPG – Fasting plasma glucose; OGTT – Oral glucose tolerance test; 
WHO – World Health Organization 
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It has been recommended that a fasting plasma glucose of ≥ 126mg/dL be 
used to determine the incidence and prevalence of diabetes in epidemiological 
studies.277 Although this is expected to lead to an underestimation of the 
prevalence of diabetes compared to the use of oral glucose tolerance tests, it 
serves to standardize and facilitate such studies.277  
The ICD-9 codes specified for diabetes mellitus are 250.1x to 250.99 with 
category designation based on the presence, or absence, of complications such as 
ketoacidosis, renal, ophthalmic or neurological complications. Further specifiers 
are used to categorize patients according to diabetes type (1 or 2), and to the level 
of control attained (uncontrolled or not stated to be uncontrolled). A new ICD-9 
code of 277.7 has recently been assigned to the insulin resistance syndrome so 
that patients with this condition can be captured in future studies. 
1.9.3 Etiology 
Type 1 diabetes is an immune-mediated condition resulting in destruction 
of β-cells and absolute insulin deficiency.204 Patients typically present as children 
or young adults. Risk factors include autoimmune, genetic and environmental 
factors.204 Type 2 diabetes is a condition associated with insulin resistance and 
relative insulin deficiency.204 It is viewed as a polygenic disorder that develops 
when a diabetogenic lifestyle is superimposed on a genetic susceptibility. The 
majority of patients are obese or have increased abdominal adiposity.204 As noted 
previously, the prevalence of diabetes increases with age and is more prevalent in 
certain racial or ethnic groups.224 In addition to a BMI of 25Kg/m2 or more, other 
risk factors for diabetes include: a family history of diabetes; sedentary lifestyle; 
hypertension; dyslipidemia (low HDL cholesterol and/or a high triglyceride 
level); a history of gestational diabetes or delivery of a baby weighing over nine 
pounds; polycystic ovarian disease; a history of vascular disease; and previously 
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identified IFG or IGT.224 The impact of weight gain / obesity and drug-induced 
diabetes will now be discussed in detail. 
1.9.3.1 Obesity 
The prevalence of obesity among U.S. adults aged 20 years and older has 
increased considerably in recent years from 19.4 percent in 1997 to 23.9 percent 
in 2002.202 When adjusted for age, 64.5 percent of U.S. adults aged 20 years or 
older were classified as overweight (BMI 25-29.9 Kg/m2) and 30.5 percent as 
obese (BMI ≥ 30Kg/m2), in 1999-2000.278 Excess weight is associated with an 
increased incidence of type 2 diabetes in addition to other diseases such as 
cardiovascular disease, dyslipidemia, hypertension, stroke, and certain cancers.279 
Specifically, the prevalence of type 2 diabetes increases with increasing severity 
of overweight and obesity.279 For example, the prevalence increases from 2.03 
percent for normal weight males (BMI 18.9 – 24.9Kg/m2) to 10.65 percent for 
males with a BMI ≥ 40Kg/m2 and from 2.38 percent for normal weight females 
to 19.89 percent for females with a BMI ≥ 40Kg/m2.279 Among patients with 
diabetes, the age-adjusted prevalence of obesity was 46.1 percent in 2002, with 
80.5 percent reported to be overweight.280 In data from the Nurse’s Health study, 
Colditz et al. reported that women who gained more than 5-7.9Kg as adults were 
1.9 times (95% CI: 1.5 to 2.3) more likely to develop type 2 diabetes than women 
who maintained a stable weight (those who gained, or lost less than 5Kg) from 
the age of 18 years.281 Larger increases in weight were associated with even 
higher relative risks: women who gained 8.0 – 10.9Kg and those who gained in 
excess of 20Kg were 2.7 (95% CI: 2.1 to 3.3) and 12.3 (95% CI: 10.9 to 13.8) 
times more likely to develop type 2 diabetes , respectively.281. When translated 
into a change in BMI, weight gain of one BMI unit has been found to correspond 
to a 2.9 to 4.3 increase in relative risk of diabetes in women, and an increase in 
risk of 1.0 to 1.5 in men.281;282 
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1.9.3.2 Drug-Induced Diabetes Mellitus 
Certain drugs have been implicated in the development of diabetes. These 
drugs typically impair insulin secretion thereby precipitating diabetes in 
susceptible individuals.204 The effect of most of these drugs is reversible on their 
discontinuation.204 The most commonly implicated agents include: 
glucocorticoids; thyroid hormones; thiazides; diazoxide; phenytoin; β-adrenergic 
agonists; nicotinic acid; and α-interferon.204 More recently, an association 
between the use of second-generation antipsychotics and diabetes has been 
proposed.20 This has been assumed to be a class-related effect, although 
aripiprazole and ziprasidone have yet to be directly implicated.20 Compared to 
patients not receiving antipsychotic therapy, a relative risk of developing diabetes 
of 3.3 to 4.7 has been described for the second-generation agents.4;10 The 
proposed link between the second-generation antipsychotics and diabetes is 
described more fully in section 6. 
1.9.4 Course 
Although type 1 diabetics can present at any age, patients typically 
present before the age of 20 years.283 Patients are typically thin and prone to 
developing diabetic ketoacidosis.283 Type 2 diabetes, previously known as adult 
onset diabetes is the most prevalent form of diabetes, and is increasingly being 
reported in younger patients including children and adolescents.204 As stated, the 
risk of type 2 diabetes increases with age, obesity and lack of physical activity, 
particularly in patients with a genetic susceptibility. The symptoms and 
consequences of chronic hyperglycemia and hyperglycemic crises will be 





1.9.4.1 Chronic hyperglycemia 
In general, patients with type 1 diabetes present at a young age with acute 
symptoms of diabetes and markedly elevated blood glucose levels.284 In contrast, 
patients with type 2 diabetes frequently go unrecognized for long periods, as 
progression to overt hyperglycemia may be slow, and patients are typically 
asymptomatic at the early stages.204 Patients may often present without 
symptoms although others present with advanced complications, particularly 
retinopathy and neuropathy.283 Symptoms of marked hyperglycemia include: 
polyuria; polydypsia; polyphagia; fatigue; blurred vision; and weight loss.204 
Chronic hyperglycemia may lead to increased susceptibility to certain infections 
and growth impairment in children.204 The morbidity and mortality associated 
with diabetes primarily relate to chronic complications of the disease including: 
retinopathy; nephropathy; neuropathy; and an increased incidence of 
atherosclerotic cardiovascular, peripheral vascular and cerebrovascular 
disease.204 Seventy-five percent of deaths in patients with diabetes are due to 
cardiovascular events.283 The morbidity and mortality associated with diabetes is 
increased further in patients who smoke due to an increased risk of microvascular 
and macrovascular complications.285 In particular, smoking impacts on the 
development and progression of microalbuminuria, renal impairment and 
neuropathy.285 There are equivocal findings on the association between 
retinopathy and smoking.285 Diabetics who smoke have an increased risk of 
coronary artery disease and stroke and have increased mortality from coronary 
heart disease.285 
1.9.4.2 Hyperglycemic Crises 
Acutely, diabetic patients may experience hyperglycemia with 
ketoacidosis or hyperosmolar hyperglycemia, both of which may be life-
threatening.286 The annual incidence of diabetic ketoacidosis is estimated to be 
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between 4.6 and 8 cases per 1,000 diabetic patients.286 Hyperosmolar 
hyperglycemia syndrome is rare, and accounts for less than one percent of 
primary diabetic hospital admissions in epidemiological studies.286 Type 1 
diabetics are prone to developing diabetic ketoacidosis with 20 to 40 percent of 
these patients actually initially presenting in diabetic ketoacidosis.283 Typically, 
both conditions are rare in patients with type 2 diabetes and only occur secondary 
to a stressor such as infection.204 Both diabetic ketoacidosis and hyperosmolar 
hyperglycemic syndrome are difficult to manage and are associated with 
mortality rates of approximately five percent and 15 percent, respectively, in 
experienced settings.286 Patients present with a history of polyuria, polydypsia, 
polyphagia, weight loss, gastrointestinal symptoms such as abdominal pain 
(diabetic ketoacidosis only), vomiting, dehydration, and weakness.286 Changes in 
mental status occur and are progressive with increasing severity of the condition, 
varying from mental alertness to profound lethargy to stupor or coma in patients 
with severe diabetic ketoacidosis or hyperosmolar hyperglycemic syndrome.286 
The second-generation antipsychotics clozapine, risperidone and 
olanzapine, have been associated with a worrying number of cases of diabetic 
ketoacidosis and hyperosmolar hyperglycemic syndrome.5;8;269 As noted, the 
presence of diabetic ketoacidosis with type 2 diabetes is rare and typically a 
marker of severe metabolic stress. Ketosis usually occurs only in those with 
impaired insulin secretion due to decreased pancreatic insulin reserve. This may 
reflect difficulties in the early recognition of symptoms of hyperglycemia in 
patients with serious mental health disorders, or inappropriate classification of 
these symptoms as medication-related adverse effects. Alternatively, it may be 
due to an increased prevalence of other risk factors for hyperglycemic crises in 
patients taking these agents. Alcohol abuse is a known precipitating factor for 
hyperglycemic crises in diabetes.286 It is also a common comorbidity in patients 
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with schizophrenia and bipolar disorder with estimated prevalence rates of 33.7 
percent and 43 percent reported, respectively.52;56 In addition, pancreatitis, 
another known precipitant of hyperglycemic crises, has been described with the 
second-generation antipsychotic agents.269 
1.9.5 Diabetes Management 
Patients with type 1 diabetes have absolute insulin deficiency; therefore, 
requiring insulin therapy, by injection or pump, to survive. Patients with type 2 
diabetes may initially be managed by lifestyle modifications alone, using a 
combination of weight loss, diet control and exercise. Most patients progress to 
requiring additional treatment with oral hypoglycemic agents and/or insulin 
sensitizing agents or insulin therapy. In 2000, among patients diagnosed with 
diabetes, 10 million patients (84.8%) reported using a diabetic medication, an 
increase from 8.4 million (82.3% ) in 1997.287 The majority of patients reported 
using oral medication only (53.3%). (Figure 1.4, page 101) 287 As illustrated in 
Table 1.9 (page 102), there are five classes of oral medication licensed by the 
FDA in addition to insulin for the management of type 2 diabetes: α-glucosidase 
inhibitors; biguanides; meglitinides; sulfonylureas and thiazolidinediones. These 
agents are disease specific for type 2 diabetes, with limited off-label use of these 
agents for other conditions. However, new treatment indications and expanded 
used of these agents is likely in the future for other conditions including diabetes 






* Estimates based on number of patients reporting a diagnosis of diabetes and use or non-use of medications for diabetes 
in the NHIS and NCHS. Given the high estimated prevalence of patients with undiagnosed diabetes, the chart 




















Figure 1.4: Percentage of Adults Diagnosed with Diabetes Reporting Use 






Table 1.9: Oral Agents Licensed for the Management of Type 2 Diabetes Mellitus 288;289 
Agent Recommended 







   
   Acarbose 75-300 50, 100 T2DM prevention; Dumping 
Syndrome; T1DM 
   Miglitol 75-300 25, 50, 100  
Thiazolidinediones 
(PPAR-γ Agonists) 
   
   Pioglitazone 15-45 15, 30, 45 Insulin resistance1; PCOS; Non-
alcoholic steatohepatitis; Werner 
syndrome 
   Rosiglitazone 2-8 2, 4, 8 Insulin resistance2; HAART-
associated lipodystrophy; Non-
alcoholic steatohepatitis; 
Metabolic syndrome; PCOS; ISR3 
Sulfonylureas    
   Acetohexamide 250-1,500 250,500  
   Chlorpropamide 100-500 100, 250 Neurogenic diabetes insipidus 
   Glimepiride 1-8 1, 2, 4  
   Glipizide 2.5-40 5, 10,  
   Glipizide-GITS (XL) 2.5-20 2.5, 5, 10 Reverse diabetic 
microangiopathy; Gestational DM 
   Glyburide 2.5-20 1.25, 2.5, 5  
   Glyburide micronized 3-12 1.5, 3, 4.5, 6  
   Tolbutamide 250-3,000 500  
   Tolazamide 100-1,000 100, 250, 500  
Biguanide    
   Metformin 500-2,550 500, 850, 
1,000, 500 
XR 
Prophylaxis gestational DM; 
Obesity; T2DM prevention; 
PCOS 
Meglitinide    
   Repaglinide 0.5-16 0.5, 1, 2  
   Nateglinide 180-360 60, 120  
Abbreviations: mg – milligrams; T1DM – Type 1 Diabetes Mellitus; T2DM – Type 2 Diabetes 
Mellitus; DM – Diabetes Mellitus; HAART – Highly Active Antiretroviral Therapy; PCOS – 
Polycystic Ovarian Syndrome; ISR – In-stent restenosis 
1. Decrease insulin resistance in stroke patients 
2. Decrease insulin resistance in non-diabetic patients receiving continuous ambulatory peritoneal 
dialysis (CAPD) 
3. Decrease in-stent restenosis in type 2 diabetic patients with coronary artery disease 
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1.9.6 Economic Burden 
As evident, there are high rates of morbidity and mortality associated 
with diabetes. In fact, diabetes is the fifth leading cause of death by disease in the 
U.S.290 In 2002, it was estimated that diabetes cost the U.S. $132 billion between 
direct medical costs and lost productivity.290 This represents a staggering increase 
of 35 percent from the previous estimate of $98 billion five years previously in 
1997.290 These estimates exclude undiagnosed cases of diabetes and, therefore, 
underestimate the true burden of the disease.290 If current prevalence rates remain 
unchanged, this estimate is expected to further increase to $156 billion by 2010 
given an aging population in the U.S. that is increasing in size and racial and 
ethnic diversity.290 However, the future cost of diabetes is likely to be higher 
given the trend toward an increasing prevalence of diabetes and obesity in the 
U.S. 
1.9.7 Diabetes and Mental Disorders 
While the second-generation antipsychotics have been associated with the 
development of diabetes, this picture is confused by a number of factors. 
Specifically, do people with serious mental illness have a genetic predisposition 
to developing diabetes? Additionally, are patients with serious mental illness 
more likely to have a diabetogenic lifestyle compared to the general population? 
Complicating the picture further are the difficulties associated with the diagnosis 
and recognition of symptoms of diabetes in patients with serious mental illness. 
These issues will be discussed in brief here. 
1.9.7.1 Predisposition of Patients with Schizophrenia and Affective 
Disorders to Diabetes 
Limited data suggest that impaired glucose tolerance and diabetes 
mellitus are more common among patients with schizophrenia and bipolar 
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disorder than the general population.13;14 While antipsychotic agents have been 
implicated in the development of diabetes, additional mechanisms have been 
proposed. These are supported by retrospective case studies, most of which 
predate the widespread availability of the second-generation antipsychotic 
agents. Additional support is provided by a clinical study that examined insulin 
resistance and diabetes in treatment naïve patients. A brief description of these 
studies is provided. 
1.9.7.1.1 Diabetes Prevalence Studies 
An Italian retrospective study of 95 chronic schizophrenic patients aged 
45 to 74 years reported an overall prevalence of diabetes of 15.8 percent (95% 
CI: 12.1 to 19.5%) which was substantially higher than the reported prevalence 
of known diabetes of 2.1 to 3.2 percent in the general adult population.14 In all 
cases, onset of psychosis preceded the onset of diabetes by many years.14 In a 
U.S. study by the Schizophrenia Patients Outcomes Research Team (PORT), 
comorbidity from schizophrenia and diabetes mellitus was examined using a 
combination of three databases: patients enrolled in Medicaid (N=6,066); 
patients enrolled in Medicare (N=14,182); and patients from a field research 
study (N=719).13 The prevalence of diabetes in these schizophrenia patients was 
contrasted with the prevalence of diabetes in the general population, as measured 
by National Health Interview Survey (NHIS) data. The Medicaid and Medicare 
data were from 1991, when only clozapine was licensed for use, and, therefore, 
predates the widespread use of the second-generation antipsychotics. In the field 
study sample, (mean age 43 years), the rates of lifetime and current diabetes were 
14.9 percent and 10.8 percent, respectively. These rates were consistent with the 
Medicaid and Medicare database results and far exceeded that of an age-matched 
general U.S. population (Table 1.10). 13 
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Table 1.10: Prevalence of Diabetes in Schizophrenia Patients Enrolled in Medicaid and 
Medicare Compared to the General U.S. population (NHIS Cohort), Stratified According to 
Age 13 
Sample 18 to 44 years 
(%) 
45 to 64 years 
(%) 
Medicaid a 6.7 18.8 
Medicare a 5.6 14.9 
NHIS b  1.2 6.3 
a 1991 Data 
b 1994 National Health Interview Survey 
 
The study concluded that rates of diagnosed diabetes in schizophrenia patients 
exceeded those reported by the general population well before the widespread 
availability and use of the second-generation antipsychotic agents. Furthermore, 
consistent with trends observed in the general population, there was an increased 
prevalence of diabetes in women, African-Americans and older patients.13 In 
contrast, Regenold et al. noted a similar prevalence of diabetes in a group of 
hospitalized patients with schizophrenia to that expected in the general U.S. 
population, after adjusting for age, race and gender.15 They did however note 
significantly higher rates of diabetes among schizoaffective and bipolar patients 
compared to national norms.15 Similar trends have been noted for other patients 
with serious mental illness. In a small retrospective study published in 1986, 
McKee et al. noted a 2.5 fold increased prevalence of diabetes among 
hospitalized patients with psychosis compared to the general population.291 
Cassidy et al. documented a three-fold increase in the prevalence of diabetes in 
hospitalized patients with bipolar disorder compared to the general U.S. 
population, after adjusting for age, weight and race.18 One hypothesis for an 
association between diabetes and bipolar disorder relates to plasma cortisol 
levels. Glucocorticoid therapy has been noted to induce diabetes, similarly, 
hypercortisolemia has been reported during both manic and depressive 
episodes.18 
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1.9.7.1.2 Clinical Studies 
Support for the hypothesis that schizophrenia and diabetes are associated 
independent of medication use, comes from a small prospective study that 
compared drug-naïve, first episode schizophrenia patients to a healthy control 
group. After matching for smoking and physical exercise habits, higher levels of 
glucose, insulin and cortisol were documented in the schizophrenia group, 
together with an increased likelihood of diabetes and impaired glucose 
tolerance.17 These findings were refuted by a small prospective study that 
contrasted schizophrenia patients that were currently antipsychotic-free with 
first-episode, antipsychotic-naïve patients. The authors concluded that while 
previous antipsychotic treatment may induce significant changes in insulin 
resistance, insulin secretion and leptin levels, these changes were not due to pre-
existing impairment of glucose metabolism.292 
1.9.7.1.3 Genetic Studies 
Support for a genetic predisposition comes from a study that documented 
an inflated prevalence of diabetes of 18 to 30 percent in family members of 
patients with schizophrenia.293 This rate is similar to that reported by known 
diabetic patients, and greatly exceeds that of the general U.S. population. 
1.9.7.2 Depression 
The prevalence of comorbid depression has been noted to be increased 
approximately two-fold in patients with diabetes compared to the general 
population.294 Whether this indicates a susceptibility of patients with depression 
to develop diabetes, or rather reactive depression occurring secondary to a 
chronic illness is not known. Typically it is proposed that patients with chronic 
illnesses such as diabetes are at an increased risk of reactive depression. Limited 
data suggest however that patients with moderate or severe depression have an 
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approximately two-fold increased risk of developing diabetes after controlling for 
established risk factors for diabetes.295-297 Apart from the depressive disorders 
major depressive disorder and bipolar disorder, comorbid depression is common 
in schizophrenia and in patients with dementia-related psychological and 
behavioral problems.52;100 Regardless of the causal direction, patients with 
comorbid depression and diabetes have decreased glycemic control and increased 
risk of diabetic complications.298 This may contribute to the higher mortality 
rates seen in patients with comorbid mental illness and diabetes than the general 
diabetic population. Alternatively, the excess morbidity and mortality may reflect 
complications of an additional disease burden or poorer quality medical care in a 
vulnerable population. Any factor that increases the risk of diabetes in patients 
with mental disorders could further compound an existing problem. 
1.9.7.3 Dementia 
There is conflicting evidence as to the association between diabetes and 
both vascular dementia and Alzheimer’s disease. Patients with diabetes have a 
high risk of underlying vascular disease, which may increase the risk of vascular 
dementia in these patients.299 Similarly, hypertension and hyperlipidemia, both 
known risk factors for diabetes are also risk factors for the development of 
vascular dementia.299 The relationship between diabetes and Alzheimer’s disease 
is less straightforward. Researchers have hypothesized that hyperinsulinemia is 
associated with the development of islet amyloid and brain amyloid in patients 
with diabetes and Alzheimer’s disease, respectively.300 In a longitudinal analysis 
of 683 people without dementia for 5.4 years, hyperinsulinemia was associated 
with an increased risk of incidence Alzheimer’s disease (HR: 2.1, 95% CI: 1.5-
2.9) and of all dementia (1.9, 95% CI: 1.4-2.7).300 The association between 
Alzheimer’s disease and hyperinsulinemia remained unchanged even after 
adjusting for diabetes and known risk factors for diabetes such as BMI, age, 
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hypertension and LDL levels.300 Equivocal results have been reported however 
regarding the prevalence of Alzheimer’s disease in patients with diabetes, with 
reports of increased,301-303 decreased304;305 and comparable prevalence rates to the 
general population.306 A number of factors have been suggested to confound this 
relationship including the association of lower BMI and lower exercise rates in 
patients with Alzheimer’s disease, which would increase, or decrease the risk of 
diabetes, respectively.299 Alternatively, the premature mortality associated with 
diabetes could obscure subsequent development of Alzheimer’s disease.299 
Another possible confounding factor is the possibility that patients with 
Alzheimer’s disease may be less aggressively investigated and treated that those 
other disease states, including vascular dementia. In a large population-based 
study by Gambassi et al., the patterns of drug use among nursing home residents 
with Alzheimer’s disease and vascular dementia were examined.307 Overall, the 
researchers found a lower prevalence rate of comorbid diseases in those with 
Alzheimer’s disease.307 After adjusting for demographic variables and the 
prevalence of comorbid disease, patients with Alzheimer’s disease had a lower 
drug use than those with vascular dementia.307 Of note, the prevalence of 
diabetes was significantly higher among those with vascular disease that those 
with Alzheimer’s disease (15% vs. 12%, p<0.01), although there was no 
difference in the use of anti-diabetic medications, after adjusting for demographic 
variables and the prevalence of comorbid disease.307 
Unlike schizophrenia and bipolar disorder which appear to predispose 
patients to the development of diabetes, it is the presence of diabetes or 
hyperinsulinemia which may increase the risk of dementia. Regardless, patients 
with dementia may be systematically different to the general population with 
regard to insulin levels and occurrence of diabetes. The use of antipsychotic 
agents in patients with possible pre-existing diabetes may serve to exacerbate the 
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situation and to increase the apparent relative risk of hyperglycemia associated 
with these agents. 
1.9.7.4 Diabetogenic Lifestyles 
As described earlier, diabetes occurs when a diabetogenic lifestyle is 
superimposed on a diathesis for diabetes. It has been estimated that 25 percent of 
insulin resistance is secondary to obesity, 25 percent secondary to inactivity and 
the remaining 50 percent due to genetic factors.308 While the burden of weight 
gain secondary to neuroleptic and psychotropic agents is well documented, 
patients with serious mental illness have also been documented to engage in 
fewer health-promoting behaviors than their counterparts in the general 
population.309;310 In particular, they are documented to smoke more, exercise less 
frequently, and eat less healthy diets.309;310 These lifestyle differences further 
increase the risk of overweight and obesity in this community and, therefore, of 
conditions including diabetes. A brief overview of these factors will now be 
provided. 
1.9.7.4.1 Body Mass Index and Weight in Schizophrenia Patients 
The association between body mass index (BMI) and weight gain in the 
pathogenesis of type 2 diabetes was outlined in section 6. Patients with 
schizophrenia tend to have higher levels of obesity than their counterparts in the 
general population as evidenced by a study by Homel et al., who conducted a 
retrospective study examining the change in BMI for individuals with, and 
without schizophrenia between 1987 and 1996.140 During this period, the use of 
the second-generation antipsychotic agents increased. The mean BMI for patients 
was found to be significantly higher for individuals with schizophrenia compared 
to those without (28.0Kg/m2 vs. 25.7Kg/m2). After stratifying according to 
gender, a significant difference was noted only for females (30.3Kg/m2 vs. 
25.5Kg/m2).140 Whereas between 1987 and 1996 a trend towards an increase in 
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BMI was noted for the non-schizophrenia population, there was little evidence of 
such a trend among patients with schizophrenia. When the data were stratified 
according to age and gender, a significant increase (p<0.001) in BMI was noted 
for young females (18 to 30 years) with schizophrenia relative to their non-
schizophrenia counterparts, causing a much higher obesity rate in this group in 
recent years.140 In a similar study in Germany, Theisen et al., documented 
prevalence rates of obesity among men and women with schizophrenia that were 
5.1 and 6.4 times, respectively, that of the German reference population.141 This 
trend was exacerbated among patients chronically treated with the second-
generation antipsychotic agents with obesity prevalence rates of 64 percent for 
clozapine, 56 percent for other second-generation agents (amisulpiride, 
olanzapine, risperidone), 30 percent for first-generation antipsychotics and 28 
percent for patients that were currently antipsychotic free. 
Using data from the National Health Interview Survey (NHIS) and the 
National Health and Nutrition Interview Examination Survey III (NHANES III), 
Allison et al. documented similar trends.142 In the NHIS dataset the mean BMI 
for men with schizophrenia was not noted to differ from that for men without 
schizophrenia (26.14 vs. 25.63 Kg/m2), whereas women with schizophrenia were 
significantly more likely to be overweight than women without schizophrenia 
(27.36 vs. 24.50 Kg/m2, p<0.001).142 This trend was consistent across each age 
decile. The datasets revealed comparable levels of overweight and obesity in men 
and women with schizophrenia to that seen in the general population.142 As with 
schizophrenia, patients with bipolar disorder have been documented to have a 
higher prevalence of obesity compared to the general population, with prevalence 
rates of 32 to 35 percent reported, compared to 18 to 22 percent.143;311 The risk of 
being overweight or obese appears to increase with increasing disease severity, 
and in turn, obesity has been correlated with a poorer outcome in bipolar I 
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disorder.311 In particular, increased levels of central adiposity, which is 
associated with insulin resistance syndrome, has been documented in bipolar 
patients when compared to the general population.144 Among bipolar patients, 
those treated with antipsychotic agents were found to be more obese and to have 
greater levels of central adiposity than patients who were not.144 
The age-adjusted prevalence rates of overweight and obesity in the 
general U.S. adult population are 64.5 and 30.5 percent, respectively.278 Patients 
with schizophrenia appear to be at least as overweight, if not more overweight, 
than the general U.S. population, and, therefore, have the same, if not a higher 
risk of developing type 2 diabetes based on weight patterns alone. 
1.9.7.4.2 Diet and Physical Activity Level 
In community studies, patients with schizophrenia have been documented 
to exercise less than their non-schizophrenia counterparts.309;310 This contrast is 
heightened among those patients that are hospitalized or institutionalized, with 
typically lower levels of physical activity documented in these patients. Exercise 
is important in the pathogenesis of diabetes, not just because of its role in 
preventing overweight and obesity, but also in terms of its ability to lower levels 
of insulin resistance.308 The sedative and fatiguing effects of the antipsychotic 
agents may contribute to reduced physical activity in patients with serious mental 
illness.31 Compared to the general population, patients with schizophrenia have 
also been noted to have diets that are lower in fiber and higher in saturated 
fats.309;310 This increases their risk of certain disease states such as dyslipidemia, 
cardiovascular disease, breast, colorectal and prostate cancers contributing 
perhaps to the excess mortality in this cohort.279 
1.9.7.4.3 Cigarette Smoking 
An additional mechanism for the comorbidity of schizophrenia and 
diabetes may relate to cigarette smoking. The prevalence of smoking and 
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nicotine dependence among patients with schizophrenia is much higher than in 
the general population at 50 to 90 percent compared to approximately 25 
percent.312 It has been suggested in two prospective longitudinal studies that 
among people who smoke 25 cigarettes a day or more, there is an increased risk 
of developing diabetes compared to non-smokers after controlling for multiple 
risk factors, with relative risks of 1.42 (95% CI: 1.18-1.72) and 1.94 (95% CI: 
1.25-3.03) reported for women and men, respectively.285 
In summary, diabetes appears to be more prevalent among patients with 
schizophrenia and affective disorders than in the general population. While the 
second-generation antipsychotics have been implicated in this process, additional 
mechanisms for the comorbidity appear to exist. These include: a genetic 
predisposition; a diabetogenic lifestyle; as a result of other psychotropic 
medications or due to biochemical disturbances including hypercortisolemia.18 
1.9.7.5 Diagnosis and Management of Diabetes in Patients with Serious 
Mental Illness 
The diagnosis of diabetes in patients with comorbid mental disorders may 
be complicated by a number of factors. Symptoms of hyperglycemia may be 
mistakenly attributed to adverse effects of the antipsychotic medications and 
other central nervous system agents. For example: polyphagia; polydypsia (dry 
mouth with a number of medications, or psychogenic polydypsia which has an 
estimated prevalence of 11 to 42 percent in severe schizophrenia52); blurred 
vision and fatigue.31 Despite frequent contact with primary care and specialist 
mental health services, patients with mental disorders do not necessarily receive 
appropriate primary health care.313;314 They are less likely to spontaneously 
report physical symptoms than the general population, and despite high rates of 
physical illness, these frequently can go undetected.313;315 This situation has been 
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exacerbated by fragmentation of healthcare services and difficulties in obtaining 
or maintaining healthcare coverage.316;317 
1.9.8 Summary 
Diabetes is a prevalent condition in the U.S. It is a leading cause of 
morbidity and mortality and is associated with a substantial healthcare and 
economic burden. While the second-generation antipsychotic agents are 
documented to be effective in the management of psychotic and affective 
disorders and allowing that their use should be encouraged in the absence of 
superior alternatives, it has been proposed that these agents may precipitate 
diabetes and are associated with an increased risk of life-threatening 
hyperglycemic crises. In consideration of the possible predisposition of patients 
with certain mental disorders to develop diabetes, and the excess morbidity and 
mortality associated with diabetes in this population, it is imperative to assess the 
differential risk of diabetes associated with the second-generation antipsychotics 
so that the safest agent may be used in this vulnerable population.  
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1.10 Section 8: Use of Second-Generation Antipsychotic Agents 
The use of second-generation antipsychotics has increased dramatically in 
the last decade. As a class, antipsychotic agents accounted for over $4 billion in 
retail drug expenditures in the U.S. in 2001, ranking thirteenth in expenditures by 
drug category.318 Ninety-one percent of this expenditure was accounted for by 
just four agents: clozapine; olanzapine; risperidone and ziprasidone; with 
olanzapine and risperidone accounting for 45 percent ($1.8 billion) and 30 
percent ($1.2 billion) of the expenditure, respectively.318 Contributing 
significantly to this expenditure is the high cost of these agents. Whereas the 
national average price for a prescription was $49.84 in 2001, the average price 
for an antipsychotic prescription was $167.61, with olanzapine the most 
expensive agent at an average prescription price of $284.07.318 Antipsychotic 
expenditures account for a considerable percentage of Medicaid prescription 
expenditure, with psychiatric drugs accounting for approximately 20 percent of 
the overall cost, 55 percent of which is attributable to antipsychotic drugs.319.  
In the following section, patterns of use of the antipsychotic agents are 
examined. Of particular interest is the impact of treatment indication on the use 
of these agents, including the dose prescribed. The influence of a number of 
demographic variables, including age and ethnicity, are discussed. Additional 
issues, such as antipsychotic polypharmacy, switch patterns in therapy and 
medication compliance are examined. This section concludes with a discussion 
about the potential impact that differences in these variables may have on the 
occurrence of new-onset diabetes in patients treated with second-generation 
antipsychotics. 
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1.10.1 Trends in Prescribing 
Using data from the National Ambulatory Medical Care Surveys 
(NAMCS), antipsychotics were prescribed during 3.2 million office visits in 
1989 (0.46% of all visits) compared to 6.9 million visits in 1997 (0.88%), with a 
total of 35.9 million visits occurring between 1997 and 2000, accounting for 
nearly 1 percent of all healthcare visits in that period.320;321 Non-psychiatric 
physicians accounted for nearly 30 percent of these prescriptions.321 The use of 
first-generation antipsychotics has declined as a proportion of all antipsychotic 
prescriptions in recent years, accounting for 48 percent of antipsychotic 
prescriptions in 1997 compared to 29 percent of prescriptions in 2000.321 In the 
NAMCS dataset, the use of second-generation antipsychotics was more prevalent 
among younger patients.321 Among the second-generation agents, while the mean 
age of patients treated with olanzapine and risperidone were similar, there were 
differences in the age distribution, with risperidone used more frequently in 
patients aged less than 20 years, and in those older than 75 years.321 By 
comparison, the odds of receiving olanzapine (OR > 1.75) was highest in those 
aged 35 to 60 years.321 When stratified according to primary diagnosis, and after 
adjusting for age, race and gender, there was a trend toward the increased use of 
risperidone compared to olanzapine for non-psychotic conditions such as 
dementia, depression, attention deficit hyperactivity disorder (ADHD), together 
with other mental disorders and non-mental disorder conditions, although these 
differences were not significant.321 In contrast, patients with a diagnosis of 
psychosis or schizophrenia were significantly more likely to be prescribed 
olanzapine (OR: 1.62, 95% CI: 1.04-2.52).321 
 In a report entitled “Care for Veterans with Psychosis in the VHA, FY02” 19 
the use of antipsychotic therapy within the National Psychosis Registry for the 
VA is outlined. (Table 1.11)  
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Table 1.11: Percentage use of Antipsychotics within the VA Psychosis Registry between 









Among all patients in the registry     
Any antipsychotic 2 56.4 57.0 59.6 59.7 
   Schizophrenia 73.5 73.3 76.1 77.9 
   Bipolar Disorder 32.1 35.2 40.8 42.9 
   Other Psychotic Disorder 3 -- -- -- 45.1 
Among patients receiving any 
antipsychotic 
    
Second-generation antipsychotic 61.7 77.7 80.1 84.9 
   Schizophrenia 58.7 70.3 77.4 82.0 
   Bipolar Disorder 69.2 82.0 85.5 89.8 
   Other Psychotic Disorder 3 -- -- -- 88.5 
1 For patients with more than one diagnosis, diagnosis was ‘assigned’ according to the 
diagnosis that appeared most frequently in 2002. Ties were resolved using a rank ordering 
of 1) Schizophrenia; 2) Bipolar Disorder; 3) Other Psychoses. 
2 First or second-generation antipsychotic. 
3 Other psychotic disorders include non-organic psychotic disorders other then schizophrenia, 
schizoaffective disorder and bipolar disorders. 
Note: Registry does not include any usage of depot antipsychotics; therefore, percentage of 
patients treated with an antipsychotic may be underrepresented between 10 and 20 percent. 
 
The percentage of patients who received treatment with an antipsychotic at 
any time increased slightly from 56.4 percent in 1999, to 59.7 percent in 2002.19 
When stratified according to diagnosis, patients with schizophrenia were most 
likely to be treated with an antipsychotic (77.9% in 2002) compared to those with 
bipolar disorder (42.9%) and those with other psychotic disorders (45.1%).19 Of 
note, the psychosis registry does not consistently include use of depot 
antipsychotic formulations; therefore, these data may under-estimate the use of 
first-generation antipsychotics in between 10 and 20 percent of patients with 
schizophrenia.19 Among those treated with an antipsychotic, the percentage 
treated with a second-generation antipsychotic increased considerably from 61.7 
percent in 1999 to 84.9 percent in 2002, with patients with bipolar disorder most 
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likely (89.8%) and those with schizophrenia least likely (82.0%) to be receiving 
second-generation agents.19 Clozapine was infrequently prescribed and use of 
this agent was primarily restricted to those with a diagnosis of schizophrenia.19 
Olanzapine and risperidone were the most commonly prescribed agents (38.9 and 
37.1%, respectively), although use of quetiapine increased rapidly from 3.2 
percent in 1999 to 20.6 percent in 2002.19 When stratified according to treatment 
indication, differences in the prescribing rates of these agents were evident, with 
olanzapine most frequently prescribed to those with a diagnosis of schizophrenia 
or bipolar disorder, and risperidone use most frequent in those with other 
psychotic disorders.19 Regional differences existed in the prescribing rates of 
these agents, for example the percentage of patients prescribed olanzapine ranged 
from 29.0 to 51.1 percent.19 Prescribing trends in North, South and Central Texas 
(VISN 17) mirrored that of the overall VA population with the exception of 
higher rates of olanzapine use in VISN 17. 19 (Table 1.12) 
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Table 1.12: Percentage Use of Second-Generation Antipsychotic Agents within the VA 
Psychosis Registry in 2002 for all Patients (N=205,620), those within VISN 171 (N=8,940), 




















Clozapine 1.9 2.0 3.0 3.7 0.2 0.2 0.1 0.1 
Olanzapine 38.9 44.9 38.4 43.2 44.7 53.0 31.3 37.8 
Quetiapine 20.6 19.9 17.9 18.4 26.0 23.2 22.5 19.4 
Risperidone 37.1 36.5 36.6 37.7 32.4 29.5 47.6 43.6 
Ziprasidone 3.5 3.2 4.0 3.8 2.9 3.2 2.3 1.4 
1 VISN 17 encompasses North, Central, and South Texas together with two counties from 
Oklahoma (Choctaw and Byran). 
2 Patients with more that one diagnosis, diagnosis were ‘assigned’ according to the diagnosis 
that appeared most frequently in 2002. Ties were resolved using a rank ordering of 1) 
Schizophrenia; 2) Bipolar Disorder; 3) Other psychotic disorder. 
3 Other psychoses include non-organic psychotic disorders other then schizophrenia, 
schizoaffective disorder and bipolar disorder.  
Note: Columns may sum to greater than 100% due to potential for dual therapy and 
antipsychotic switching. 
 
1.10.2 Differences in Prescribing Patterns According to 
Treatment Indication  
As noted in the reports using the National Ambulatory Medical Care 
Survey (NAMCS) and VA National Psychosis Registry Data, differences exist in 
the prescribing patterns of the various second-generation antipsychotics.19;320;321 
With the exception of clozapine, the use of which tends to be limited and 
restricted to that of the licensed indications, the second-generation antipsychotics 
are widely used in clinical practice.19;320;321 This includes their use for the 
licensed indications of schizophrenia and bipolar disorder; but also for a wide-
range of ‘off-label’ indications.19;37-39 In particular, there is a consensus in 
clinical practice that these agents are indicated in any psychotic disorder where 
 119
the term “psychotic disorder” includes: schizophrenia; schizophreniform 
disorder; schizoaffective disorder; delusional disorder; and brief psychotic 
disorder.94 In an expert consensus guideline considering the use of antipsychotics 
in older patients, it was concluded that antipsychotics were recommended for 
disorders with psychotic symptoms, i.e., schizophrenia, mania with psychosis, 
agitated dementia with delusions, psychotic major depression and delusional 
disorder.11  It was also recommended that the use of antipsychotics was 
occasionally indicated in mania without psychosis, delirium, and agitated 
dementia without delusions. However, the experts did not recommend the use of 
antipsychotics in the following conditions: non-psychotic major depression; 
generalized anxiety disorder; panic disorder; hypochondriasis; or for irritability, 
hostility or sleep disturbance in the absence of a major mental disorder.11 
As noted earlier, there appears to be a trend toward the increased use of 
risperidone compared to olanzapine in patients aged less than 18 years, and in 
those aged 65 years or older, in non-psychotic conditions, and in psychotic 
conditions other than schizophrenia.19;321;322 Supporting this are the results from a 
large study examining the use of antipsychotics in nursing homes between 1999 
and 2000, where 15 percent of patients received treatment with an 
antipsychotic.103 Among those with behavioral and psychological problems 
associated with cognitive impairment (N=86,514), 18.2 percent received an 
antipsychotic, of whom approximately 60 percent received a second-generation 
agent.103 A clear difference in the rate of prescribing of the various agents was 
evident with 66.5 percent of the second-generation antipsychotic use accounted 
for by risperidone.103 Olanzapine was the next most widely used agent (38.2%) 
with limited use of clozapine and quetiapine noted.103 Similar findings were 
documented in a study using a large national database of psychogeriatric 
inpatients with dementia disorder from 1996 to 1998, where 36.6 percent of the 
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patients were receiving antipsychotic therapy, of whom 50.1 percent were treated 
with risperidone, and 20.9 percent with olanzapine.101 
Antipsychotics are widely used in bipolar disorder. In a national study of 
patients aged 18 years and older admitted to psychiatric inpatient units between 
1996 and 2000, 75 percent of patients with bipolar I disorder with psychotic 
features (74% manic; 78% depressed), and 36 percent of those without psychotic 
features (33% manic; 41% depressed) were prescribed an antipsychotic.65 Of 
these, approximately two-thirds received a second-generation agent, with 
olanzapine and risperidone most commonly prescribed.65 Lower prescription 
rates were documented in a study of privately insured patients with bipolar 
disorder aged 18 to 64 years between 1994 and 1998.88 Antipsychotics were used 
by 24.8 percent of the population, with a total of 16.4 percent of patients using a 
first-generation agent and 12.4 percent a second-generation agent at any time 
during the study.88 Patients treated with an antipsychotic tended to remain on 
therapy for a minimum of 12 months.88 
 While only olanzapine is licensed as maintenance therapy (since January 
2004) in patients with bipolar disorder, there is considerable evidence that a high 
percentage of these patients are maintained for long-periods on second-
generation antipsychotics. Among patients with psychosis in the VA, patients 
with bipolar disorder received an average of 6.1 prescription refills in 2002, 
indicating that many of patients were receiving long-term antipsychotic 
therapy.19 In the same cohort, patients with schizophrenia refilled an average of 
8.3 antipsychotic prescriptions in 2002, while those with other psychotic 
disorders refilled an average of 5.3 prescriptions.19  
1.10.3 Dose of Antipsychotic 
Independent of age, the dose of antipsychotic recommended in clinical 
practice is higher for patients with schizophrenia or acute mania with psychosis 
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than for non-psychotic conditions and conditions such as delirium or dementia 
with agitation. In the aforementioned expert consensus guideline developed by 
specialists in the management of older adults, the dose recommended for patients 
with schizophrenia ranged from 8 to 9.6 percent higher than for acute psychotic 
mania, and 33 to 59 percent higher than that recommended for patients with 
delirium or dementia with agitation. (Table 1.13) 11 
 
Table 1.13: Recommended Mean Daily Dose of Second-Generation Antipsychotic Agents 
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** Also considered treatment 
 
In a study of patients enrolled in Texas Medicaid, results consistent with these 
guidelines were found, i.e., doses prescribed to patients with schizophrenia were 
40 to 80 percent higher than those prescribed for other indications (p<0.001); and 
that regardless of mental disorder diagnosis or agent used, the dose prescribed in 
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patients aged 65 years and older was significantly lower than in patients aged less 
than 65 years (p<0.001).12  
1.10.3.1 Schizophrenia 
The use of an algorithm for schizophrenia was evaluated in a feasibility 
study by the Texas Medication Algorithm Program (TMAP). The mean 
maximum daily doses for olanzapine (N=24) and risperidone (N=62) were 14.6 
milligrams and 5.7 milligrams, respectively, in 91 inpatients and outpatients with 
schizophrenia. Overall, dosages were generally considered to be adequate, in that 
they were within the ranges recommended in the algorithm.323 The olanzapine 
doses were comparable to those in a study of schizophrenia patients enrolled in 
Michigan Medicaid by Gibson et al., where mean initial daily doses of 
olanzapine and haloperidol were 9.9 milligrams and 3.8 milligrams, respectively, 
increasing to 14.2 milligrams and 4.5 milligrams, respectively, three months after 
treatment initiation.324 Similarly in a Spanish, open-label prospective study 
evaluating outpatient use of olanzapine and risperidone in schizophrenia patients, 
mean initial daily doses were 12.2 milligrams (SD: 4.8mg) and 5.2 milligrams 
(SD: 2.3mg), respectively, with overall mean daily doses of 13.0 milligrams (SD: 
5.0mg) and 5.4 milligrams (SD: 2.5mg), respectively.325 The dose prescribed 
correlated with the severity of disease, with significantly higher overall mean 
daily doses (p<0.001) prescribed to those with more severe disease at baseline.325 
Again, comparable results were obtained by Buchanan et al. in the Schizophrenia 
Patient Outcomes Research Team (PORT) study, where mean daily doses for 
risperidone were 6.3 milligrams (SD: 2.6mg) for inpatients, and 6.1milligrams 
(SD: 2.6mg) for outpatients. 326 Mean daily doses of clozapine reported in this 
study were 382.8 milligrams (SD: 172.9mg) for inpatients, and 393.9 milligrams 
(SD: 187.6mg) for outpatients.326 
 
 123
1.10.3.2 Conditions other than Schizophrenia 
As noted, lower doses of antipsychotics are frequently used in other 
psychotic and non-psychotic conditions compared to schizophrenia. Particular 
examples include the management of drug-induced psychoses in Parkinson’s 
disease where the use of antipsychotics is generally limited by their propensity to 
aggravate Parkinsonian symptoms. Clozapine at a dose of 6.25 to 50 milligrams 
daily and quetiapine 12.5 to 50 milligrams daily have been noted to be 
efficacious with minimal toxicity.327 Clearly, these doses are considerably lower 
than the recommended target daily doses used in schizophrenia (clozapine: 300 
to 450 milligrams, and quetiapine 300 to 400 milligrams daily, respectively).36;38 
In patients with dementia, maintenance doses of antipsychotics that have been 
recommended include: clozapine 12.5 to 100 milligrams; olanzapine 5 to 10 
milligrams; quetiapine 25 to 200 milligrams; and risperidone 0.5 to 2.0 
milligrams.102 These mirror the modal doses observed in a study of 86,514 
nursing home residents, 18.2 percent of whom were receiving an 
antipsychotic.103 Modal daily doses were: clozapine 25 milligrams (range 12.5-
300mg); olanzapine 5 milligrams (2.5-10mg); quetiapine 50 milligrams (25-
400mg) and risperidone 1 milligram (0.5-4mg).103 Consistent with the 
recommendations for the management of psychotic major depressive disorder 
(Table 1.13), the dose of antipsychotic used in patients with major depressive 
disorder with and without treatment-resistant depression is lower that that seen in 
schizophrenia. In a 76-week, open-label study of olanzapine plus fluoxetine in 
major depressive disorder, the mean modal dose of olanzapine for patients with 
treatment-resistant depression was 7.7 milligrams (SD=3.9mg), and 7.4 




1.10.4 Age-Related Differences in Prescribing 
Antipsychotics are widely used in geriatric patients; however, there are 
only a limited number of controlled clinical trials that have examined their use 
agents in this population. Issues regarding the use of antipsychotics in the 
geriatric population include: excessive use in this population compared to those 
under the age of 65 years; increased susceptibility to adverse drug reactions due 
to altered rates of metabolism, polypharmacy with psychotropics and other 
agents; and increased medical comorbidities.11 As noted earlier, in an expert 
consensus guideline series considering the use of antipsychotics in patients over 
the age of 65 years, the dose of antipsychotic recommended was consistently 
lower than that recommended in non-geriatric populations regardless of the 
treatment indication.11 (Table 1.13) Of interest, in a similar consensus guideline, 
developed by national experts in the management of psychotic conditions, but 
not necessarily specialists in geriatric care, the doses recommended for older 
adults, while lower than recommended for patients aged less than 65 years, were 
higher than those recommended by the geriatricians.94 
1.10.5 Ethnic Differences in Prescribing 
A number of studies have highlighted racial disparities in the prescribing 
of antipsychotic medications. After controlling for other demographic and 
utilization factors, African-Americans and Hispanic-Americans have been noted 
to be less likely to receive treatment with second-generation antipsychotics.328-332 
Furthermore, African-Americans have been documented to be more likely to 
receive treatment with depot therapy and to receive higher doses of first-
generation antipsychotics.326;331;333 Among the second-generation antipsychotic 
agents, there are equivocal findings regarding the influence of race on 
prescribing patterns. Non-white race was associated with a greater likelihood of 
receiving olanzapine compared to risperidone (OR =1.58, 95% CI: 1.02-2.47) in 
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one study, whereas no such association was found in another study (African-
American: OR: 0.83, 95% CI: 0.69-1.00; Mexican-American: OR 1.00, 95% CI 
0.77-1.30).321;332 Differential rates of prescribing of antipsychotics by race are an 
important consideration in any study seeking to examine differences in adverse 
effects profiles. In particular, it is an important consideration with diabetes, as it 
is well documented that the incidence and prevalence of diabetes varies by race 
/ethnicity, with higher rates of diabetes documented among blacks and 
Hispanics.201 
1.10.6 Antipsychotic Polypharmacy 
Concomitant prescribing of two or more antipsychotics is well described. 
Estimates of antipsychotic polypharmacy range from 6.8 to 25 percent.330;334-337 
One study of hospitalized patients in the U.K. described a rate of polypharmacy 
of 48 percent, although this figure included patients prescribed as required, or 
PRN medications in addition to a routine antipsychotic.338 Within the VA, 
antipsychotic polypharmacy rates have increased annually among all patients 
registered in the National Psychosis Registry, from 8.7 percent in 1999 to 11.1 
percent in 2002.19 When stratified by diagnosis, antipsychotic polypharmacy was 
reported in 15.0 percent of patients with schizophrenia, 5.0 percent of those with 
bipolar disorder and 5.0 percent of those with other psychosis.19 Combination 
therapy typically involves a combination of a first- and second-generation 
antipsychotic (70 to 86%), although combinations of two first-generation agents; 
two second-generation agents and use of more than two agents have also been 
described.19;336;338;339 The use of dual therapy is considered fifth-line in the 
management of schizophrenia, to be reserved for use in patients who have failed 
multiple agents (first or second-generation) when used as monotherapy, in 
addition to being refractory or only partially responsive to clozapine.340 Little 
empiric evidence is available to support the efficacy of such combinations and 
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there is an acknowledged increase in cost and adverse effects.338;340 Co-
prescribing of first- and second-generation agents nullifies the potential benefits 
of decreased extrapyramidal effects, while maintaining the high cost of therapy, 
associated with the second-generation agents.338 It may be difficult to ascertain 
the extent of true antipsychotic polypharmacy in database studies as patients are 
frequently cross-tapered when switching from one agent to another.334;336 While 
the necessity of such a process is disputed, gradual withdrawal of clozapine is 
recommended with the patient gradually discontinued over a three month 
period.340 Studies have, therefore, used concurrent therapy for 60 days or more as 
a criterion for antipsychotic polypharmacy.19;341 
1.10.7 Switch Rates 
A retrospective Dutch study examined the extent of switching 
antipsychotic therapy in 522 newly admitted patients who commenced 
antipsychotic therapy.342 Patients commencing treatment with a first-generation 
antipsychotic were more likely to switch therapy than those commencing a 
second-generation agent (OR: 1.79, 95% CI: 1.15-2.78), with switch rates of 54.5 
percent and 34.4 percent, and median times to switch of 24 days and 170 days 
reported, respectively.342 Switching to another oral antipsychotic agent is 
typically described due to inadequate effectiveness or intolerable adverse 
effects.342 Switches may be within class or inter-class. In the VA National 
Psychosis Registry, the percentage of patients receiving only one kind of 
antipsychotic ranged from 70.4 percent for those with schizophrenia, to 78.6 
percent for those with other psychoses, with an overall rate of 73.6 percent in 
2002.19 Even after accounting for possible concomitant therapy, it is apparent 
that switching therapy is not infrequent in this population.19 
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1.10.8 Medication Compliance 
Medication non-compliance is a major health care problem that impacts 
the management of all disease states. Estimates of non-compliance range from 30 
to 60 percent with higher rates reported in asymptomatic patients.343 The issue of 
non-compliance is particularly important in patients with serious mental illness 
where poor adherence is associated with higher rates of relapse, increased 
hospitalization rates, increased number of hospital bed days and higher hospital 
costs.341;344;345 Factors that may contribute to non-compliance include: ethnic 
background; severity of psychotic symptoms; cognitive impairment; comorbid 
substance abuse; poor insight; financial status; polypharmacy; poor medication 
tolerability; delayed onset of medication action and delayed time to relapse.346;347 
Two aspects of medication compliance, adherence and persistence will be 
considered here, with specific emphasis on compliance with antipsychotic 
therapy in patients with schizophrenia and bipolar disorder. 
1.10.8.1 Adherence to Antipsychotic Therapy 
Rates of adherence to antipsychotics range from 11 to 80 percent, with an 
average rate of adherence of approximately 50 percent.348 In a study using 
ambulatory pharmacy refill prescription records from a VA database, adherence 
rates to first- and second-generation antipsychotics were compared. Although not 
statistically significant, higher rates of adherence were reported with the second-
generation agents with rates of 49.9 percent (SD: 33.3%) and 57.4 percent (SD: 
33.4%), respectively, reported for first- and second-generation agents at six 
months (t=1.97, df=286, p=0.05), and 50.1 percent (SD: 30.6%) and 54.9 percent 





Adherence to antipsychotic therapy by schizophrenia patients was 
examined using Medicaid data in a study by Gilmer et al.345 Using a definition of 
80 to 110 percent adherence as being adherent, 41 percent of patients were 
deemed adherent to therapy, with 41 percent categorized as partially, or non-
adherent, and 19 percent categorized as excess fillers (that is adherence rates 
greater than 110 percent.345 Characteristics associated with lower adherence rates 
included: comorbid substance abuse; younger age; African-American and Latino 
ethnicity; and living status, with lower adherence in homeless patients and those 
living independently compared to those living with family or in assisted living 
facilities. 345 When compared to the first-generation antipsychotics (adherence 
rate 36.9%), similar rates of adherence were found for patients taking second-
generation antipsychotics (40.7%, p=0.13), with the exception of clozapine 
(adherence rate: 60.1%, p<0.001); and among those taking multiple drugs 
(34.2%, p=0.42).345 Comparable adherence rates were documented in a study 
using data from the VA National Psychosis Registry.341 Among 67,079 patients 
with schizophrenia or schizoaffective disorder, the mean adherence rate (as 
measured by medication possession ratio (MPR)) was 0.80 (SD: 0.33) with 60 
percent of patients having an adherence rate of 0.80 or higher.19;341 Contrary to 
the findings in other studies, poorer adherence was noted in patients prescribed 
second-generation compared to first-generation antipsychotics (OR: 1.8, 95% CI: 
1.7-1.9).341;345;348 Using data from the Schizophrenia Care and Assessment 
Program (SCAP), significantly higher adherence rates (as measured by MPR) 
were noted for patients newly initiated on olanzapine (MPR: 0.75) compared to 




1.10.8.1.2 Bipolar Disorder 
In a prospective, 12-month study of patients with bipolar disorder 
following hospitalization for a manic or mixed episode, only 47 percent of 
patients were documented to be fully adherent to therapy (defined as an 
adherence rate of 75% or greater), with non-adherence (zero to 25% adherence) 
reported for 26 percent of patients.60 The rate of adherence to therapy did not 
differ between medication regimens that is between: mood stabilizer alone; mood 
stabilizer plus antipsychotic; mood stabilizer plus antidepressant; antipsychotic 
alone; or antidepressant alone.60 Comorbid substance misuse was predictive of 
nonadherence and as anticipated, patients that were fully adherent to therapy 
were more likely to achieve syndromic recovery.60 Higher adherence rates were 
reported in a small study (N=44) where patterns of medication adherence were 
examined in a structured interview of patients with concurrent bipolar and 
substance abuse disorders, 31 of whom (70%) were prescribed neuroleptic 
agents.350 Approximately 65 percent of patients reported being adherent to 
neuroleptic therapy at least two-thirds of the time, with 13 percent of patients 
reporting being adherent only one-third of the time.350 
1.10.8.2 Persistence with Antipsychotic Therapy 
A Canadian population-based cohort study examined persistence with 
ambulatory therapy in first-time users of the second-generation antipsychotics: 
clozapine; olanzapine; quetiapine and risperidone.351 Persistence rates were 
highest for patients treated with clozapine without prior use of first-generation 
antipsychotics (hazard rate (HR) of discontinuation 0.33, 95% CI: 0.26-0.41) and 
in those treated with olanzapine regardless of prior antipsychotic use (HR: 0.78, 
95% CI: 0.74-0.81 (past use); HR: 0.88, 95% CI: 0.85-0.92 (no past use)).351 
While patients treated with risperidone had lower persistence rates, they were 
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also less likely to receive concomitant antipsychotic therapy, as well as less 
likely to have any antipsychotic agent prescribed after discontinuation.351 
A number of studies have compared persistence rates in patients 
prescribed first- and second-generation antipsychotics. Contrary to expectations, 
superior persistence rates were documented with first-generation antipsychotics 
after eight months of treatment (χ2=5.58, df=1, p<0.02) in a study of prescription 
refill records of 25,000 patients from a national refill chain.352 Among the 
second-generation agents, persistence with clozapine was significantly higher 
than with olanzapine (71% vs. 40%, χ2=39.72, df=1, p<0.001); quetiapine (33%, 
χ2=46.98, df=1, p<0.001); and risperidone (40%, χ2=41.37, df=1, p<0.001).352 
Zhu et al. documented longer rates of persistence with olanzapine (259 days) 
than with risperidone (237 days) or quetiapine (212 days) in a study using data 
from the Schizophrenia Care and Assessment Program (SCAP).349 When 
examined independently of the gap between prescriptions, patients treated with 
olanzapine had the lowest treatment discontinuation rate, and those treated with 
quetiapine the highest.349 Similar findings were documented in a study by Opolka 
et al. using data from Texas Medicaid with olanzapine associated with 
significantly longer persistence rates (p<0.001) than risperidone or haloperidol. 
347 
1.10.8.3 Summary 
In summary, non-compliance with medications is prevalent in patients 
receiving antipsychotic therapy regardless of the indication for treatment. While 
superior compliance would be anticipated with second-generation compared to 
first-generation antipsychotics based on improved tolerability, results from such 
comparisons have been equivocal. Among the second-generation antipsychotics, 
superior adherence and persistence rates have been documented with clozapine 
and olanzapine. 
 131
1.10.9 Potential Impact of Prescribing Trends on the Occurrence 
of Antipsychotic-Induced New-Onset Diabetes 
While glucose dysregulation appears to be associated with the use of 
second-generation antipsychotics, it is difficult to ascertain the extent of the 
problem. Differential patterns and rates of prescribing of antipsychotics may 
influence the findings of any study that seeks to examine this adverse effect. 
Important considerations include the impact of dose and treatment indication. It 
has been noted that there is a higher prevalence of diabetes in patients with 
schizophrenia and bipolar disorder than in the general population, which is 
independent of antipsychotic use.13-15;17;18;291 Cohort studies indicate that patients 
with conditions other than schizophrenia tend to be treated with lower doses of 
antipsychotics than those with schizophrenia.12;103 
Studies with a preponderance of older patients may include 
disproportionate numbers with dementia and other psychotic disorders. The use 
of lower treatment doses in this population may limit the potential to detect a 
dose-related effect, should one exist. However, it may not be sufficient to control 
for age differences alone, as it has been shown that independent of age, patients 
with schizophrenia are treated with higher doses than those with other psychotic 
and non-psychotic conditions.11;12 This, combined with the fact that older patients 
may lack the diathesis for developing diabetes, may skew study findings 
particularly if the various second-generation antipsychotics are prescribed at 
different rates in this population. 
Differential rates of prescribing of antipsychotics by race are also an 
important consideration in any study seeking to examine differences in adverse 
effects profiles. In particular, it is an important consideration with diabetes, given 
the well documented genetic predisposition of certain racial/ethnic groups for 
diabetes.201 
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 Finally, in any study examining treatment-related adverse effects, the 
level of treatment exposure is an important consideration. Differential rates of 
medication compliance between the various antipsychotic agents may bias 
findings, and as such compliance represents an important control variable. 
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1.11 Section 9: The Use of Large Databases in Health Outcomes 
Research 
1.11 1 Introduction 
While randomized controlled trials are historically the gold standard in 
objective research, they are expensive and time-consuming to conduct.215;353;354 
In addition, they have a number of limitations which reduce their external 
validity or generalizability. 215;353;354 Specifically, randomized controlled trials 
tend to have strict inclusion and exclusion criteria, are frequently conducted in 
specialized clinical settings, are often short-term in nature, and may have an 
added limitation of the Hawthorne effect.353;354 Claims databases are increasingly 
being used to provide answers to healthcare questions.353 Although developed for 
the purpose of claims processing and tracking, these databases are increasingly 
being adapted to facilitate both retrospective and prospective analyses.353 
In this study, data from a large claims database, Texas Medicaid were 
used. This section will proceed with a brief overview of the advantages and 
limitations of using claims databases, with specific reference to the use of the 
Medicaid database for health care research. 
1.11.2 Advantages 
Key advantages of claims database research are the size and ease of 
access of many of these databases. As these databases are not custom-generated 
for the purpose of research, they tend to be less costly than clinical trials.353 Due 
to the large size of many of these databases, they facilitate longitudinal research 
of healthcare utilization by large cohorts of patients, providing considerable 
statistical power at low cost.215;353 In epidemiological studies, these databases are 
realistically the only feasible means for studying risk factors for rare diseases and 
the occurrence of rare adverse events.215 By virtue of the fact that these databases 
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reflect ‘real life’ healthcare and are not limited by strict inclusion entry criteria, 
they include subjects that are more representative of the population to whom the 
results will be applied.354 Due to their retrospective nature, these databases allow 
for flexible methodological study designs that are non-intrusive and inherently 
free of recall or interviewer bias.353 
Support for the validity of observational studies comes from a number of 
sources. In a study published in the New England Journal of Medicine in 2000 
that included studies reported between 1985 and 1988, the results from 
observational studies and randomized clinical trials were compared.355 Little 
evidence of systematic bias with observational studies was found, and the authors 
concluded that there was no evidence that these studies provided estimates of 
treatment effects that were either consistently larger, or qualitatively different 
than those obtained in randomized clinical trials.355 Comparable findings have 
been documented in a number of similar studies.354;356 
1.11.3 Limitations 
As noted, claims databases are usually not custom-generated for the 
purpose of research and thus represent secondary data sources. A key 
disadvantage to their use is, therefore, that they may not contain information on 
variables of interest to the researcher. Claims database research may have a 
number of limitations which impact on the validity of study results. For the 
purpose of clarity, these limitations will be discussed in terms of threats to 
specific types of study validity: construct validity; internal validity; and external 
validity. The relevance of these threats to this study proposal, and mechanisms of 




1.11.3.1 Construct Validity 
This refers to the degree to which an instrument or variable measures the 
underlying trait or phenomenon that it claims to measure. In this study, the 
dependent variable of interest was the occurrence of new-onset diabetes. This 
was detected by an ICD-9 code of 250.xx for diabetes, or a prescription for 
insulin, an oral hypoglycemic agent or an insulin sensitizing agent. As noted 
previously in Table 1.9, the medications to treat diabetes are disease-specific for 
diabetes, with limited off-label use for other conditions. New indications and off-
label use of these medications for conditions such as for insulin-resistance 
syndrome and the prevention of diabetes is expanding; however, the literature 
supporting such use is relatively new. Off-label use of these agents in the 
timeframe of this study was, therefore, thought to be negligible and the use of 
these medications as a proxy for a diabetes diagnosis is a reasonable assumption. 
1.11.3.2 Internal Validity 
Internal validity has been defined as “the degree to which it can be 
inferred that the experimental treatment (independent variable), rather than 
uncontrolled extraneous factors, is responsible for observed effects.”357 That is, 
the extent to which we are making appropriate inferences about the relationships 
between study variables. With regard to database research, a number of threats to 
internal validity have been identified as being particularly important. These 
include: validity of diagnostic information; exposure misclassification; and 
problems with confounding, including channeling bias. A brief discussion of 
these threats with reference to the Medicaid database will follow. 
1.11.3.2.1 Diagnostic Information 
The successful use of databases in studies is dependent on the accuracy of 
the information contained therein. The ICD-9 patient diagnostic coding system is 
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frequently used in claims based research to identify populations of interest.353 
The reliability and validity of this coding have been disputed, and found to vary 
by disease state.353 In a study that attempted to verify the accuracy of 
schizophrenia diagnoses among Medicaid patients, psychiatrists classified 86.8 
percent of patients with a treatment claim for schizophrenia as definitely (78.3%) 
or probably (8.5%) having schizophrenia.358 In contrast, among patients with 
claims for chronic mental illness other than schizophrenia, 27.5 percent (N=43) 
were classified as definitely or probably having schizophrenia.358 The authors 
concluded that most diagnoses of schizophrenia in the Medicaid claims database 
are accurate, but that claims data may underestimate the true number of affected 
patients.358  
Complicating the picture of accuracy of diagnoses within a database is the 
inherent difficulty in differentiating between a number of disease states, 
including between schizophrenia and bipolar disorder. While considered to be 
separate entities with distinguishing clinical characteristics, differentiating 
between these disorders may be complicated by factors such as: changes in the 
manifestation of the disease over time; changes in the course or appearance of the 
disorder due to comorbid diseases including substance abuse; demographic 
variables that alter the symptoms, course or perception of the illness; and the fact 
that there appears to be a shared genetic link between the disorders.359;360 
In a study using data from a non-VA public inpatient psychiatric hospital 
that examined the stability of diagnosis in bipolar disorder, 28.5 percent (N=68) 
of patients with an initial diagnosis of bipolar disorder had a change of diagnosis 
within a seven-year period.359 Of these, 70.6 percent (N=48) were subsequently 
identified as having schizophrenia.359 Similarly, among 701 patients with an 
initial diagnosis other than bipolar disorder, 16.1 percent (N=113) were 
subsequently identified as having bipolar disorder, of whom 24.8 percent (N=28) 
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had an initial diagnosis of schizophrenia.359 Factors that were significantly 
associated with a diagnostic change from bipolar disorder included: male gender; 
African-American ethnicity and comorbid substance abuse.359 Similar findings 
were documented in a study by the same authors investigating the stability of 
diagnosis in schizophrenia.361 Of 256 patients with an initial diagnosis of 
schizophrenia, 21.9 percent received a different diagnosis during a subsequent 
hospitalization, and 32.8 percent of 680 patients with an initial diagnosis other 
than schizophrenia were subsequently diagnosed as having schizophrenia.361 
Good reliability of the VA administrative files was demonstrated in a 
1995 study that compared details from administrative files and patient medical 
records.362 In particular, there was good agreement between the files for the 
demographic variables of gender and ethnicity (kappa (κ): 0.897–0.978), for 
principal diagnoses for inpatient discharges (e.g., schizophrenia, κ: 1.000; 
affective psychoses, κ: 0.794; diabetes, κ: 0.795); and for secondary diagnoses 
for inpatient discharges (e.g., diabetes, κ: 0.823).362 The authors did note that 
using the administrative files may overestimate the prevalence of specific 
medical conditions compared to patient medical records, including: a significant 
overestimation of the prevalence of diabetes by 19.1 percent (p=0.003); and a 
non-significant overestimation of the prevalence of schizophrenia by 8.0 percent 
(p=0.318).362 Among patients with psychoses enrolled within the VA in 2001 and 
2002, 94.5 percent of patients with schizophrenia had the same diagnosis in both 
years while 93.7 percent of those with bipolar disorder, and 81.6 percent of those 
with a diagnosis of other psychoses maintained the same diagnosis in both 
years.19 
Based on these findings, it appears that longitudinal follow-up is 
necessary in order to validate diagnoses in database studies. Database studies 
have used a variety of techniques to counteract diagnostic instability including 
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using the modal diagnosis (based on ICD-9 medical code) as the primary 
diagnosis, and using a hierarchical taxonomy where the patient is classified 
according to mutually exclusive diagnostic categories of: schizophrenia; bipolar 
disorder; other psychotic /delusional disorder; and other mental health 
diagnoses.19 
1.11.3.2.2 Exposure Misclassification 
With claims database research, it is rarely possible to verify patient 
exposure or non-exposure to a treatment. In the absence of a superior method, 
drug exposure is typically inferred from prescription redemption records.363 This 
may over- or under-estimate exposure in that patients may not take prescriptions 
that they fill, or alternatively obtain prescription medications from sources other 
than that recorded. There is good consensus that automated pharmacy claims are 
one of the best sources of information on drug utilization.363 The primary issue 
then is patient compliance and use of drugs from other sources. Antipsychotic 
medications are all prescription-only medications, which limits the potential to 
source them from alternate routes. There is a potential for exposure 
misclassification with injectable antipsychotic preparations which are not 
uniformly recorded in pharmacy claims databases, and this will be a limitation of 
this study.19;363 By incorporating patient adherence and persistence with 
treatment as control variables, the potential for bias as a result of exposure 
misclassification can be minimized. 
As noted, a further source of exposure bias relates to the potential for 
patients to obtain services from alternate systems other than Medicaid. It is 
counterintuitive that patients enrolled in Medicaid who maintain eligibility of 
coverage, would obtain medical care, in particular prescription medications, from 
elsewhere given that these medications are available free of charge to them from 
Medicaid. An exception would be in states, including Texas, that impose a three-
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prescription maximum per month cap, with the potential that patients have out-
of-pocket expenditure for medications and that these are then omitted from the 
database. The potential for misclassification bias is, therefore, a limitation 
associated with the Medicaid database. In that it is limited in nature, and unlikely 
to systematically differ between the antipsychotic agents, it is unlikely to 
interfere significantly with the inferences drawn from the study. 
1.11.3.2.3 Confounding 
Confounding has been defined as “differences between the study cohorts 
that may affect treatment outcome.”353 Typically, it is addressed through 
statistical techniques. Inherent in this method however is the assumption that the 
researcher is aware of, or has access to all the variables that may confound the 
results. In a study of new-onset diabetes this would include controlling for known 
risk factors for diabetes such as age, race, family history, lifestyle, BMI, and a 
history or hypertension, dyslipidemia, gestation diabetes, or IGT.224 In the 
absence of this information, the statistical adjustment may be incomplete, thereby 
threatening the validity of the study findings. One particular form of 
confounding, “confounding by indication” or channeling bias, will be discussed 
in detail now. 
1.11.3.2.3.1 Channeling Bias 
This has also been referred to as “confounding by indication,” and occurs 
when a potential association between a drug and disease is altered by disease 
severity.364 For example, based on information from case reports, adverse drug 
surveillance systems and cohort studies, an expert panel has recommended that 
the use of clozapine and olanzapine should be avoided if possible in patients with 
multiple risk factors for diabetes.261 Instead, they recommend that the patients be 
treated preferentially with aripiprazole or ziprasidone, two agents not associated 
with significant weight gain or diabetes to date.261 An increase in the number of 
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cases of diabetes in patients treated with these agents may, therefore, 
inappropriately be inferred to be due to these “low risk” agents, rather than due to 
an inherently higher risk of diabetes in the baseline population. Equally, 
channeling only patients with a perceived low risk of diabetes onto olanzapine 
therapy may lead to an apparent lower risk of diabetes in olanzapine users. As the 
data for this study are from 1997 to 2001, they pre-date both the 
recommendations from the expert committee in 2004 and the retrospective case-
control and cohort studies published in December 2001 to 2004.3;4;9;10;228;230-
232;235-238;241;243;246;250;261 Therefore, this particular form of channeling bias is an 
unlikely confounder in this study. 
A further potential source of channeling bias is the differential rates and 
extent of prescribing of antipsychotics according to mental health diagnosis. It 
has been noted that both schizophrenia and bipolar disorder are associated with a 
higher prevalence of diabetes than in the general population.13-15;17;291 If the 
profile of antipsychotic prescribing differs in these patients compared to, for 
example the profile of prescribing in patients with other psychotic conditions 
which have not been associated with an increased risk of diabetes, then there is 
the potential that differences in the incidence of diabetes would be 
inappropriately assumed to be due to differences in risk associated with the 
various agents as opposed to differences in baseline population risk. While of 
major concern, this effect could be controlled for by stratifying patients 
according to treatment indication and dose of antipsychotic. 
1.11.3.3 External Validity 
This refers to study generalizability, that is, the extent to which inferences 
from the study results may be generalized to other study populations.353 A key 
feature is, therefore, the characteristics of the proposed study population and the 
extent to which it is representative of the overall U.S. population. Eligibility for 
 141
Medicaid, which was created in 1965 as a health insurance system to provide 
access to medical care for indigent and disabled, is determined at a state level; 
however, there are certain groups for which mandatory coverage is required in 
order for the program to maintain federal funding.363 Because of these 
requirements, the enrolled Medicaid population may differ from year to year, and 
from state to state.363 Furthermore, it is systematically different from the general 
population in the U.S., being characterized by an over-representation of children, 
females and nonwhites.363 While problematic for many population based studies, 
the use of the Medicaid database to study patients with serious mental illness is 
reasonable. Specifically, in the area of schizophrenia, public funding has been 
reported to account for 81 percent of health care needs of this population. In a 
study of ambulatory care patients with serious mental illness, 52.4 percent of 
patients had Medicaid coverage, 46.4 percent Medicare coverage, and 20.8 
percent of patients were dual-eligible.365 A further 5.3 percent of this group was 
in receipt of veteran’s benefits, while 9.4 percent were uninsured and 9.1 percent 
had private insurance.365 A higher percentage of patients with schizophrenia were 
reported to be uninsured or privately insured in a study using data from the 
National Comorbidity Study, with 25.3 percent uninsured, 43.6 percent privately 
insured and 31.3 percent insured by public sources (primarily Medicaid and 
Medicare).366 However, these patients did not necessarily meet the criteria for 
‘seriously mentally ill’, and while based also on an ambulatory population, 
included only those with residences.366 Using either sample, 30 to 50 percent of 
patients were in receipt of Medicaid coverage; therefore, a study using this 
claims database is representative of a high percentage of patients with 
schizophrenia. Other issues that may reduce the external validity of a study 
include differences in regional prescribing practices, formularies, and co-
payment structures, all of which may limit the generalizability of the study.353 
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1.11.4 Summary 
The use of claims databases in outcomes research is common. These 
databases allow for cost-efficient and timely retrieval of information and have the 
advantage of good external validity or generalizability. There are a number of 
important considerations in the use of these databases, particularly in relation to 
the internal validity of the proposed study. Careful study design, accompanied by 
an acknowledgment and correction for limitations where possible, allows high-
quality and useful information to be derived in an efficient manner. The use of 
the Medicaid claims database was discussed briefly with regard to this study. 
Possible limitations in using this dataset and their implication for study validity 
were highlighted. 
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1.12 Section 10: Study Rationale, Objectives and Hypotheses 
1.12.1 Study Rationale 
In September 2003, the Center for Drug Evaluation and Research 
(CDER) requested that the labeling for second-generation antipsychotic agents be 
changed to acknowledge the perceived association between the use of these 
agents and the development of hyperglycemia.20 In requesting this change, the 
CDER acknowledged the limitations of the available data. Although there are 
multiple case reports, there is a dearth of well-controlled trials. Many of the 
studies conducted were limited by small sample sizes, absence of control groups, 
and an inability to confirm fasting blood glucose levels. Cohort studies have used 
varied eligibility criteria and methodologies with the result that the findings are 
conflicting. To date, there is insufficient evidence to determine the differential 
propensities of the various second-generation agents to cause diabetes. The 
CDER highlighted the need for additional research to assess this relative risk and 
to identify patient sub-groups that may be more susceptible to this adverse event. 
This study had two overall goals. The primary goal was to determine the 
relative risk of new-onset diabetes associated with the different second-
generation antipsychotic agents. Secondary goals included profiling the 
characteristics of patients taking second-generation agents within the Medicaid 
database, and profiling the antipsychotic prescriptions for these patients. The 
primary goal of the study (ascertaining relative risk) aimed to facilitate clinicians 
in assessing the implication of using the different antipsychotics in Medicaid 
patients. The secondary goals (profiling patients and prescriptions) aimed to 
allow these decision-makers gain better insight into the characteristics of patients 
receiving antipsychotic treatment, and the manner in which these patients are 
treated. This study aimed to identify susceptible sub-groups so that antipsychotic 
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treatment could be more precisely tailored to patient need while considering the 
potential hazards associated with such treatment. 
The study was comprised of three phases. In phase I, the Texas Medicaid 
study population was described with regard to demographic variables and 
antipsychotic utilization patterns. Phase II of the study measured the prevalence 
of diabetes in the study population. Finally, phase III of the study examined the 
incidence of diabetes in the study population. 
1.12.2 Objectives and Hypotheses 
The following objectives were the focus of this study. Please note that the 
analyses conducted depended on the extent and quality of the available data. All 
hypotheses relating to these objectives were tested in the null. 
1.12.2.1 Phase I: Epidemiology and Antipsychotic Utilization Patterns 
1.12.2.1.1 Objective 1 
To profile the demographic and clinical characteristics of the Texas 
Medicaid study population. The demographic characteristics available from 
patient medical records were age, gender and race/ethnicity. Clinical 
characteristics with the potential to confound the relationship between exposure 
to an antipsychotic and the development of diabetes were examined. These 
included: mental health diagnoses, dyslipidemia and hypertension. 
1.12.2.1.2 Objective 2 
To examine antipsychotic utilization patterns in the Texas Medicaid study 
population. Of interest were variations in treatment patterns that may confound 
the relationship between antipsychotic exposure and the development of diabetes. 
These included differences in prescribing rates of the different agents, differences 
in treatment doses and differences in patient compliance. 
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H0 (1a-d) The percentage of patients receiving treatment with the 
different antipsychotic agents (first-generation agents, 
clozapine, olanzapine, quetiapine, risperidone, 
ziprasidone) will not differ significantly when stratified 
according to patient age H0(1a); gender H0(1b); race/ethnicity 
H0(1c); or primary mental health diagnosis H0(1d). 
H0(2a) The classification of mean daily antipsychotic dose as 
‘Low,’ ‘Medium,’ or ‘High’ will not differ when stratified 
according to the second-generation antipsychotic agent 
(clozapine, olanzapine, quetiapine, risperidone, 
ziprasidone) used. 
H0(2b-f) The mean daily dose for the second-generation 
antipsychotics clozapine H0(2b), olanzapine H0(2c), 
quetiapine H0(2d), risperidone H0(2e), and ziprasidone H0(2f) 
will not differ significantly when stratified according to 
patient age. 
H0(2g-k) The mean daily antipsychotic dose for the second-
generation antipsychotics clozapine H0(2g), olanzapine 
H0(2h), quetiapine H0(2i), risperidone H0(2j), and ziprasidone 
H0(2k) will not differ significantly when stratified according 
to the primary mental health diagnosis. 
H0(3a-j) Adherence and persistence with the second-generation 
antipsychotic agents will not differ significantly when 
stratified according to patient age H0(3a-b); gender H0(3c-d); 
race/ethnicity H0(3e-f); primary mental disorder diagnosis 
H0(3g-h); or type of agent H0(3i-j). 
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1.12.2.2 Phase II: Evaluation of the Prevalence of Diabetes 
1.12.2.2.1 Objective 3 
To examine the prevalence of diabetes mellitus in patients enrolled in the 
Texas Medicaid study population according to the primary mental health 
diagnosis after controlling for demographic (age, gender, race/ethnicity), clinical 
(i.e., hypertension, dyslipidemia) and medication (use of concomitant 
diabetogenic medications) risk factors for diabetes. 
H0(4a) The prevalence of diabetes will not differ significantly 
when stratified according to the primary mental disorder 
diagnosis after controlling for demographic, clinical and 
medication risk factors for diabetes. 
1.12.2.3 Phase III: Evaluation of the Incidence of Diabetes 
1.12.2.3.1 Objective 4 
To examine the incidence of diabetes in patients enrolled in the Texas 
Medicaid study population according to the class of antipsychotic and according 
to the type, dose and treatment indication for the second-generation 
antipsychotics after controlling for demographic (i.e., age, gender, race/ethnicity) 
clinical (i.e., hypertension, dyslipidemia, primary mental disorder diagnosis) and 
medication (i.e., antipsychotic therapy compliance, mean daily dose, use of 
concomitant diabetogenic medications for diabetes) risk factors for diabetes. 
H0(5a-b) The time to occurrence of diabetes will not differ 
significantly when stratified according to the class of 
antipsychotic agent H0(5a), or specific type of second-
generation agent H0(5b) after controlling for demographic, 
clinical and medication risk factors for diabetes. 
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H0(6a-b) The incidence of diabetes will not differ significantly 
when stratified according to the class of antipsychotic 
agent H0(6a), or specific type of second-generation agent 
H0(6b) after controlling for demographic, clinical and 
medication risk factors for diabetes. 
H0(7a-e) The incidence of diabetes will not differ significantly 
according to the dose of the second-generation 
antipsychotic agents: clozapine H0(7a); olanzapine H0(7b); 
quetiapine H0(7c); risperidone H0(7d); or ziprasidone H0(7e); 
after controlling for demographic, clinical and medication 
risk factors for diabetes.  
H0(8a-e) The incidence of diabetes will not differ significantly 
when stratified according to the primary mental disorder 
diagnosis for the second-generation antipsychotic agents: 
clozapine H0(8a); olanzapine H0(8b); quetiapine H0(8c); 
risperidone H0(8d); or ziprasidone H0(8e); after controlling 
for demographic, clinical and medication risk factors for 
diabetes. 
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Chapter 2: Methodology 
2.1 Chapter Overview 
This chapter describes the methods used to evaluate the association 
between second-generation antipsychotic use and diabetes. The study design is 
described including details of the data source, the study population and the 
timeframe of the study. A detailed presentation of the study variables and how 
they were operationalized follows. The chapter concludes with a description of 
the data collection methods, the estimated sample size required for the study and 
a discussion of the statistical analyses employed for each of the specific study 
objectives. 
2.2 Institutional Review Board Approval 
This study was approved by the institutional review boards (IRB) of The 
University of Texas at Austin and Texas Medicaid. A waiver of informed consent 
was obtained from the relevant review boards as the research contained no more 
than minimal risk to the research subjects, the waiver did not affect the rights and 
welfare of the subjects, and the research could not reasonably have been 
conducted without the waiver. In accordance with the IRB requirements of the 
relevant institutions, only de-identified data were collected to ensure 
confidentiality of patient information. 
2.3 Study Design 
This was a retrospective analysis using demographic, prescription and 
medical records for adults aged 18 years or older enrolled in Texas Medicaid 
who received at least one antipsychotic prescription (first or second-generation) 
between 1997 and 2001 (see section 2.3.3). 
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This study encompassed three phases. In phase I, the study population 
was described with regard to demographic variables and antipsychotic utilization 
patterns. In phase II, the prevalence of diabetes was examined. Finally, phase III 
of the study examined the incidence of diabetes in the population. 
2.3.1 Data Source 
Data were derived from Medicaid, as represented by Texas Medicaid, a 
brief background of which is included here. 
2.3.1.1 Medicaid 
The Medicaid program, which was established in 1965, is the largest 
single source of health insurance in the U.S. Eligibility for this program is based 
on financial and categorical eligibility requirements and is determined at a state 
level; however, there are certain groups for which mandatory coverage is 
required in order for the programs to maintain federal funding.367 Because of 
these requirements, the Medicaid population is systematically different from the 
general population in the U.S., being characterized by an over-representation of 
children, females and nonwhites.367 
Medicaid provided health insurance or long-term care services to nearly 
10 percent of Texans in 2002, with an average monthly enrollment of 2.10 
million beneficiaries. The majority of these beneficiaries were non-disabled 
children (59%). The remainder of the population was comprised of blind and 
disabled (11%), aged (9%), adults (16%) and others (5%, primarily those 
receiving long-term care). The population was primarily female (56%), non-
white (74%) and young, with 64 percent of beneficiaries under the age of 21 
years. Hispanics (51%) and African Americans (19%) represented the largest 
minority populations. Of note however, Caucasians comprised 42 percent of the 
population over the age of 65 years. Services provided by Medicaid include: 
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basic health services such as physician services; inpatient and outpatient hospital 
services; long-term care; pharmacy; and lab and x-ray services. Of note, adult 
hospitalization in a free-standing psychiatric hospital is not reimbursed in the fee-
for-service Medicaid program. The state currently limits the number of 
prescriptions covered under the program to a maximum of three prescriptions per 
month, each with a maximum of 120 days supply. This restriction does not 
however apply to children, those in nursing homes or those enrolled in Medicaid 
managed care plans. In 2003, Texas Medicaid paid in excess of $1.9 billion for 
over 34 million prescriptions.367 
In 2003, over 95,000 Texas Medicaid enrollees had a diagnosis of 
diabetes with diabetes-related expenditures estimated to be over $400 million for 
that year.368  In an earlier report from 2002, the majority of patients with a 
diagnosis of diabetes were aged 18 years or older (93.7%), with patients aged 45 
to 64 years representing the largest cohort (54.2%). (Data on file, Texas Health 
and Human Services Commission (THHSC), obtained 10/15/2004) Assuming 
these percentages did not change between 2002 and 2003, it can be estimated that 
approximately 89,000 adults had a diagnosis of diabetes in 2002, giving a 
prevalence of 10.7 percent among adults enrolled in Texas Medicaid that year. 
The majority of Texas Medicaid patients with diabetes are Hispanic (47.3%), 
with Blacks accounting for 24.7 percent, and Whites 22.2 percent of this cohort. 
(Data on file, THHSC, obtained 10/15/2004) 
Mental disorders are also prevalent among Medicaid enrollees. The 
Medicaid program accounts for over one-third of all public health spending and 
one-fifth of all spending on mental health and substance abuse treatment.369 In a 
study of ten state Medicaid programs, Buck et al. examined the use of mental 
health and substance abuse services by Medicaid enrollees under the age of 65 
years who were not dual-eligible for Medicare.370 Users of these services 
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comprised seven to 13 percent of the study population, the majority of whom 
received only mental health services (86.4%).370 The expenditure on these 
services accounted for 11 percent of the total Medicaid budget in those states.370 
When all healthcare expenditures for users of mental health and substance abuse 
services were included, this figure increased to 28 percent of the state budgets.370 
Use of these services increased with enrollee age, with over 15 percent of the 
population aged 21 to 44 years, and 20 percent of the population aged 45 to 64 
years receiving mental health and substance abuse services.370 
2.3.2 Study Population 
Patient level data were collected according to strict inclusion / exclusion 
criteria as detailed below. 
2.3.2.1 Inclusion / Exclusion Criteria 
To be eligible for inclusion in the study, patients were required to meet 
the following criteria: 1) age 18 years or older; 2) receiving a first or second-
generation antipsychotic agent, but having a six-month (180-day) antipsychotic-
free window prior to the identification of the index prescription; 3) continuous 
enrollment for six months (180 days) prior to, and 12 months (365 days) 
subsequent to the index date; with 4) evidence of at least one medical claim in 
that period. The study was limited to those receiving antipsychotic monotherapy. 
For phase III of the study, examining the incidence of diabetes, patients had to 
meet an additional criterion, that is, no history of diabetes in the 180 days prior to 
study enrollment. 
All antipsychotic dosage forms (oral, liquid, short-acting injectable and 
depot formulations) were included in the data set. No limits on the duration of 
antipsychotic treatment were set. No data were collected on the second-
generation antipsychotic aripiprazole (Abilify®) as this product was not licensed 
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by the FDA until after the study period. Data relating to another agent, 
ziprasidone (Geodon®) were limited, as this product was licensed in February 
2001. 
Patients were followed for a maximum of 365 days from the index date, 
or until an endpoint occurred, where an endpoint was defined as: occurrence of 
diabetes; switching of antipsychotic therapy (including commencing dual 
antipsychotic therapy); discontinuation of the antipsychotic agent (with the 
patient observed for an additional 30 days lag-time for the occurrence of 
diabetes); or the end of follow-up data. Patients could be enrolled in the study on 
one occasion only. 
As noted, to ensure the completeness of the service and prescription data, 
subjects were required to have continuous enrollment in the program, with 
evidence of at least one medical claim, during the 180 days prior to, or the 365 
days subsequent to the index prescription date. 
2.3.3 Timeframe 
The overall timeframe of this study was a five-year period from January 
1, 1997 to December 31, 2001. As discussed in Chapter 1 (section eight), this 
period was selected to minimize the risk of channeling bias, as it predated the 
publication of studies on the association between antipsychotic use and diabetes 
and also the recommendations of an expert panel regarding the choice of 
antipsychotics for patients at risk of diabetes.3;4;9;10;222;227;228;230-232;235-
238;241;243;246;250;277 As previously outlined, to be eligible for the study, patients 
were required to have six months of continuous enrollment prior to the index date 
and a minimum of 12 months follow-up data. Therefore, while the maximum 
observation period for the study was five years, patients could only be enrolled in 
the study between July 1, 1997 and January 1, 2001. The duration of follow-up 
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varied by patient as patients could enter or exit the study at different times. The 
latest possible date of follow-up was December 31, 2001. 
A schematic illustration of the study timeline with patient examples is 
outlined in Figure 2.1. 
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2.3.4 Study Phases 
This study included three phases. Phase I described the study population 
with regard to demographic variables and antipsychotic utilization patterns. 
Phase II examined the prevalence of diabetes in the population. Finally, phase III 
of the study examined the incidence of diabetes in the population. Eligibility for 
the study was determined by the inclusion and exclusion criteria outlined above, 
with as noted, the additional restriction for phase III of the study that participants 
not have diabetes at the time of study enrollment, or in the preceding six months. 
 154
2.4 Study Variables 
In the following section, an operational definition is provided for each of 
the dependent and independent variables included in the study. A complete 
overview of the variables is provided in Appendix C, with a description of the 
Medicaid data files, and the variables included therein, included in Appendix D. 
2.4.1 Dependent Variables 
2.4.1.1 Medication Compliance 
Two components of medication compliance were assessed in this study: 
adherence and persistence. In measuring compliance, prescriptions for different 
dosage strengths of a drug filled on the same day were considered to be part of 
the same prescription. The follow-up period varied by patient and consisted of 
the time from the index prescription to either the development of diabetes, 
discontinuation of therapy, switching of therapy to another antipsychotic, 
addition of another antipsychotic, or end of follow-up data. The two aspects of 
medication compliance, adherence and persistence, were used as covariates in the 
logistic regression analysis examining the relationship between antipsychotic use 
and development of diabetes. 
2.4.1.1.1 Adherence to Antipsychotic Therapy 
Adherence was assessed using a method called medication possession 
ratio (MPR). This technique uses prescription redemption records to reflect the 
number of days that the patient was in possession of their medication and was 
first described in 1991.371 There are a number of assumptions inherent in this 
technique, the most important of which is that the patient is assumed to have 
consumed all the medication in their possession prior to obtaining their next 
refill. MPR was calculated using the following formula: 
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Figure 2.2: Medication Possession Ratio Calculation 371 
MPR =     Σ Number of days of medication supplied 
(Date of last refill + number of days supplied in 
last prescription) – Date of first prescription fill 
 
In order to obtain stable estimates, MPRs were only calculated for 
patients who obtained at least one prescription refill. In addition to examining 
mean MPR rates, patients were categorized according to their level of adherence 
using the following designations: MPR = 0.00 to <0.50, non-adherent; MPR = 
0.50 to <0.80, partially adherent; MPR = 0.80 to <1.10, adherent; and MPR > 
1.10, excess medication filler.341;344;345 As a form of sensitivity analysis, 
adherence was also calculated using an intent-to-treat approach, whereby it was 
measured over a 365-day period for all patients filling more than one 
antipsychotic prescription. That is: 
Figure 2.3: Modified Medication Possession Ratio Calculation 
MPR_365 days =  Σ Number of days of medication supplied 
         365 
 
2.4.1.1.2 Persistence with Antipsychotic Therapy 
Persistence with therapy was defined as the number of days of continuous 
therapy during the follow-up period. In calculating persistence, a 50 percent 
grace-period between prescriptions was allowed.372 For example, patients 
receiving a 30-day supply were considered to have persisted with therapy if they 
refilled their prescription within a 45-day (30 x 1.5) window from that date. 
Patients receiving a 90-day prescription were considered persistent with therapy 
if they refilled their prescription within a 135-day window. Overall persistence 
was then calculated using the following formula: 
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Figure 2.4: Calculation of Persistence 373 
Persistence = Σ Number of persistent days 
 
As a form of sensitivity analysis, persistence was also calculated using a 100 
percent grace-period between prescriptions. That is, a patient was considered 
persistent if they refilled a 30-day prescription within a 60-day window, or a 90-
day prescription within a 180-day window, from the first dispensing date. 
2.4.1.2 Prevalence of diabetes 
In phase II of the study, the primary dependent variable was the 
prevalence of diabetes. This was defined as the detection of a medical claim with 
an ICD-9 code for diabetes (ICD-9 code: 250.0-250.99); or a pharmacy claim for 
insulin, an insulin sensitizing or glucose lowering agent (sulfonylurea, biguanide, 
thiazolidinedione, meglitinide or α-glucosidase inhibitor) at the time of study 
enrollment or in the preceding 180 days. 
2.4.1.3 Time to Occurrence of Diabetes 
This was defined as the duration of time, in days, from the index 
prescription date to the date of a new diagnosis of diabetes as defined by this 
study. 
2.4.1.4 Incidence of diabetes 
In phase III, the primary dependent variable was the incidence of 
diabetes. This was defined as a new medical claim with an ICD-9 code for 
diabetes (ICD-9 code: 250.0-250.99); or a new pharmacy claim or a pharmacy 
claim for insulin, an insulin sensitizing or glucose lowering agent (sulfonylurea, 
biguanide, thiazolidinedione, meglitinide or α-glucosidase inhibitor). The date of 
first recording of one of these events served as the date of diagnosis of new-onset 
diabetes, and was used to estimate the duration of time to the development of 
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diabetes. To ensure that only incident cases were included, the event was 
required to occur at least seven days subsequent to the index antipsychotic 
prescription. In addition, all patients were prescreened to ensure the absence of 
diabetes as defined in this study, during the 180 days preceding the index 
prescription. Finally, to reduce the risk of missing new-onset cases that may have 
been attributable to antipsychotic therapy, new cases of diabetes detected in the 
first 30 days after discontinuation of an antipsychotic agent were attributed to 
that agent. As noted, patients were followed for a maximum of 365 days from the 
index date. 
2.4.2 Independent Variables 
In an attempt to control for factors that may confound the relationship 
between exposure to antipsychotic therapy and the development of diabetes, 
known and possible risk factors for diabetes were included as independent 
variables. These variables were categorized as demographic, clinical, or 
medication variables. The operational definition used for each variable follows.  
2.4.2.1 Demographic Variables: 
2.4.2.1.1 Age 
The reference age used for each study participant was their age in years at 
the time of first dispensing of an antipsychotic agent. This was included as a 
continuous variable. Age was also stratified according to the following 
groupings: 18-34; 35-44; 45-54; 55-64 and age ≥65 years. 
2.4.2.1.2 Gender 





2.4.2.1.3 Race / Ethnicity 
Patients were categorized according to the following racial/ethnic groups: 
Asian-American; Black; Hispanic-American; Native-American; Pacific Islander; 
White; and ‘Others.’ 
2.4.2.2 Clinical Variables 
2.4.2.2.1 Mental Disorder Diagnoses 
Mental disorders were identified by the International Classification of 
Diseases, Ninth Revision diagnostic codes (ICD-9) for mental disorders (ICD-9: 
290 – 319).374 Patients were also stratified into one of six mutually exclusive, 
jointly exhaustive categories. These were: schizophrenia disorders; bipolar 
disorder; dementias; other psychotic disorders; other non-psychotic mental 
disorders; and ‘no mental health diagnosis.’ These categories were created in 
consultation with a clinical expert in the field of psychiatry. A description of the 
conditions contained within each of these groups, together with their ICD-9 
codes, is outlined in Appendix E. Patients with a diagnosis of mental retardation 
(ICD-9: 317-319) were excluded from further analyses because of the difficulty 
of making accurate diagnoses of other mental disorders in this cohort. 
Patients with more than one mental disorder diagnosis were classified 
according to the following rules. If a patient had medical claims with ICD-9 
codes for both schizophrenia and bipolar disorder, the modal diagnosis was used. 
If these diagnoses were present in equal numbers, the diagnosis closest in time to 
the index prescription was used. If the patient had medical claims for 
schizophrenia or bipolar disorder in addition to diagnoses for other psychotic 
disorders, dementia, or non-psychotic disorders, the patient was classified in 
terms of their schizophrenia or bipolar diagnosis. That is, a hierarchical approach 
was taken to the stratification, with other mental disorders being considered to be 
co-morbid to the primary mental disorder diagnosis of schizophrenia or bipolar 
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disorder. For example, a patient with diagnoses of schizophrenia, alcoholic 
psychosis and anxiety disorder was classified as being schizophrenic. A similar 
approach was adopted for patients who had diagnoses for both other psychotic 
disorders and non-psychotic disorders (but not schizophrenia or bipolar disorder). 
It was assumed that these patients received the antipsychotic because of their 
psychotic condition, and they were, therefore, stratified into the ‘other psychotic 
conditions’ group. As an example, a patient with diagnoses for both depressive 
psychoses and anxiety was classified in the ‘other psychotic disorders’ group. 
Patients with comorbid dementia and non-psychotic disorders were preferentially 
categorized in the dementia group. As noted earlier, a breakdown of each of the 
mental disorders by ICD-9 code included in each of the five diagnostic categories 
is included in Appendix E. 
2.4.2.2.2 Hypertension 
This was included as a dichotomous variable: ‘no hypertension’ or 
‘hypertension.’ A diagnosis of hypertension was defined as a medical claim with 
an ICD-9 code of 401.x to 405.x. 
2.4.2.2.3 Dyslipidemia 
Dyslipidemia was defined as a medical claim with an ICD-9 code for 
dyslipidemia (ICD-9 code: 272.0 to 272.4), or a pharmacy claim for lipid 
lowering therapy. A list of these therapies is included in Appendix F. Using these 
specifications, dyslipidemia was included as a dichotomous variable, that is, ‘no 
dyslipidemia’ or ‘dyslipidemia.’ 
2.4.2.3 Medication Variables 
Exposure to an antipsychotic was inferred from a pharmacy claim for one 
of these agents, identified on the basis of their National Drug Code (NDC) 
medication class code. The first identified antipsychotic claim served as the 
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index prescription, with the proviso that no other antipsychotic was issued in the 
preceding 180 days. As noted previously, patients receiving more than one 
antipsychotic on the index date, regardless of antipsychotic class, were not 
included in this study. Commencement of a second antipsychotic agent, 
switching of treatment to another agent or discontinuation of antipsychotic 
treatment constituted a study endpoint. 
2.4.2.3.1 Antipsychotic Class 
Antipsychotic agents were classified as first-generation (Table 2.1), or 
second-generation agents (clozapine, olanzapine, quetiapine, risperidone, 
ziprasidone). 
 








2.4.2.3.2 Antipsychotic Agent 
Patients receiving treatment with a second-generation agent were further 
classified according to the specific agent they received, that is, clozapine, 
olanzapine, quetiapine, risperidone or ziprasidone. 
2.4.2.3.3 Dose 
The daily dose of antipsychotic for any given prescription dispensed was 
inferred from the product of the quantity and strength of the drug dispensed 
divided by the number of days supplied. For example, if a patient received 60, 
three milligram risperidone tablets and had an entry of ‘30’ in the ‘days supply’ 
field, it was inferred that their daily dose of risperidone was six milligrams. Mean 
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and median daily doses were then calculated and examined for appropriateness 
based on achievable doses given known product preparation availability. For 
example, it is inconceivable that doses representing less than a half of a tablet 
could be administered (i.e., a mean daily dose of risperidone less than 0.125mg, 
given the smallest available tablet size of 0.25mg). Similarly, taking more than 
ten tablets a day of a given preparation is unlikely. Any inferred doses falling 
outside these dosage ranges were examined for coding errors. In consultation 
with a clinical expert in psychiatry, extreme maximum daily doses for each agent 
were defined based on knowledge of prescribing practices in this field. For the 
purpose of this study, the accepted mean daily dose for each agent, therefore, 
ranged from a minimum of half the lowest tablet strength available for that agent, 
to the maximum defined by the clinical expert (Table 2.2).  
 
Table 2.2: Available Product Strengths and Mean Daily Dose Ranges Considered for the 
Second-Generation Antipsychotic Agents 
Agent Available Tablet Strengths Dose Range 
Clozapine 36 25mg, 100mg 12.5mg – 1600mg 
Olanzapine37 2.5mg, 5mg, 7.5mg, 10mg, 15mg, 
20mg 
1.25mg – 80mg 
Quetiapine38 25mg, 100mg, 200mg, 300mg 12.5mg – 2400mg 
Risperidone39 0.25mg, 0.5mg, 1mg, 2mg, 3mg, 4mg 0.125mg – 16mg 
Ziprasidone40 20mg, 40mg, 60mg, 80mg 20mg* – 260mg 
* Minimum strength available is a 20mg capsule. 
Calculated mean daily doses for antipsychotics falling outside this range 
were excluded from analyses to prevent the undue influence of outliers, and to 
minimize the impact of coding errors. As a form of sensitivity analysis, mean 
(median) daily doses were also calculated taking into account gaps in patient 
therapy (which were presumably due to non-adherence). For example, a patient 
receiving three, thirty-day prescriptions for risperidone three milligrams over a 
110-day period (that is, with two 10-day gaps between refill prescriptions) would 
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have a calculated mean daily dose of 2.45 milligrams (3x30x3/110) compared to 
a calculated dose of 3 milligrams (3x30x3/90) using the former method of 
calculating mean daily dose. 
To facilitate dose-based comparisons between the second-generation 
antipsychotic agents, patients were classified as receiving ‘Low,’ ‘Medium,’ or 
‘High’ dose antipsychotic therapy based on their derived mean daily dose of 
antipsychotic. These strata were developed in consultation with a clinical expert 
in psychiatry and were based on the therapeutic efficacy of the agents (Table 
2.3). As discussed in section 1.10.4 (Chapter 1), lower doses of antipsychotics 
are typically recommended in elderly patients due to differences in the efficacy 
and tolerability of these agents in this population. A modified dose stratification 
was, therefore, also used for patients aged 65 years or older (Table 2.3). 
 
Table 2.3: Classification of Mean Daily Dose (Milligrams) of Olanzapine, Quetiapine and 
Risperidone as ‘Low,’ ‘Medium,’ or ‘High’ Dose Therapy and Modified Classification for 
Patients Aged 65 Years or Older 
Agent Olanzapine Quetiapine Risperidone 
All Patients    
 Low Dose ≤ 10 ≤ 300 ≤ 2 
 Medium Dose >10 - 15 >300 – 600 >2 – 6 
 High Dose > 15 > 600 > 6 
≥ 65 Years    
 Low Dose ≤ 5 ≤ 100 ≤ 0.5 
 Medium Dose 5 - 10 >100 – 300 >0.5 – 1.5 
 High Dose > 10 > 300 > 1.5 
 
2.4.2.3.4 Duration of Antipsychotic Treatment 
The duration of treatment of the antipsychotic was inferred from the sum 
of the number of days supplied. A patient was considered to have discontinued 
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treatment if a refill for the prescription did not occur within a specified timeframe 
(i.e., refill of the prescription during the time covered by the existing prescription 
plus a 50% grace-period). For example, if a prescription was for a 30-day supply, 
it was assumed that the treatment was discontinued if no refill occurred within 45 
days (30 x 1.5) of dispensing. As an additional sensitivity analysis, the duration 
of therapy was also calculated allowing for a 100 percent grace-period between 
prescriptions (e.g., a patient with a 30-day prescription was considered to have 
discontinued therapy if they did not refill the prescription within 60 days of this 
being dispensed). Duration of therapy and persistence with therapy were 
synonymous terms, with the exception that persistence was only calculated for 
patients filling more than one antipsychotic prescription. 
2.4.2.3.5 Concomitant Diabetogenic Medications 
Certain agents are known to increase the risk of diabetes and had the 
potential to confound the study. These included: ß-adrenergic blockers; 
glucocorticoids; oral contraceptive pills containing norgesterol; phenytoin; 
thiazide diuretics and valproic acid.204 Consideration was given only to 
concurrent prescriptions for any of these agents. Data were dichotomized on the 
basis of presence (1) or absence (0) of any one of the drug classes here listed. 
2.4.2.4 Unavailable Variables 
Several variables known to increase the risk of diabetes were not included 
in this study as this information was not available in the Medicaid database. 
These included a family history of diabetes, measures of weight, body mass 
index, central adiposity, and lifestyle issues such as a sedentary lifestyle or 
consumption of a high caloric diet. The absence of this information represents a 
limitation of this study. 
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2.5 Sample Size Calculations 
To determine the minimum sample size required in a cohort study, four 
pieces of information are required: 1) the desired type I error rate, α, including 
details of its use for one-tailed or two-tailed statistical analyses; 2) the desired 
type II error rate; 3) the incidence of disease in the unexposed population; and 4) 
the relative risk of disease in the exposed population that it is important to detect. 
In this study, the type I error rate (α-level) was set at 0.05 for all statistical 
analyses. Although larger or smaller values can be used, 0.05 is conventionally 
used in cohort studies. Likewise, the maximal type II error rate (β-level) viewed 
to be acceptable was 0.2, giving a minimum accepted power level of 0.8 (i.e., 1- 
β). Again, by convention, a type II error rate of 0.2 is commonly used in cohort 
studies. The incidence of diagnosed diabetes among adults aged 18 to 79 years 
was estimated to be 7.0 per 1,000 population in the U.S. in 2000.375 Of note, this 
incidence is dependent on age, gender and race/ethnicity with a higher incidence 
noted in older adults, males and among Blacks and Hispanics.375 The highest 
incidence of diagnosed diabetes in 2002 was among men aged 45 to 64 years 
with 13.5 new cases per 1,000 population noted (compared to 12.0 new cases per 
1,000 population for women of a similar age).375 As the majority of patients 
within the dataset were older adults; an incidence of 12.5 per 1,000 population 
was arbitrarily selected, as opposed to the national average, to reflect the study 
population. Based on the available literature, the relative risk of developing 
diabetes ranged from 1.05–4.97* in patients treated with first-generation 
antipsychotics and from 0.9–4.7* for those treated with second-generation 
antipsychotics compared to patients not treated with antipsychotics.3;4;9;10;232;236-
238 Similarly, when compared to patients treated with first-generation 
antipsychotics, the relative risk of developing diabetes ranged from 1.0–2.6* for 
those treated with a second-generation agent.4;241;243;246;250 To be conservative, 
* Statistically significant finding 
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and taking into consideration the minimum accepted relative risk to determine 
clinical significance, a relative risk of 2.0 was selected.375 This ratio of exposed 
to unexposed study subjects impacts the statistical power of the study, with an 
equal number of exposed to unexposed subjects required to obtain an 80 percent 
power of detecting an effect.375 Further increases in the size of the unexposed 
group compared to the exposed group, for example from 1:1 to 2:1 to 3:1, 
provides progressively smaller gains in statistical power while greatly increasing 
the sample size required.375 In this study, the ratio of exposed to unexposed study 
subjects was set at 1:1. 
A number of different formulae have been used to estimate sample size 
based on the parameters specified above. One commonly used formula in cohort 
studies is: 
Figure 2.5: Sample Size Calculation 375 
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where p is the incidence of the disease in the unexposed population, R is the 
minimum relative risk, α is the type I error rate, β is the type II error rate, Z1-α/2 
and Z1-β are the unit normal deviates corresponding to α (two-tailed testing) and 
β, and K is the ratio of control subjects to the number of exposed subjects.375 
Finally U is defined as:  






Using these defined parameters, the number of subjects required in each 
comparison group was 1,927 in two-tailed analyses. 
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2.6 Data Collection 
As noted, this was a retrospective database analysis using electronic 
medical and prescription records of Texas Medicaid enrollees aged 18 years or 
older, who received antipsychotic medications. Medicaid enrollee and clinical 
data were collected with the assistance of the Research and Forecasting 
Department of the Texas Health and Human Services Commission (THHSC). 
Data included age, gender, race/ethnicity and information on mental disorder, 
hypertension and diabetes-related medical claims as identified by ICD-9 codes. 
Medicaid pharmacy data were collected, with the permission of the THHSC, 
from The University of Texas at Austin, which is licensed to use these data. 
Pertinent data from the pharmacy databases included age, gender, date of service 
and information on the medications dispensed. Unique identifiers assigned to the 
patient-level data were used to merge the various data files. Appendix D includes 
a description of the Medicaid data files and the variables included therein. 
2.7 Data Analyses 
All data manipulation, descriptive and inferential statistical analyses were 
performed using SPSS software (version 13.0 for Windows, Chicago, 2004) and 
Visual FoxPro software. A preliminary examination of the data was conducted 
using frequencies for each variable to check for data abnormalities. Statistical 
analyses appropriate for testing the stated hypotheses were used. All statistical 
analyses were two-tailed, with statistical significance set a priori at 0.05. 
Differences in demographic and clinical variables were analyzed as follows. 
Categorical variables, such as gender, were examined using chi-square tests. 
Continuous variables such as age and duration of follow-up were examined for 
normality and analyzed using Student’s t-tests or analysis of variance (ANOVA) 
or, if violating the assumption of normality, with the Mann-Whitney or Kruskal-
Wallis tests, respectively. Post-hoc analyses to investigate significant differences 
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in ANOVA tests were conducted as appropriate. The Scheffé test was used where 
sample sizes differed, but group variances were equal. The Games-Howell test 
was used in instances where both sample size and group variances were unequal. 
2.7.1 Medication Compliance 
As noted previously, two components of medication compliance were 
assessed in this study: adherence and persistence, with adherence being assessed 
using the medication possession ratio (MPR) method. Bivariate analyses were 
conducted comparing mean (median) MPR rates according to demographic 
variables (age, gender, ethnicity), by class of antipsychotic (first-generation vs. 
second-generation), by the specific second-generation antipsychotic (clozapine, 
olanzapine, quetiapine, risperidone and ziprasidone) and by primary mental 
disorder diagnosis (schizophrenia, bipolar disorders, other psychotic disorders, 
dementias, other non-psychotic mental disorder diagnoses, and no mental health 
diagnosis). In addition, patients were categorized and compared according to 
their level of adherence using the following designations: MPR = 0 to < 0.5, non-
adherent; MPR = 0.50 to <0.8, partially adherent; MPR = 0.80-1.10, adherent; 
and MPR > 1.10, excess medication filler. Mean MPR rates were compared using 
the Student’s t test or ANOVA (or if violating the assumption of normality, with 
the Mann-Whitney test) as appropriate. Post-hoc analyses to investigate 
significant differences in ANOVA tests were conducted where necessary.  
As with adherence, bivariate analyses were conducted examining 
differences in mean persistence rates according to patient demographic variables, 
by class of antipsychotic (first-generation vs. second-generation), by specific 
second-generation antipsychotic (clozapine, olanzapine, quetiapine, risperidone 
and ziprasidone) and by primary mental disorder diagnosis (schizophrenia, 
bipolar disorders, other psychotic disorders, dementias, other non-psychotic 
mental disorder diagnoses, and no mental health diagnosis). The statistical 
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techniques used to make these comparisons were as for those used to compare 
adherence rates. 
Adherence and persistence with antipsychotic therapy were used as 
covariates in the logistic regression analysis examining the relationship between 
antipsychotic use and development of diabetes. 
2.7.2 Prevalence of Diabetes 
The prevalence of diabetes was defined as the number of cases of 
prevalent diabetes as a percentage of eligible patients. This definition applied 
regardless of the stratification used: age; gender; race/ethnicity or primary mental 
disorder diagnosis. Despite the fact that patients may have had multiple mental 
disorder diagnoses during the study period, all patients were classified according 
to their primary mental disorder diagnosis, as defined for the purpose of this 
study. Additional or secondary mental disorder diagnoses were not considered 
when prevalence rates were examined. Patients could, therefore, only contribute 
as a single case to the denominator for each of the strata examined: age; gender; 
race/ethnicity or primary mental disorder diagnosis. Comparison of prevalence 
rates between strata were examined using the Pearson chi-square test. In addition, 
patients were dichotomized into two groups: those with a diagnosis of diabetes 
during the study period; and those without, and logistic regression analyses were 
used to assess the prevalence of diabetes after controlling for demographic (i.e., 
age, gender, race/ethnicity), and clinical (i.e., primary mental disorder diagnosis, 
hypertension, dyslipidemia) risk factors for diabetes. This is the preferred method 
of biostatistical analysis because of its robustness against violations of 
multivariate normality.376 This method of analysis allows multiple comparisons 
to be made without inflation of the type I error rate of the study.376 Variables 
with high correlations were assessed to avoid multicollinearity. The following 
model was used: 
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Where Ŷi was the estimated probability of individual i developing diabetes and u 
was the linear combination  
Figure 2.8: Definition of U for the Regression Model376 
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with constant B0, coefficients Bj and predictors Xj for k predictors (j = 1,2…..k). 
Taking the natural logarithm of both sides, the model was rewritten as: 













Where the odds of developing diabetes for an individual i, depended on the value 
of the constant B0, as well as the contribution of the variables used in the model. 
The variables included in the study model are outlined in Appendix G. Using this 
model, one hypothesis was tested: that the prevalence of diabetes did not differ 
based on primary mental health diagnosis, after controlling for all other variables. 
2.7.3 Time to Occurrence of Diabetes 
The time to occurrence of diabetes was compared between the first- and 
second-generation antipsychotics (as groups), and among the individual second-
generation antipsychotics. The Cox proportional hazards regression model was 
used in these analyses to estimate survival. This method describes the time-to-
event for all observations, predicts the association between a set of independent 
variables (continuous or categorical) and a dependent variable, and has the 
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advantage of allowing the use of censored data.377 The data in this study were 
right-censored, in that the outcome of interest (i.e., development of diabetes) may 
not have occurred during the study follow-up period. That is, data were 
considered censored for any patient who did not develop diabetes and for whom 
the study endpoint was the discontinuation or switching of antipsychotic therapy, 
or who had not developed diabetes by the end of the study follow-up period. This 
method examines the cumulative probability of surviving (i.e., remaining 
diabetes-free) over time, and provides an unbiased estimate of this survival time 
when censored data are being used.377 
2.7.4 Incidence of diabetes 
Phase III of the study related to the incidence of diabetes and was defined 
as the number of new-onset cases of diabetes as a percentage of the number of 
eligible patients. As outlined in the inclusion criteria, to be eligible for this phase 
of the study, patients were required to meet an additional criterion, that is, no 
history of diabetes in the 180 days prior to study enrollment. This applied 
regardless of the stratification used: age; gender; race/ethnicity; primary mental 
health diagnosis; class of antipsychotic or specific type of second-generation 
antipsychotic used. Comparisons of incidence rates between strata were 
examined using the Pearson chi-square test. Logistic regression analysis was 
used to determine the relative odds of diabetes according to the specific second-
generation antipsychotic agent after adjusting for demographic, clinical and 
medication variables. Patients were again dichotomized into two groups: those 
developing diabetes during the study period; and those who did not. Three study 
models were developed. Model 1 tested the hypothesis that the incidence of 
diabetes did not differ based on class of antipsychotic agent, while controlling for 
all other variables. Model 2 tested the hypothesis that the incidence of diabetes 
did not differ according to the specific type of second-generation antipsychotic 
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used (olanzapine, quetiapine or risperidone), while controlling for all other 
variables. Model 3 tested six hypotheses, that is, that the incidence of diabetes 
did not differ according to the dose of antipsychotic used, for each of the three 
different second-generation antipsychotic agents (olanzapine, quetiapine, 
risperidone) and that the incidence of diabetes did not differ according to the 
primary mental diagnosis for each of the three different second-generation 
antipsychotic agents, while controlling for other variables. The variables included 
in each of these study models are outlined in Appendix H. No patient received 
ziprasidone as their index antipsychotic agent, and the used of clozapine was 
limited; therefore, regression analysis were not performed for these agents.  
2.7.5 Hypothesis Testing and Associated Statistical Methods 
Table 2.4 contains a summary of the hypotheses that were tested in this 
study, the study measures used for each hypothesis and the statistical techniques 
used to test the hypotheses. 
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Table 2.4: Hypotheses Tested, Study Measure(s) and Statistical Techniques 
Hypothesis Study Measure Statistical Technique 
Phase 1: Epidemiology and Antipsychotic 
Utilization Patterns (Objective 1) 
H0(1a): The percentage of patients receiving 
treatment with the different antipsychotic 
agents will not differ significantly when 
stratified according to patient age. 
 
 





Pearson Chi-square (χ2) 
 
H0(1b): The percentage of patients receiving 
treatment with the different antipsychotic 
agents will not differ significantly when 
stratified according to patient gender. 
Agent (class) specific 
prevalence of 
antipsychotic use 
Pearson Chi-square (χ2) 
 
H0(1c): The percentage of patients receiving 
treatment with the different antipsychotic 
agents will not differ significantly when 
stratified according to patient race/ethnicity. 
Agent (class) specific 
prevalence of 
antipsychotic use 
Pearson Chi-square (χ2) 
 
H0(1d): The percentage of patients receiving 
treatment with the different antipsychotic 
agents will not differ significantly when 
stratified according to patient primary mental 
health diagnosis. 
Agent (class) specific 
prevalence of 
antipsychotic use 
Pearson Chi-square (χ2) 
 
Phase 1: Epidemiology and Antipsychotic 
Utilization Patterns (Objective 2) 
H0(2a): The classification of mean daily 
antipsychotic dose as ‘Low,’ ‘Medium,’ or 
‘High’ will not differ significantly when 
stratified according to the second-generation 
antipsychotic (clozapine, olanzapine, 
quetiapine, risperidone, ziprasidone) used. 
 
 
Categorized mean daily 





Pearson Chi-square (χ2) 
 
H0(2b-f): The mean daily dose for the second-
generation antipsychotics (clozapine (2b) 
olanzapine (2c), quetiapine (2d), risperidone 
(2e), and ziprasidone (2f)) will not differ 
significantly when stratified according to 
patient age. 
Mean daily dose of the 
specific second-
generation antipsychotics 
stratified by age 
ANOVA 
 
H0(2g-k): The mean daily dose for the second-
generation antipsychotics (clozapine (2g), 
olanzapine (2h), quetiapine (2i), risperidone 
(2j), ziprasidone (2k)) will not differ 
significantly when stratified according to the 
primary mental health diagnosis. 
 
Mean daily dose of the 
specific second-
generation antipsychotics 




Table 2.4: Hypotheses Tested, Study Measure(s) and Statistical Techniques (continued) 
Hypothesis Study Measure Statistical Technique 
Phase 1: Epidemiology and Antipsychotic 
Utilization Patterns (Objective 2 continued) 
H0(3a): Adherence with antipsychotic therapy 
will not differ significantly when stratified 








H0(3b): Persistence with antipsychotic therapy 
will not differ significantly when stratified 
according to patient age. 
Age-specific persistence 
with antipsychotic therapy 
ANOVA 
H0(3c): Adherence with antipsychotic therapy 
will not differ significantly when stratified 





H0(3d): Persistence with antipsychotic therapy 
will not differ significantly when stratified 





H0(3e): Adherence with antipsychotic therapy 
will not differ significantly when stratified 





H0(3f): Persistence with antipsychotic therapy 
will not differ significantly when stratified 





H0(3g): Adherence with antipsychotic therapy 
will not differ significantly when stratified 






H0(3h): Persistence with antipsychotic therapy 
will not differ significantly when stratified 






H0(3i): Adherence with antipsychotic therapy 
will not differ significantly when stratified 
according to the antipsychotic agent 
prescribed. 
Agent-specific adherence 
with antipsychotic therapy 
ANOVA 
H0(3j): Persistence with antipsychotic therapy 
will not differ significantly when stratified 




with antipsychotic therapy 
ANOVA 
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Table 2.4: Hypotheses Tested, Study Measure(s) and Statistical Techniques (continued) 
Hypothesis Study Measure Statistical Technique 
Phase II: Prevalence of Diabetes (Objective 3) 
H0(4a): The prevalence of diabetes will not differ 
significantly according to the primary mental 
health diagnosis, after controlling for 
demographic, clinical and medication risk 
factors for diabetes. 
 
Diagnosis-specific 
prevalence of diabetes 
 
Pearson Chi-square (χ2)* 
Logistic regression 
Phase III: Incidence of Diabetes (Objective 4) 
H0(5a): The time to occurrence of diabetes will 
not differ significantly according to the class of 
antipsychotic agent (first or second-generation) 
used, after controlling for demographic, clinical 
and medication risk factors for diabetes. 
 
Class-specific time to 






H0(5b): The time to occurrence of diabetes will 
not differ significantly according to the specific 
second-generation antipsychotic used, after 
controlling for demographic, clinical and 
medication risk factors for diabetes. 
Agent-specific time to 





H0(6a): The incidence of diabetes will not differ 
significantly according to the class of 
antipsychotic agent used (first or second-
generation) after controlling for demographic, 
clinical and medication risk factors for diabetes. 
Class-specific 
incidence of diabetes 
Pearson Chi-square (χ2)* 
Logistic regression 
H0(6b): The incidence of diabetes will not differ 
significantly according to the specific second-
generation antipsychotic agent used after 
controlling for demographic, clinical and 
medication risk factors for diabetes. 
Agent-specific 
incidence of diabetes 
Pearson Chi-square (χ2)* 
Logistic regression 
H0(7a-e): The incidence of diabetes will not differ 
significantly according to the dose used for the 
second-generation antipsychotic agents 
(clozapine (7a), olanzapine (7b), quetiapine (7c), 
risperidone (7d), ziprasidone (7e)) after 
controlling for demographic, clinical and 
medication risk factors for diabetes. 
Dose-specific 
incidence of diabetes 
Pearson Chi-square (χ2)* 
Logistic regression 
H0(8a-e): The incidence of diabetes will not differ 
significantly according to the primary mental 
disorder diagnosis for the second-generation 
antipsychotic agents (clozapine (8a), olanzapine 
(8b), quetiapine (8c), risperidone (8d), 
ziprasidone (8e)) after controlling for 
demographic, clinical and medication risk 
factors for diabetes. 
Indication-specific 
incidence of diabetes 
Pearson Chi-square (χ2)* 
Logistic regression 
* Refers to bivariate analysis 
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Chapter 3: Results 
This chapter details the results of the study, and includes a description of 
the study population and analysis of each of the study objectives. Patients who 
filled at least one prescription for an antipsychotic agent were identified using 
electronic medical records over a five-year period from January 1, 1997 to 
December 31, 2001, as depicted in Figure 2.1, Chapter 2. The date of the first 
antipsychotic prescription was selected as the index date. These patients were 
followed for a maximum of 12 months from the index date until a study endpoint 
occurred, with each patient eligible for enrollment in the study on one occasion 
only. The study sample consisted of 19,430 Texas Medicaid enrollees. The study 
was divided into three phases: phase I described demographic and antipsychotic 
utilization patterns; phase II described the prevalence of diabetes; and phase III 
described the incidence of diabetes in the study population. Eligibility criteria for 
the study were: 1) age 18 years or older; 2) receipt of a first- or second-
generation antipsychotic agent, but having a six-month (180-day) antipsychotic-
free window prior to the identification of the index prescription; 3) continuous 
enrollment for six months prior to, and 12 months subsequent to the index date; 
with 4) evidence of at least one medical claim in this time. The study was limited 
to patients receiving antipsychotic monotherapy, with an additional restriction for 
phase III of the study that the patients not have a history of diabetes at the time of 
study enrollment, or in the preceding six months. Table 3.1 outlines the study’s 
exclusion criteria with the corresponding sample size remaining after the 
implementation of each criterion. 
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Table 3.1: Study Exclusion Criteria and Sample Size 
Exclusion Criteria Excluded Sample Size 
Patients receiving an antipsychotic 
prescription 
 129,860 
Age < 18 years 9,090 120,770 
No antipsychotic-free window1 78,796 41,974 
Not continuously enrolled2 18,261 23,713 
Absence of a medical claim3 4,046 19,667 
Combination antipsychotic therapy4 237 19,430 
Phases I & II 
 Study sample size 
  
19,430 
Preexisting diabetes5 3,293 16,137 
Phase III 
 Study sample size 
  
16,137 
1. No antipsychotic dispensed in six-months prior to index prescription date. 
2  For six-months prior to, and 12-months post the index prescription date. 
3  Minimum one medical claim in the six-months prior to, or 12-months post the index 
prescription date. 
4  Receiving more than one antipsychotic agent on the index date. 
5  History of diabetes in the six months prior to, or six days post the index date. 
 
The results of the study are presented in order of the study objectives and 
in accordance with the relevant study phase, i.e.: 
• Phase I: Epidemiology and Antipsychotic Utilization Patterns (Objectives 1-2); 
• Phase II: Prevalence of Diabetes (Objective 3); 
• Phase III: Incidence of Diabetes (Objective 4). 
Within each section, the hypotheses and associated statistical analyses are 
presented. 
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3.1 Phase I: Epidemiology and Antipsychotic Utilization Patterns 
Three categories of independent study variables were examined: 
demographic, clinical and medication-related variables. The demographic 
variables examined were the age, gender and race/ethnicity of the study 
participants. The clinical variables comprised: primary mental health diagnosis, 
and diagnosis of hypertension or dyslipidemia. Medication variables included: 
class of antipsychotic; specific second-generation antipsychotic used; mean daily 
antipsychotic dose; compliance with antipsychotic therapy; duration of 
antipsychotic therapy and use of concomitant diabetogenic medications. 
3.1.1 Demographic Variables 
Demographic characteristics available from patient medical records were 
age, gender and race/ethnicity. The statistics to describe these variables are 
discussed below, with the data shown in Tables 3.2 to 3.5. 
3.1.1.1 Age and Gender (Objective 1) 
The average patient age was 60.3 years (SD: 21.9). As specified in the 
inclusion criteria, patients were required to be 18 years or older at the index date. 
In accordance with HIPAA regulations, age data for patients aged greater than 89 
years were collapsed to a maximum value of 89 years. When stratified according 
to the age groupings: 18-34; 35-44; 45-54; 55-64; and ≥65, the majority of 
patients (47.6%) were 65 years or older (Table 3.2). Patients were approximately 
equally distributed between the first three strata, with these strata accounting for 
44.3 percent of the overall cohort. As illustrated in Table 3.3, approximately two-
thirds of the population was female. 
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Table 3.2: Age Distribution in the Texas Medicaid Study Population 
Age Group (Years) N Percent (%) 
18-34 2,835 14.6 
35-44 3,063 15.8 
45-54 2,700 13.9 
55-64 1,581 8.1 
≥ 65 9,251 47.6 
Total 19,430 100.0 
 
 
Table 3.3: Gender Distribution in the Texas Medicaid Study Population 
Gender N Percent (%) 
Male 6,659 34.3 
Female 12,771 65.7 
Total 19,430 100.0 
 
A bivariate analysis of age and gender revealed that patient age differed 
significantly by gender. Male enrollees were significantly younger (t=-37.469, 
df=19,428, p<0.001) than their female counterparts, with a mean age of 52.4 
years (SD: 21.5) for men compared to 64.4 years (SD: 21.0) for women. 
3.1.1.2 Race/Ethnicity (Objective 1) 
Table 3.4 outlines the racial/ethnic distributions of the study population. 
The majority of enrollees were White (55.1%), with Blacks the next largest 
racial/ethnic group (21.4%), followed by Hispanics (16.4%). 
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Table 3.4: Race/Ethnicity Distribution in the Texas Medicaid Study Population 
Race/Ethnicity N Percent (%)1 
White 10,712 55.1 
Black 4,148 21.4 
Hispanic 3,190 16.4 
Native American 55 0.3 
Asian 127 0.7 
Other 1,198 6.2 
Total 19,430 100.1 
1. Percentage does not add to 100.0, due to rounding. 
 
In a bivariate analysis of race and age, the mean age of enrollees differed 
significantly (F=361.953, df=3, p<0.001) according to race/ethnicity with White 
enrollees being the oldest (Table 3.5).  Post-hoc analyses revealed significant 
differences (p<0.001) between all possible contrasts. 
 
Table 3.5: Distribution of Race/Ethnicity by Age in the Texas Medicaid Study Population 
Race/Ethnicity Mean Age (Years)1 SD2 
White 64.3 21.9 
Black 53.8 20.3 
Hispanic 59.7 21.1 
Native American/Asian/Other  49.9 20.2 
All 60.3 21.9 
1. p<0.001 for both ANOVA and Kruskal-Wallis tests. 
2. Abbreviations: SD – Standard Deviation. 
 
The race/ethnicity of the study population also differed significantly by 
gender (χ2=94.225, df=3, p<0.001). For example, women accounted for only 
60.1 percent of Hispanic enrollees compared to 68.1 percent of White enrollees.  
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3.1.2 Clinical Variables 
Clinical factors with the potential to confound the relationship between 
exposure to an antipsychotic and development of diabetes were examined in the 
study. Descriptive statistics for each of the variables are outlined below, with 
summary data outlined in Tables 3.6 to 3.8. 
3.1.2.1 Primary Mental Health Diagnosis (Objective 1) 
Mental health diagnoses were identified using ICD-9 diagnostic codes, a 
breakdown of which is included in Appendix E. Patients were stratified into one 
of five mutually exclusive, jointly exhaustive categories in accordance with the 
criteria outlined in section 2.4.2.2.1 (Chapter 2). Patients with a diagnosis of 
mental retardation were excluded from further analyses because of the difficulty 
in making accurate diagnoses of other mental disorders in this cohort. Two 
thousand, two hundred patients (11.3%) had a diagnosis of mental retardation. 
Thirty-one percent of the remaining 17,230 of enrollees had no mental health 
diagnosis. Whereas antipsychotics are only approved for use in schizophrenia 
and bipolar disorder, only 16.5 percent of enrollees were classified as having 
schizophrenia with a further 15.5 percent classified as having bipolar disorder 
(Table 3.6). 
Approximately one-third of the enrollees (32.1%) had more than one type 
of mental health diagnosis. For example, among patients classified as having 
schizophrenia, 52.8 percent had at least one other type of mental health 
diagnosis, with 37.4 percent having two other types of mental health diagnoses. 
Common comorbid mental health conditions are outlined in Table 3.7.  
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Table 3.6: Frequency Distribution of Primary Mental Health Diagnoses in the Texas 
Medicaid Study Population 
Diagnostic Category N Percent (%)2 
Schizophrenia 2,836 16.5 
Bipolar Disorder 2,678 15.5 
Dementia 2,465 14.3 
Psychotic Disorder 1,402 8.1 
Non-Psychotic Disorder 2,503 14.5 
No Mental Health Diagnosis 5,346 31.0 
Total 17,2301 99.9 
1. N=2,200 Medicaid enrollees (11.3%) with diagnosis of mental retardation excluded. 




Table 3.7: Frequency of Comorbid Mental Health Conditions for Texas Medicaid Enrollees 
Stratified according to Primary Mental Health Category 
 Comorbid Condition(s) (%) 




Schizophrenia 100.0 13.12 3.1 11.4 45.8 
Bipolar Disorder 11.62 100.0 9.6 14.1 66.6 
Dementia N/A N/A 100.0 32.3 43.1 
Psychotic 
Disorder 
N/A N/A N/A 100.0 43.6 
Non-Psychotic 
Disorder 
N/A N/A N/A N/A 100.0 
1. All patients categorized according to hierarchical process. 




3.1.2.2 Hypertension (Objective 1) 
Hypertension was included as a dichotomous variable: ‘no hypertension,’ 
or ‘hypertension,’ and was defined as a medical claim with an ICD-9 code for 
hypertension. Overall, 24.9 percent of the population was defined as being 
hypertensive. 
3.1.2.3 Dyslipidemia (Objective 1) 
Dyslipidemia was defined as a medical claim with an ICD-9 for 
dyslipidemia, or a pharmacy claim for lipid lowering therapy. Using these 
specifications, it was included as a dichotomous variable: ‘no dyslipidemia,’ or 
‘dyslipidemia,’ and accordingly 9.2 percent of the population was defined as 
having dyslipidemia (Table 3.8). 
 
Table 3.8: Diagnosis of Dyslipidemia in the Texas Medicaid Study Population 
Diagnosis N Percent (%) 
Dyslipidemia 1,790 9.2 
 Identified by:   
  ICD-9 code only 1 731 3.8 
  Rx only 1 741 3.8 
  ICD-9 code and Rx 1 318 1.6 
No Dyslipidemia 17,640 90.8 
Total 19,430 100.0 
1. Abbreviations: ICD-9 - International Classification of Diseases, Ninth revision; Rx - 




3.1.3 Medication Variables 
3.1.3.1 Concomitant Diabetogenic Medications (Objective 1) 
Several classes of medications are known to increase the risk of diabetes 
and had the potential to confound this study. Overall, 26.2 percent of the 
population received a concomitant diabetogenic medication during the interval 
between their index antipsychotic prescription and their study endpoint. The 
frequency distribution of patients who received concomitant diabetogenic 
medications is illustrated in Table 3.9. 
 
Table 3.9: Percentage of Texas Medicaid Study Population Treated with Concomitant 
Diabetogenic Medications 
Concomitant Diabetogenic Medications N % 
Beta-adrenergic-blocker 1,228 6.3 
Glucocorticoid 646 3.3 
Oral contraceptive agent containing norgesterol 176 0.9 
Phenytoin 988 5.1 
Thiazide diuretic 1,103 5.7 
Valproic acid 1,821 9.4 
Total1 5,099 26.2 
1.  Categories were not mutually exclusive; therefore, the total represents the percentage of the 
population that received one or more classes of a concomitant diabetogenic medication. 
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3.1.3.2 Antipsychotic Medication Class and Specific Type (Objective 2) 
This study examined the use of antipsychotic monotherapy, whereby 
exposure was inferred from a pharmacy claim for one of these agents. The first 
identified antipsychotic agent was considered to be the index agent with the 
proviso that no other antipsychotic was dispensed in the preceding 180 days. A 
first-generation antipsychotic was prescribed as index therapy to 29.3 percent of 
the population, with haloperidol the most commonly used (52.3%) of these 
agents (Table 3.10). Risperidone was the most commonly used second-
generation agent, accounting for 42.2 percent of all antipsychotic therapy and 
approximately 60 percent of all second-generation antipsychotic therapy (Table 
3.10). Clozapine was infrequently used, and no patient received ziprasidone as 
their index agent.  
 
Table 3.10: Frequency Distribution of Index Antipsychotic Therapy for the Texas Medicaid 
Study Population 
Antipsychotic Class (Agent) N Percent (%) 
First-Generation Agent 1 5,699 29.3 
Second-Generation Agent 13,731 70.7 
 Clozapine 93 0.5 
 Olanzapine 4,199 21.6 
 Quetiapine 1,231 6.3 
 Risperidone 8,208 42.2 
Total 19,430 100.0 
1. First-generation agents included: Chlorpromazine; Fluphenazine; Haloperidol; Loxapine; 




3.1.3.2.1 Use of Specific Antipsychotic Agents According to Age 
H1a: The percentage of patients treated with the different antipsychotic 
agents will not differ significantly when stratified according to patient 
age.  
 
A significant difference was noted in a Chi-square analysis testing the 
relationship between choice of index antipsychotic agent and patient age (χ2 = 
416.748, df=16, p<0.001). While quetiapine use did not vary by age strata (range 
6.2% to 6.6%), use of other agents varied considerably (Table 3.11). In 
particular, the percentage of patients treated with risperidone varied from 34.6 
percent for those aged between 35 and 44 years, to 48.3 percent of those aged 65 
years or older. Compared to their younger counterparts, patients age 65 years or 
older were less likely to receive clozapine, olanzapine or a first-generation 
antipsychotic, but more likely to receive risperidone (Table 3.11).  
H1a:   Rejected. 
 
3.1.3.2.2 Use of Specific Antipsychotic Agents According to Gender 
H1b: The percentage of patients treated with the different antipsychotic 
agents will not differ significantly when stratified according to patient 
gender. 
 
As seen in Table 3.11, Chi-square analysis showed a significant 
relationship between choice of index antipsychotic agent and patient gender (χ2 = 
76.901, df=4, p<0.001). When compared to their female counterparts, male 
patients were more likely to receive a first-generation antipsychotic (31.6% vs. 
28.2%), clozapine (0.8% vs. 0.3%) or olanzapine (22.4% vs. 21.2%). In contrast, 
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risperidone and quetiapine use were more common in women than men (43.5% 
vs. 39.9%, and 6.9% vs. 5.3%, respectively). 
H1b:   Rejected. 
3.1.3.2.3 Use of Specific Antipsychotic Agents According to Race/Ethnicity 
H1c: The percentage of patients treated with the different antipsychotic 
agents will not differ significantly when stratified according to patient 
race/ethnicity.  
. 
The use of the various antipsychotic agents differed significantly when 
stratified according to patient race/ethnicity (χ2 = 160.710, df=12, p<0.001). 
Blacks were less likely to receive olanzapine or risperidone, and more likely to 
receive a first-generation antipsychotic when compared to the other racial/ethnic 
groups (Table 3.11). Conversely, Hispanic patients were more likely to receive 
risperidone, and less likely to receive a first-generation antipsychotic. 
H1c:    Rejected. 
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Table 3.11: Distribution of Index Antipsychotic Agent for Texas Medicaid and when 
Stratified According to Age, Gender, Race/Ethnicity and Primary Mental Health Diagnosis 
 Index Antipsychotic Agent (%)1 
Stratifications FGA Clozapine 2 Olanzapine Quetiapine Risperidone 
Overall 3 29.3 0.5 21.6 6.3 42.2 
Age (years)       
 18-34 29.2 1.7 16.7 6.3 46.1 
 35-44 33.0 0.8 25.4 6.3 34.6 
 45-54 33.6 0.4 23.9 6.2 35.8 
 55-64 30.6 0.3 22.1 6.6 40.4 
 ≥ 65 26.7 0.1 18.7 6.3 48.3 
Gender      
 Male 31.6 0.8 22.4 5.3 39.9 
 Female 28.2 0.3 21.2 6.9 43.5 
Race/Ethnicity 4      
 White 27.7 0.5 21.9 7.3 42.7 
 Black 35.4 0.3 20.6 5.2 38.5 
 Hispanic 26.4 0.3 21.6 5.0 46.7 
 Other 30.9 1.2 22.7 5.7 39.4 
Primary Mental Health 
Diagnosis 5 
     
 Schizophrenia 36.5 2.4 26.1 4.5 30.5 
 Bipolar Disorder 22.1 0.3 27.7 8.5 41.4 
 Dementia 20.9 0.0 21.5 7.5 50.1 
 Psychotic Disorder 27.4 0.0 18.8 7.5 46.3 
 Non-Psychotic Disorder 25.0 0.0 21.4 8.7 44.8 
 No Mental Health Diagnosis 35.1 0.2 17.3 4.6 42.8 
1. Age Strata: χ2 =416.748, df=16, p<0.001; Gender: χ2 = 76.901, df=4, p<0.001; Race/Ethnicity: 
χ2 =160.710, df=12, p<0.001; Primary Mental Health Diagnosis: χ2 =845.046, df=20, p<0.001. 
2. N=93. 
3. N=19,430 for all comparisons except Primary Mental Health Diagnosis (N=17,230). 
4. ‘Other’ category comprised of Native American, Asian American and Others. 
5. N= 17,230 (Patients with mental retardation (N=2,200) excluded). 
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3.1.3.2.4 Use of Antipsychotic Agents According to Primary Mental Health 
Diagnosis 
H1d: The percentage of patients treated with the different antipsychotic 
agents will not differ significantly when stratified according to patient 
primary mental health diagnosis. 
 
After excluding patients with a diagnosis of mental retardation (N=2,200) 
because of the unreliability of other mental health diagnoses in this group, Chi-
square analysis indicated a significant relationship between choice of 
antipsychotic agent and primary mental health diagnosis (χ2 = 845.046, df=20, 
p<0.001). Clozapine and the first-generation antipsychotics were more likely to 
be used in patients with schizophrenia, whereas olanzapine was more likely to be 
used in patients with bipolar disorder (Table 3.11). While risperidone was used 
as index therapy in 42.2 percent of the overall population, the use of this agent 
varied from 30.5 percent in patients with schizophrenia, to 50.1 percent in 
patients with dementia (Table 3.11). 
H1d:   Rejected. 
3.1.3.3 Antipsychotic Medication: Dose of Second-Generation Antipsychotic 
Agents (Objective 2) 
As outlined in section 2.4.2.3.3 (Chapter 2), the dose for each second-
generation antipsychotic agent was inferred from the information available on the 
quantity, strength and number of days supplied for each prescription. The mean 
daily treatment dose was calculated for each patient from their index date to their 
study endpoint date. The calculated doses were examined for appropriateness 
based on the dose ranges outlined in Table 2.2, and outliers excluded 
accordingly. Table 3.12 illustrates the average treatment doses for the second-
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generation antipsychotics. As these were not normally distributed (positively 
skewed), both mean and median daily doses are reported.  
As a form of sensitivity analysis, two additional dose calculation methods 
were examined. In the first, mean daily treatment doses were calculated from the 
index date to the study endpoint date for each patient but gaps in patient therapy 
(which were presumably due to non-adherence) were excluded. Secondly, the 
dose a patient was receiving on the day they experienced their study endpoint 
was also examined. For each agent, while the calculated doses in both of these 
methods were slightly higher than those reported in Table 3.12, they did not 
differ clinically. For example, the mean daily dose for risperidone excluding gaps 
in therapy was 1.87mg (SD: 1.67) with a median of 1.12mg; the mean dose on 
the day of the study endpoint was 1.91mg (SD: 2.15), with a median of 1.00mg; 
as compared to 1.82mg (SD: 1.67) and a median of 1.09 reported in Table 3.12. 
The average daily doses reported in Table 3.12 were, therefore, assumed to be a 
reliable estimate of patient’s antipsychotic dose for this study. 
 
Table 3.12: Average Daily Dose (Milligrams) for the Second-Generation Antipsychotics in 
the Texas Medicaid Study Population 
Agent  N1 Mean (SD) Median 
Clozapine 91 426.21 (289.54) 400.00 
Olanzapine 4,191 8.21 (5.80) 5.77 
Quetiapine 1,228 128.09 (138.03) 75.00 
Risperidone 8,197 1.82 (1.67) 1.09 
1. N=24 dose outliers excluded (N=2: clozapine; N=8: olanzapine; N=3: quetiapine; N=11: 
risperidone). 
 
To allow for dose-based comparisons between the second-generation 
antipsychotic agents, patients were classified as receiving ‘Low,’ ‘Medium, or 
‘High’ dose antipsychotic therapy based on the mean daily dose of antipsychotic 
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they received. These strata were based on therapeutic efficacy as discussed in 
Chapter 2, section 2.4.2.3.3. Because of concerns that these dose strata may not 
be relevant for elderly patients due to differences in treatment tolerability and 
effect, a modified dose stratification was proposed for patients aged 65 years or 
older. The results of these classifications are illustrated in Table 3.13. Using the 
standard dose classification, the majority of patients were identified as receiving 
a low dose of antipsychotic. Using the revised stratification scheme for patients 
aged 65 years or older, 36.7 percent of patients were classified as taking a low 
dose, with 17.7 percent regarded as taking a high dose. 
 
Table 3.13: Classification of Mean Daily Antipsychotic Dose as ‘Low,’ ‘Medium’ or ‘High’ 
Dose for All Patients, by Agent, and by Age < 65 or ≥65 years for the Texas Medicaid Study 
Population 
 N (%) 
Stratification Low Dose  Medium Dose High Dose 
All Patients1,2 10,444 (76.6) 2,426 (17.8) 746 (5.5) 
By Agent    
 Olanzapine 3,211 (76.6) 484 (11.5) 496 (11.8) 
 Quetiapine 1,115 (90.8) 92 (7.5) 21 (1.7) 
 Risperidone 6,118 (74.6) 1850 (22.6) 229 (2.8) 
By Age Group    
Patients < 65 Years2,3 4,292 (62.6) 1,870 (27.3) 686 (10.0) 
Patients ≥ 65 Years4,5 2,488 (36.7) 3,083 (45.5) 1,197 (17.7) 
1. N = 13,616 (Dose outliers (N=22) and patients treated with clozapine (N=93) omitted). 
2. Mean Daily Dose Reference Ranges: Olanzapine - Low: ≤ 10mg; Medium: >10mg to ≤ 15mg; 
High: >15mg; Quetiapine - Low: ≤ 300mg; Medium: >300mg to ≤ 600mg; High: >600mg; 
Risperidone - Low: ≤ 2mg; Medium: >2mg to ≤ 6mg; High: >6mg. 
3. N = 6,848 (Dose outliers (N=13) and patients treated with clozapine (N=74) omitted). 
4. N = 6,768 (Dose outliers (N=9) and patients treated with clozapine (N=19) omitted). 
5. Mean Daily Dose Reference Ranges: Olanzapine - Low: ≤ 5mg; Medium: >5mg to ≤ 10mg; 
High: >10mg; Quetiapine - Low: ≤ 100mg; Medium: >100mg to ≤ 300mg; High: >300mg; 
Risperidone - Low: ≤ 0.5mg; Medium: >0.5mg to ≤ 1.5mg; High: >1.5mg. 
 191
3.1.3.3.1 Dose Classification according to Agent 
H2a: The classification of mean daily antipsychotic dose as ‘Low,’ 
‘Medium,’ or ‘High’ dose will not differ significantly when stratified 
according to the second-generation agent used. 
 
Table 3.13 and Figures 3.1 to 3.3 illustrate the stratification of patients 
according to antipsychotic dose range for patients treated with olanzapine, 
quetiapine or risperidone. For each of the three agents, the majority were 
categorized as taking low-dose therapy when examined without regard to patient 
age. Patients taking olanzapine were most likely to receive high-dose therapy 
(11.8% vs. 1.7% and 2.8% for quetiapine and risperidone, respectively). This 
difference between agents was significant when examined using chi-square 
analysis (χ2=754.098, df=4, p<0.001). A similar trend in distribution was noted 
for patients aged less than 65 years. Using the modified dose stratification system 
for patients aged 65 years or older resulted in a similar distribution of patients 
into ‘Low,’ ‘Medium,’ or ‘High’ dose for those treated with olanzapine and 
quetiapine. A difference was noted for patients aged 65 years or older treated 
with risperidone; however, under the modified dose stratification, the majority of 
these patients (56.5%) were classified as receiving medium-dose therapy and 
only 20.2 percent classified as receiving low-dose therapy (Figure 3.3). 
H2a:   Rejected. 
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Figure 3.1 :  Stratification of Mean Daily Olanzapine Dose into 'Low,' 
'Medium' and 'High' Dose  for Texas Medicaid Patients, and 



















1. Dose Reference Ranges for ‘All’ patients and ‘< 65 years’: - ‘Low’: ≤ 10mg; ‘Medium’ : 
>10mg to ≤ 15mg; ‘High’ : >15mg; Patients ‘≥65 years’: ‘Low’: ≤ 5mg; ‘Medium’ : >5mg to 
≤ 10mg; ‘High’ : >10mg. 
Figure 3.2:  Stratification of Mean Daily Quetiapine Dose into 'Low,' 
'Medium' and 'High' Dose  for Texas Medicaid Patients, and 

















1. Dose Reference Ranges for ‘All’ patients and ‘<65 years’: - ‘Low’: ≤ 300mg; ‘Medium’ : 
>300mg to ≤ 600mg; ‘High’ : >600mg; Patients ‘≥65 years’: ‘Low’: ≤ 100mg; ‘Medium’ : 
>100mg to ≤ 300mg; ‘High’ : >300mg. 
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Figure 3.3:  Stratification of Mean Daily Risperidone Dose into 'Low,' 
'Medium' and 'High' Dose  for Texas Medicaid Patients, and 



















1. Dose Reference Ranges for ‘All’ patients and ‘<65 years’: - ‘Low’: ≤ 2mg; ‘Medium’ : >2mg 
to ≤ 6mg; ‘High’ : >6mg; Patients ‘≥65 years’: ‘Low’: ≤ 0.5mg; ‘Medium’ : >0.5mg to ≤ 
1.5mg; ‘High’ : >1.5mg. 
 
3.1.3.3.2 Dose of Second-Generation Antipsychotic Agents According to Patient 
Age 
For each of the second-generation agents, olanzapine, quetiapine and 
risperidone, the mean daily dose use was examined according to patient age 
(Table 3.14). Hypotheses 2b and 2f relating to clozapine and ziprasidone were 
not tested due to the inadequate sample sizes. 
H2c-e: The mean daily antipsychotic dose for the second-generation 
antipsychotics (olanzapine, quetiapine, risperidone) will not differ when 
stratified according to patient age.  
 
ANOVA and Kruskal-Wallis tests revealed significant differences 
(p<0.001) in the mean daily dose for all three agents according to patient age 
(Table 3.14). For each agent, the mean daily dose was highest for patients aged 
 194
44 years or younger, decreasing thereafter with increasing patient age. Post-hoc 
analyses for both risperidone and olanzapine showed significant differences 
between patients aged 55 to 64 years, and those 65 years or older, when 
compared to each other (p≤0.002), to patients aged less than 35 years, between 
35 and 44 years, and those aged between 45 and 54 years. A similar pattern was 
evident for quetiapine, with the exception that the mean daily dose for patients 
aged 55 to 64 years did not differ significantly from that for patients aged 45 to 
54 years (p=0.073). 
H2c:   Rejected (Olanzapine). 
H2d:   Rejected (Quetiapine). 
H2e:   Rejected (Risperidone). 
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Table 3.14: Mean Daily Dose (Milligrams) of the Second-Generation Antipsychotic Agents 
for Texas Medicaid Enrollees and when Stratified According to Age and Primary Mental 
Health Diagnosis 
 Mean Daily Dose (SD) 
Stratifications Olanzapine  Quetiapine Risperidone 
Overall4 8.21 (5.87) 124.39 (136.77) 1.80 (1.70) 
Age (years)     
 18-34 10.82 (6.18) 205.39 (191.29) 2.87 (2.15) 
 35-44 11.19 (6.52) 183.22 (160.11) 2.99 (2.27) 
 45-54 10.42 (6.40) 176.85 (167.57) 2.81 (2.11) 
 55-64 8.91 (5.32) 124.32 (141.73) 2.15 (1.82) 
 ≥ 65 5.39 (3.76) 76.50 (70.43) 1.19 (0.94) 
ANOVA p<0.001 1 p<0.001 2 p<0.001 3 
Primary Mental Health Diagnosis    
 Schizophrenia 12.04 (6.73) 273.16 (203.86) 3.55 (2.37) 
 Bipolar Disorder 8.91 (5.78) 146.33 (149.29) 2.05 (1.76) 
 Dementia 4.87 (3.00) 79.59 (82.57) 1.12 (0.85) 
 Psychotic Disorder 6.13 (4.38) 85.36 (75.69) 1.34 (1.05) 
 Non-Psychotic Disorder 6.77 (4.61) 95.51 (93.60) 1.57 (1.44) 
 No Mental Health Diagnosis 7.92 (5.70) 102.56 (108.37) 1.63 (1.52) 
ANOVA p<0.001 1 p<0.001 2 p<0.001 3 
1. Olanzapine (N=3,731 excluding outliers and patients with mental retardation): Age strata: F 
=231.437, df=4, p<0.001; Primary Mental Health Diagnosis: F = 132.517, df=5, p<0.001. 
2. Quetiapine (N=1,106 excluding outliers and patients with mental retardation): Age strata: F 
=48.910, df=4, p<0.001; Primary Mental Health Diagnosis: F=49.085, df=5, p<0.001. 
3. Risperidone (N=7,258 excluding outliers and patients with mental retardation): Age strata: F 
=483.399, df=4, p<0.001; Primary Mental Health Diagnosis: F=294.518, df=5, p<0.001. 
4. N= 12,095 (N=1,543 patients with mental retardation and dose outliers excluded). 
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3.1.3.3.3 Dose of Second-Generation Antipsychotic Agents According to Primary 
Mental Health Diagnosis 
The mean daily doses for olanzapine, quetiapine and risperidone were 
examined according to the primary mental diagnosis for which they were 
presumed to be prescribed (Table 3.14). Hypotheses 2g and 2k relating to 
clozapine and ziprasidone were not tested due to inadequate sample size. Patients 
with a diagnosis of mental retardation were excluded from this analysis due to 
the difficulty of making other mental health diagnoses in this population. 
H2h-j: The mean daily antipsychotic dose for the second-generation 
antipsychotics (olanzapine, quetiapine, risperidone) will not differ 
significantly when stratified according to the primary mental health 
diagnosis. 
 
Regardless of agent, when examined using ANOVA and Kruskal-Wallis 
tests, the mean daily treatment dose differed significantly (p<0.001) according to 
the presumed treatment indication (Table 3.14). A similar dosing pattern was 
seen for the three agents, with the highest doses prescribed for patients with 
schizophrenia, decreasing in the following order: bipolar disorder; no mental 
health diagnosis; non-psychotic disorder; psychotic disorder; with the lowest 
doses prescribed for patients with dementia (Table 3.14). Doses for 
schizophrenia ranged from 26 to 46 percent higher than those prescribed for 
bipolar disorder, and were approximately 60 to 70 percent higher than those 
prescribed for patients with dementia (Table 3.14). Post-hoc analysis for 
olanzapine and risperidone were significant (p≤0.007 and p≤0.002, respectively) 
for all comparisons, with the exception of doses prescribed to patients with a 
non-psychotic disorder compared to those without a mental health diagnosis 
(p=0.410 and p=0.848, respectively). In contrast, whereas the doses of quetiapine 
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prescribed for schizophrenia and bipolar disorder differed significantly from each 
other, and from those used for each of the other diagnoses, no other comparisons 
between treatment indications were significantly different for this agent. 
H2h:   Rejected (Olanzapine). 
H2i:   Rejected (Quetiapine). 
H2j:   Rejected (Risperidone). 
 
Initial analyses showed a difference in antipsychotic dose according to 
both patient age and treatment indication. Additional bivariate analyses were 
conducted to further examine the pattern of prescribing after stratifying the 
population into those less than 65 years, and those aged 65 years or older. 
Figures 3.4 to 3.6 illustrate the mean daily doses for olanzapine, quetiapine and 
risperidone according to treatment indication and within these age strata. With 
the exception of quetiapine prescribing in patients aged 65 years or older, 
ANOVA revealed that the dose of antipsychotic varied significantly according to 
treatment indication (p<0.001) in both age strata. Regardless of the antipsychotic 
agent, when compared to patients aged less than 65 years, older patients received 
approximately 50 percent of the dose prescribed to their younger counterparts 
(range: 43.4% to 51.2%). Consistent with previous findings, the mean daily dose 
was highest for patients with a diagnosis of schizophrenia regardless of agent or 
age group. With the exception of quetiapine prescribing in patients aged 65 years 
or older, the lowest mean daily dose of antipsychotic was prescribed to patients 
with a diagnosis of dementia. 
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Figure 3.4:  Mean Daily Doseof Olanzapine (Milligrams) Prescribed in Texas 
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Figure 3.5:  Mean Daily Dose of Quetiapine (Milligrams) Prescribed in 
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Figure 3.6:  Mean Daily Dose of Risperidone  (Milligrams) Prescribed in 
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3.1.3.4 Antipsychotic Medication: Duration of Antipsychotic Therapy 
(Objective 2) 
The duration of antipsychotic treatment was inferred from the number of 
days of medication supplied to a patient from their index date until a study 
endpoint occurred, with a maximum period of follow-up of 365 days. Treatment 
was assumed to have been discontinued if a prescription refill did not occur 
within the time covered by the existing prescription plus a 50 percent grace-
period (e.g., refill within 45 days of a 30-day prescription being dispensed). The 
mean duration of antipsychotic treatment was 115.2 days (SD: 118.5), with 
treatment ranging in duration from one to 365 days. Table 3.15 describes the 
average duration of antipsychotic therapy stratified according to the index 
antipsychotic agent. 
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On average, patients remained on treatment longer on the second-
generation antipsychotics than the first-generation agents (128.4 days (SD: 
123.3) versus 83.3 days (SD: 99.2). This difference was significant (p<0.001) for 
both the Student T-test and the Mann Whitney test. Within the second-generation 
agents, the duration of treatment was longest for quetiapine (135.0 days (SD: 
126.6)) and shortest for clozapine (80.8 days (SD: 102.7). After excluding 
patients treated with clozapine from the analysis due to the small sample size, 
ANOVA and Kruskal-Wallis tests indicated the difference between the second-
generation agents to be significant (p<0.001). A subsequent post-hoc analysis 
revealed significant differences in the duration of treatment with olanzapine or 
quetiapine compared to risperidone (p≤0.032), but not between olanzapine and 
quetiapine (p=0.946).  
 
Table 3.15: Average Duration of Antipsychotic Therapy (Days) for the Texas Medicaid 
Study Population Stratified According to the Index Antipsychotic Agent 
Antipsychotic Agent Mean (SD) Median 
First-Generation Agent1 83.3 (99.2) 31.0 
Second-Generation Agent2 128.4 (123.3) 68.0 
 Clozapine 80.8 (102.7) 30.0 
 Olanzapine 133.7 (125.0) 75.0 
 Quetiapine 135.0 (126.6) 77.0 
 Risperidone 125.3 (121.8) 65.0 
All 115.2 (118.5) 60.0 
1. First-generation agents included: Chlorpromazine; Fluphenazine; Haloperidol; Loxapine; 
Mesoridazine; Molindone; Perphenazine; Pimozide; Thioridazine; Thiothixene and 
Trifluoperazine. 
2. No patient received Ziprasidone as their index antipsychotic agent. 
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3.1.3.5 Antipsychotic Medication: Compliance (Objective 2) 
Two components of medication compliance were assessed in this study: 
adherence and persistence. In order to obtain stable estimates, compliance was 
assessed only for patients who obtained at least one prescription refill. When 
records indicated that two or more prescriptions for the same strength of an agent 
were dispensed on the same day, an assumption was made that an order-entry 
error had occurred and that invalid entries had not been reversed. These extra 
prescriptions were omitted from calculations, with only the last prescription entry 
for that day arbitrarily selected to calculate compliance measures. Adherence was 
assessed by means of the medication possession ratio (MPR), which reflects the 
number of days a patient was in possession of their medication. The prescription 
records of patients with an MPR in excess of 1.5 were evaluated for 
appropriateness. As outlined in section 2.4.1.1 (Chapter 2), the follow-up period 
varied for each patient and consisted of the time from the index prescription to 
the development of a study endpoint (development of diabetes; switching to, or 
the addition of another antipsychotic agent; absence of any further prescriptions 
for the agent, or end of follow-up data). The maximum period of follow-up was 
365 days. As a form of sensitivity analysis, adherence was also calculated using 
an intent-to-treat approach, whereby it was measured over a 365-day period for 
all patients filling more than one antipsychotic prescription (Figure 2.3, Chapter 
2). 
Persistence was defined as the number of days of continuous therapy 
during the 365-day follow-up period. Patients refilling their prescription within a 
50 percent grace-period were considered to be persistent (e.g., refill within 45 
days (30 x 1.5) of a 30-day prescription being dispensed) with therapy. 
Persistence with therapy and duration of therapy were synonymous terms, with 
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the exception that persistence was calculated only for patients filling more than 
one antipsychotic prescription. 
The mean adherence to antipsychotic therapy for the Medicaid population 
was 0.803 (SD: 0.266) (Table 3.16). When examined over a 365-day period for 
all patients, a mean adherence rate of 0.600 (SD: 0.316) was noted (Table 3.16). 
Persistence to antipsychotic therapy varied widely in the study population. As the 
data were not normally distributed (positive skew) both mean and median values 
are reported in Table 3.16. The mean persistence with therapy was 128.7 days 
(SD: 120.2) with a median value of 77.0 days (range: 1 to 365 days). 
 
Table 3.16: Compliance with Antipsychotic Therapy for the Texas Medicaid Study 
Population as Reflected by Adherence (Medication Possession Ratio) and Persistence (Days) 
Measures1 
Compliance Measure Mean (SD) Median 
Adherence    
 MPR2 0.803 (0.266) 0.875 
 MPR_365 days3 0.600 (0.316) 0.605 
Persistence   
 Number of Persistent Days 128.74 (120.24) 77.00 
1. N=15,098 (N=4,332 excluded as only one prescription filled in 365-day follow-up period). 
2. Adherence calculated until the patient developed diabetes, switched or added an 
antipsychotic, or had no further refills for the agent within the 365-day follow-up period. 
3. Adherence calculated over 365 days for all patients 
 
In addition to calculating mean MPR rates, patients were also categorized 
according to their level of adherence as outlined in Chapter 2, section 2.4.1.1. As 
evident in Table 3.17, approximately 40 percent of patients were found to adhere 
poorly to their antipsychotic therapy, as indicated by MPR rates of less than 0.8. 
The percentage of patients who filled their prescriptions more frequently than 
appeared necessary (MPR > 1.1) was 6.2 percent. Using the intent-to-treat 
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approach (MPR_365 days), 34.6 percent of Texas Medicaid enrollees were 
categorized as being adherent (MPR_365 days ≥ 0.8) with therapy (Table 3.17). 
 
Table 3.17: Frequency Distribution of Adherence to Antipsychotic Therapy as Measured by 
Medication Possession Ratios (MPR) for the Texas Medicaid Study Population 1 
Antipsychotic Therapy Adherence N (%)2 
MPR3  
 0.00 to <0.50 (Non-Adherent) 2,325 (15.4) 
 0.50 to <0.80 (Partially Adherent) 3,792 (25.1) 
 0.80 to 1.10 (Adherent) 8,038 (53.2) 
 >1.10 (Excess Medication Filler) 943 (6.2) 
 Total 15,098 (99.9) 
MPR_365 days4  
 0.00 to <0.50 (Non-Adherent) 6,349 (42.1) 
 0.50 to <0.80 (Partially Adherent) 3,519 (23.3) 
 0.80 to 1.10 (Adherent) 4,956 (32.8) 
 >1.10 (Excess Medication Filler) 274 (1.8) 
 Total 15,098 (100.0) 
1. N=4,332 excluded as only one prescription filled in 365-day follow-up period. 
2. Percentage does not add to 100 due to rounding. 
3  MPR calculated until a study endpoint occurred (development of diabetes, addition of an 
antipsychotic, switching of an antipsychotic), no further prescriptions for the agent were 
redeemed, or a maximum of 365 days of follow-up. 
4  MPR_365 days based on the number of days of medication available to a patient during 365 







3.1.3.5.1 Compliance According to Patient Age 
As noted, two measures of compliance with antipsychotic therapy were 
used in this study: adherence and persistence. The impact of patient age on these 
outcomes is reported here.  
H3a: Adherence with antipsychotic therapy will not differ significantly when 
stratified according to patient age. 
 
Adherence to therapy differed significantly (p<0.001) according to patient 
age, with the highest adherence rates documented in patients aged 65 years or 
older, and the lowest rates documented in patients aged between 35 and 44 years 
(Table 3.18). Post-hoc analyses revealed significant differences between those 
aged 65 years or older, compared with all other age strata (p<0.001), and 
between those aged between 35 and 44 years and all other strata (p≤0.003). 
When adherence was assessed over 365 days (MPR_365 days), a similar trend in 
adherence according to patient age was noted. 
H3a:   Rejected. 
 
H3b: Persistence with antipsychotic therapy will not differ significantly when 
stratified according to patient age. 
 
Persistence with antipsychotic therapy was noted to differ according to 
patient age (Table 3.18). Persistence was highest for patients aged 65 years and 
older, and lowest for patients aged between 35 and 44 years. The variation in 
persistence with patient age was significant when analyzed using ANOVA and 
Kruskal-Wallis tests (p<0.001). Post-hoc analyses revealed that patients aged 65 
years or older had significantly higher persistence levels compared with all other 
age-strata (p≤0.029). The only other significant comparison was for patients aged 
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between 18 and 34 years, who were significantly more persistent with therapy 
compared to those aged between 35 and 44 years (p=0.015). 
H3b:   Rejected. 
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Table 3.18: Adherence to Antipsychotic Therapy for Texas Medicaid Patients Stratified 
According to Age, Gender, Race/Ethnicity, Primary Mental Health Diagnosis and Index 
Antipsychotic Agent 
  Adherence 
(MPR) 1 
Adherence 
(MPR_365 days) 2 
Persistence 
(Days) 3 
Stratification N Mean (SD) Mean (SD) Mean (SD) 
All 15,098 0.803 (2.66) 0.600 (0.316) 128.7 (120.2) 
Age (years)      
 18-34 2,192 0.778 (0.256) 0.587 (0.309) 125.8 (117.6) 
 35-44 2,338 0.744 (0.273) 0.566 (0.305) 115.0 (114.0) 
 45-54 2,081 0.773 (0.263) 0.590 (0.308) 122.9 (116.7) 
 55-64 1,207 0.794 (0.263) 0.603 (0.311) 125.5 (116.6) 
 ≥ 65 7,280 0.838 (0.264) 0.617 (0.323) 136.2 (124.0) 
ANOVA  p<0.001 p<0.001 p<0.001 
Gender     
 Male 5,291 0.791 (0.269) 0.605 (0.316) 128.1 (120.7) 
 Female 9,807 0.808 (0.264) 0.597 (0.316) 129.1 (120.0) 
Student T-test  p<0.001 p=0.141 p=0.653 
Race/Ethnicity 4     
 White 8,545 0.831 (0.259) 0.628 (0.319) 139.3 (124.9) 
 Black 3,124 0.756 (0.275) 0.558 (0.307) 111.8 (111.3) 
 Hispanic 2,359 0.774 (0.269) 0.559 (0.308) 115.5 (111.6) 
 Other 1,070 0.774 (0.257) 0.586 (0.306) 122.9 (117.1) 
ANOVA 
 
 p<0.001 p<0.001 p<0.001 
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Table 3.18 (cont): Adherence to Antipsychotic Therapy for Texas Medicaid Patients 
Stratified According to Age, Gender, Race/Ethnicity, Primary Mental Health Diagnosis and 
Index Antipsychotic Agent 
  Adherence 
(MPR)  
Adherence 
(MPR_365 days)  
Persistence 
(Days)  
Stratification N Mean (SD) Mean (SD) Mean (SD) 
Primary Mental Health 
Diagnosis 5 
    
 Schizophrenia 2,361 0.761 (0.259) 0.598 (0.297) 118.7 (115.4) 
 Bipolar Disorder 2,071 0.785 (0.262) 0.570 (0.303) 117.2 (110.1) 
 Dementia 2,045 0.853 (0.252) 0.628 (0.315) 136.9 (123.8) 
 Psychotic Disorder 1,089 0.825 (0.267) 0.602 (0.325) 131.0 (121.1) 
 Non-Psychotic 
 Disorder 
1,835 0.807 (0.272) 0.575 (0.322) 124.0 (116.7) 
 No Mental Health 
 Diagnosis 
3,923 0.798 (0.274) 0.592 (0.327) 130.1 (123.1) 
ANOVA  p<0.001 p<0.001 p<0.001 
Antipsychotic Agent 6 15,012    
 First-Generation 
 Agent 7 
4,065 0.723 (0.299) 0.494 (0.309) 96.2 (103.7) 
 Olanzapine 3,437 0.833 (0.241) 0.642 (0.307) 144.8 (125.2) 
 Quetiapine 954 0.854 (0.235) 0.685 (0.310) 149.8 (126.6) 
 Risperidone 6,556 0.828 (0.251) 0.630 (0.311) 138.1 (122.4) 
ANOVA  p<0.001 p<0.001 p<0.001 
1. Adherence (MPR): Age strata: F=73.175, df=4, p<0.001; Gender: t=-3.688, df=10675.3, 
p<0.001; Race/Ethnicity: F=77.829, df=3, p<0.001; Primary Mental Health Diagnosis: 
F=30.023, df=5, p<0.001; Antipsychotic Agent: F=173.120, df=3, p<0.001. 
2. Adherence (MPR_365 days): Age strata: F=13.258, df=4, p<0.001; Gender: t=1.472, 
df=15,096, p=0.141; Race/Ethnicity: F=54.001, df=3, p<0.001; Primary Mental Health 
Diagnosis: F=8.691, df=5, p<0.001; Antipsychotic Agent: F=225.643, df=3, p<0.001. 
3. Persistence: Age strata: F=16.419, df=4, p<0.001; Gender: t=-0.450, df=15,096, p=0.653; 
Race/Ethnicity: F=53.613, df=3, p<0.001; Primary Mental Health Diagnosis: F=6.704, df=5, 
p<0.001; Antipsychotic Agent: F=146.6, df=3, p<0.001. 
4. ‘Other’ category comprised of Asian American, Native American and ‘Other’ racial/ethnic 
groups. 
5. Patients with Mental Retardation (N=1,784) excluded. 
6. Patients treated with Clozapine (N=86) excluded due to small sample size. 
7. First-generation agents included: Chlorpromazine; Fluphenazine; Haloperidol; Loxapine; 
Mesoridazine; Molindone; Perphenazine; Pimozide; Thioridazine; Thiothixene and 
Trifluoperazine. 
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3.1.3.5.2 Compliance According to Patient Gender 
The effect of patient gender on the two measures of compliance with 
antipsychotic therapy examined in this study (adherence and persistence) is 
reported here.  
 
H3c: Adherence with antipsychotic therapy will not differ significantly when 
stratified according to patient gender. 
Women were found to be significantly more adherent to therapy than men 
(p<0.001 for Student t-test and the Mann Whitney test) with a mean adherence 
rate of 0.808 (SD: 0.264) compared to 0.791 (SD: 0.269) for men (Table 3.18). 
The results from the sensitivity analysis comparing adherence over 365 days for 
men and women did not confirm this finding, with no difference in adherence 
based on patient gender noted (p=0.141 for Student t-test, and p=0.164 for the 
Mann Whitney test).  
H3c:   Rejected. 
 
H3c: Persistence with antipsychotic therapy will not differ significantly when 
stratified according to patient gender. 
 
No difference in persistence levels were found between women and men, 
with mean levels of 129.1 and 128.1 days, respectively, noted (Table 3.18). 







3.1.3.5.3 Compliance According to Patient Race/Ethnicity 
As before, in testing these hypotheses, adherence and persistence were 
used as measures of compliance with antipsychotic therapy.  
 
H3e: Adherence with antipsychotic therapy will not differ significantly when 
stratified according to patient race/ethnicity. 
 
Adherence to therapy differed significantly (p<0.001) according to patient 
race/ethnicity when examined using ANOVA and Kruskal-Wallis tests, with the 
highest adherence rates documented for Whites, and the lowest rates documented 
for Black patients (Table 3.18). Post-hoc analyses revealed significant 
differences between Whites compared with any minority group (p<0.001). The 
results from the sensitivity analysis examining adherence over 365 days were 
consistent with these findings, with the exception that the comparison between 
Black patients and those in the ‘Other’ group also differed significantly 
(p≤0.046). 
H3e:   Rejected. 
 
H3f: Persistence with antipsychotic therapy will not differ significantly when 
stratified according to patient race/ethnicity. 
 
A similar pattern was noted for persistence with antipsychotic therapy 
(Table 3.18). Persistence was highest for White patients, and lowest for Black 
patients. The variation in persistence with patient race/ethnicity was significant 
when analyzed using ANOVA and Kruskal-Wallis tests (p<0.001). Post-hoc 
analyses revealed that White patients had significantly higher persistence levels 
compared with all other racial/ethnic groups (p≤0.001). The only other 
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significant comparison was for Black patients, who were significantly less 
persistent with therapy compared to patients in the ‘Other’ racial /ethnic group 
(p=0.035). 
H3f:   Rejected. 
 
3.1.3.5.4 Compliance According to Primary Mental Health Diagnosis 
Patient compliance with antipsychotic therapy, as reflected by adherence 
and persistence measures, was assessed after stratifying the population according 
to the primary mental health diagnosis for which antipsychotic therapy was 
presumed to be prescribed. Patients with a diagnosis of mental retardation were 
excluded from this analysis due to the difficulty of making other mental health 
diagnoses in this population. 
H3g: Adherence with antipsychotic therapy will not differ significantly when 
stratified according to primary mental health diagnosis. 
 
Adherence to therapy differed significantly (p<0.001) according to mental 
health diagnosis when examined using ANOVA and Kruskal-Wallis tests, with 
the highest adherence rates documented for patients with dementia, and the 
lowest rates documented for patients with schizophrenia (Table 3.18). Post-hoc 
analyses revealed that patients with schizophrenia had significantly lower 
adherence rates compared with any other diagnostic group (p≤0.031). In contrast, 
patients with dementia had significantly higher adherence rates compared to all 
other diagnostic groups (p<0.001), with the exception of those with a psychotic 
disorder (p=0.053). Other significant contrasts were for patients with bipolar 
disorder and those with no mental health diagnosis, who had lower adherence 
rates when compared to those with a psychotic disorder (p=0.001 and p=0.038, 
respectively). In the sensitivity analysis examining adherence over 365 days, 
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adherence varied by diagnosis (p<0.001), and was again noted to be highest for 
patients with dementia. Using this methodology however, the lowest adherence 
rates were noted for patients with bipolar disorder (Table 3.18). 
H3g:   Rejected. 
 
H3h: Persistence with antipsychotic therapy will not differ significantly when 
stratified according to primary mental health diagnosis. 
 
Persistence with antipsychotic therapy was also noted to vary 
significantly according to mental health diagnosis (Table 3.18) when analyzed 
using ANOVA and Kruskal-Wallis tests (p<0.001). Persistence was highest for 
patients with dementia, and lowest for patients with bipolar disorder, with mean 
numbers of persistent days of 136.9 (SD: 123.8) and 117.2 (SD: 110.1), 
respectively. Post-hoc analyses revealed significant comparisons in persistence 
levels for patients with dementia compared to patients with schizophrenia, 
bipolar disorder and those with non-psychotic disorders (p≤0.011). The mean 
number of persistent days for patients with no mental health diagnosis was 130.1 
days (SD: 123.1) which was significantly higher than for patients with 
schizophrenia or bipolar disorder (p≤0.003). The only other significant contrast 
was between patients with bipolar disorder compared to those with a psychotic 
disorder (p=0.021). 






3.1.3.5.5 Compliance According to the Antipsychotic Agent Prescribed 
After stratifying patients according to their index antipsychotic therapy, 
compliance with therapy was again assessed using adherence and persistence 
measures. Patients treated with clozapine (n=93) were excluded from this 
analysis due to the small sample size. No patient received ziprasidone as their 
index antipsychotic agent. Patients treated with any first-generation antipsychotic 
agent were assessed as a single group.  
H3i: Adherence with antipsychotic therapy will not differ significantly when 
stratified according to the specific antipsychotic agent prescribed. 
 
Adherence to therapy was found to differ significantly (p<0.001) 
according to the specific agent prescribed, when examined using ANOVA and 
Kruskal-Wallis tests. Adherence rates were noted to decline in the following 
order: quetiapine, olanzapine, risperidone, first-generation antipsychotic (Table 
3.18). Post-hoc analyses revealed that adherence rates were lower for patients 
treated with a first-generation antipsychotic compared with those treated with 
any other agent (p<0.001). The only other significant contrast was between 
quetiapine and risperidone (p=0.009), with mean adherence rates of 0.854 (SD: 
0.235) and 0.828 (SD: 0.251), respectively. The results from the sensitivity 
analysis examining adherence over 365 days (MPR_365 days) confirmed these 
findings (Table 3.18). 
H3i :  Rejected. 
 
H3j: Persistence with antipsychotic therapy will not differ significantly when 
stratified according to the specific antipsychotic agent prescribed. 
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ANOVA and Kruskal-Wallis tests indicated that persistence with 
antipsychotic therapy varied significantly (p<0.001) according to the agent 
prescribed (Table 3.18). Persistence was highest for patients treated with 
quetiapine, and lowest for patients treated with a first-generation antipsychotic 
agent, with mean numbers of persistent days of 149.8 (SD: 126.6) and 96.2 (SD: 
103.7), respectively. In post-hoc analyses, all comparisons were significant 
(p≤0.049), with the exception of that between olanzapine and quetiapine 
(p=0.703). 
H3j :  Rejected. 
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3.2 Phase II: Prevalence of Diabetes 
In phase II of this study, the primary dependent variable was the 
prevalence of diabetes among patients meeting the study inclusion criteria. This 
variable was defined as detection of a medical claim with an ICD-9 code for 
diabetes (ICD-9 code: 250.0-250.99) or a pharmacy claim for insulin, an insulin 
sensitizing or glucose lowering agent within the 180 days preceding the index 
antipsychotic prescription. Cases of diabetes noted within the first seven days of 
antipsychotic therapy were also considered to be prevalent cases and were 
included in this analysis. 
3.2.1 Prevalence of Diabetes 
The prevalence of diabetes among patients meeting the inclusion criteria 
for this study was 16.9 percent. Over 97 percent of these cases (N=3,207) were 
identified in the 180-day period preceding the index antipsychotic prescription, 
with only 86 patients identified during the first seven days of antipsychotic 
therapy. As illustrated in Table 3.19, over 85 percent of prevalent cases were 
detected by a pharmacy claim (N=2,800), whereas nearly 49 percent were 
detected by a medical claim (1,611). 
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Table 3.19: Prevalence of Diabetes in the Texas Medicaid Study Population as Detected by 
Medical and Pharmacy Claims 
Classification and Detection Method N Percent (%) 
No Diabetes Claim 16,137 83.1 
Prevalent Diabetes1 3,293 16.9 
 Pharmacy Claim only 1,682 8.7 
 Medical Claim only 493 2.5 
 Pharmacy and Medical Claim 1,118 5.8 
Total 19,430 100.0 
1. Prevalence defined as detection of diabetes in the 180 days preceding, or six days subsequent 
to the index antipsychotic prescription. 
 
 
When examined according to patient age, the largest number of prevalent 
cases was among patients aged 65 years or older, with the lowest number of 
cases identified among patients aged between 18 and 34 years (Table 3.20). 
When compared to a population prevalence of 16.9 percent, the prevalence of 
diabetes increased with increasing age, to a maximum of 25.0 percent among 
patients aged between 54 and 64 years, declining to 21.6 percent thereafter 
(Table 3.20). This variation in prevalence was significant when examined using 
Chi-square analysis (p<0.001). When the population was stratified by gender, 
significant differences in the prevalence of diabetes were again noticed 
(p<0.001), with prevalence rates of 13.6 percent and 18.7 percent noted for men 
and women, respectively (Table 3.20). The prevalence of diabetes also differed 
according to racial/ethnic group, with the prevalence for Hispanic patients 
(25.5%) approximately double that for patients in the ‘Other’ racial/ethnic group 
(12.4%) (Table 3.20). Again, differences in the prevalence of diabetes by 
racial/ethnic group were significant when examined using Chi-square analysis 
(p<0.001). The prevalence of diabetes was also examined after stratifying the 
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population according to their primary mental health diagnosis (Table 3.20). After 
excluding patients with a diagnosis of mental retardation (N=2,200), the 
population prevalence of diabetes in the cohort was 18.0 percent. Within the 
cohort, the prevalence varied from 20.6 percent for patients with a psychotic 
disorder to 12.4 percent for patients with schizophrenia. The differences between 
the diagnostic groups was significant when analyzed using Chi-square analysis 
(p<0.001). Finally, the choice of index antipsychotic agent for patients with 
prevalent diabetes was examined (Table 3.20). Patients prescribed clozapine 
(N=93) were excluded from this analysis due to the small treatment numbers. 
The prevalence of diabetes among patients prescribed a first-generation 
antipsychotic was 14.8 percent compared to 19.0 percent among those prescribed 
risperidone. Chi-square analysis was significant (p<0.001) for comparisons in 
prevalence of diabetes according to the antipsychotic agent prescribed. 
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Table 3.20: Prevalence of Diabetes in the Texas Medicaid Study Population and Stratified 
According to Age, Gender, Race/Ethnicity, Primary Mental Health Diagnosis and Index 
Antipsychotic Agent 
Prevalent Cases1 N Percent (%) 2 Chi-Square 
p value 
All 3,293 16.9  
Age (years)    <0.001 
 18-34 123 4.3  
 35-44 298 9.7  
 45-54 480 17.8  
 55-64 305 25.0  
 ≥ 65 1,997 21.6  
Gender   <0.001 
 Male 903 13.6  
 Female 2,390 18.7  
Race/Ethnicity 3   <0.001 
 White 1,570 14.7  
 Black 739 17.8  
 Hispanic 813 25.5  
 Other 171 12.4  
Primary Mental Health Diagnosis 4   <0.001 
 Schizophrenia 353 12.4  
 Bipolar Disorder 499 18.6  
 Dementia 502 20.4  
 Psychotic Disorder 289 20.6  
 Non-Psychotic  Disorder 480 19.2  
 No Mental Health Diagnosis 983 18.4  
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Table 3.20 (cont): Prevalence of Diabetes in the Texas Medicaid Study Population and 
Stratified According to Age, Gender, Race/Ethnicity, Primary Mental Health Diagnosis and 
Index Antipsychotic Agent 
Prevalent Cases1 N Percent (%) Chi-Square 
p value 
All 3,293 16.9  
Antipsychotic Agent 5   <0.001 
 First-Generation Agent 6 842 14.8  
 Olanzapine 675 16.1  
 Quetiapine 207 16.8  
 Risperidone 1,561 19.0  
1. N=19,430. 
2. ‘Percent’ refers to the percentage of prevalent cases within each individual stratum. 
3. ‘Other’ category comprised of Asian American, Native American and ‘Other’ racial/ethnic 
groups. 
4. Patients with a diagnosis of mental retardation excluded (N=2,200). Adjusted population 
prevalence of diabetes: 18.0%. 
5. Patients treated with Clozapine excluded (N=93). Adjusted population prevalence of diabetes: 
17.0%. 
6. First-generation agents included: Chlorpromazine; Fluphenazine; Haloperidol; Loxapine; 
Mesoridazine; Molindone; Perphenazine; Pimozide; Thioridazine; Thiothixene and 
Trifluoperazine. 
 
3.2.1.1 Prevalence of Diabetes According to Primary Mental Health 
Diagnosis (Objective 3) 
H4a: The prevalence of diabetes will not differ significantly when stratified 
according to the primary mental health diagnosis, after controlling for 
demographic, clinical and medication risk factors for diabetes. 
 
As noted previously, the prevalence of diabetes was 18.0 percent for 
eligible Texas Medicaid patients after excluding those with a diagnosis of mental 
retardation. Multivariate logistic regression analysis showed that after controlling 
for differences in other variables, mental health diagnosis was significantly 
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associated (p=0.006) with the prevalence of diabetes (Table 3.21). The odds of 
prevalent diabetes were increased for patients with a diagnosis of bipolar disorder 
(OR=1.268, 95% CI=1.085 to 1.481), a non-psychotic disorder (OR=1.253, 95% 
CI=1.068 to 1.470), or no mental health diagnosis (OR=1.250, 95% CI=1.080 to 
1.448) compared to patients with schizophrenia. Patient race/ethnicity was also 
significantly associated with the prevalence of diabetes (p<0.001). Compared to 
Whites, the odds of prevalent diabetes were 50 percent higher for Blacks 
(OR=1.494, 95% CI=1.344 to 1.661) and over two-fold higher for Hispanic 
patients (OR=2.106, 95% CI=1.898 to 2.336). Other variables noted to be 
significantly associated with an increased prevalence of diabetes were increasing 
patient age (OR=1.014, 95% CI=1.011 to 1.017), female gender (OR=1.164, 
95% CI=1.061 to 1.276), a diagnosis of hypertension (OR=1.814, 95% CI=1.662 
to 1.980) or dyslipidemia (OR=2.230, 95% CI=1.980 to 2.511). Of interest, use 
of a concomitant diabetogenic medication was associated with an 11 percent 
decrease in the odds of prevalent diabetes (OR=0.887, 95% CI=0.808 to 0.974). 
H4a:   Rejected. 
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Table 3.21: Logistic Regression Analysis of the Risk of Prevalent Diabetes in the Texas 
Medicaid Study Population after Controlling for Demographic (Age, Gender, 
Race/Ethnicity), Clinical (Mental Health Diagnosis, Hypertension, Dyslipidemia) and 
Medication (Use of a Concomitant Diabetogenic Medication) Variables 1,2 
Variables β(SE)
3 Wald F p 4 OR 3 95% CI 3 
Intercept -3.178 (0.096) 1104.907 <0.001* 0.042  
Age  0.014 (0.001) 113.958 <0.001* 1.014 1.011-1.017 
Race/Ethnicity 5  214.252 <0.001*   
 Black 0.402 (0.054) 55.386 <0.001* 1.494 1.344-1.661 
 Hispanic 0.745 (0.053) 197.848 <0.001* 2.106 1.898-2.336 
 Other 6 0.062 (0.092) 0.455 0.500 1.064 0.889-1.273 
Gender 5      
 Female 0.152 (0.047) 10.315 0.001* 1.164 1.061-1.276 
Primary Mental Health 
Diagnosis 52 
 16.370 0.006*   
 Bipolar Disorder 0.237 (0.079) 8.913 0.003* 1.268 1.085-1.481 
 Dementia 0.081 (0.088) 0.849 0.357 1.084 0.913-1.289 
 Psychotic Disorder 0.144 (0.096) 2.256 0.133 1.155 0.957-1.393 
 Non-Psychotic Disorder 0.225 (0.081) 7.670 0.006* 1.253 1.068-1.470 
 No Mental Health Diagnosis 0.224 (0.075) 8.590 0.003* 1.250 1.080-1.448 
Hypertension 0.595 (0.045) 177.670 <0.001* 1.814 1.662-1.980 
Dyslipidemia 0.802 (0.061) 174.998 <0.001* 2.230 1.980-2.511 
Concomitant Diabetogenic 
Medication 
-0.120 (0.048) 6.351 0.012* 0.887 0.808-0.974 
1. Model χ2= 908.861, df=13, p<0.001. 
2. N=17,230 (N=2,200 patients with Mental Retardation excluded). 
3. Abbreviations: SE – Standard Error; OR = Odds Ratio; CI = Confidence Interval. 
4. * Indicates statistical significance at p< 0.05. 
5. Reference category for each variable: Race/Ethnicity (White); Gender (Male); Primary Mental 
Health Diagnosis (Schizophrenia). 
6. ‘Other’ category comprised of Native American, Asian American and ‘Others.’ 
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3.3 Phase III: Incidence of Diabetes 
In phase III, the primary dependent variable was the incidence of diabetes 
among patients meeting the inclusion criteria for the study. This variable was 
defined as detection of a medical claim with an ICD-9 code for diabetes (ICD-9 
code: 250.0-250.99) or a pharmacy claim for insulin, an insulin sensitizing or 
glucose lowering agent in the 12 months subsequent to the prescribing of an 
antipsychotic prescription. The date of first recording of one of these events 
served as the date of diagnosis of new-onset diabetes, and was used to estimate 
the duration of time to the development of diabetes. To ensure that only incident 
cases were included, only cases of diabetes occurring at least seven days 
subsequent to the index antipsychotic prescription were considered. New cases of 
diabetes noted in the first 30 days after discontinuation of antipsychotic therapy 
were also considered to be attributed to that agent. 
3.3.1 Incidence of Diabetes 
The incidence of diabetes among patients meeting the inclusion criteria 
for this study was 2.37 percent (N=382) for this Texas Medicaid population. Of 
these, 44 patients (11.5%) were identified during the 30-day period following the 
discontinuation of antipsychotic therapy. Over 59 percent (N=226) of new-onset 
cases were detected by a pharmacy claim, whereas over 75 percent (N=288) were 
detected by a medical claim (Table 3.22). The mean time to onset of diabetes was 
95.9 days (SD: 85.1), with a median time to onset of 62.5 days (range: 7 to 362 
days). 
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Table 3.22: Incidence of Diabetes in the Texas Medicaid Study Population as Detected by 
Medical and Pharmacy Claims 
Classification and Detection Method N 2 Percent (%) 
No Diabetes Claim 15,755 97.63 
New-Onset Diabetes1 382 2.37 
 Pharmacy Claim only 94 0.58 
 Medical Claim only 156 0.97 
 Pharmacy and Medical Claim 132 0.82 
Total 16,137 100.0 
1. Incidence defined as detection of diabetes between 7 and 365 days subsequent to the index 
antipsychotic prescription. 
2. N=3,293 patients with prevalent diabetes excluded. 
 
When compared to a population incidence of 2.4 percent, the incidence of 
diabetes increased with increasing age, to a maximum of 3.4 percent among 
patients aged between 55 and 64 years, declining to 2.8 percent thereafter (Table 
3.23). This variation in incidence was significant when examined using Chi-
square analysis (p<0.001). When the population was stratified by gender, a 
significant difference in the incidence of diabetes was again noticed (p<0.001) 
with incidence rates of 1.7 percent and 2.7 percent noted for men and women, 
respectively, (Table 3.23). The incidence of diabetes also differed according to 
racial/ethnic group with the incidence for Hispanic patients double that for 
patients in the in the ‘Other’ racial/ethnic group (Table 3.23). Again, differences 
in the incidence of diabetes by racial/ethnic group were significant when 
examined using Chi-square analysis (p<0.001). The incidence of diabetes was 
also examined after stratifying the population according to their primary mental 
health diagnosis (Table 3.23). After excluding patients with a diagnosis of mental 
retardation (N=2,013), the population incidence of diabetes was 2.6 percent. This 
varied from 2.0 percent for patients with schizophrenia, to 3.2 percent for 
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patients with a non-psychotic disorder. This difference between the diagnostic 
groups was not significant when analyzed using Chi-square analysis (p=0.051). 
Finally, the association between the index antipsychotic agent and the 
development of diabetes was examined (Table 3.23). Patients prescribed 
clozapine (N=75) were excluded from this analysis due to the small treatment 
numbers. No patients received ziprasidone as their index antipsychotic agent. 
The incidence of diabetes among patients prescribed a first-generation 
antipsychotic was 1.6 percent compared to 2.8 percent for those prescribed 
risperidone. Chi-square analysis was significant (p=0.001) for this comparison of 
incidence of diabetes according to the index antipsychotic agent. 
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Table 3.23: Incidence of Diabetes in the Texas Medicaid Study Population and Stratified 
According to Age, Gender, Race/Ethnicity, Primary Mental Health Diagnosis and Index 
Antipsychotic Agent 
Stratification N Percent (%) Chi-Square 
p value  
All 1 382 2.4  
Age (years)    <0.001 
 18-34 21 0.8  
 35-44 47 1.7  
 45-54 73 3.3  
 55-64 40 3.4  
 ≥ 65 201 2.8  
Gender   <0.001 
 Male 100 1.7  
 Female 282 2.7  
Race/Ethnicity 2   <0.001 
 White 184 2.0  
 Black 95 2.8  
 Hispanic 82 3.4  
 Other 21 1.7  
Primary Mental Health Diagnosis 3   0.051 
 Schizophrenia 49 2.0  
 Bipolar Disorder 62 2.8  
 Dementia 58 3.0  
 Psychotic Disorder 31 2.8  
 Non-Psychotic Disorder 65 3.2  
 No Mental Health Diagnosis 97 2.2  
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Table 3.23 (cont): Incidence of Diabetes in the Texas Medicaid Study Population and 
Stratified According to Age, Gender, Race/Ethnicity, Primary Mental Health Diagnosis and 
Index Antipsychotic Agent 
Stratification N Percent (%) Chi-Square 
p value 
All 1 382 2.4  
Antipsychotic Agent 4   <0.001 
 First-Generation Agent 5 80 1.6  
 Olanzapine 89 2.5  
 Quetiapine 25 2.4  
 Risperidone 187 2.8  
1. N=16,137 (N=3,293 Prevalent Cases excluded). 
2. ‘Other’ category comprised of Asian American, Native American and ‘Other’ racial/ethnic 
groups. 
3. N= 14,124 (N=2,013 patients with a diagnosis of mental retardation excluded). Adjusted 
population incidence of diabetes: 2.6%. 
4. N= 16,052 (N=75 patients treated with Clozapine excluded). Adjusted population incidence of 
diabetes: 2.4%. 
5. First-generation agents included: Chlorpromazine; Fluphenazine; Haloperidol; Loxapine; 
Mesoridazine; Molindone; Perphenazine; Pimozide; Thioridazine; Thiothixene and 
Trifluoperazine. 
 
3.3.2 Time to Occurrence of Diabetes 
The mean time to occurrence of diabetes was 95.9 days (SD: 85.1) (Table 
3.24), with onset ranging from seven to 362 days. As the distributions were not 
normally distributed (positive skew), both the mean and median time to 
occurrence of diabetes are reported in Table 3.24. 
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Table 3.24: Average Time to Occurrence (Days) of New-Onset Diabetes in the Texas 
Medicaid Study Population  
Index Antipsychotic N Mean (SD) Median 
First-Generation Agent 80 82.0 (79.5) 56.0 
Second-Generation Agent1 302 99.6 (83.2) 66.0 
 Olanzapine 89 100.9 (82.2) 73.0 
 Quetiapine 25 87.0 (80.1) 51.0 
 Risperidone 187 100.3 (89.2) 61.0 
Total 382 95.9 (85.1) 62.5 
1. N=302 new-onset cases (N=1 case treated with Clozapine excluded from further report due to 
small sample size). 
 
3.3.2.1 Time to Occurrence of Diabetes According to the Class of 
Antipsychotic Used (Objective 4) 
H5a: The time to occurrence of diabetes will not differ significantly when 
patients are stratified according to the class of antipsychotic used (first 
or second-generation), after controlling for demographic, clinical and 
medication risk factors for diabetes. 
 
As noted, the mean time to occurrence of diabetes was 82.0 days (SD: 
79.5) for patients treated with a first-generation antipsychotic agent, and 99.6 
days (SD: 83.2) for patients treated with a second-generation agent (Table 3.24). 
This difference was not significant when analyzed by Student T-test and the 
Mann-Whitney test (p=0.099 and p=0.071, respectively). Consistent with this, 
Cox proportional hazards regression analysis showed that, after controlling for 
differences in demographic, clinical and medication variables in Texas Medicaid, 
the class of antipsychotic agent was not significantly associated (HR: 0.902, 95% 
CI: 0.675 to 1.205) with the time to occurrence of diabetes (Table 3.25). 
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Covariates that were significantly associated with the outcome were patient age 
(p=0.011) and race/ethnicity (p<0.001). Compared to patients aged 18 to 34 
years, the time to occurrence of diabetes was increased for patients aged 45 to 54 
years (HR: 2.748, 95% CI: 1.489 to 5.072); 55 to 64 years (HR: 2.365, 95% CI: 
1.165 to 4.404); and for those aged 65 years or older (HR: 1.924, 95% CI: 1.052 
to 3.521). The time to onset of diabetes was increased for minority patients 
compared to Whites, with significant differences noted for Blacks (HR: 1.588, 
95% CI: 1.192-2.117) and Hispanics (HR: 1.830, 95% CI: 1.353 to 2.475). Other 
covariates associated with a significant increase in time to occurrence of diabetes 
were female gender, and a comorbid diagnosis of hypertension or dyslipidemia 
(Table 3.25). In contrast, use of a concomitant diabetogenic medication and 
adherence to antipsychotic therapy were associated with a shorter time to 
occurrence of diabetes (HR=0.720, 95% CI=0.562 to 0.923; and HR=0.718, 95% 
CI=0.559 to 0.924, respectively). 




Table 3.25: Cox Regression Analysis Comparing the Time to Occurrence of Diabetes in 
Texas Medicaid Patients Treated with a First- or Second-Generation Antipsychotic after 
Controlling for Demographic (Age, Gender, Race/Ethnicity), Clinical (Mental Health 
Diagnosis, Hypertension, Dyslipidemia) and Medication (Use of a Concomitant 
Diabetogenic Medication, Antipsychotic Adherence) Variables 1,2 
Variables β(SE)
3 Wald F p 4 OR 3 95% CI 3 
Index Antipsychotic Agent 5      
 Second-Generation Agent -0.104 (0.148) 0.490 0.484 0.902 0.675-1.205 
Adherence 5      
 MPR_365 days ≥ 0.8 6 -0.331 (0.128) 6.652 0.010* 0.718 0.559-0.924 
Concomitant Diabetogenic 
Medication 
-0.328 (0.127) 6.705 0.010* 0.720 0.562-0.923 
Age 5  13.107 0.011*   
 35 to 44 0.523 (0.328) 2.533 0.112 1.686 0.886-3.210 
 45 to 54 1.011 (0.313) 10.457 0.001* 2.748 1.489-5.072 
 55 to 64 0.818 (0.339) 5.809 0.016* 2.365 1.165-4.404 
 ≥ 65 0.655 (0.308) 4.509 0.034* 1.924 1.052-3.521 
Gender 5      
 Female 0.269 (0.135) 3.955 <0.001* 1.309 1.004-1.706 
Race/Ethnicity 5  20.733 <0.001*   
 Black 0.463 (0.147) 9.956 0.002* 1.588 1.192-2.117 
 Hispanic 0.604 (0.154) 15.409 <0.001* 1.830 1.353-2.475 
 Other7 0.006 (0.260) 0.001 0.980 1.006 0.604-1.676 
Primary Mental Health 
Diagnosis 52 
 3.099 0.685   
 Bipolar Disorder 0.090 (0.210) 0.183 0.669 1.094 0.725-1.652 
 Dementia 0.088 (0.234) 0.141 0.707 1.092 0.691-1.726 
 Psychotic Disorder 0.074 (0.261) 0.081 0.777 1.077 0.646-1.796 
 Non-Psychotic Disorder 0.318 (0.211) 2.266 0.132 1.374 0.909-2.078 
 No Mental Health Diagnosis 0.065 (0.204) 0.101 0.750 1.067 0.715-1.593 
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Table 3.25 (cont.): Cox Regression Analysis Comparing the Time to Occurrence of Diabetes 
in Texas Medicaid Patients Treated with a First- or Second-Generation Antipsychotic after 
Controlling for Demographic (Age, Gender, Race/Ethnicity), Clinical (Mental Health 
Diagnosis, Hypertension, Dyslipidemia) and Medication (Use of a Concomitant 
Diabetogenic Medication, Antipsychotic Adherence) Variables 1,2 
Variables β(SE)
3 Wald F p 4 OR 3 95% CI 3 
Hypertension 0.949 (0.125) 57.843 0.002* 1.610 1.184-2.189 
Dyslipidemia 0.476 (0.157) 9.218 <0.001* 2.583 2.023-3.298 
1. Model χ2= 173.699, df=18, p<0.001. 
2. N=10,652 (Patients with prevalent diabetes, mental retardation or filling only one 
antipsychotic prescription excluded). 
3.  Abbreviations: SE: Standard Error; HR = Hazard Ratio; CI = Confidence Interval. 
4.  *Indicates statistical significance at p< 0.05. 
5. Reference category for each variable: Index Antipsychotic (First-Generation Agent); 
Adherence (MPR_365 days <0.8); Age (18-34 years); Gender (Male); Race/Ethnicity (White); 
Primary Mental Health Diagnosis (Schizophrenia). 
6.  “MPR_356 days” reflects medication possession ratio calculated over a 365 day period. 
7. ‘Other’ category comprised of Native American, Asian American and ‘Others.’ 
 
3.3.2.2 Time to Occurrence of Diabetes According to the Specific Second-
Generation Antipsychotic Agent Used (Objective 4) 
H5b: The time to occurrence of diabetes will not differ significantly when 
stratified according to the specific second-generation antipsychotic 
agent used, after controlling for demographic, clinical and medication 
risk factors for diabetes. 
 
The time to occurrence of diabetes was analyzed according to the specific 
index second-generation antipsychotic agent prescribed. Patients treated with 
clozapine were excluded from this analysis due to the small treatment numbers. 
No patients received ziprasidone as their index antipsychotic agent. As shown in 
Table 3.24, without controlling for other variables, the time to occurrence of 
diabetes was shortest for quetiapine and longest for olanzapine. This finding was 
not significant when examined using ANOVA or Kruskal-Wallis tests (p=0.754 
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and p=0.590, respectively). When analyzed using Cox proportional hazards 
regression model, again no difference was noted in the time to occurrence of 
diabetes based on the specific second-generation antipsychotic agent used 
(p=0.278), even after controlling for differences in demographic, clinical and 
medication variables (Table 3.26). Hazard ratios indicated that olanzapine and 
quetiapine were associated with a shorter time to occurrence of diabetes 
compared to risperidone; however, as noted these differences were not significant 
(HR: 0.842, 95% CI=0.634 to 1.120; and HR: 0.726, 95% CI=0.447 to 1.178, 
respectively). Covariates that were significantly associated with the time to 
occurrence of diabetes included patient race/ethnicity, and a comorbid diagnosis 
with hypertension or dyslipidemia (Table 3.26). The time to onset of diabetes 
was increased for minority patients compared to Whites, with significant 
differences noted for Blacks (HR: 1.516, 95% CI: 1.109 to 2.107) and Hispanics 
(HR: 1.712, 95% CI: 1.223 to 2.397). While overall age was not associated with 
the time to occurrence of diabetes, a significant increase in the time to onset was 
noted for patients aged between 55 and 64 years compared to those aged 18 to 34 
years (HR: 2.383, 95% CI: 1.123 to 5.059). Use of a concomitant diabetogenic 
medication and adherence to antipsychotic therapy were associated with a shorter 
time to occurrence of diabetes (HR=0.712, 95% CI=0.540 to 0.939; and 
HR=0.678, 95% CI=0.512 to 0.898, respectively). 
H5b:   Accepted. 
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Table 3.26: Cox Regression Analysis Comparing the Time to Occurrence of Diabetes for 
Texas Medicaid Patients Treated with Second-Generation Antipsychotics after Controlling 
for Demographic (Age, Gender, Race/Ethnicity), Clinical (Mental Health Diagnosis, 
Hypertension, Dyslipidemia) and Medication (Dose, Adherence, Use of a Concomitant 
Diabetogenic Medication) Variables 1, 2 
Variables β(SE)
3 Wald F p 4 OR 3 95% CI 3 
Index Antipsychotic Agent 5  2.560 0.278   
 Olanzapine -0.172 (0.145) 0.145 0.238 0.842 0.634-1.120 
 Quetiapine -0.320 (0.247) 0.247 0.195 0.726 0.447-1.178 
Antipsychotic Dose 5, 6  3.554 0.169   
 Moderate Dose -0.360 (0.207) 0.207 0.082 0.698 0.465-1.047 
 High Dose 0.091 (0.299) 0.299 0.761 1.095 0.609-1.970 
Adherence 5      
 MPR_365 days ≥ 0.8 7 -0.388 (0.143) 7.360 0.007* 0.678 0.512-0.898 
Concomitant Diabetogenic 
Medication 
-0.339 (0.141) 5.769 0.016* 0.712 0.540-0.939 
Age 5  6.800 0.147   
 35 to 44 0.649 (0.370) 3.087 0.079 1.914 0.928-3.950 
 45 to 54 0.718 (0.369) 3.782 0.052 2.050 0.994-4.225 
 55 to 64 0.869 (0.384) 5.115 0.024* 2.383 1.123-5.059 
 ≥ 65 0.484 (0.356) 1.850 0.174 1.623 0.808-3.262 
Gender 5      
 Female 0.144 (0.150) 0.916 0.339 1.155 0.860-1.550 
Race/Ethnicity 5  14.197 0.003*   
 Black 0.416 (0.168) 6.114 0.013* 1.516 1.109-2.107 
 Hispanic 0.538 (0.172) 9.793 0.002* 1.712 1.223-2.397 
 Other 8 -0.172 (0.319) 0.291 0.590 0.842 0.450-1.574 
Hypertension 0.928 (0.138) 45.276 <0.001* 2.530 1.931-3.315 
Dyslipidemia 0.497 (0.174) 8.121 0.004* 1.644 1.168-2.314 
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Table 3.26 (cont.): Cox Regression Analysis Comparing the Time to Occurrence of Diabetes 
for Texas Medicaid Patients Treated with Second-Generation Antipsychotics after 
Controlling for Demographic (Age, Gender, Race/Ethnicity), Clinical (Mental Health 
Diagnosis, Hypertension, Dyslipidemia) and Medication (Dose, Adherence, Use of a 
Concomitant Diabetogenic Medication) Variables 1, 2 
Variables β(SE)
3 Wald F p 4 OR 3 95% CI 3 
Primary Mental Health 
Diagnosis 52 
 1.203 0.945   
 Bipolar Disorder 0.041 (0.251) 0.026 0.871 1.042 0.636-1.705 
 Dementia 0.131 (0.270) 0.234 0.628 1.140 0.671-1.937 
 Psychotic Disorder 0.100 (0.303) 0.108 0.742 1.105 0.611-1.999 
 Non-Psychotic Disorder 0.235 (0.256) 0.843 0.359 1.265 0.766-2.091 
 No Mental Health Diagnosis 0.070 (0.251) 0.079 0.779 1.073 0.656-1.756 
1. Model χ2= 132.115, df=21, p<0.001. 
2. N=7,732 (Patients with prevalent diabetes, mental retardation, treated with clozapine or a first-
generation antipsychotic, or filling only one prescription excluded). 
3. Abbreviations: SE = Standard Error; HR = Hazard Ratio; CI = Confidence Interval. 
4. *Indicates statistical significance at p< 0.05. 
5. Reference category for each variable: Index Antipsychotic (Risperidone); Dose (Low-Dose); 
Adherence (MPR_365 days <0.8); Age (18-34 years); Gender (Male); Race/Ethnicity (White); 
Primary Mental Health Diagnosis (Schizophrenia). 
6. Mean Daily Dose Reference Ranges: Olanzapine - Low: ≤ 10mg; Medium: >10mg to ≤ 15mg; 
High: >15mg; Quetiapine - Low: ≤ 300mg; Medium: >300mg to ≤ 600mg; High: >600mg; 
Risperidone - Low: ≤ 2mg; Medium: >2mg to ≤ 6mg; High: >6mg. 
7. ‘MPR_356 days’ reflects medication possession ratio calculated over a 365-day period. 




3.3.3 Incidence of Diabetes – Contributing Factors 
The potential of several variables to influence the incidence of diabetes in 
the study population were investigated in detail. These included: the class of 
antipsychotic agent used (first-generation vs. second-generation); the specific 
type of second-generation antipsychotic agent (clozapine, olanzapine, quetiapine, 
risperidone or ziprasidone); the dose of the individual second-generation agents; 
and the primary mental health diagnosis for which these agents were presumed to 
be prescribed. The results of these investigations are discussed below. 
3.3.3.1 Incidence of Diabetes According to the Class of Antipsychotic Agent 
(Objective 4) 
H6a: The incidence of diabetes will not differ significantly according to the 
class of antipsychotic agent used (first- or second-generation), after 
controlling for demographic, clinical and medication risk factors for 
diabetes. 
 
The incidence of diabetes was 2.4 percent (1.6% and 2.7%, respectively 
of those treated with a first- or second-generation antipsychotic). After excluding 
patients treated with clozapine and those with a diagnosis of mental retardation 
from the analysis, the incidence of diabetes was 2.6 percent in the population 
(1.8% and 2.9%, respectively, of those treated with a first- or second-generation 
antipsychotic). Multivariate logistic regression analysis showed that after 
controlling for differences in other variables, the class of antipsychotic agent 
used was not significantly associated with the incidence of diabetes (Table 3.27). 
Compared to patients receiving a first-generation antipsychotic, the odds of new-
onset diabetes increased by 21.6 percent with use of a second-generation agent; 
but as noted, this result was not significant (OR=1.216, 95% CI=0.905 to 1.634). 
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Compliance with antipsychotic therapy was significantly associated with the 
odds of new-onset diabetes. Compared to non-adherent patients (MPR_365 days 
<0.8), adherent patients were almost 3.9 times more likely to develop diabetes 
(OR: 3.889, 95% CI: 2.999 to 5.044). In contrast, increasing persistence with 
therapy was associated with a decreased odds of new-onset diabetes (OR: 0.995, 
95% CI: 0.993 to 0.996). A diagnosis of comorbid hypertension or dyslipidemia 
were both associated with an increased odds of new-onset diabetes (OR: 2.487, 
95% CI: 1.939 to 3.190; and OR: 2.020, 95% CI: 1.461 to 2.793, respectively). 
Women had a higher odds of new-onset diabetes compared to men (OR: 1.396, 
95% CI: 1.061 to 1.837). Other variables that were significantly associated with 
the occurrence of new-onset diabetes were increasing patient age (p=0.007) and 
patient race/ethnicity (p=0.002). Compared to patients aged between 18 and 34 
years, the odds of new-onset diabetes increased between 1.7 and almost three-
fold for patients in the higher age strata, with the largest comparative increase for 
patients aged between 45 and 54 years (OR: 2.944, 95% CI: 1.581 to 5.480). 
With regard to race/ethnicity, the odds of new-onset diabetes were increased for 
Black (OR=1.454, 95% CI=1.076 to 1.965) and Hispanic patients (OR=1.722, 
95% CI=1.257 to 2.360) compared to Whites.  
H6a:    Accepted. 
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Table 3.27: Logistic Regression Analysis Comparing the Risk of New-Onset Diabetes in 
Texas Medicaid Patients Treated with a First-Generation versus a Second-Generation 
Antipsychotic after Controlling for Demographic (Age, Gender, Race/Ethnicity), Clinical 
(Mental Health Diagnosis, Hypertension, Dyslipidemia) and Medication (Antipsychotic 
Compliance, Use of a Concomitant Diabetogenic Medication) Variables 1,2 
Variables β(SE)
3 Wald F p 4 OR 3 95% CI 3 
Intercept -5.251 (0.343) 234.654 <0.001* 0.005  
Antipsychotic Class 5      
 Second-Generation Agent 0.196 (0.151) 1.691 0.193 1.216 0.905-1.634 
Adherence 5      
 MPR_365 days ≥ 0.8 3,6 1.358 (0.133) 104.793 <0.001* 3.889 2.999-5.044 
Persistence -0.004 (0.001) 75.567 <0.001* 0.995 0.993-0.996 
Age 5  14.174 0.007*   
 35 to 44 0.557 (0.332) 2.814 0.093 1.746 0.910-3.348 
 45 to 54 1.080 (0.317) 11.591 <0.001* 2.944 1.581-5.480 
 55 to 64 1.922 (0.344) 7.178 0.007* 2.513 1.281-4.932 
 ≥ 65 0.757 (0.312) 5.868 0.015* 2.132 1.155-3.933 
Gender 5      
 Female 0.334 (0.154) 5.947 0.017* 1.396 1.061-1.837 
Race/Ethnicity 5  14.927 0.002*   
 Black 0.375 (0.154) 5.947 0.015* 1.454 1.076-1.965 
 Hispanic 0.544 (0.161) 11.435 <0.001* 1.722 1.257-2.360 
 Other 7 -0.069 (0.270) 0.066 0.798 0.933 0.550-1.583 
Hypertension 0.911 (0.127) 51.496 <0.001* 2.487 1.939-3.190 
Dyslipidemia 0.703 (0.165) 18.118 <0.001* 2.020 1.461-2.793 
Concomitant Diabetogenic 
Medication 
-0.080 (0.132) 0.364 0.546 0.923 0.712-1.196 
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Table 3.27 (cont): Logistic Regression Analysis Comparing the Risk of New-Onset Diabetes 
in Texas Medicaid Patients Treated with a First-Generation versus a Second-Generation 
Antipsychotic after Controlling for Demographic (Age, Gender, Race/Ethnicity), Clinical 
(Mental Health Diagnosis, Hypertension, Dyslipidemia) and Medication (Antipsychotic 
Compliance, Use of a Concomitant Diabetogenic Medication) Variables 1,2 
Variables β(SE)
3 Wald F p 4 OR 3 95% CI 3 
Primary Mental Health 
Diagnosis 5 
 5.108 0.403   
 Bipolar Disorder 0.058 (0.217) 0.071 0.790 1.060 0.692-1.622 
 Dementia 0.152 (0.241) 0.400 0.527 1.165 0.726-1.867 
 Psychotic Disorder 0.027 (0.269) 0.010 0.921 1.027 0.606-1.741 
 Non-Psychotic Disorder 0.401 (0.217) 3.416 0.065 1.493 0.976-2.284 
 No Mental Health 
 Diagnosis 
0.079 (0.211) 0.139 0.709 1.082 0.716-1.634 
1. Model χ2 = 266.411, df = 19, p <0.001.  
2. N=10,953 (Patients with mental retardation, prevalent diabetes and those filling only one 
antipsychotic prescription excluded: N=8,477). 
3. Abbreviations: SE = Standard Error; OR = Odds Ratio; CI = Confidence Interval; MPR = 
Medication Possession Ratio. 
4. * Indicates statistical significance at p< 0.05. 
5. Reference category for each variable: Antipsychotic Class (First-Generation Agent); 
Adherence (MPR_365 days <0.8); Age 18-34 years); Race/Ethnicity (White); Gender (Male); 
Primary Mental Health Diagnosis (Schizophrenia). 
6. ‘MPR_365 days’ refers to adherence measured over a 365-day period. 
7. ‘Other’ category comprised of Native American, Asian American and ‘Others.’ 
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3.3.3.2 Incidence of Diabetes According to the Specific Second-Generation 
Antipsychotic Agent (Objective 4) 
H6b: The incidence of diabetes will not differ significantly according to the 
specific second-generation antipsychotic agent used, after controlling 
for demographic, clinical and medication risk factors for diabetes. 
 
The incidence of diabetes was 2.9 percent (olanzapine: 2.7%; quetiapine: 
2.6%; risperidone: 3.1%) among eligible patients taking a second-generation 
antipsychotic after excluding those treated with clozapine and those with a 
diagnosis of mental retardation from the analysis. Multivariate logistic regression 
analysis showed that after controlling for differences in other variables, there was 
no difference (p=0.281) in the incidence of diabetes according to the specific 
second-generation antipsychotic prescribed (Table 3.28). Compared to patients 
receiving risperidone, the odds of new-onset diabetes were reduced by 12.1 
percent with olanzapine (OR=0.879, 95% CI=0.653 to 1.184), and by 31.7 
percent with quetiapine (OR=0.683, 95% CI=0.414 to 1.126); but as noted, these 
results were not significant. 
While the choice of antipsychotic did not alter the odds of new-onset 
diabetes, compliance with therapy was significantly associated with the outcome. 
Compared to non-adherent patients (MPR_365 days <0.8), adherent patients 
were 3.7 times more likely to develop diabetes (OR: 3.710, 95% CI: 2.777 to 
4.956). In contrast, increasing persistence with therapy was associated with a 
marginally decreased odds of new-onset diabetes (OR: 0.995, 95% CI: 0.993 to 
0.996). 
Diagnoses of comorbid hypertension or dyslipidemia were associated 
with an increased odds of new-onset diabetes (OR: 2.480, 95% CI: 1.881 to 
3.269; and OR: 2.034, 95% CI: 1.418 to 2.916, respectively) however, the type of 
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mental health diagnosis for which the antipsychotic was presumed to be 
prescribed was not associated with the outcome (p=0.683). Patient race/ethnicity 
was again significantly associated with the occurrence of new-onset diabetes 
(p=0.020). Compared to Whites, the odds of new-onset diabetes increased for 
Hispanic patients (OR=1.612, 95% CI=1.133 to 2.294). While overall age was 
not associated with the risk of new-onset diabetes, an increase in risk was noted 
for patients aged between 45 and 54 years (OR: 2.222, 95% CI: 1.066 to 4.634), 
55 and 64 years (OR: 2.748, 95% CI: 1.280 to 5.900), and those aged 65 years or 
older (OR: 1.232, 95% CI: 1.006 to 4.130) when compared to patients aged 
between 18 and 34 years. 
H6b:  Accepted. 
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Table 3.28: Logistic Regression Analysis Comparing the Risk of New-Onset Diabetes in 
Texas Medicaid Patients Treated with Specific Second-Generation Antipsychotic Agents 
after Controlling for Demographic (Age, Gender, Race/Ethnicity), Clinical (Mental Health 
Diagnosis, Hypertension, Dyslipidemia) and Medication (Antipsychotic Dose, Compliance, 
Use of a Concomitant Diabetogenic Medication) Variables 1,2 
Variables β(SE)
3 Wald F p 4 OR 3 95% CI 3 
Intercept -4.371 (0.404) 136.931 <0.001* 0.009  
Antipsychotic Agent 5  2.537 0.281   
 Olanzapine -0.128 (0.152) 0.717 0.397 0.879 0.653-1.184 
 Quetiapine 0.381 (0.255) 2.233 0.135 0.683 0.414-1.126 
Antipsychotic Dose 5,6  2.590 0.274   
 Medium Dose -0.294 (0.208) 1.987 0.159 0.746 0.496-1.121 
 High Dose 0.148 (0.304) 0.236 0.627 1.159 0.639-2.104 
Adherence 5      
 MPR_365 days ≥ 0.8 7 1.311 (0.148) 76.648 <0.001* 3.710 2.777-4.956 
Persistence -0.005 (0.001) 64.997 <0.001* 0.995 0.993-0.996 
Age 5  7.000 0.136   
 35 to 44 0.727 (0.375) 3.758 0.053 2.069 0.992-4.314 
 45 to 54 0.799 (0.375) 4.536 0.033* 2.222 1.066-4.634 
 55 to 64 1.011 (0.390) 6.727 0.009* 2.748 1.280-5.900 
 ≥ 65 0.712 (0.360) 3.907 0.048* 1.232 1.006-4.130 
Gender 5      
 Female 0.209 (0.156) 1.797 0.180 1.232 0.908-1.673 
Race/Ethnicity 5  9.859 0.020*   
 Black 0.310 (0.176) 3.084 0.079 1.363 0.965-1.925 
 Hispanic 0.478 (0.180) 7.044 0.008* 1.612 1.133-2.294 
 Other 8 -0.236 (0.330) 0.509 0.475 0.790 0.413-1.510 
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Table 3.28 (cont.): Logistic Regression Analysis Comparing the Risk of New-Onset Diabetes 
in Texas Medicaid Patients Treated with Specific Second-Generation Antipsychotic Agents 
after Controlling for Demographic (Age, Gender, Race/Ethnicity), Clinical (Mental Health 
Diagnosis, Hypertension, Dyslipidemia) and Medication (Antipsychotic Dose, Compliance, 
Use of a Concomitant Diabetogenic Medication) Variables 1,2 
Variables β(SE)
3 Wald F p 4 OR 3 95% CI 3 
Primary Mental Health 
Diagnosis 5 
 3.113 0.683   
 Bipolar Disorder 0.008 (0.260) 0.001 0.976 1.008 0.606-1.676 
 Dementia 0.196 (0.278) 0.495 0.482 1.216 0.705-2.099 
 Psychotic Disorder 0.029 (0.312) 0.009 0.926 1.030 0.559-1.898 
 Non-Psychotic Disorder 0.337 (0.263) 1.645 0.200 1.401 0.837-2.345 
 No Mental Health 
 Diagnosis 
0.074 (0.256) 0.083 0.773 1.077 0.651-1.780 
Hypertension 0.908 (0.141) 41.517 <0.001* 2.480 1.881-3.269 
Dyslipidemia 0.710 (0.184) 14.911 <0.001* 2.034 1.418-2.916 
Concomitant Diabetogenic 
Medication 
-0.091 (0.147) 0.377 0.539 0.913 0.684-1.219 
1. Model χ2 = 200.212, df = 22, p<0.001.  
2. N=7,842 (Patients with mental retardation, prevalent diabetes, patients treated with clozapine, 
filling only one antipsychotic prescription and dose outliers excluded: N=5,889). 
3. Abbreviations: SE – Standard Error; OR = Odds Ratio; CI = Confidence Interval; MPR = 
Medication Possession Ratio. 
4. *Indicates statistical significance at p< 0.05. 
5. Reference category for each variable: Index Antipsychotic (Risperidone); Race/Ethnicity 
(White); Gender (Male); Age (18-34 years); Primary Mental Health Diagnosis 
(Schizophrenia); Adherence (MPR_365 days <0.8) Dose (Low-Dose). 
6. Mean Daily Dose Reference Ranges: Olanzapine - Low: ≤ 10mg; Medium: >10mg to ≤ 15mg; 
High: >15mg; Quetiapine - Low: ≤ 300mg; Medium: >300mg to ≤ 600mg; High: >600mg; 
Risperidone - Low: ≤ 2mg; Medium: >2mg to ≤ 6mg; High: >6mg. 
7. ‘MPR_356 days’ reflects medication possession ratio calculated over a 365-day period. 
8. ‘Other’ category comprised of Native American, Asian American and ‘Others.’ 
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3.3.3.3 Incidence of Diabetes According to Antipsychotic Dose (Objective 4) 
A central theory in this study was the possibility that the incidence of 
diabetes may be associated with the dose of antipsychotic used. The association 
between treatment dose for olanzapine, quetiapine and risperidone and the 
incidence of diabetes are reported in the following section. Hypotheses 7a and 7e 
relating to clozapine and ziprasidone, respectively, were not tested due to the 
inadequate sample sizes. 
3.3.3.3.1 Incidence of Diabetes According to the Mean Daily Dose of Olanzapine 
H7b: The incidence of diabetes will not differ significantly according to the 
dose of olanzapine used, after controlling for demographic, clinical and 
medication risk factors for diabetes. 
 
The incidence of diabetes was 2.9 percent (N=74) for patients treated 
with olanzapine, after excluding those with prevalent diabetes, a diagnosis of 
mental retardation, and patients who redeemed only one prescription from the 
analysis. Multivariate logistic regression analysis showed that, after controlling 
for differences in other variables, the incidence of diabetes did not differ 
according to the dose of olanzapine used (OR: 1.019, 95% CI: 0.976 to 1.065) 
(Table 3.29). 
While the dose of olanzapine did not alter the odds of new-onset diabetes, 
compliance with therapy was significantly associated with the outcome. 
Compared to non-adherent patients (MPR_365 days <0.8), adherent patients 
were approximately 2.5 times more likely to develop diabetes (OR: 2.485, 95% 
CI: 1.449 to 4.262). In contrast, increasing persistence with therapy was 
associated with a decreased odds of new-onset diabetes (OR: 0.995, 95% CI: 
0.993 to 0.998). Diagnosis of comorbid hypertension was associated with an 
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increased odds of new-onset diabetes (OR: 2.543, 95% CI: 1.525 to 4.240). The 
relevance of mental health diagnoses will be discussed in hypothesis 8b. 
H7b:    Accepted. 
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Table 3.29: Logistic Regression Analysis of the Association between Mean Daily Dose and 
Primary Mental Health Diagnosis for Texas Medicaid Patients Treated with Olanzapine 
and Risk of New-Onset Diabetes after Controlling for Demographic (Age, Gender, 
Race/Ethnicity), Clinical (Hypertension, Dyslipidemia) and Medication (Compliance, Use of 
a Concomitant Diabetogenic Medication) Variables 1,2 
Variables β(SE)
3 Wald F p 4 OR 3 95% CI 3 
Intercept -5.002 (0.657) 657.865 <0.001* 0.007  
Mean Daily Dose 0.019 (0.022) 0.759 0.384 1.019 0.976-1.065 
Adherence 5,6      
 MPR_365 days ≥ 0.8 3 0.910 (0.275) 10.929 <0.001* 2.485 1.449-4.262 
Persistence -0.005 (0.001) 15.150 <0.001* 0.995 0.993-0.998 
Age 5  1.582 0.812   
 35 to 44 0.467 (0.544) 0.737 0.391 1.595 0.549-4.634 
 45 to 54 0.595 (0.550) 1.167 0.280 1.812 0.616-5.331 
 55 to 64 0.712 (0.600) 1.408 0.235 2.037 0.629-6.600 
 ≥ 65 0.497 (0.543) 0.836 0.360 1.643 0.567-4.765 
Gender 5      
 Female 0.547 (0.297) 3.407 0.065 1.729 0.967-3.091 
Race/Ethnicity 5  1.353 0.717   
 Black 0.378 (0.335) 1.272 0.259 1.459 0.757-2.813 
 Hispanic 0.128 (0.323) 0.158 0.691 1.137 0.604-2.140 
 Other 7 -0.019 (0.500) 0.001 0.969 1.981 0.368-2.614 
Hypertension 0.933 (0.261) 12.798 <0.001* 2.543 1.525-4.240 
Dyslipidemia 0.031 (0.386) 0.001 0.973 1.013 1.476-2.158 
Concomitant Diabetogenic 
Medication 
-0.291 (0.279) 1.087 0.297 0.748 0.433-1.292 
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Table 3.29 (cont.): Logistic Regression Analysis of the Association between Mean Daily 
Dose and Primary Mental Health Diagnosis for Texas Medicaid Patients Treated with 
Olanzapine and Risk of New-Onset Diabetes after Controlling for Demographic (Age, 
Gender, Race/Ethnicity), Clinical (Hypertension, Dyslipidemia) and Medication 
(Compliance, Use of a Concomitant Diabetogenic Medication) Variables 1,2 
Variables β(SE)
3 Wald F p 4 OR 3 95% CI 3 
Primary Mental Health 
Diagnosis 5 
 12.047 0.034*   
 Bipolar Disorder 0.116 (0.444) 0.069 0.793 1.123 0.470-2.682 
 Dementia -0.198 (0.556) 0.127 0.722 0.820 0.276-2.441 
 Psychotic Disorder 1.069 (0.502) 4.529 0.033* 2.911 1.088-7.790 
 Non-Psychotic Disorder 0.889 (0.433) 4.227 0.040* 2.433 1.042-5.680 
 No Mental Health 
 Diagnosis 
0.521 (0.419) 1.542 0.214 1.683 0.740-3.827 
1. Model χ2 = 54.652, df = 19, p<0.001.  
2. N=2,521 (Patients with mental retardation, prevalent diabetes, dose outliers and those filling 
only one antipsychotic prescription excluded: N=1,678). 
3. Abbreviations: OR = Odds Ratio; CI = Confidence Interval; MPR_365 days = Medication 
Possession Ratio over 365 days. 
4. *Indicates statistical significance at p< 0.05. 
5. Reference category for each variable: Age (18-34 years); Race/Ethnicity (White); Gender 
(Male); Primary Mental Health Diagnosis (Schizophrenia); Adherence (MPR_365 days <0.8). 
6. ‘MPR_356 days’ reflects medication possession ratio calculated over a 365-day period. 
7. ‘Other’ category comprised of Native American, Asian American and ‘Others.’ 
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3.3.3.3.2 Incidence of Diabetes According to the Mean Daily Dose of Quetiapine 
H7c: The incidence of diabetes will not differ significantly according to the 
dose of quetiapine used, after controlling for demographic, clinical and 
medication risk factors for diabetes. 
 
The incidence of diabetes was 2.7 percent (N=19) for patients treated 
with quetiapine after excluding those with prevalent diabetes, a diagnosis of 
mental retardation, and patients filling only one prescription from the analysis. 
Multivariate logistic regression analysis showed that, after controlling for 
differences in other variables, there was no association between quetiapine dose 
and incidence of diabetes (OR: 1.001, 95% CI: 0.997 to 1.004) (Table 3.30). The 
only variables that were significantly associated with the occurrence of diabetes 
in patients taking quetiapine therapy were adherence and persistence to 
quetiapine therapy. Compared to non-adherent patients (MPR_365 days <0.8), 
adherent patients were 10.7 times more likely to develop diabetes (OR: 10.657, 
95% CI: 3.141 to 36.161). Increasing persistence with therapy was however 
associated with a decreased odds of new-onset diabetes (OR: 0.993, 95% CI: 
0.988 to 0.997). The relevance of mental health diagnoses will be discussed in 
hypothesis 8c. 
H7c:   Accepted. 
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Table 3.30: Logistic Regression Analysis of the Association between Mean Daily Dose and 
Primary Mental Health Diagnosis for Texas Medicaid Patients Treated with Quetiapine 
and Risk of New-Onset Diabetes after Controlling for Demographic (Age, Gender, 
Race/Ethnicity), Clinical (Hypertension, Dyslipidemia) and Medication (Compliance, Use of 
a Concomitant Diabetogenic Medication) Variables 1,2 
Variables β(SE)
3 Wald F p 4 OR 3 95% CI 3 
Intercept -4.126 (1.148) 12.922 <0.001* 0.016  
Mean Daily Dose 0.000 (0.002) 0.082 0.774 1.001 0.997-1.004 
Adherence 5,6      
 MPR_365 days ≥ 0.8 2 2.366 (0.623) 14.408 <0.001* 10.657 3.141-36.161 
Persistence -0.007 (0.002) 9.848 0.002* 0.993 0.988-0.997 
Age 5  0.771 0.680   
 45 to 64 -0.401 (0.846) 0.225 0.636 0.670 0.128-3.517 
 ≥ 65 0.283 (0.751) 0.142 0.707 1.327 0.304-5.787 
Gender 5      
 Female -0.038 (0.565) 0.004 0.947 0.963 0.318-2.914 
Race/Ethnicity 5  1.515 0.679   
 Black -0.352 (0.818) 0.185 0.667 0.703 0.142-3.497 
 Hispanic -0.370 (1.090) 0.115 0.734 0.691 0.082-5.847 
 Other 6 0.870 (0.865) 1.012 0.314 2.387 0.438-12.999 
Hypertension 0.082 (0.536) 0.023 0.879 1.085 0.379-3.102 
Dyslipidemia 0.690 (0.667) 1.070 0.301 1.993 0.540-7.360 
Concomitant Diabetogenic 
Medication 
-0.227 (0.561) 0.164 0.686 0.797 0.266-2.391 
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Table 3.30 (cont): Logistic Regression Analysis of the Association between Mean Daily Dose 
and Primary Mental Health Diagnosis for Texas Medicaid Patients Treated with 
Quetiapine and Risk of New-Onset Diabetes after Controlling for Demographic (Age, 
Gender, Race/Ethnicity), Clinical (Hypertension, Dyslipidemia) and Medication 
(Compliance, Use of a Concomitant Diabetogenic Medication) Variables 1,2 
Variables β(SE)
3 Wald F p 4 OR 3 95% CI 3 
Primary Mental Health 
Diagnosis 5 
 1.988 0.851   
 Bipolar Disorder 0.350 (0.914) 0.147 0.701 1.420 0.237-8.512 
 Dementia -0.195 (1.075) 0.033 0.856 0.823 0.100-6.754 
 Psychotic Disorder -1.063 (1.365) 0.607 0.436 0.345 0.024-5.014 
 Non-Psychotic Disorder -0.169 (1.051) 0.026 0.872 0.844 0.108-6.623 
 No Mental Health 
 Diagnosis 
-0.439 (1.067) 0.169 0.681 0.645 0.080-5.220 
1. Model χ2 = 27.927 df = 17, p=0.046.  
2. N=700 (Patients with mental retardation, prevalent diabetes, dose outliers and those filling 
only one antipsychotic prescription excluded: N=531). 
3. Abbreviations: OR = Odds Ratio; CI = Confidence Interval; MPR_365 days = Medication 
Possession Ratio over 365 days. 
4. *Indicates statistical significance at p< 0.05. 
5. Reference category for each variable: Age (< 45 years); Race/Ethnicity (White); Gender 
(Male); Primary Mental Health Diagnosis (Schizophrenia); Adherence (MPR_365 days <0.8). 
6. ‘MPR_356 days’ reflects medication possession ratio calculated over a 365-day period. 





3.3.3.3.3 Incidence of Diabetes According to the Mean Daily Dose of 
Risperidone 
H7d: The incidence of diabetes will not differ significantly according to the 
dose of risperidone used, after controlling for demographic, clinical and 
medication risk factors for diabetes. 
 
The incidence of diabetes was 3.3 percent (N=153) for patients treated 
with risperidone after excluding those with prevalent diabetes, a diagnosis of 
mental retardation, and patients filling only one prescription from the analysis. 
Multivariate logistic regression analysis showed that, after controlling for 
differences in other variables, there was no association between the incidence of 
diabetes and the dose of risperidone used (OR: 0.970, 95% CI: 0.854 to 1.102) 
(Table 3.31). Variables that were significantly associated with the incidence of 
diabetes were a diagnosis of hypertension (OR: 2.790, 95% CI: 1.957 to 3.976), 
or dyslipidemia (OR: 2.988, 95% CI: 1.916 to 4.659), and adherence to 
antipsychotic therapy (OR: 4.284, 95% CI: 2.928 to 6.163). Increasing 
persistence with therapy was associated with decreased odds of new-onset 
diabetes (OR: 0.994; 95% CI: 0.993 to 0.996). Patient race/ethnicity was also 
associated with the incidence of diabetes in patients prescribed risperidone 
(p=0.004). Compared to White patients, Black and Hispanic patients had 
increased odds of developing new-onset diabetes (OR: 1.586; 95% CI: 1.027 to 
2.451; and OR: 1.874; 95% CI: 1.210 to 2.901, respectively). While overall age 
was not associated with the risk of new-onset diabetes, an increase in risk was 
noted for patients aged between 55 and 64 years, compared to those aged 
between 18 and 34 years (OR: 4.267; 95% CI: 1.372 to 13.268). The relevance of 
mental health diagnoses will be discussed in hypothesis 8d. 
H7d:    Accepted. 
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Table 3.31: Logistic Regression Analysis of the Association between Mean Daily Dose and 
Primary Mental Health Diagnosis for Texas Medicaid Patients Treated with Risperidone 
and Risk of New-Onset Diabetes after Controlling for Demographic (Age, Gender, 
Race/Ethnicity), Clinical (Hypertension, Dyslipidemia) and Medication (Compliance, Use of 
a Concomitant Diabetogenic Medication) Variables 1,2 
Variables β(SE)
3 Wald F p 4 OR 3 95% CI 3 
Intercept -5.017 (0.625) 64.339 <0.001* 0.007  
Mean Daily Dose -0.031 (0.065) 0.221 0.639 0.970 0.854-1.102 
Adherence 5      
 MPR_365 days ≥ 0.8 2 1.446 (0.190) 58.065 <0.001* 4.248 2.928-6.163 
Persistence -0.006 (0.001) 42.232 <0.001* 0.994 0.993-0.996 
Age 5  6.881 0.142   
 35 to 44 0.963 (0.584) 2.723 0.099 2.620 0.835-8.223 
 45 to 54 0.976 (0.578) 2.850 0.091 2.653 0.855-8.238 
 55 to 64 1.451 (0.579) 6.281 0.012* 4.267 1.372-13.268 
 ≥ 65 0.996 (0.555) 3.224 0.073 2.707 0.913-8.030 
Gender 5      
 Female 0.071 (0.195) 0.131 0.717 1.073 0.732-1.573 
Race/Ethnicity 5  13.444 0.004*   
 Black 0.461 (0.222) 4.319 0.038* 1.586 1.027-2.451 
 Hispanic 0.628 (0.223) 7.916 0.005* 1.874 1.210-2.901 
 Other 6 -0.760 (0.5340 2.022 0.155 0.468 0.164-1.333 
Hypertension 1.026 (0.181) 32.211 <0.001* 2.790 1.957-3.976 
Dyslipidemia 1.094 (0.227) 23.304 <0.001* 2.988 1.916-4.659 
Concomitant Diabetogenic 
Medication 
0.055 (0.185) 0.087 0.768 1.056 0.735-1.518 
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Table 3.31 (cont.): Logistic Regression Analysis of the Association between Mean Daily 
Dose and Primary Mental Health Diagnosis for Texas Medicaid Patients Treated with 
Risperidone and Risk of New-Onset Diabetes after Controlling for Demographic (Age, 
Gender, Race/Ethnicity), Clinical (Hypertension, Dyslipidemia) and Medication 
(Compliance, Use of a Concomitant Diabetogenic Medication) Variables 1,2 
Variables β(SE)
3 Wald F p 4 OR 3 95% CI 3 
Primary Mental Health 
Diagnosis 5 
 6.147 0.292   
 Bipolar Disorder -0.214 (0.354) 0.365 0.545 0.807 0.403-1.616 
 Dementia 0.248 (0.359) 0.476 0.490 1.282 0.634-2.593 
 Psychotic Disorder -0.487 (0.427) 1.300 0.254 0.614 0.266-1.420 
 Non-Psychotic Disorder 0.124 (0.355) 0.122 0.727 1.132 0.565-2.269 
 No Mental Health 
 Diagnosis 
-0.107 (0.344) 0.097 0.755 0.898 0.457-1.764 
1. Model χ2 = 160.747, df = 19, p<0.001.  
2. N=4,621 (Patients with mental retardation, prevalent diabetes, dose outliers and those filling 
only one antipsychotic prescription excluded: N=3,587). 
3. Abbreviations: OR = Odds Ratio; CI = Confidence Interval; MPR_365 days = Medication 
Possession Ratio over 365 days. 
4. *Indicates statistical significance at p< 0.05. 
5. Reference category for each variable: Age (18-34 years); Race/Ethnicity (White); Gender 
(Male); Primary Mental Health Diagnosis (Schizophrenia); Adherence (MPR_365 days <0.8). 
6. ‘MPR_356 days’ reflects medication possession ratio calculated over a 365-day period. 
7. ‘Other’ category comprised of Native American, Asian American and ‘Others.’ 
 
3.3.3.4 Incidence of Diabetes According to Primary Mental Health Diagnosis 
(Objective 4) 
Another key theory in this study was the possibility that the incidence of 
diabetes may be associated with the primary mental health diagnosis for which 
antipsychotic therapy was presumed to be prescribed. The association between 
the presumed indication for olanzapine, quetiapine and risperidone and the 
incidence of diabetes are reported in the following section. Hypotheses 8a and 8e 
relating to clozapine and ziprasidone, respectively, were not tested due to 
inadequate sample size. 
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3.3.3.4.1 Incidence of Diabetes with Olanzapine According to the Primary 
Mental Health Diagnosis 
H8b: For patients treated with olanzapine, the incidence of diabetes will not 
differ significantly when stratified according to primary mental health 
diagnosis, after controlling for demographic, clinical and medication 
risk factors for diabetes. 
 
The incidence of diabetes was 2.9 percent (N=74) for patients treated 
with olanzapine, after excluding those with prevalent diabetes, a diagnosis of 
mental retardation, and patients who redeemed only one prescription from the 
analysis. Multivariate logistic regression analysis showed that, after controlling 
for differences in other variables, the incidence of diabetes differed according to 
the primary mental health diagnosis for which olanzapine was presumed to be 
used (p=0.034) (Table 3.29). With the exception of patients with dementia, the 
odds of developing new-onset diabetes were increased for all diagnostic groups 
when compared to schizophrenia. Only two contrasts were significant, however. 
Patients with a psychotic disorder other than schizophrenia were 2.9 times more 
likely to develop diabetes than those with schizophrenia (OR: 2.911, 95% CI: 
1.088 to 7.790). Similarly, patients with a non-psychotic disorder had a 2.4-fold 
increase in odds of diabetes compared to those with schizophrenia (OR: 2.433, 
95% CI: 1.042 to 5.680). 
H8b:   Rejected. 
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3.3.3.4.2 Incidence of Diabetes with Quetiapine According to Primary Mental 
Health Diagnosis 
H8c: For patients treated with quetiapine, the incidence of diabetes will not 
differ significantly when stratified according to primary mental health 
diagnosis, after controlling for demographic, clinical and medication 
risk factors for diabetes. 
 
The incidence of diabetes was 2.7 percent (N=19) for patients treated 
with quetiapine after excluding those with prevalent diabetes, a diagnosis of 
mental retardation, and patients who redeemed only one prescription from the 
analysis. Multivariate logistic regression analysis showed that, after controlling 
for differences in other variables, the incidence of diabetes did not differ 
according to the primary mental health diagnosis for which quetiapine was 
presumed to be prescribed (p=0.851) (Table 3.30). With the exception of bipolar 
disorder, the odds of developing new-onset diabetes were reduced for all 
diagnostic categories when compared to schizophrenia; however, none of these 
contrasts were significant. 
H8c:   Accepted. 
 
 253
3.3.3.4.3 Incidence of Diabetes with Risperidone According to Primary Mental 
Health Diagnosis 
H8d: For patients treated with risperidone, the incidence of diabetes will not 
differ significantly according to primary mental health diagnosis, after 
controlling for demographic, clinical and medication risk factors for 
diabetes. 
 
The incidence of diabetes was 3.3 percent (N=153) for patients treated 
with risperidone after excluding those with prevalent diabetes, a diagnosis of 
mental retardation, and patients who redeemed only one prescription from the 
analysis. Multivariate logistic regression analysis showed that after controlling 
for differences in other variables, the incidence of diabetes did not differ 
according to the primary mental health diagnosis for which risperidone was 
presumed to be prescribed (p=0.292) (Table 3.31). Compared to patients with 
schizophrenia, the odds of new-onset diabetes were increased for patients with 
dementia or a non-psychotic disorder, and reduced for those with bipolar 
disorder, a psychotic disorder or no mental health diagnosis. None of these 
contrasts were significant, however. 
H8d:   Accepted. 
 254
3.4 Summary 
Included in this chapter were a description of the study population and an 
analysis of the study objectives. It was comprised of 19,430 eligible patients, the 
majority of whom were older, white women. Differences were found in the 
choice of antipsychotic agent when examined according to age, gender, 
race/ethnicity and mental health diagnosis, with differences in the prescribed 
dose of antipsychotic noted when examined according to patient age and mental 
health diagnosis. Compliance with antipsychotic therapy varied according to 
patient age, race/ethnicity, mental health diagnosis and antipsychotic agent. 
Logistic regression analysis examining the prevalence of diabetes in the 
population revealed differences in prevalence rates based on mental health 
diagnoses. Regarding the central theme of the association between antipsychotic 
use and the risk of new-onset diabetes, no difference was found between the 
different classes of antipsychotic (first-generation vs. second-generation), 
between the specific second-generation agents (olanzapine, quetiapine, or 
risperidone), based on antipsychotic treatment indication for the second-
generation agents olanzapine, quetiapine and risperidone, or based on treatment 
dose for quetiapine or risperidone. Table 3.32 summarizes the results of the 
hypothesis testing for objectives two, three and four. 
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Table 3.32: Summary of Hypotheses Testing  
Hypotheses Results 
Phase I: Demographic and Antipsychotic Utilization Patterns (Objective 2)  
H1a: The percentage of patients treated with the different antipsychotic agents 
will not differ significantly when stratified according to patient age.  
Rejected 
H1b: The percentage of patients treated with the different antipsychotic agents 
will not differ significantly when stratified according to patient gender. 
Rejected 
H1c: The percentage of patients treated with the different antipsychotic agents 
will not differ significantly when stratified according to patient race/ethnicity. 
Rejected 
H1d: The percentage of patients treated with the different antipsychotic agents 
will not differ significantly when stratified according to patient primary mental 
health diagnosis. 
Rejected 
H2a: The classification of mean daily antipsychotic dose as ‘Low,’ ‘Medium,’ or 
‘High’ dose will not differ significantly when stratified according to the second-
generation antipsychotic agent used. 
Rejected 
H2b: The mean daily antipsychotic dose for clozapine will not differ significantly 
when stratified according to patient age.  
Not tested 
H2c: The mean daily antipsychotic dose for olanzapine will not differ 
significantly when stratified according to patient age.  
Rejected 
H2d: The mean daily antipsychotic dose for quetiapine will not differ significantly 
when stratified according to patient age.  
Rejected 
H2e: The mean daily antipsychotic dose for risperidone will not differ 
significantly when stratified according to patient age.  
Rejected 
H2f: The mean daily antipsychotic dose for ziprasidone will not differ 
significantly when stratified according to patient age.  
Not tested 
H2g: The mean daily antipsychotic dose for the clozapine will not differ 
significantly when stratified according to primary mental health diagnosis. 
Not tested 
H2h: The mean daily antipsychotic dose for olanzapine will not differ 
significantly when stratified according to primary mental health diagnosis. 
Rejected 
H2i: The mean daily antipsychotic dose for quetiapine will not differ significantly 
when stratified according to primary mental health diagnosis. 
Rejected 
H2j: The mean daily antipsychotic dose for risperidone will not differ 
significantly when stratified according to primary mental health diagnosis. 
Rejected 
H2k: The mean daily antipsychotic dose for ziprasidone will not differ 
significantly when stratified according to primary mental health diagnosis. 
Not tested 
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Table 3.32: Summary of Hypotheses Testing  
Hypotheses Results 
Phase I: Demographic and Antipsychotic Utilization Patterns (Objective 2)  
H3a: Adherence with antipsychotic therapy will not differ significantly when 
stratified according to patient age.  
Rejected 
H3b: Persistence with antipsychotic therapy will not differ significantly when 
stratified according to patient age.  
Rejected 
H3c: Adherence with antipsychotic therapy will not differ significantly when 
stratified according to patient gender. 
Rejected 
H3d: Persistence with antipsychotic therapy will not differ significantly when 
stratified according to patient gender. 
Accepted 
H3e: Adherence with antipsychotic therapy will not differ significantly when 
stratified according to patient race/ethnicity. 
Rejected 
H3f: Persistence with antipsychotic therapy will not differ significantly when 
stratified according to patient race/ethnicity. 
Rejected 
H3g: Adherence with antipsychotic therapy will not differ significantly when 
stratified according to primary mental health diagnosis. 
Rejected 
H3h: Persistence with antipsychotic therapy will not differ significantly when 
stratified according to primary mental health diagnosis. 
Rejected 
H3i: Adherence with antipsychotic therapy will not differ significantly when 
stratified according to antipsychotic agent. 
Rejected 
H3j: Persistence with antipsychotic therapy will not differ significantly when 
stratified according to antipsychotic agent. 
Rejected 
Phase II: Prevalence of Diabetes (Objective 3)  
H4a: The prevalence of diabetes will not differ significantly when stratified 
according to the primary mental health diagnosis, after controlling for demographic, 
clinical and medication risk factors for diabetes. 
Rejected 
Phase III: Incidence of Diabetes (Objective 4) 
H5a: The time to occurrence of diabetes will not differ significantly when patients 
are stratified according to the class of antipsychotic used, after controlling for 
demographic, clinical and medication risk factors for diabetes.  
 
Accepted 
H5b: The time to occurrence of diabetes will not differ significantly when patients 
are stratified according to the specific second-generation antipsychotic used, after 




Table 3.32 (cont.): Summary of Hypotheses Testing  
Hypotheses Results 
Phase III: Incidence of Diabetes (Objective 4) 
H6a: The incidence of diabetes will not differ significantly according to the class 
of antipsychotic used (first-generation vs. second-generation), after controlling for 
demographic, clinical and medication risk factors for diabetes.  
 
Accepted 
H6b: The incidence of diabetes will not differ significantly according to the 
specific second-generation antipsychotic used, after controlling for demographic, 
clinical and medication risk factors for diabetes. 
Accepted 
H7a: The incidence of diabetes will not differ significantly according to the dose 
of clozapine used, after controlling for demographic, clinical and medication risk 
factors for diabetes.  
Not tested 
H7b: The incidence of diabetes will not differ significantly according to the dose 
of olanzapine used, after controlling for demographic, clinical and medication risk 
factors for diabetes.  
Accepted 
H7c: The incidence of diabetes will not differ significantly according to the dose 
of quetiapine used, after controlling for demographic, clinical and medication risk 
factors for diabetes.  
Accepted 
H7d: The incidence of diabetes will not differ significantly according to the dose 
of risperidone used, after controlling for demographic, clinical and medication risk 
factors for diabetes.  
Accepted 
H7e: The incidence of diabetes will not differ significantly according to the dose 
of ziprasidone used, after controlling for demographic, clinical and medication risk 
factors for diabetes.  
Not tested 
H8a: For patients treated with clozapine, the incidence of diabetes will not differ 
significantly according to the primary mental health diagnosis, after controlling for 
demographic, clinical and medication risk factors for diabetes.  
Not tested 
H8b: For patients treated with olanzapine, the incidence of diabetes will not 
differ significantly according to the primary mental health diagnosis, after 
controlling for demographic, clinical and medication risk factors for diabetes.  
Rejected 
H8c: For patients treated with quetiapine the incidence of diabetes will not differ 
significantly when stratified according to the primary mental health diagnosis, 
after controlling for demographic, clinical and medication risk factors for diabetes.  
Accepted 
H8d: For patients treated with risperidone the incidence of diabetes will not 
differ significantly according to the primary mental health diagnosis, after 
controlling for demographic, clinical and medication risk factors for diabetes.  
Accepted 
H8e: For patients treated with ziprasidone the incidence of diabetes will not 
differ significantly according to the primary mental health diagnosis, after 
controlling for demographic, clinical and medication risk factors for diabetes.  
Not tested 
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Chapter 4: Discussion 
This chapter provides a detailed discussion of the study results. First, the 
goals of the study are summarized briefly. The results are then reviewed 
according to the study phases: Phase I - demographic and antipsychotic 
utilization patterns; Phase II – the prevalence of diabetes; and Phase III – the 
incidence of diabetes in the study population. Possible explanations for the study 
findings are proposed, and the potential implications of the study reported. 
Following a review of the study limitations, directions for future research in this 
area are suggested. 
4.1 Review of Study Goals 
The primary goals of this study were to determine the impact of 
antipsychotic dose and treatment indication on the relative risk of new-onset 
diabetes associated with the second-generation antipsychotic agents. Secondary 
goals included: profiling the demographic characteristics and antipsychotic 
utilization patterns of the study population, and examining the prevalence of 
diabetes in this cohort. These goals were addressed using Texas Medicaid data 
for a five-year period from 1997 to 2001. The study expanded on findings from 
previous investigations by investigating the impact of dose and treatment 
indication, while controlling for a wide-range of demographic, clinical and 
medication risk factors for diabetes. The large sample size in this study allowed 







4.2 Study Objectives 
Four study objectives were addressed in this study. The results for each of 
these will now be discussed in the context of the available literature in this area. 
4.2.1 Objective 1: Epidemiology 
The first objective of this study was to describe the demographic and 
clinical characteristics of the study population. Patients aged 18 years and older 
enrolled in Texas Medicaid who received antipsychotic monotherapy served as 
the study cohort. Of 129,860 patients who redeemed a prescription for an 
antipsychotic agent, 19,430 met the eligibility criteria for this phase. 
4.2.1.1 Demographic Variables 
The average patient age was 60.3 years (SD: 21.9), with patients aged 65 
years or older most commonly (47.6%) represented. Women accounted for 65.7 
percent of the population, and were significantly older than their male 
counterparts, with a mean age difference of 12 years between the groups. The 
majority of enrollees were White (55.1%), with minorities, and in particular 
Blacks (21.4%) over-represented in this study population. These demographics 
are consistent with those expected from an adult Medicaid population.367 
Compared to published studies in this area, patients were on average older and 
more likely to be female in this dataset.3;4;9;10;225-241;243;245-252;378;379 
The majority of these studies did not report the race/ethnicity of the study 
population. Typically, higher percentages of White enrollees (range: 61-73 %) 
were noted in studies reporting race/ethnicity when compared to this study. 
227;228;235;239;249;251;252 In a study involving patients with schizophrenia enrolled in 
California Medicaid, a comparable 54.9 percent of the population was White.226 
Higher percentages of non-white enrollees were reported in two studies which 
used claims data from hospital inpatient and ambulatory care clinics for indigent 
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patients.225;233 The demographic differences between this study and the published 
literature can be explained by the nature of the database (that is, a care provider 
for the indigent and disabled) and the fact that unlike a number of published 
studies, this study did not restrict eligibility to specific diagnostic categories, or 
to patients aged 65 years or less. 
Both the prevalence and incidence of diabetes vary by age and 
race/ethnicity, being higher in older adults, Blacks and Hispanics.201;202;224;276 
Based on the demographics of this study population, both the prevalence and 
annual incidence of diabetes would be expected to exceed rates reported in 
previous studies and the national age-adjusted estimates of 8.7 percent and 0.7 
percent, respectively.201;276 As noted in Chapter 1 (section 1.11.3.3), although 
systematically different from the general U.S. population, the Medicaid database 
is generalizable to patients receiving antipsychotic therapy, that is, for patients 
with serious mental illness, indigent patients, and those who are elderly or infirm 
in receipt of long-term care. 
4.2.1.2 Clinical Variables 
A number of clinical variables with the potential to confound the 
relationship between antipsychotic exposure and development of diabetes were 
examined in the study. These included mental health diagnoses, hypertension and 
dyslipidemia. The prevalence of these conditions in this population relative to the 
published literature and the potential impact on the study findings will now be 
discussed. 
4.2.1.2.1 Primary Mental Health Diagnosis 
The indication for which an antipsychotic was presumed to be prescribed 
was a primary consideration. Patients with schizophrenia or bipolar disorder 
appear to be at an increased risk of diabetes, independent of antipsychotic use.13-
15;17;18;291 Differences in the prevalence of these conditions in this population 
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relative to those reported in the published literature could contribute to 
differences in study findings. 
After excluding patients with a diagnosis of mental retardation, 69 
percent of the population had at least one mental health diagnosis, with 32.1 
percent having more than one diagnosis. While it is possible that antipsychotic 
therapy was inappropriately prescribed for patients, the absence of a mental 
health diagnosis for over 30 percent of this study population may be an artifact of 
coding practices rather than a statement that these patients did not actually have a 
mental health disorder. Schizophrenia and bipolar disorder were the most 
frequent indications for treatment; however, they accounted for only 32 percent 
of the study population (16.5 and 15.5%, respectively). This finding is consistent 
with national prescribing practices for antipsychotic therapy where ‘off-label’ 
prescribing has been widely reported.88;320;321 
Among the published retrospective studies in this field, approximately 50 
percent restricted inclusion to patients with specific mental diagnoses, for 
example, patients with a diagnosis of schizophrenia, 3;226;231;242;246;250;251 a mood 
disorder,238 a psychotic disorder236;237 or dementia.252 The prospective CATIE 
trial limited inclusion to patients with chronic schizophrenia.254 Less than one-
third of the retrospective trials permitting inclusion of any patient treated with an 
antipsychotic reported the prevalence of mental health diagnoses in the 
population.4;9;10;225;228-230;232-235;241;245;247-249 While the majority reported a non-
significant association between mental health diagnosis and development of new-
onset diabetes, 10;228;230;233;236;238;239;242;246 others reported significant differences 
in risk based on diagnosis. 237;240;241;244 Patient clinical characteristics, therefore, 
represent an important control variable when examining the association between 
antipsychotic use and the risk of new-onset diabetes. The importance of mental 
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health diagnosis will be further discussed in section 4.2.2, examining the pattern 
of antipsychotic prescribing according to treatment indication. 
4.2.1.2.2 Hypertension 
Hypertension is a known risk factor for diabetes.224 Overall, 24.9 percent 
of patients were identified as having hypertension on the basis of having a 
medical claim with an ICD-9 diagnosis for hypertension. The estimated 
prevalence of hypertension in the U.S. population is 15 percent, but is increased 
among minority races and in older adults.380;381 The baseline prevalence of 
hypertension in the CATIE trial, a population of younger patients with diagnosed 
schizophrenia, was 20 percent.254 Several of the published retrospective studies 
in this area included hypertension as a covariate in their analyses, 10;228;241;247;250-
252 with four studies reporting a significant increase in risk of new-onset diabetes 
for patients with comorbid hypertension after controlling for all other 
factors.10;241;247;251  
4.2.1.2.3 Dyslipidemia 
Dyslipidemia (specifically high triglycerides and low HDL cholesterol) is 
a known risk factor for diabetes.224 In this study, 9.2 percent were defined as 
having dyslipidemia on the basis of a medical claim with an ICD-9 code for 
dyslipidemia, or a prescription for a lipid-lowering agent. The prevalence of 
dyslipidemia in the CATIE trial, as determined by laboratory testing at baseline 
was 14 percent.254 The difference in prevalence rates may relate to a number of 
factors including: under-detection of dyslipidemia in the Medicaid cohort; an 
increased detection of dyslipidemia in the CATIE trial because of baseline 
testing; and systematic differences in health-seeking behavior between patients 
who prospectively consent to inclusion in a clinical trial compared to the general 
population. The inclusion of dyslipidemia as a covariate in the published 
retrospective studies in this area was limited; however, several reported a 
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significant increase in risk of new-onset diabetes in patients with comorbid 
dyslipidemia after controlling for all other factors.228;239;247;250;251 
4.2.1.3 Medication Variables 
Several classes of medications have the potential to increase the risk of 
diabetes and had the potential to confound this study.204 Prescriptions for a 
concomitant diabetogenic medication were redeemed by 26.2 percent of the 
population, with valproic acid and beta-blockers the most commonly used (9.4 
and 6.3% of the population, respectively). Several published retrospective studies 
in this area controlled for use of other diabetogenic medications, 3;226;229;231;232;235-
240;245 with approximately half finding a significant increase in risk of new-onset 
diabetes associated with their use, after controlling for all other factors. 226;232;236-
238;240 
4.2.1.4 Summary 
The demographic and clinical characteristics considered herein are 
important with regard to the epidemiology of diabetes. Differences were 
observed between this study cohort and those examined in published prospective 
and retrospective studies in this area. These differences may help explain any 
variability between the study findings. 
4.2.2 Objective 2: Antipsychotic Utilization Patterns 
The second objective of this study was to examine antipsychotic 
utilization patterns in the study cohort. Of interest were differences in treatment 
patterns that may confound the relationship between antipsychotic exposure and 
the development of diabetes. The choice of antipsychotic agent, doses used, 
duration of treatment and compliance with therapy will now be discussed relative 
to the available literature. 
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4.2.2.1 Choice of Agent 
This study examined the use of antipsychotic monotherapy. The first 
identified antipsychotic agent was considered to be the index agent with the 
proviso that no other antipsychotic agent was dispensed in the preceding six 
months (180 days). The majority of patients (70.7%) received a second-
generation antipsychotic as their index agent. Risperidone was the most 
frequently prescribed of these agents, accounting for approximately 60 percent of 
second-generation agent prescriptions, and 42.4 percent of all prescriptions. 
Other frequently prescribed agents were olanzapine (21.6%) and quetiapine 
(6.3%). Clozapine was infrequently prescribed (93 patients); and no patient 
received ziprasidone as index therapy. 
These trends are consistent with national trends during the time period of 
this study (1997 to 2001). For example, data from the National Ambulatory 
Medical Care Surveys (NAMCS) indicated a decline in the use of first-generation 
antipsychotics from 40 percent of prescriptions in 1997 to 29 percent in 2000.321 
A similar trend has been noted in the Veterans Affairs Administration database.19 
Likewise, in a study of national retail drug expenditures in 2001, 75 percent of 
the expenditure on antipsychotic agents was accounted for by olanzapine (45%) 
and risperidone (30%).318 
Four hypotheses (1a-d) were tested regarding the choice of antipsychotic 
agents. The study hypotheses and results of the associated statistical analyses are 
summarized in Table 3.32. 
4.2.2.1.1 Age 
When stratified according to patient age, the rate of prescribing of the 
various antipsychotic agents differed (χ2 = 416.748, df=16, p<0.001), and 
accordingly hypothesis 1a was rejected. Although used by 42.2 percent of the 
study cohort, risperidone was proportionately more frequently used by patients 
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aged 18 to 34 years (46.1 %) and patients aged 65 years or more (48.3%). This 
contrasted with the prescribing of olanzapine, which was less likely to be used at 
the extremes of age (16.7 and 18.7%, respectively, compared to 21.6% overall). 
This trend was consistent with that observed in the National Ambulatory Medical 
Care Survey (NAMCS).321 
Significant differences were also observed in the mean patient age for the 
different agents (F = 85.83, df=4, p<0.001). Compared to a population mean of 
60.3 years (SD: 21.9), patient age ranged from 37.4 years (SD: 13.3) for patients 
treated with clozapine to 63.1 years (SD: 22.0) for patients treated with 
risperidone. Patients treated with olanzapine had a mean age of 57.3 years (SD: 
21.6). Post-hoc analyses were significant (p≤0.02) for all comparisons, with the 
exception of that between recipients of quetiapine and recipients of the first-
generation antipsychotics (p=0.423). As noted previously, this study did not limit 
inclusion to patients aged between 18 and 65 years. Not surprisingly then, 
regardless of the agent used, patients were older in this cohort than those enrolled 
in comparable prospective and retrospective studies.235-241;244;246-248;250;254 
Both the prevalence and incidence of diabetes are known to increase with 
increasing patient age.201;276 Differences in patient age according to the agent 
used could have important implications with regard to the relative risk of 
diabetes attributed to the various agents. 
4.2.2.1.2 Gender 
A significant relationship was noted between choice of index 
antipsychotic agent and patient gender (χ2 = 416.748, df=16, p<0.001). 
Risperidone and quetiapine were more commonly used in women, with first-
generation antipsychotics, clozapine and olanzapine more commonly used in 
men. The second hypothesis (1b) was, therefore, rejected. Within each agent, the 
percentage of female recipients varied from 39.8 percent for clozapine to 71.2 
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percent for quetiapine, as compared to 65.7 percent for the overall population (χ2 
= 76.901, df=4, p<0.001). The results of these evaluations must be considered in 
the context of the information presented in section 4.2.1.1, that is, that this study 
cohort had a higher percentage of females than comparable studies in the 
literature. Nationally, the highest incidence of diagnosed diabetes is among men 
aged 65-79 years, with 14.5 cases per 1,000 population reported in 2000, 
compared to 9.4 cases per 1,000 population among women of the same age.276 
These results support the inclusion of patient gender as a control variable in 
analyses examining the relative risk of new-onset diabetes attributed to the 
various antipsychotic agents. 
4.2.2.1.3 Race/Ethnicity 
A significant relationship was noted between choice of index 
antipsychotic agent and patient race/ethnicity (χ2 = 160.710, df=12, p<0.001); 
hence, the third hypothesis (1c) was rejected. Compared to the cohort as a whole, 
Black patients were more likely to receive a first-generation antipsychotic, 
whereas Hispanic patients were more likely to receive risperidone. Both the 
prevalence and incidence of diabetes vary according to patient race/ethnicity, 
with higher rates reported among Blacks and Hispanics.201;276 As noted in section 
4.2.1.1, the majority of studies published in this area did not report the 
race/ethnicity of the study population. Among studies reporting race/ethnicity, 
the percentage of White enrollees (range: 61-73%) was typically higher than in 
this cohort.227;228;235;239;249;251;252 The variation in prescribing according to 
race/ethnicity supports the inclusion of patient race/ethnicity as a control variable 
in analyses examining the relative risk of new-onset diabetes attributed to the 




4.2.2.1.4 Primary Mental Health Diagnosis 
Chi-square analysis indicated a significant relationship between choice of 
antipsychotic agent and primary mental health diagnosis (χ2 = 845.046, df=20, 
p<0.001). Hypothesis 1d was, therefore, rejected. The second-generation 
antipsychotics are indicated for the management of schizophrenia, and with the 
exception of clozapine, bipolar disorder.36-40 It is noteworthy, however, that at the 
time these data were collected (1997 to 2001), only olanzapine was licensed for 
use in bipolar disorder, having been licensed for management of acute bipolar 
mania in September 2000. After excluding patients with mental retardation, ‘off-
label’ prescribing varied from 19.8 percent for patients receiving clozapine to 
72.9 percent of risperidone recipients, while acknowledging that some of the 
patients without a mental health diagnosis may have had schizophrenia or bipolar 
disorder. This trend in ‘off-label’ prescribing is consistent with that observed in a 
number of national surveys of ambulatory antipsychotic use.320;321 As previously 
noted, patients with schizophrenia or bipolar disorder appear to be at an increased 
risk of diabetes, independent of antipsychotic use.13-15;17;18;291 This has not been 
consistently observed in studies that controlled for treatment indication while 
testing the association between antipsychotic use and new-onset 
diabetes.10;228;230;233;236-242;244;246 Regardless, differences in prescribing rates of the 
antipsychotic agents could serve to confound this relationship, hence the 
inclusion of primary mental health indication as a control variable in later 
analyses. 
4.2.2.2 Antipsychotic Dose 
The mean daily dose for each antipsychotic agent was inferred from 
information available on the quantity, strength and number of days supplied for 
each prescription. As outlined in section 3.1.3.3, calculated doses were examined 
for appropriateness and outliers excluded accordingly. In addition, a number of 
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sensitivity analyses were conducted in an attempt to ensure that the calculated 
doses were a reliable estimate of the prescribed mean daily antipsychotic dose for 
enrollees. 
The calculated mean daily doses for the second-generation antipsychotics 
were: clozapine 426.21 milligrams (SD: 289.54); olanzapine 8.21 milligrams 
(SD: 5.80); quetiapine 128.09 milligrams (SD: 138.03); and risperidone 1.82 
milligrams (SD: 1.67). With the exception of studies that limited enrollment to 
patients aged 60 years or older,234;252 the calculated mean daily antipsychotic 
doses for clozapine, olanzapine quetiapine and risperidone were lower that those 
noted in other retrospective studies in this area, most likely because of the greater 
diversity in treatment indications and the higher average age in this 
study.226;235;236;238-240;244;250 
There were eleven hypotheses (H2a-k) regarding trends in antipsychotic 
dosing. Four hypotheses relating to the impact of age (2b and 2e) and treatment 
indication (2g and 2k) on the prescribing of clozapine and ziprasidone, 
respectively, were not tested due to the inadequate sample sizes. The study 
hypotheses and the results of the associated statistical analyses are summarized in 
Table 3.32. 
4.2.2.2.1 Dose Classification 
The mean daily doses for the second-generation antipsychotics were 
stratified as ‘low,’ ‘medium’ or ‘high dose’ based on consultation with a clinical 
expert. Patients treated with clozapine were omitted from these analyses due to 
the small sample size (N=93). Overall, 76.6 percent of patients were classified as 
receiving ‘low dose’ therapy, with only 5.5 percent classified as receiving ‘high 
dose’ therapy. Chi-square analysis indicated a significant relationship between 
antipsychotic dose classification and the specific antipsychotic agent used (χ2 = 
754.098, df=4, p<0.001). Hypothesis 2a was, therefore, rejected. Among 
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olanzapine recipients, 11.8 percent received ‘high dose’ therapy (>15 milligrams 
daily) compared to 1.7 percent of quetiapine patients (>600 milligrams daily) and 
2.8 percent of risperidone patients (>6 milligrams daily). Among quetiapine 
patients, 90.8 percent were classified as receiving ‘low dose therapy (≤300 
milligrams daily), compared to 76.6 percent of olanzapine patients (≤10 
milligrams daily) and 74.6 percent of risperidone patients (≤2 milligrams daily). 
Lower doses of antipsychotics are typically recommended in elderly 
patients due to age-related differences in efficacy and tolerability of the 
antipsychotics. Accordingly, further analyses were conducted using a modified 
dose-stratification for patients aged 65 years or older. When limited to patients 
aged 18 to 65 years, and using the original dose stratification discussed above, 
62.6 percent received ‘high dose’, 27.3 percent ‘medium dose’ and 10.0 percent 
‘low dose’ therapy. In contrast, using the modified dose stratification for patients 
aged 65 years or older, 36.7 percent received ‘low dose,’ 45.5 percent ‘medium 
dose,’ and 17.7 percent ‘high dose’ therapy. 
A number of studies published in this area have also classified treatment 
doses so as to facilitate dose-based comparisons between the antipsychotic 
agents.226;239 In a case-control study of schizophrenia patients enrolled in 
California Medicaid, Lambert et al. classified doses based on the empirical 
distribution of the actual doses and expert clinical knowledge. Although the dose 
stratifications differed somewhat from this study (e.g., less than 3 milligrams 
risperidone considered as ‘low dose,’ compared to doses less than 2 milligrams in 
this study), overall patients were less likely to be on low dose therapy (i.e., 
17.2% for olanzapine, 34.4% for quetiapine and 20.0% for risperidone patients 
compared to 76.7%, 90.8% and 74.6%, respectively).226 Gianfrancesco et al. also 
stratified patients as receiving ‘low,’ ‘medium’ or ‘high dose’ therapy in a study 
involving patients with psychoses enrolled in Ohio Medicaid. This stratification 
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was based on the empirical distribution of the actual doses, adjusted for gender 
and age (child <18 years, or adult). Again, patients were less likely to be 
classified as receiving ‘low dose’ therapy with 27.1, 37.1 and 36.0 percent of 
olanzapine, quetiapine and risperidone recipients, respectively, receiving ‘low 
dose’ therapy.239 Both of these studies examined the impact of treatment dose on 
the incidence of diabetes as will be discussed later. Differences in the study 
findings may relate to differences in the antipsychotic doses employed. 
4.2.2.2.2 Age 
Overall, the mean daily antipsychotic doses prescribed to the study 
population were: olanzapine 8.21 milligrams (SD: 5.87); quetiapine 124.39 
milligrams (SD: 136.77); and risperidone 1.80 milligrams (SD: 1.70). Patients 
treated with clozapine were excluded from this analysis due to the small sample 
size (N=93). Regardless of the agent, ANOVA and Kruskal-Wallis tests revealed 
significant differences (p<0.001) in the mean daily dose according to patient age. 
All post-hoc comparisons between age strata were significant (p≤0.002) for 
patients treated with olanzapine and risperidone. A similar pattern was evident 
for quetiapine, with the exception of the comparison between patients aged 45 to 
54 years and those aged 55 to 64 years (p=0.073). Hypotheses 2c, 2d and 2e 
were, therefore, rejected. 
Regardless of the agent, patients aged 65 years or older, received 
approximately 50 percent (range: 43.4% to 51.2%) of the dose prescribed to 
those aged less than 65 years. As noted previously, the calculated mean daily 
antipsychotic doses in this study were lower that those noted in other 
retrospective studies in this area.226;235;236;238-240;244;250 However, the doses used 
for patients aged 65 years or older in this study were very similar to those 
reported in studies that limited enrollment to patients aged 60 years or 
older.234;252 For example, Feldman et al. examined the incidence of new-onset 
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diabetes in patients aged 60 years or older treated with antipsychotic 
monotherapy. The reported mean daily doses were: olanzapine 5.1 milligrams 
(SD: 4.3); quetiapine 95.5 milligrams (SD: 83.4); and risperidone 1.2 milligrams 
(SD: 1.0).234 This compares to 5.4 milligrams (SD: 3.8), 76.5 milligrams (SD: 
70.4), and 1.2 milligrams (SD: 0.9), respectively, for patients aged 65 years or 
older in this study. Similar dosing patterns were noted when comparing the doses 
used for patients aged less than 65 years in this study to the doses reported in 
studies that limited enrollment to patients aged less than 65 years,250 or had 
younger patient populations than this study.235;236;238;240;244 The similarity in 
dosing patterns between the studies serves to corroborate the inferred daily doses 
used in this study. 
4.2.2.2.3 Primary Mental Health Diagnosis 
The mean daily doses for the second-generation antipsychotics were 
examined according to the primary mental health indication for which they were 
presumed to be prescribed. As described in section 2.4.2.2.1, a hierarchical 
approach was taken when stratifying patients according to their mental health 
diagnoses. For example, a patient with diagnoses for schizophrenia, major 
depressive disorder and anxiety disorder, was classified as having schizophrenia 
in this study, with the other conditions considered to be comorbid to the primary 
diagnosis of schizophrenia. It was then presumed that antipsychotic therapy was 
prescribed for the primary condition. Patients with an ICD-9 code for mental 
retardation were excluded from this analysis due to the difficulty of making other 
mental health diagnoses in this population. As noted previously, hypotheses 
relating to clozapine (2g) and ziprasidone (2k) were not tested due to inadequate 
sample sizes. Regardless of the antipsychotic agent, when examined using 
ANOVA and Kruskal-Wallis tests, mean daily treatment doses varied 
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significantly (p<0.001) according to the treatment indication. Hypotheses 2h 
(olanzapine), 2i (quetiapine) and 2j (risperidone) were, therefore, rejected. 
Trends in the prescribing of the antipsychotic agents merit further 
discussion. Regardless of the agent, mean daily treatment doses declined in the 
following order: schizophrenia; bipolar disorder; no mental health diagnosis; 
non-psychotic disorder; psychotic disorder; with the lowest calculated doses 
prescribed to patients with dementia. Doses for schizophrenia and bipolar 
disorder differed significantly (p≤0.005) from each other, and from those used 
for each of the other indications. Additional analyses were conducted after 
stratifying the population into patients aged less than 65 years, and those aged 65 
years or older and similar trends in prescribing were noted. With the exception of 
quetiapine prescribing in patients aged 65 years or older, antipsychotic doses 
differed significantly (p<0.001) according to the treatment indication in both age 
strata. Regardless of age or agent, patients with schizophrenia were prescribed 
the highest doses. Of interest also was the comparison of treatment dose between 
the two age groups. Regardless of indication or agent, patients aged 65 years or 
older, received approximately 50 percent of that prescribed to their younger 
counterparts. 
This additional information facilitates comparison with the published 
literature in this area, where many of the studies restricted eligibility based on 
age (< 65 years, or ≥65 years) or mental health diagnosis or both. Micca et al. 
examined the association between new-onset diabetes and use of olanzapine in 
patients with dementia aged 65 years or older. The modal dose of olanzapine was 
4.87 milligrams, which is comparable to the mean daily dose of olanzapine (4.79 
milligrams (SD: 2.92)) prescribed to patients with dementia aged 65 years or 
older, in this study.252 Zhao et al. tested for antipsychotic-associated new-onset 
diabetes in a population of patients with diagnosed schizophrenia aged between 
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18 and 64 years who were enrolled in a private health care plan. The mean daily 
doses of olanzapine and risperidone were 9.96 milligrams and 3.39 milligrams, 
respectively, (standard deviations not reported).250 These were somewhat lower 
than the doses noted for the same cohort in this study (olanzapine 12.6 
milligrams (SD: 6.70); risperidone 3.83 milligrams (SD: 2.34). A number of 
other studies, using data from private insurance plans, limited inclusion to 
patients with a diagnosis of a psychotic disorder or any mental health diagnosis. 
Although not limiting enrollment to patients less than 65 years, they were 
comprised primarily of younger patients (as reflected by the mean age) and were 
thus more comparable to the patients aged 65 years or less in this study. Doses 
for olanzapine and risperidone were comparable, if somewhat lower than those 
calculated for patients aged 65 years or less in this study.236;238;240;244 These 
differences may be explained by the difference in insurance coverage. Patients 
with mental health disorders who have private health insurance generally are less 
severely ill, or have been ill for a shorter period of time than patients receiving 
treatment through publicly-funded sources. This is exemplified by the CATIE 
trial, where although insurance coverage was not reported, 85 percent of these 
patients with moderate to severe chronic schizophrenia were unemployed, with 
88 percent previously, or never married and, therefore, unlikely to be covered by 
private health insurance by virtue of their own, or a spouse’s employment.254 
While serving to corroborate the antipsychotic doses and the mental 
health stratifications used in this study, the results from these analyses highlight 
the differences between this study and the published literature in terms of the 
composition and treatment of the study populations. Failure to control for dose 
and treatment indication in a heterogeneous population such as this could obscure 
the relationship between antipsychotic use and the development of new-onset 
diabetes. 
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4.2.2.3 Duration of Treatment 
The mean duration of treatment was 115.2 days (SD: 118.5), ranging 
from one day to 365 days (the maximum period of follow-up). A significant 
difference (p<0.001) was observed according to the class of antipsychotic used. 
Patients treated with a second-generation antipsychotic remained on treatment for 
an average of 128.4 days (SD: 123.3) compared to 83.3 days (SD: 99.2) for 
patients treated with a first-generation antipsychotic. The duration of treatment 
also varied significantly (p<0.001) within the second-generation agents, 
decreasing in the following order: quetiapine 135.0 days (SD: 126.6); olanzapine 
133.7 days (SD: 125.0); and risperidone 125.3 days (SD: 121.8). 
These trends were comparable to those observed in a number of the 
studies published in this area, 234;241;243;250 although differences in the duration of 
treatment and comparative trends were also reported.236-240;246;248;249 The studies 
all differed in their interpretation of treatment discontinuation and the maximum 
possible duration of follow-up. Consistent with this study however, was the 
considerable interpatient variability as evidenced by the large standard deviations 
reported. Many of the studies controlled for duration of treatment when 
analyzing the association between antipsychotic use and development of new-
onset diabetes,3;9;230;234-239;241;243;246;248;249 with a number reporting a significant 
association between increasing duration of treatment and onset of diabetes.237-
239;241 
4.2.2.4 Compliance 
Two measures of antipsychotic compliance were assessed in this study: 
adherence and persistence. A total of ten hypotheses (H3a-j) were tested regarding 
trends in compliance, a summary of which is included in Table 3.32. While 
duration of therapy was frequently included as a covariate in retrospective studies 
examining the association between antipsychotic use and new-onset diabetes, 
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3;9;230;234-239;241;243;246;248;249 measures of compliance with therapy were rarely 
included.228 It was important to incorporate compliance as a surrogate measure of 
drug exposure as, to paraphrase the saying: “Drugs don’t work in patients who 
don’t take them;” it is equally probable that drugs won’t cause adverse effects in 
patients who don’t take them. 
4.2.2.4.1 Adherence 
Adherence to therapy was measured using the medication possession ratio 
(MPR). This is a widely used measure of treatment compliance in automated 
databases, with advantages including ease of calculation and interpretability. The 
MPR is typically calculated in one of two ways: using the interval between the 
first prescription and exhaustion of the last prescription refill, or using a defined 
period of follow-up (e.g., 365 days) as the denominator. An MPR of 0.8 or 
greater is frequently applied as a threshold for adherence, that is patients with an 
MPR of 0.8 or more are considered to be adherent with therapy, while those with 
an MPR less than 0.8 are considered non-adherent.382  Using the former 
classification, the mean adherence to therapy in this study was 0.803 (SD: 0.266) 
with 59.4 percent classified as adherent with therapy, while for the latter 
(MPR_365 days), the mean adherence was 0.600 (SD: 0.316) with 34.6 percent 
considered adherent. These figures correspond with reports in the literature of 
adherence with antipsychotic therapy. In a study of antipsychotic adherence by 
patients with schizophrenia enrolled in Medicaid, 41 percent were considered 
adherent with therapy (MPR 0.80-1.10). 345 Likewise, using data from the 
Veterans Affairs National Psychosis Registry, the mean adherence rate for 
patients with schizophrenia or schizoaffective disorder was 0.80 (SD: 0.33) with 





The second measure of compliance used in this study was persistence 
with antipsychotic therapy. This is another widely used measure of treatment 
compliance in automated databases; however, studies vary in how persistence is 
calculated.382 In this study, a patient was considered persistent with therapy if 
they refilled their prescription within a given grace-period of the previous 
prescription being exhausted. The grace period was calculated using 50 percent 
of the number of days in the previous prescription. This method of calculating 
persistence has been commonly used in the literature.382 It was chosen in 
preference to another common method which uses defined grace-periods in days 
(typically 7-180 days), largely because of the requirement at the time that 
clozapine prescriptions be dispensed for a maximum of seven days.36 The 
primary objective of this study was to estimate the incidence of diabetes 
associated with exposure to antipsychotic therapy. Using a set grace period (such 
as 30 days), a patient with medication available for at least 30 out of 60 days 
would be considered persistent with therapy, but equally a patient with 
medication available for only seven out of every 37 days would be considered 
persistent, reducing the specificity of this measure of drug exposure. The mean 
number of persistent days in the study was 128.7 days (SD: 120.2), with a 
median of 77 days. This measure will be discussed in greater detail in the next 
section examining trends in compliance. 
4.2.2.4.3 Factors Affecting Compliance 
As noted, a total of ten hypotheses (H3a-j) were tested regarding trends in 
compliance. A summary of the hypotheses and the associated statistical analyses 
is included in Table 3.32. In each instance, factors affecting adherence to therapy 
were analyzed twice, once using an MPR calculated using the interval between 
the first prescription and exhaustion of the last prescription refill as the 
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denominator (MPR), and also as a sensitivity analysis using 365 days as the 
denominator (MPR_365). Unless specified otherwise it may be assumed that the 
results of the bivariate analyses were the same regardless of which measure of 
adherence (MPR or MPR_365) was used. As a second sensitivity analysis, 
persistence with therapy was recalculated using a 100 percent grace period, that 
is, a patient would be considered persistent with therapy if they obtained a refill 
of a 30-day prescription within 30 days of the first prescription being exhausted. 
Again, unless specified otherwise, it may be assumed that the results from the 
bivariate analyses were the same regardless of which measure of persistence was 
used. 
4.2.2.4.3.1 Age 
ANOVA and Kruskal-Wallis tests revealed significant differences in 
adherence (p<0.001) and persistence (p<0.001) with antipsychotic therapy 
according to patient age. Similar trends were noted on post-hoc analyses for both 
measures, that is, the highest level of compliance was noted for patients aged 65 
years or older, with the lowest levels noted for patients aged between 18 and 34 
years. Hypotheses 3a and 3b were, therefore, rejected. 
This result is consistent with reports of decreased adherence to 
antipsychotic therapy among younger patients.341;345;347 Living status has also 
been associated with adherence, with lower rates reported in homeless patients 
and those living independently compared to those living with family or assisted 
living facilities.345 While housing status was not included in this dataset, it is 
probable that a higher proportion of elderly patients in this dataset were residing 
in nursing homes or assisted living facilities, not least because of the higher 
prevalence of dementia in this cohort. Medication administration tends to be 
supervised in these settings, increasing adherence with therapy and reducing the 
risk of self-discontinuation of therapy, ergo higher persistence rates. 
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4.2.2.4.3.2 Gender 
As noted previously, adherence as measured by medication possession 
ratios were calculated to a treatment endpoint (MPR) and as a sensitivity analysis 
for a fixed 365-day follow-up period (MPR_365). Whereas by the former, a 
significant difference was noted in adherence according to patient gender (Mean 
MPR men: 0.791 (SD: 0.269); mean MPR women 0.808 (SD: 0.264) p<0.001), 
no difference was noted for the latter (Mean MPR_365 men: 0.605 (SD: 0.316); 
mean MPR_365 women 0.597 (SD: 0.316) p=0.141). While hypothesis 3c was 
rejected, it is unlikely that the observed difference in MPR for men and women 
(mean difference: 0.017) would be of any clinical significance. No difference 
was noted in persistence (0.653) with antipsychotic therapy according to patient 
gender. Accordingly, hypothesis 3d was accepted. 
These results are consistent with reports in the published literature both 
for antipsychotics345 and other medications,383;384 that gender is not a significant 
predictor of adherence or persistence with antipsychotic therapy. 
4.2.2.4.3.3 Race/Ethnicity 
ANOVA and Kruskal-Wallis tests revealed significant differences in 
adherence (p<0.001) and persistence (p<0.001) with antipsychotic therapy 
according to patient race/ethnicity. Similar trends were noted on post-hoc 
analyses for both measures, that is, the highest level of compliance was noted for 
Whites and the lowest levels noted for Blacks. Hypotheses 3e and 3f were, 
therefore, rejected. 
These results are consistent with published literature on compliance with 
antipsychotic therapy. Opolka et al. noted a significant association between 
ethnicity and adherence in a study using patients with schizophrenia or 
schizoaffective disorder enrolled in Texas Medicaid. As in this study, the lowest 
rates of adherence were noted for Blacks, followed by Hispanic patients with the 
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highest adherence among Whites.347 Likewise in a study of treatment adherence 
in patients with schizophrenia enrolled in California Medicaid, adherence was 
noted to be lowest among African Americans and Latinos, with higher rates 
among Non-Latino Whites, Asians and those in the ‘Other’ race/ethnicity 
group.345  Similar results have been reported by Valenstein et al. in a study of 
patients with schizophrenia using the Veterans Affairs National Psychoses 
Registry.341 
4.2.2.4.3.4 Primary Mental Health Diagnosis 
ANOVA and Kruskal-Wallis tests revealed significant differences in 
adherence (p<0.001) and persistence (p<0.001) with antipsychotic therapy 
according to the primary mental health diagnosis. The highest rates of adherence 
and persistence were noted for patients with a diagnosis of dementia, with the 
lowest adherence and persistence rates noted in patients with schizophrenia and 
bipolar disorder, respectively. Hypotheses 3g and 3h were, therefore, rejected. 
These results support an earlier theory that older patients with dementia 
are more likely to reside in nursing homes or assisted-living facilities, with 
greater opportunity for caregiver supervision and intervention, resulting in higher 
compliance with therapy. The mean MPR of 0.761(SD: 0.259) for patients with 
schizophrenia is comparable to that noted in a study of a younger, less racially 
diverse cohort of patients with schizophrenia enrolled in the Veterans Affairs 
Health Care System (MPR: 0.80 (SD: 0.33). 341 Likewise, comparable rates of 
adherence with therapy have been documented for psychoses, depression and 
bipolar disorder to those noted in this study. 344;384 The long persistence with 
therapy (124.0 days (SD: 116.7)) observed for patients with non-psychotic 
disorders is at odds with clinical guidelines than recommend a short (range: one 
week to two months) duration of treatment for these conditions.11 Similarly, for 
patients with dementia, guidelines suggest episodic, rather than continuous 
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therapy with antipsychotics, and accordingly a shorter persistence with therapy 
might have been expected here.11 
4.2.2.4.3.5 Antipsychotic Agent 
After excluding patients treated with clozapine due to the small sample 
size, ANOVA and Kruskal-Wallis tests revealed significant differences in 
adherence (p<0.001) and persistence (p<0.001) with therapy according to the 
specific antipsychotic prescribed (olanzapine, quetiapine, risperidone or a first-
generation agent). Regardless of the measure used, compliance was seen to 
decline in the following order: quetiapine, olanzapine, risperidone, with the 
lowest compliance rates noted for patients treated with a first-generation agent. 
Hypotheses 3i and 3j were, therefore, rejected. 
Similar results were noted in a study of adherence to antipsychotic 
therapy among schizophrenia patients enrolled in Texas Medicaid. Opolka et al. 
noted the highest adherence with olanzapine, then risperidone with the lowest 
adherence among patients prescribed haloperidol, a first-generation 
antipsychotic.347 Using different measures of treatment adherence, Dolder et al. 
reported increased adherence with second-generation compared to first-
generation antipsychotics after six (p=0.05) and 12 months (p=0.11) of treatment, 
in a small study of patients with psychosis enrolled in the Veterans Affairs 
Health Care Administration. However, aside from a significant difference in 
adherence between olanzapine and haloperidol (p=0.008) at six-months, no other 
contrasts between the individual antipsychotics (haloperidol, perphenazine, 
olanzapine, quetiapine, risperidone) were significant.348 
The results contrast with findings from a number of other studies. In a 
prospective study of compliance with antipsychotic therapy among patients with 
schizophrenia, levels of adherence and persistence with therapy were consistently 
and significantly higher for patients treated with olanzapine (MPR: 0.75; 
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persistence: 259 days) than for patients treated with risperidone (MPR: 0.69; 
persistence 237 days) or quetiapine (MPR: 0.61; persistence 212 days).349 In the 
CATIE trial, the time to discontinuation of therapy (which approximates 
persistence with therapy) decreased in the order: olanzapine, perphenazine (a 
first-generation antipsychotic), risperidone, quetiapine, with the shortest time to 
treatment discontinuation in those treated with ziprasidone.254 It is important to 
remember that clinical guidelines recommend life-long antipsychotic therapy for 
patients with schizophrenia and shorter periods of treatment (range: one week to 
six months), including the use of episodic rather than continuous therapy, for 
patients with other mental health diagnoses.11 As the prescribing of the various 
antipsychotics varied according to the treatment indication in this study, it is 
possible that the observed differences in persistence rates reflect use of practice 
guidelines rather than necessarily differences in tolerability of the antipsychotic 
agents. 
The differences observed between the studies may relate to differences 
between the study populations, or to differences in the measures of compliance 
used. Regardless, it is notable that compliance with antipsychotic therapy is low 
overall, and that it may vary according to the demographic and clinical 
characteristics of the population. 
4.2.2.5 Summary 
Significant differences were noted in the patterns of prescribing and 
compliance with antipsychotic therapy according to demographic and clinical 
variables. Failure to control for these differences could confound any association 
between the use of individual antipsychotic agents and the risk of new-onset 
diabetes. Differences in patterns of antipsychotic utilization in this study cohort 
relative to those in related prospective and retrospective studies may help to 
explain variability in the incidence and relative risk of diabetes reported.  
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4.2.3 Objective 3: Prevalence of Diabetes 
In phase II of this study, the primary dependent variable was the 
prevalence of diabetes at baseline. Patients were screened for diabetes, as 
indicated by a medical claim with an ICD-9 code for diabetes or a prescription 
claim for insulin, an insulin-sensitizing agent or a glucose-lowering agent in the 
180 days preceding the index prescription claim. Cases of diabetes noted in the 
first seven days of antipsychotic treatment were considered prevalent cases and 
were included in this analysis. This may have resulted in a misclassification of 
some incident cases, as cases of new-onset diabetes have been reported to occur 
as early as four to five days after initiating antipsychotic treatment.185;200 Patients 
with a history of diabetes but without a medical or pharmacy claim for same 
during the 180-day pre-screening period may also have been misclassified. The 
criteria for the diagnosis of diabetes changed slightly in July 1997, from a fasting 
plasma glucose level ≥140mg/dL to ≥126mg/dL. It is possible that between 
January and July 1997, a small number of cases of prevalent diabetes may not 
have been included, only later to be misclassified as new-onset cases on the basis 
of the revised criteria. Patients in this study (particularly older patients) may have 
been dual-eligible for Medicaid and Medicare benefits. No medical claims data 
were available from Medicare, with the result that, again, prevalent cases of 
diabetes may have been underestimated in the study. Clearly, the prevalent cases 
of diabetes noted here are limited to patients with diagnosed diabetes. In 2002, it 
was estimated that five million (29%) of a possible 13 million patients with 
diabetes in the U.S. were undiagnosed.224 It is possible that the prevalence of 
diagnosed diabetes in this study is similarly underestimated. 
The prevalence of diabetes in the study population was 16.9 percent. This 
is considerably higher than the estimated prevalence of diagnosed diabetes of 5.3 
percent in the U.S. adult population.224 This figure also contrasts with an 
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estimated prevalence of diabetes of 10.7 percent among adults enrolled in Texas 
Medicaid in 2002. (Data on file, Texas Department of Health and Human 
Services, obtained 10/15/2004) The prevalence is also comparatively higher than 
that noted in the CATIE study (11.0%), that is, among a younger, primarily male, 
chronic schizophrenia cohort.254 Consistent with the well-documented 
epidemiology of diabetes, significant differences were seen in the prevalence of 
diabetes according to patient age (higher among older patients), and 
race/ethnicity (higher among Black and Hispanic patients compared to 
Whites).224 The prevalence was noted to be higher among women than men, 
possibly because of the higher percentages of older women in the study 
population. The majority of patients (85%) were captured by a pharmacy claim, 
with 49 percent captured by a medical claim, or a combination thereof. Studies 
that restricted the detection of diabetes to patients with a medical claim only 
225;231;242;244 or a prescription claim only 9;227;232;234;240;245;247;248 clearly risked 
misclassifying prevalent cases. Nondifferential disease misclassification at 
baseline has been shown to bias incidence ratios away from the null, particularly 
in diseases where the prevalence at baseline is high relative to the incidence of 
the disease.385 
The prevalence of diabetes at baseline varied significantly (p<0.001) 
according to the index agent prescribed. Patients with prevalent diabetes were 
least likely to be prescribed a first-generation antipsychotic (14.8 %) and most 
likely to be prescribed risperidone (19.0%), assuming the physician prescribing 
the antipsychotic was aware the patient had established diabetes. As the data 
from this study were from 1997 to 2001, they predated both the expert panel 
recommendations regarding choice of antipsychotics in patients with multiple 
risk factors for diabetes,261 and publication of the results from various 
prospective254 and retrospective studies in this area.3;4;9;10 It is possible that 
 284
physicians were cautious about prescribing olanzapine to patients with prevalent 
diabetes due to concerns regarding additional weight gain. It is also possible 
though, that this pattern of prescribing was due to age, and indication-related 
differences in prescribing patterns noted in sections 4.2.2.1.1 and 4.2.2.1.4, rather 
than concerns regarding the potential for metabolic effects associated with the 
various antipsychotic agents. 
The prevalence of diabetes varied significantly when stratified according 
to primary mental health diagnosis. After excluding patients with mental 
retardation, the unadjusted prevalence of diabetes ranged from 12.4 percent 
among patients with schizophrenia to 20.6 percent among patients with a 
psychotic disorder (p<0.001). Multivariate logistic regression analysis showed 
that even after controlling for differences in demographic and clinical risk factors 
for diabetes, mental health diagnosis remained significantly associated with the 
prevalence of diabetes (p=0.006). Accordingly, hypothesis 4a was rejected. 
Compared to patients with schizophrenia, the odds of prevalent diabetes were 
increased by 26 percent for patients with bipolar disorder (p=0.003), 25.3 percent 
for patients with a non-psychotic disorder (p=0.006) and 25.0 percent for patients 
with no mental health diagnosis (p=0.003). These results are not inconsistent 
with published literature, suggesting a higher prevalence of diabetes in patients 
with mental disorders including schizophrenia and bipolar disorder when 
compared to the general population.13-15;17;18;291 It is possible that the difference 
in prevalence between the mental health categories reflects a difference in access 
to care by the various patient groups, as opposed to true differences in the risk of 
diabetes. It is well documented that, despite frequent contact with health services, 
patients with serious mental illness do not necessarily receive appropriate 
primary healthcare.313;314 In addition, there are reports of provider difficulties in 
performing and receiving reimbursement for diagnostic tests in ambulatory 
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psychiatry clinics. These factors may have combined to reduce the detection of 
prevalent diabetes in patients with schizophrenia. 
Consistent with the standard literature, several known risk factors for 
diabetes were shown to be significantly associated with prevalent diabetes that is, 
increasing age, minority race/ethnicity, hypertension and dyslipidemia.224 
Somewhat curious was the negative association between use of other 
diabetogenic medications and the odds of prevalent diabetes. This may have 
related to variability in the risk of diabetes associated with the different 
medications in this group. Alternatively, as the risk of diabetes has been well 
established with these agents, it is possible that clinicians avoided prescribing 
these medications to patients with known diabetes for fear of exacerbating their 
condition. 
In summary, the baseline prevalence of diabetes was higher in the study 
population compared to both the general U.S. population and to the general adult 
Texas Medicaid population. A significant association was noted between mental 
health diagnosis and the prevalence of diabetes, although the absolute difference 
in risk between the various diagnoses was relatively small. Use of a six-month 
prescreening period for diabetes and consideration of both medical and pharmacy 
claims for diabetes may have diminished the misclassification of prevalent cases 
at baseline. 
4.2.4 Objective 4: Incidence of Diabetes 
In phase III, the primary dependent variable was the incidence of diabetes 
as detected by a new medical claim with an ICD-9 code for diabetes, or a new 
prescription for insulin, an insulin-sensitizing agent or a glucose-lowering agent. 
The incidence of diabetes in this study population was 2.37 percent, with 59 
percent of new cases identified by a pharmacy claim and 75 percent of cases 
identified by a new medical claim (35.5% identified by both pharmacy and 
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medical claims). This contrasted with the pattern of identification of prevalent 
cases where more patients were detected on the basis of a pharmacy claim, or 
combination of a pharmacy and medical claim. This result is not inconsistent 
with patterns of medical coding in clinician practice, where chronic conditions 
are relegated to secondary diagnoses, or possibly omitted altogether. It is 
reasonable that more patients were classified as having new-onset diabetes on the 
basis of having a new medical claim, or a combination of medical and pharmacy 
claims for diabetes, as patients may have sought medical care when symptoms of 
diabetes manifested. This pattern is consistent with the typical management of 
type 2 diabetes where patients may initially be managed by lifestyle 
modifications alone. In particular, if an iatrogenic cause is suspected, a ‘wait and 
see’ approach may be adopted to see if the hyperglycemia reverses with 
withdrawal of the suspected agent. Regardless, this result again serves to 
highlight the need to include both medical and pharmacy claims when using 
surrogate markers to identify cases of diabetes.  
The incidence of diabetes in this study was higher than that reported for 
the U.S. general population. In 2001, the age-adjusted incidence of diabetes was 
0.29 percent for those aged 18 to 44 years, 1.14 percent for those aged between 
45 and 64 years, and 1.18 percent for those age 65 and 79 years.276 This contrasts 
with rates of 1.26 percent, 3.33 percent and 2.80 percent, respectively, in this 
study population (noting that there was no upper age limit in this study). 
Medicaid is over-represented by minorities and those with a lower socio-
economic status, both of which have been associated with an increased risk of 
diabetes.386;387 These demographic differences may account for the discrepancy 
between the incidence rates.  
The unadjusted incidence of diabetes in the population varied 
significantly according to age (p<0.001), gender (p<0.001) and race/ethnicity 
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(p<0.001) when examined using Chi-square analysis. These results were 
consistent with those observed in the prevalence study, and with the exception of 
gender, with the known epidemiology of diabetes in the U.S. population.276 The 
higher unadjusted incidence of diabetes in women compared to men (2.7% 
versus 1.7%), may have resulted from an over-representation of older women in 
this cohort. However, while female gender is not a risk factor for diabetes, the 
impact of low socioeconomic status is greater among women regardless of 
ethnicity, with higher rates of diabetes noted in poor women.386  
The unadjusted incidence of diabetes did not differ significantly 
according to treatment indication (p=0.051). The trend in rates was similar to that 
noted in the prevalence study, that is, a trend towards fewer cases of diabetes 
among patients with schizophrenia or no mental health diagnosis. As noted 
previously, this trend may reflect differences in the access to primary care and 
monitoring between diagnostic groups. Chi-square analysis did reveal a 
significant association between the index antipsychotic agent and the unadjusted 
incidence of diabetes. While higher rates of diabetes were noted for patients 
treated with risperidone (2.8%) and olanzapine (2.5%), these results need to be 
considered in the context of earlier bivariate analyses regarding age and 
indication-related prescribing of the antipsychotic agents. The association 
between antipsychotic agent and incidence of diabetes will be discussed further 
in section 4.2.4.2. 
4.2.4.1 Time to Development of Diabetes 
The mean time to development of diabetes (using the date of the first 
medical or pharmacy claim for diabetes as a proxy for the date of onset of 
diabetes) was 95.9 days (SD: 85.1) with a median time to onset of 62.5 days. 
This varied by agent, ranging from a median of 51.0 days for quetiapine to 73.0 
days for olanzapine. Data were positively skewed. This is not inconsistent with 
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reports in the literature. Specifically, among the published case reports 
(Appendix A, Table 2.4), more than 50 percent of cases occurred within three 
months of initiating antipsychotic therapy with over two-thirds (69.7%) reported 
within six months of initiating therapy. In this study, 59.9 percent of cases 
occurred within three months, 83.8 percent within six months, and 93.5 percent 
within nine months of commencing therapy. 
Two Cox regression models were developed to test hypotheses 5a and 5b 
regarding the time to occurrence of diabetes. The same demographic and clinical 
variables were entered into both models. The models differed in the medication 
variables included. Model 1, compared the time to onset of diabetes between 
first- and second-generation antipsychotics. Model 2, compared between the 
second-generation antipsychotics. This model also controlled for the dose of the 
second-generation antipsychotic used. Both models were significantly different 
from the null model as indicated by the Model Chi-squares (χ2 = 173.699, df=18, 
p<0.001 and χ2 = 132.115, df=21, p<0.001, respectively). Due to inadequate 
sample size, clozapine and ziprasidone were not included in this analysis. 
Hypotheses 5a and 5b and the results of the associated statistical analyses are 
summarized in Table 3.32. 
4.2.4.1 1 Class of Antipsychotic 
Overall, 14,124 patients were included in this analysis, of whom 381 
(2.70%) developed diabetes. No difference was noted in the unadjusted 
(p≥0.071) or adjusted (p=0.484) time to occurrence of diabetes between patients 
treated with first or second-generation antipsychotics. Hypothesis 5a was, 
therefore, accepted. 
Covariates in the Cox proportional hazards regression model that were 
significantly associated with an increased time to development of diabetes were 
female gender, Black or Hispanic race/ethnicity, increasing age, and a diagnosis 
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of comorbid hypertension or dyslipidemia. These results are somewhat 
counterintuitive. As noted previously, risk factors for the development of 
diabetes include minority race, increasing age and a history of hypertension or 
dyslipidemia.224 Accordingly, one might expect clinicians to screen for diabetes 
more frequently in these patients, ergo an apparent quicker time to onset of 
diabetes. It is noteworthy, however, that disparity in both the access to, and 
quality of medical care for ethnic minorities has been documented – factors 
which could delay the time to detection of diabetes.387 Access and quality of 
preventative care has also noted to be lower among women, which may explain 
the apparent increase in time to development of diabetes in this group.386  
Two covariates were associated with a shorter time to onset of diabetes – 
adherence to antipsychotic therapy (compared to non-adherence) and use of a 
concomitant diabetogenic medication. The former may be due to an increased 
risk of diabetes associated with increased exposure to antipsychotic medications. 
It is also plausible that differences in health-seeking behavior by adherent 
patients, with possible greater contact with physician services and more 
opportunities for the detection of diabetes may explain the apparent earlier time 
to onset in these patients. Regarding the latter, use of additional medications 
known to increase the risk of diabetes may hasten the time to onset, or time to 
screening and detection of diabetes in these patients.  
4.2.4.1 2 Type of Second-Generation Antipsychotic 
Overall, 9,799 patients were included in this analysis, of whom 301 
(3.07%) developed diabetes. No difference was noted in the unadjusted 
(p≥0.590) or adjusted (p=0.278) time to occurrence of diabetes between patients 
treated with the second-generation antipsychotics olanzapine, quetiapine or 
risperidone. Hypothesis 5b was, therefore, accepted. 
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Consistent with Model 1, differences in the time to onset of diabetes were 
noted according to patient race/ethnicity, history of hypertension or dyslipidemia, 
level of adherence with antipsychotic therapy and use of concomitant 
diabetogenic medications. While age and gender were no longer significantly 
associated with the outcome, the trend towards an increased time to development 
of diabetes with increasing age and female gender were again observed. 
After adjusting for all other covariates, no association was noted between 
the dose of antipsychotic prescribed and the time to development of diabetes, 
supporting a hypothesis that the time to development of diabetes is not a dose-
related phenomenon. The size of the confidence intervals associated with the 
parameter estimates indicates considerable variability in the data. The limited 
numbers of patients categorized as receiving high-dose therapy may have 
reduced the power of the study to detect a dose-response relationship, increasing 
the risk of a Type I error. The relationship between antipsychotic dose and time 
to onset of diabetes has not been discussed in the published literature in this area 
so it is difficult to draw further inferences from this result. 
4.2.4.1.3 Summary 
As noted previously, a surrogate marker was used in this study for this 
variable, that is, time to detection (as identified by a pharmacy or a medical claim 
for diabetes) versus actual time to development of diabetes. It is noteworthy that 
many patients may have diabetes for several years before first being diagnosed 
with the condition.204 The association between class and type of antipsychotic 
and time to development of diabetes was examined because of published case 
reports indicating rapid-onset diabetes (25% of cases occurring within four 
weeks of initiating antipsychotic therapy) which could be severe in nature (31 
percent presenting in hyperglycemic crisis) associated with use of the second-
generation antipsychotics, (Table 1.5) and more commonly, clozapine and 
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olanzapine. In this study, no difference in the time to onset of diabetes was noted 
between antipsychotic classes (first or second-generation) or between the specific 
second-generation agents. 
4.2.4.2 Incidence of Diabetes – Contributing Factors 
The potential for several variables to influence the incidence of diabetes 
in this cohort were investigated in detail using multivariate logistic regression 
analyses. Three study models were developed, each of which included the same 
demographic and clinical variables. Model 1 was used to test the hypothesis that 
the incidence of diabetes did not differ based on the class of antipsychotic agent, 
while controlling for all other variables. Model 2 was used to test the hypothesis 
that the incidence of diabetes did not differ according to the specific second-
generation agent used, while controlling for all other variables. Additional 
variables included this model were antipsychotic dose (stratified as ‘low,’ 
‘medium’ or ‘high’) and compliance (as measured by adherence and persistence) 
with therapy. Six of a planned ten hypotheses were tested using Model 3, that is, 
that the incidence of diabetes did not differ according to the dose or primary 
mental health diagnosis for each of the individual second-generation 
antipsychotic agents (olanzapine, quetiapine, risperidone) while controlling for 
all other variables. Due to inadequate sample size, hypotheses 7a, 7e, 8a and 8e 
relating to dose and treatment indication for clozapine and ziprasidone patients, 
respectively, were not tested. This model controlled for the dose of the individual 
antipsychotic (as a continuous variable). All three models differed significantly 
from the null model as indicated by the Model Chi-square values (p≤0.046). 
Multicollinearity was excluded as a threat in an examination of the correlation 




4.2.4.2.1 Class of Antipsychotic 
Multivariate logistic regression analysis showed a non-significant 
(p=0.193) increase in the odds of new-onset diabetes of 21.6 percent for patients 
treated with a second versus a first-generation antipsychotic, after controlling for 
all other variables. Hypothesis 6a was, therefore, accepted. 
This result is consistent with reports from the published literature in this 
area. Of nine studies that compared second-generation agents as a class to first-
generation antipsychotic agents, 3;4;228;229;234;241;246;247;250 eight reported an 
increase in the odds of diabetes with the second-generation agents (range: 1.1 to 
2.6),3;4;228;229;234;241;246;250 with six reporting odds ratios less than 1.6. 
3;228;229;234;241;246 Only two studies reported a statistical difference in risk.4;246 
Ollendorf et al. reported an increased odds of new-onset diabetes of 17.2 percent 
(95% CI: 1.061 to 1.130) with second-generation therapy in a study of patients 
with schizophrenia enrolled in private health care plans in the U.S. 246 Likewise, 
Kwong et al. reported a significant increase in the odds of diabetes (OR: 2.6 
(95% CI: 1.3 to 5.3) with second versus first-generation antipsychotic therapy in 
a study of antipsychotic recipients enrolled in the U.K General Practice Research 
Database. The number of patients prescribed a second-generation agent was 
small (N=2,550) relative to the number receiving a first-generation agent 
(N=43,561). Covariates included in the regression model were limited to age, 
gender and the presence or absence of obesity. Published in 2002, it is possible 
that the recipients of second-generation agents were systematically different from 
those receiving first-generation agents, and from those enrolled in this study.4 In 
the best known prospective study published in this area, the CATIE study, the 
time to treatment discontinuation due to intolerable side effects did not differ 
between the individual agents: olanzapine, risperidone, quetiapine, ziprasidone 
and the first-generation agent, perphenazine. It is notable however, that 
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olanzapine was associated with greater increases in weight (p<0.001) and 
glycosylated hemoglobin (p<0.01), but not mean serum glucose levels (p=0.59) 
compared to the other agents.254 
Covariates that were significantly associated with an increased risk of 
diabetes included: age (increased with increasing age); female gender; 
race/ethnicity (increased risk for Black and Hispanic patients compared to 
Whites); comorbid hypertension or dyslipidemia. These findings are consistent 
with the known epidemiology of diabetes.224 Primary mental health diagnosis 
was not associated with the outcome (p=0.403). Compared to patients with 
schizophrenia, the odds of diabetes were increased for all diagnostic categories 
including those with no mental health diagnosis, although none of these 
comparisons were statistically significant. This is not inconsistent with the 
literature published on this topic. While patients with schizophrenia or bipolar 
disorder appear to have an increased risk of diabetes compared to the general 
population, 13-15;17;18;291 reports also indicate an increase risk of diabetes in 
patients with depression.295-297 These studies did not compare the relative risk of 
diabetes among patients with mental health disorders. As noted previously, 
differences in healthcare utilization and access to medical monitoring may have 
led to an under-detection of diabetes in patients with schizophrenia reducing the 
apparent odds of diabetes associated with this condition. 
The impact of compliance with antipsychotic therapy on the odds of 
diabetes in this analysis merits discussion. Two measures of compliance were 
included: adherence and persistence. The odds of new-onset diabetes decreased 
with increasing persistence with therapy. This finding is not unexpected given 
that published case reports and case series suggest that the majority of cases of 
diabetes associated with antipsychotic therapy occur early in the course of 
treatment. Patients who do not develop diabetes during the initial phase of 
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treatment may lack the diathesis to do so. Persistence with therapy was 
synonymous with duration of therapy in this study, except that compliance 
measures were limited to patients filling more than one prescription. Many of the 
studies in this area included duration of treatment as a covariate when analyzing 
the association between antipsychotic use and development of new-onset 
diabetes.3;9;230;234-239;241;243;246;248;249 Four reported a significant association 
between increasing duration of treatment and onset of diabetes,237-239;241 and 
while the magnitude of the increase in risk was small (OR range: 1.067-1.128) 
these results contrast with the findings of this study. As a sensitivity analysis, the 
analysis was repeated using persistence with therapy calculated using a 100 
percent grace period between prescriptions with no difference in the final 
outcome. 
Assuming that the risk of diabetes is increased with any, compared to no 
antipsychotic therapy, it is intuitive that the risk of diabetes would increase with 
increasing level of exposure to therapy. It is, therefore, reasonable then that the 
odds of new-onset diabetes increased for adherent patients (medication 
possession ratio (MPR) ≥ 80%) compared to non-adherent patients (MPR < 
80%). What is questionable is the magnitude of the increase in risk in this 
analysis (OR: 3.889, 95% CI: 2.999-5.044). This may represent an artifact of 
how adherence is calculated. As noted previously, among published case reports 
of diabetes associated with antipsychotic therapy, over 50 percent occurred 
within three months, with over two-thirds of cases occurring within six months of 
initiating therapy (Table 1.5, Appendix A). In contrast, adherence with therapy 
tends to decline with increasing duration of therapy. In this study, while each 
patient was followed for a maximum of one year, data were censored once a 
study endpoint occurred resulting in different lengths of patient follow-up. This 
potentially exaggerated the impact of treatment adherence, appearing higher for 
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patients with a short period of follow-up. Previous hypothesis testing in section 
4.2.2.4 had indicated that trends in adherence were consistent regardless of the 
assessment period. To circumvent issues arising from variable periods of follow-
up, adherence over a 365-day period was used as the covariate in the regression 
analysis. Several sensitivity analyses were conducted where adherence to therapy 
was included as a continuous variable, as a measure of adherence to a study 
endpoint only, substituting duration of therapy (that is, including patients who 
redeemed only one prescription), and using the final day on which a drug was 
available in lieu of adherence over 365 days. Regardless of the analysis, the net 
result was a failure to reject the null hypothesis, that the incidence of diabetes 
differs according to the class of antipsychotic used. What did vary was the 
estimate of risk associated with increasing adherence to therapy (e.g., odds ratios 
greater than 100 for adherent versus non-adherent patients). While the impact of 
treatment adherence may still be exaggerated using an intent-to-treat approach, 
the resulting odds ratio is more credible. 
In summary, the findings of this study concur with published studies in 
this area that as a class, while the risk of diabetes may be increased with second-
generation relative to first-generation antipsychotic agents, the magnitude of the 
increase is small, and typically not statistically significant. 
4.2.4.2.2 Type of Second-Generation Antipsychotic 
Using multivariate logistic regression analysis, a decrease in the odds of 
new-onset diabetes were noted with olanzapine (12.1%) and quetiapine (31.7%) 
compared to risperidone, after controlling for all other variables. These 
differences were not statistically significant (p=0.397 and p=0.135, respectively). 
Hypothesis 6b was, therefore, accepted. 
As previously reported, prescribing of the second-generation 
antipsychotics varied according to patient age, gender, race/ethnicity and primary 
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mental health diagnosis. While these were included as covariates in the 
regression analysis, the study did not control for potential differences in access to 
medical monitoring for patients in the different mental health categories. This 
may have confounded the study findings, leading to an apparent increase in the 
odds of diabetes for patients prescribed risperidone – an agent that was 
preferentially prescribed to older patients with dementia. Also noted previously, 
it is possible that new-onset cases of diabetes were missed in patients that were 
dual-eligible for both Medicaid and Medicare, as the Medicare medical claims 
were not included in this study. This has particular implications for patients 
prescribed risperidone, the majority of whom were older and more likely to be 
dual-eligible for benefits, possibly reducing the apparent risk of diabetes in 
patients prescribed risperidone. The use of prescription claims data in addition to 
medical claims to identify new-onset cases of diabetes may have negated the 
possibility of such misclassification bias in this study. 
Several retrospective studies have examined the relative risk of diabetes 
associated with the second-generation antipsychotics with variable findings. 
Consistent with this study, quetiapine has been associated with a comparable or 
lower risk of diabetes compared to risperidone.232;247;248 Etminan et al. reported 
‘comparable risk’ between the two agents – the unadjusted risk of diabetes was 
0.68 for quetiapine compared to risperidone.232 Sacchetti et al. noted ‘no 
significant comparison’ between any of the second-generation agents, including 
between quetiapine and risperidone.248 Finally, Ostbye et al. reported a relative 
risk of diabetes of 0.66 (95% CI: 0.28-1.57) for quetiapine compared to 
risperidone.247 
The relative risk of diabetes between olanzapine and risperidone is more 
contentious. Six of fourteen published retrospective studies reported a 
comparable or lower relative risk of diabetes with olanzapine compared to 
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risperidone (RR: 0.3–1.0),9;232;241;246;248;250 while eight studies reported an 
increased relative risk of diabetes with olanzapine (RR: 1.2-
4.2),229;230;235;236;238;245;247;249 with the majority of studies reporting relative risks 
between 0.79 and 1.37. 9;230;232;235;241;245-249 Of note, statistical significance was 
reported in only five studies, that is, in four of the studies reporting an increase in 
risk 230;235;236;238 and in one study reporting a decrease in risk.250 The reliability of 
some of the results may be questioned. Whereas, Gianfrancesco et al. reported 
relative risks of diabetes of 3.53 (95% CI: 1.620-5.934) and 4.189 (95% CI: 
2.102-8.827) for olanzapine compared to risperidone, these results were derived 
by extrapolating the odds of diabetes compared to untreated patients at one 
month to a 12-month exposure and then transforming the effect sizes so that a 
comparison could be made between the two agents.236;238  
This result compares to that noted in the CATIE study, which examined 
safety and tolerability measures as secondary goals. This study noted no 
significant difference in the time to treatment discontinuation due to intolerable 
side effects between the individual agents: olanzapine, risperidone, quetiapine, 
ziprasidone, and the first-generation agent, perphenazine. It is worth noting 
however, that olanzapine was associated with greater increases in weight 
(p<0.001) and glycosylated hemoglobin (p<0.01), but not mean serum glucose 
levels (p=0.59), compared to the other agents. For example, the mean exposure-
adjusted difference in blood glucose from baseline was 13.7±2.5 milligrams per 
deciliter for olanzapine and 6.6±2.5 for risperidone, a net mean difference of 7.1 
milligrams per deciliter. The net mean difference in glycosylated hemoglobin 
between the two agents was 0.29 percent, which would correspond with a net 
difference in mean serum glucose levels of approximately ten milligrams per 
deciliter over a three-month period. 254  
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Antipsychotic dose was not significantly associated with the outcome. 
Compared to patients stratified as receiving ‘low’ dose therapy, a non-significant 
decrease in the odds of diabetes (25.4%) was seen with ‘medium’ dose therapy, 
whereas ‘high’ dose therapy was associated with a non-significant increase in the 
odds of diabetes of 15.9 percent. It is possible that the small number of cases 
among patients receiving high-dose therapy may have reduced the power of the 
study to detect an effect, increasing the risk of a type I error. 
There is limited information on the association between antipsychotic 
dose and development of new-onset of diabetes in the literature. Gianfrancesco et 
al. reported a 10 to 25 percent increase in the risk of diabetes with medium or 
high-dose antipsychotic (first- or second-generation) therapy compared to no or 
low-dose therapy in a study of Ohio Medicaid enrollees with schizophrenia, 
bipolar disorder or major depressive disorder. This result is difficult to interpret. 
The comparator group included patients not receiving antipsychotic therapy. As 
there is a general consensus that the risk of new-onset diabetes is increased with 
first or second-generation antipsychotic therapy compared to no therapy, the 
significance of the dose related-effect proposed in this study becomes 
questionable.239 
In a study of patients with schizophrenia enrolled in California Medicaid, 
Lambert et al. reported no association between antipsychotic dose (compared to 
any dose of a first-generation agent) and risk of diabetes for clozapine, 
olanzapine, quetiapine or risperidone using 12 or 24-week exposure windows. 
The possible dose-response for olanzapine found by Lambert et al. using a 52-
week exposure window is not refuted by this study as the majority of patients in 
this study did not remain on treatment for 52 weeks. The difference between the 
two studies may alternatively be explained by the difference in patterns of 
antipsychotic prescribing. For example, 36.8 percent of enrollees in the 
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California Medicaid study received doses greater than 12.5 milligrams of 
olanzapine, compared to 11.5 percent with doses between 10 and 15 milligrams 
and 11.6 percent with doses greater than 15 milligrams in the Texas Medicaid; 
cohort, that is, there was a more pronounced dosing curve in the former.226 
Consistent with earlier analyses, comorbid hypertension or dyslipidemia 
were significantly associated with the outcome. While no longer statistically 
significant, the trend towards an increased risk of diabetes with increasing age, 
female gender and Black or Hispanic race/ethnicity compared to Whites was 
again observed. As with Model 1, adherence with therapy was associated with a 
significant increase in the odds of diabetes, while increasing persistence was 
associated with a small, but statistically significant decrease in the odds of 
diabetes. Again, mimicking Model 1, the use of concomitant diabetogenic 
medications was paradoxically associated with a decrease (albeit non-significant) 
in the odds of new-onset diabetes. Likewise, while primary mental health 
diagnosis was not associated with the outcome, a trend toward an increase in the 
odds of diabetes for all mental health strata compared to schizophrenia was 
observed. 
In summary, this study corroborates the findings of previous retrospective 
studies regarding the relative risk of diabetes between quetiapine and risperidone. 
While the non-significant reduction in risk with olanzapine compared to 
risperidone contrasts with the findings of several studies, it is noteworthy that the 
magnitude of the risk difference was typically small between the studies, with 
few reporting a significant difference in risk.  
4.2.4.2.3 Antipsychotic Dose 
The association between antipsychotic dose and the incidence of diabetes 
was examined individually for the second-generation antipsychotic agents 
(olanzapine, quetiapine and risperidone) using Model 3. The hypothesis testing 
 300
and statistical results are summarized in Table 3.32. As noted previously, 
hypotheses 7a and 7e relating to clozapine and ziprasidone, respectively, were 
not tested due to inadequate sample sizes. 
4.2.4.2.3.1 Olanzapine  
A total of 74 cases of diabetes (2.9%) were noted in the cohort of 2,521 
patients included in this analysis. Using multivariate logistic regression analysis 
to control for other variables, each one milligram increase in olanzapine dose was 
associated with a 1.9 percent increase in the odds of diabetes. This difference was 
not however statistically significant (p=0.995). Trends in the odds of diabetes for 
all other covariates were consistent with those discussed in previous analyses. 
Hypothesis 7b was, therefore, accepted. The small number of cases of diabetes 
relative to the number of independent variables in the analysis may have 
increased the risk of a type I error in this analysis, limiting the interpretability of 
this result.  
As noted previously, literature on a dose-related effect of olanzapine is 
sparse, and the results conflicting. While Buse et al. reported no dose-response 
with olanzapine,9 Lambert et al. reported a possible dose-response after 52-weeks 
exposure when compared to any dose of a first-generation antipsychotic in a 
case-control study of schizophrenia patients enrolled in California Medicaid. 
This response was not observed with 12- or 24-week exposure windows. 226 A 
dose-response relationship for olanzapine was also reported in two studies by 
Gianfrancesco et al., with increases in the odds of diabetes of 22 percent 
(p<0.002) and 34 percent (p<0.001), respectively, noted for each 2.6 milligram 
increase in olanzapine dose.236;238 As previously noted, these results were derived 
by extrapolating the odds of diabetes compared to untreated patients at one 
month to a 12-month exposure.236;238 In a further study published in 2006, the 
same authors reported that compared to untreated patients, the odds of 
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developing diabetes increased with increasing olanzapine dose, which were 
significant for those receiving medium or high dose olanzapine.240  
The discrepancies between the study findings may relate to differences in 
the study populations, the calculation and categorization of the treatment doses, 
and the range of doses used. 
4.2.4.2.3.2 Quetiapine  
Nineteen cases of diabetes (2.7%) were noted in the cohort of 700 
patients treated with quetiapine included in this analysis. Using multivariate 
logistic regression analysis to control for differences in other variables, each one 
milligram increase in quetiapine dose was associated with a 0.1 percent increase 
in risk of diabetes, although this result was not statistically significant (p=0.774). 
Hypothesis 7c was, therefore, accepted. 
Consistent with previous findings and the known epidemiology of 
diabetes, an increase in the odds of diabetes was noted with a comorbid diagnosis 
of hypertension or dyslipidemia and with increasing patient age. Increasing 
persistence with therapy was associated with lower odds of diabetes, while as 
before increased adherence was associated with higher odds of diabetes. 
Information on a dose-related effect of quetiapine is sparse in the 
literature, with both a possible dose-related increase in risk of diabetes reported9 
and no dose-related effect reported.226 The small number of cases in this analysis 
relative to the number of independent variables may have biased the findings 
towards the null, thereby limiting the interpretability of this result.  
4.2.4.2.3.3 Risperidone  
Of 4,621 patients included in this analysis, 153 (3.3%) were classified as 
developing new-onset diabetes. Using multivariate logistic regression analysis to 
control for differences in other variables, each one milligram increase in 
risperidone dose was associated with a three percent reduction in the risk of 
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diabetes, although this result was not statistically significant (p=0.639). 
Hypothesis 7d was, therefore, accepted. Trends in the odds of diabetes for all 
other covariates were consistent with those discussed in previous analyses.  
This result supports the limited findings in the literature that the risk of 
diabetes does not alter according to the dose of risperidone used.9;226;236;238 
4.2.4.2.4 Treatment Indication 
The association between treatment indication and the incidence of 
diabetes was examined individually for the second-generation antipsychotic 
agents (olanzapine, quetiapine and risperidone) using Model 3. The hypothesis 
testing and statistical results are summarized in Table 3.32. As noted previously, 
hypotheses 8a and 8e relating to clozapine and ziprasidone, respectively, were 
not tested due to inadequate sample sizes. 
Whereas the incidence of diabetes was found to differ according to the 
treatment indication for patients treated with olanzapine (p=0.034), no 
association was found for patients treated with quetiapine (0.851) or risperidone 
(p=0.292). Therefore, hypothesis 8b (olanzapine) was rejected and hypotheses 8c 
(quetiapine) and 8d (risperidone) were accepted. For patients treated with 
olanzapine, the odds of new-onset diabetes were increased for all treatment 
indications (with the exception of dementia) when compared to a diagnosis of 
schizophrenia, after controlling for all other variables. Only two contrasts were 
significant, that is, when comparing a diagnosis of psychotic or nonpsychotic 
disorder to schizophrenia. Trends in the incidence of diabetes according to 
mental health diagnosis were not consistent between the olanzapine, quetiapine 
and risperidone. As noted previously, possible differences in access to care, and 
in particular to medical monitoring, according to the primary mental health 
diagnosis may have contributed to an under-detection of new-onset of diabetes 
among patients with schizophrenia  
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While schizophrenia and the affective disorders have been associated 
with an increased risk of diabetes independent of antipsychotic use, the literature 
among patients taking antipsychotics is sparse. The majority of studies have 
reported a non-significant association between patient mental health diagnosis 
and risk of diabetes. Conflicting findings have been reported from four U.S. 
studies using cohorts of patients enrolled in managed care organizations. Using a 
cohort of patients with an ICD-9 for schizophrenia, bipolar disorder or major 
depressive disorder, Gianfrancesco et al. noted an increase in odds of diabetes 
with a schizophrenia diagnosis compared to bipolar disorder (30-70%) or major 
depressive disorder (40-100%), after controlling for all other factors. In a study 
including all patients with a mental health disorder, Miller et al. noted an increase 
in risk of diabetes with a diagnosis of schizophrenia (HR: 1.622; 95%CI: 1.232-
2.132), bipolar disorder (HR: 1.355; 95%CI: 1.073-1.711) and post-traumatic 
stress disorder (HR: 1.691; 95%CI: 1.019-2.806) and a decreased risk with ‘other 
psychoses (HR: 0.602; 95%CI: 0.389-0.931). In direct contrast, Gianfrancesco et 
al. reported a decrease in the odds of diabetes associated with a diagnosis of 
schizophrenia (OR: 0.445; p=0.1076), bipolar disorder (OR: 0.444, p=0.0100) or 
major depression (OR: 0.449, p=0.0015) compared to patients with other 
psychoses. Lee et al. in a study of patients prescribed first or second-generation 
antipsychotics noted a similar decrease in the odds of diabetes for patients with 
bipolar disorder p=0.425). 
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4.3 Study Limitations 
Several factors limit the validity of the study findings, many of which 
were inherent to the nature of the study, that is, a retrospective cohort study using 
a claims database. Although considered to be reliable and valid for the study of 
drug use, exposure to a drug was inferred from claims filed as opposed to having 
information on drug taken. It is possible that patients may have had other sources 
of prescription medication coverage, although, the more likely reason for not 
capturing data would be if patients were hospitalized or incarcerated during the 
follow-up period. The absence of Medicare claims data for patients that were 
dual-eligible for Medicaid and Medicare benefits may have let to an 
underreporting of both prevalent and incident cases of diabetes. This may have 
preferentially affected patients prescribed risperidone, the majority of whom 
were older and more likely to be dual-eligible for benefits. The study was 
strengthened, however, by the use of both medical and prescription claims to 
detect diabetes, reducing the risk of possible misclassification bias. 
Information on several important risk factors for diabetes was missing 
from this database and had the potential to confound the results. These included: 
patient weight or body mass index; family history of diabetes; lifestyle habits; 
and fasting insulin and blood glucose levels. The period for this study was 
chosen as it predated the publication of studies regarding the association between 
antipsychotic use and development of diabetes, that is, to minimize channeling 
bias whereby patients at high risk of diabetes could be channeled away from 
agents perceived to have a higher risk of diabetes. It is possible that channeling 
still occurred, in that physicians may have channeled overweight or obese 
patients, or those perceived to be at higher risk of diabetes, away from clozapine 
and olanzapine, because of concerns about the greater potential for weight gain 
with these agents. This may have spuriously lowered the association between use 
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of clozapine or olanzapine and risk of diabetes and increased the apparent risk of 
diabetes with a more weight-neutral agent such as risperidone. 
The primary dependent variable in this study was the occurrence of new-
onset diabetes which was measured by the detection of an ICD-9 code for 
diabetes, or the prescription of insulin, an oral hypoglycemic agent, or an insulin 
sensitizing agent. As previously noted, the prescription medications used to treat 
diabetes are disease-specific for diabetes, with limited off-label use for other 
indications. This study was strengthened by the consideration of both medical 
and pharmacy claims for diabetes, reducing the likelihood that either prevalent of 
incident cases were misclassified. Because of possible left-censoring of the data, 
it is not certain, however, that all of the first-listed claims for diabetes represent 
new-onset of illness. This concern is mitigated by the use of a 6-month window 
prior to the index data. Similarly, it is possible that patients with latent diabetes 
were included among the incident cases because of the clinical nature of this 
disease, that is, a prolonged asymptomatic course with detection based on contact 
with a physician and testing. It is unlikely however, that this would distribute 
differently between the index agents. Possible differences in the access to care 
for patients with serious mental illness, and also the availability of medical 
monitoring in ambulatory mental health settings may have reduced the apparent 
risk of prevalent or new-onset diabetes in the cohort, confounding the study 
findings. In particular, diabetes may have been under detected in patients with 
schizophrenia, possibility distorting the studies findings with regard to the 
association between risk of diabetes and the primary mental health diagnosis. 
A limitation of the study is that the ICD-9 codes were not independently 
validated, resulting in possible misclassification of the mental health diagnoses 
and of cases of diabetes. The ICD-9 coding system has been widely used in 
claims based research, and although the true number of affected patients may be 
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over or underestimated, this system has been shown to be accurate for 
schizophrenia patients enrolled in Medicaid.358 While acknowledging that 
misclassification of diagnoses may have occurred, it is unlikely that these were 
unevenly distributed between the index agents. It is possible that the hierarchical 
approach used to classify patients according to their primary mental health 
diagnosis may have led to a number of patients being misclassified. The 
approach was nevertheless supported by the consistency in treatment-related 
antipsychotic dosing patterns between this and other studies. 
As this study was limited to those patients that were prescribed 
antipsychotic monotherapy and may, therefore, not be generalizable to the use of 
antipsychotic polypharmacy. Anecdotal reports suggest that the prevalence of 
antipsychotic polypharmacy may have been lower during the time-frame of this 
study (1997-2001), but that it has increased in recent years. It is also possible that 
the use of polypharmacy is lower in Texas Medicaid than elsewhere because of 
the restriction of program recipients to a maximum of three prescriptions per 
month. While antipsychotic polypharmacy was not explicitly examined in this 
study, 1,300 patients, (6.7%) had a switch to polypharmacy as their study 
endpoint. The risk of new-onset diabetes associated with use of combination 
antipsychotic therapy may need to be addressed in the future, particularly given 
reports of the increasing prevalence of polypharmacy with these agents. 
The large sample size strengthened the study providing adequate power 
for the majority of the statistical analyses. However, the study may not have been 
adequately powered to detect the impact of treatment dose given the small 
number of cases of diabetes among those categorized as receiving ‘high dose’ 
therapy and among quetiapine recipients. The risk of type I errors may have been 
further increased by the large number of pair-wise comparisons in the regression 
analyses. 
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The study population may not be generalizable to the U.S. population 
prescribed antipsychotic therapy. The cohort was a heterogeneous group with a 
diverse range of treatment conditions and was comprised of mainly older adults, 
with an over-representation of women and minorities. While the prescribing of 
antipsychotics varied according to demographic and clinical variables, these 
variables were included as covariates in the regression analyses and accordingly 
were not expected to bias the study findings. Those with a lower socio-economic 
status are over-represented in Medicaid compared to the national population; 
however, this is less of a concern in a study of patients with serious mental 
illness, the majority of whom receive publicly funded healthcare.365  
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4.4 Practical Significance and Future Research 
In spite of the limitations reported herein, the pattern of results observed 
is consistent with those of previously published studies. That is, after controlling 
for other risk factors, the second-generation antipsychotics do not differ 
significantly in their potential to cause new-onset diabetes. This consistency 
across studies that differed in study design, study population and analysis plan, 
increases the credibility of the findings. Discrepancies between the findings of 
this and other studies may possibly be explained by differences in the population 
studied, differences in the definition of diabetes and antipsychotic exposure used, 
the number and type of covariates included, and statistical analysis plans.  
What deserves elaboration is the magnitude of the association reported in 
the different studies. When compared to a first-generation antipsychotic, the 
relative risk of diabetes associated with the second-generation antipsychotics has 
ranged from 1.1 to 2.6 in the published literature, with the majority reporting a 
relative risk of 1.6 or less. It is important to assess this risk in terms of the 
absolute rather than the relative risk of diabetes. In 2004, the annual incidence of 
diabetes among adults between 18 and 79 years of age was 0.7 percent (1 in 
1,429).276 Using a conservative estimate that the incidence of diabetes does not 
differ for those with a mental health diagnosis compared to the general U.S. 
population, an odds ratio of 1.6 would increase the absolute risk of diabetes to 
1.12 percent (1 in 892). Under the more conservative assumption that patients 
with mental health diagnoses have an incidence of diabetes that is twice that of 
the general U.S. population (1.4%), exposure to a second-generation instead of a 
first-generation antipsychotic would increase that risk to 2.24 percent (1 in 446). 
Similarly, using the annual incidence of diabetes established in this study 
population of 2.37 percent (1 in 422), exposure to a second-generation versus a 
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first-generation agent would increase the absolute risk to 3.79 percent (1 in 264) 
cases per year. 
While not diminishing the importance of such an increase in risk of 
diabetes with the second-generation antipsychotics, the clinical implication of 
such an increase must be considered in the context of the available options. For a 
patient with treatment-refractory schizophrenia, the additional risk of diabetes 
that may present with use of clozapine is likely to be off-set by the benefit of 
treatment. Among non-refractory patients, while there is little to discriminate 
between the other second-generation agents, although olanzapine was found to 
have a modest increase in efficacy in the CATIE trial. Allowing that patients 
treated with olanzapine were also more likely to discontinue treatment because of 
metabolic effects, the possible increase in effectiveness would need to be 
considered in the context of other risk factors that the patient may have for 
diabetes. 254 It is worth reiterating that the increase in mean exposure-adjusted 
blood glucose levels for olanzapine and risperidone were 13.7±2.5 milligrams 
per deciliter (mg/dL) and 6.6±2.5mg/dL, respectively, representing a net mean 
difference of only 7.1mg/dL. 254 This could be sufficient to precipitate diabetes in 
a patient with baseline glucose intolerance; however, such an increase in blood 
glucose levels could be easily managed with either lifestyle intervention or 
minimal pharmacological therapy. The efficacy of education and lifestyle-
intervention to delay the onset, or decrease the incidence of diabetes in a non-
psychotic population has been well documented.388;389 When considered in the 
context of a high-risk cohort such as patients with schizophrenia or bipolar 
disorder, such intervention could be of even greater benefit, acknowledging of 
course the difficulties of implementing such programs in patients with serious 
mental illness. 
 310
Suggestions for future research include further prospective trials to assess 
the metabolic effects of antipsychotic treatment in conditions other than 
schizophrenia, such as bipolar disorder and dementia. The risk of new-onset 
diabetes associated with use of antipsychotic polypharmacy should also be 
considered, particularly given the reports of the increasing prevalence of 
antipsychotic polypharmacy prescribing. The efficacy of intensive lifestyle 
education programs in patients with serious mental illness to delay or prevent 
complications of diabetes would also be of interest. 
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4.5 Conclusions 
Among patients enrolled in Texas Medicaid taking antipsychotic therapy, 
the risk of new-onset diabetes did not vary based on exposure to a first-
generation antipsychotic, olanzapine, quetiapine or risperidone; a finding that 
persisted after controlling for demographic, clinical and other medication-related 
variables. Consistent with other studies and national trends, increasing age, 
Hispanic and African American race or ethnicity, comorbid hypertension and 
dyslipidemia were significant independent risk factors for the development of 
diabetes. With the exception of a possible association between mental health 
diagnosis and diabetes in patients treated with olanzapine, neither antipsychotic 
dose nor treatment indication was associated with the risk of new-onset diabetes. 
This study contributes to the body of literature on the comparative safety 
of the second-generation antipsychotic agents. It expands on the previous 
literature in that it considered a heterogeneous patient population prescribed 
antipsychotics – in line with the diverse range of patients that are treated with 
these agents in clinical practice. Given the baseline risk of cardiovascular and 
metabolic disorders in the elderly, and among patients with schizophrenia and 
bipolar disorder, the risks associated with use of the second-generation 
antipsychotics must be considered in the context of the clinical benefits and the 
financial setting. All patients should be assessed at baseline for diabetes and 
monitored routinely in accordance with recent guidelines, with appropriate 
allocation of funding to enable providers provide such services in ambulatory 
mental health clinics. 
Use of the second-generation antipsychotic must also be placed in context 
of the rapid and occasionally fatal acute metabolic decompensation (including 
ketoacidosis) that has been reported with these agents. Although rare, these 
events have been reported with all of the second-generation agents, albeit more 
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frequently with olanzapine and clozapine. While insufficient to avoid use of 
these agents, healthcare providers and patients must be alert to this potential so 
that patients can be rapidly identified and treated.
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Appendix A: Summary of Case Reports of New-Onset Diabetes, Hyperglycemia, or Diabetic Ketoacidosis Associated with Second-Generation 


























1145 AA, M, 41 Clozapine 
900mg 
Benztropine Schizophrenia N/NR 8 New onset 
diabetes 
NR 829 NR Resolved on DC 
of SGA 




Schizophrenia N/Y 6 DKA NR 1224 NR Resolved on DC 
of SGA 







N/Y 4 DKA NR 447 NR Ongoing IGT 
despite DC SGA 
4148 AA, M, 46 Clozapine 
500mg 
Lithium Schizophrenia N/Y 5 DKA NR 762 NR Continued DM 
(insulin) despite 
DC SGA 















SAD N/N 5 New onset 
diabetes  
8.7 494 +1.4 Clozapine & 
OHA 
7149 C, M, 51 Clozapine 
200mg 
Glyburide  Schizophrenia Y/NR 5 Decreased 
glycemic 
control 
NR 500 0 Clozapine & 
insulin 




Schizophrenia Y/NR 2 Decreased 
glycemic 
control 
NR 311 NR Risperidone, 
chlorpromazine 
& OHA 
9149 NR, M, 50 Clozapine 
300mg 
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10150 C, M, 37 Clozapine 
Dose NR 
NR Schizophrenia N/NR 11 New onset 
diabetes, 
Lactic acidosis 





Minocycline Schizophrenia N/N 20 DKA NR 448 NR Olanzapine & 
OHA 




Schizophrenia N/NR 2.6 New onset 
diabetes  
NR 267 NR Resolved on 
switching to 
risperidone 




NR Schizophrenia N/N 8 New onset 
diabetes  
NR NR +10.9 Ongoing DM 
(OHA) despite 
DC SGA 




NR SAD N/N 72 DKA NR NR +25.5 Clozapine & 
OHA 




NR Schizophrenia N/Y NR New onset 
diabetes  




16153 AA, M, 41 
38% > IBW 
Clozapine 
200mg 
NR NR N/N 5 New onset 
diabetes  
NR 1028 NR Risperidone & 
OHA 
17153 AA, M, 38 
50% > IBW 
Olanzapine 
25mg 
NR Schizophrenia N/Y 12 New onset 
diabetes  
NR NR +5 Olanzapine & 
OHA 
18153 C, M, 56 
25% > IBW 
Olanzapine 
25mg 
NR Schizophrenia N/N 12 New onset 
diabetes  
NR NR 0 Olanzapine & 
OHA 
19154 AA, M, 32 







N/N 6 New onset 
diabetes  
13.8 402 NR Resolved on 
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20155 C, M, 31 
BMI = 29 
Clozapine 
200mg 
NR SAD N/N 12 DKA NR 756 +3.2 Resolved on 







NR Schizophrenia N/N 2.3 DKA NR 990 NR Clozapine & 
insulin 
22157 AA, M, 30 Clozapine 
325mg 
NR Schizophrenia N/N 12 DKA NR 342 NR FGA & OHA 






N/Y 4 DKA NR 1000 NR Resolved 
(ongoing IGT) 
on reduced dose 
(100mg) 
 
24159 C, M, 31 
BMI = 40 
Olanzapine 
10mg 
NR Schizophrenia N/N 12 DKA 14.7 648 -4.1 Resolved on DC 







Schizophrenia  N/N 32 DKA NR 1200 +9.5 Resolved on DC  
26161 C, F, 42 
BMI = 36 
Olanzapine 
10mg 
NR SAD N/Y 24 DKA NR 1274 +32.3 Quetiapine & 
insulin 
27161 C, F, 40 
BMI = 27.2 
Olanzapine 
10mg 
NR Schizophrenia  N/N 68 DKA NR 1160 +4.5-
6.8 
Resolved on DC  











N/N 20 New onset 
diabetes  
NR 766 NR Resolved on DC 
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29161 C, M, 47 
BMI = 40 
Olanzapine 
10mg 
CBZ SAD N/Y 5 New onset 
diabetes  
NR 878 +13.6 Resolved on DC 















N/N 2 New onset 
diabetes  
10.4 567 +25 Quetiapine & 
OHA 
31161 C, M, 39, 








SAD N/Y 14 New onset 
diabetes  
NR 686 -2.7 Risperidone & 
OHA 
32161 C, M, 38 





N/N 12 New onset 
diabetes  
NR 372 0 Resolved on DC 
(diet control) 
33162 AA, M, 45 Olanzapine 
10mg 
Glyburide MDD Y/N 4 Decreased 
glycemic 
control 
NR 500 ↑ 25% Resolved on DC 






N/N 4 New onset 
diabetes  





NR Schizophrenia N/N 4 DKA 18.6 876 -3 Risperidone & 
insulin 
36165 NR, M, 45 
BMI = 35.2 
Clozapine 
900mg 
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37165 NR, M, 45 













38166 NR, M, 38 
BMI = 27 
Clozapine 
(Dose NR) 
NR Schizophrenia N/N 24 DKA 10.7 450 -3.2 Resolved on DC 
39166 NR, M, 55, 





N/Y 16 New onset 
diabetes  
16.7 342 -7.0 Resolved on DC 
40167 AA, F, 54 
BMI = 25 
Olanzapine 
10mg 
Fluoxetine MDD with 
psychoses 
Y/NR 1.7 Decreased 
glycemic 
control 
6.5 536 + 13.2 Poor control 
despite switch to 
quetiapine, 
improved on DC 






N/N 28 DKA 11.4 565 NR Quetiapine & 
insulin 
42169 AA, M, 30 






SAD N/N 16.5 New onset 
diabetes  
13.3 382 +5.0 Resolved on DC 
43170 AA, M, 38, 





N/N 9.5 New onset 
diabetes  
NR 1000 NR Resolved on DC 




NR Schizophrenia NR 10 New onset 
diabetes  
NR 404 +7.7 Olanzapine & 
insulin 




Valproate SAD NR/Y 4 New onset 
diabetes  
NR 249 +3.6 Resolved on DC 




NR NR NR 4 New onset 
diabetes  
NR 405 +9.5 Olanzapine, 
OHA & insulin 





Valproate Schizophrenia NR/Y 18 Diabetic 
coma 
NR 800 +9.5 Olanzapine & 
insulin 
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NR Schizophrenia NR/Y 12 New onset 
diabetes  
NR 395 +2.7 Ongoing DM 
(insulin) despite 
DC  
49171 AA, M 53 Olanzapine 
20mg 
NR Schizophrenia NR/Y 24 New onset 
diabetes  
NR 220 +23.6 Olanzapine & 
OHA & insulin 
50171 AA, F, 35 Olanzapine 
10-20mg 
Valproate Schizophrenia NR/Y 20 New onset 
diabetes  
NR 374 NR Olanzapine, 
OHA & insulin 




NR Schizophrenia NR 4 New onset 
diabetes  
NR 125 +11.8 Olanzapine & 
OHA 
52172 C, M, 33 





Schizophrenia N/N 32 DKA 14 626 -20.9  Resolved on DC 
53173 AA, F, 46 







N/Y 60 DKA 
Pancreatitis 
11.7 957 +2.7 Risperidone, 
OHA & insulin 








SAD N/N 156 New onset 
diabetes  
11 417 +1.8 DM resolved on 
switching to 
risperidone3 
55175 AA, M, 52 
BMI = 30.1 
Risperidone 
8mg 
NR Schizophrenia N/Y 64 New onset 
diabetes  
NR 436 - 0.9 Risperidone & 
insulin 
56175 HIS, M, 50 
BMI = 26.9 
Risperidone 
6mg 
NR Schizophrenia NR/NR 132 New onset 
diabetes  
NR 158 + 29.5 Risperidone & 
OHA 




Paroxetine Schizophrenia N/Y 24 New onset 
diabetes  
NR 153 +15.9 Resolved on 
switch to 
quetiapine 




SAD N/Y 52 New onset 
diabetes  
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N/Y 8 New onset 
diabetes  
NR 182 + 4.5 Risperidone & 
diet control 




Schizophrenia N/Y 64 New onset 
diabetes  
NR 271 NR Risperidone & 
diet control 
61177 C, M, 43 
BMI = 29 
Clozapine 
400mg 
NR Schizophrenia NR/NR 208 New onset 
diabetes  
NR 181 + 18.2 Olanzapine & 
OHA 
62177 C, M, 28 
BMI = 23.4 
Clozapine 
350mg 
NR Schizophrenia NR/NR 104 New onset 
diabetes  
 
NR 407 + 13.6 Olanzapine & 
OHA 
63178 C, M, 38 







Schizophrenia N/Y 36 DKA 13.4 765 +13.6  Olanzapine & 
insulin 
64180 C, M, 51 
7% > IBW 
Olanzapine 
25mg 
NR PTSD & 
Bipolar 
disorder 




13.3 1596 0 Resolved on DC 
65179 AA, M, 31 





SAD N/Y 6 New onset 
diabetes  






66179 C, M, 44 






SAD N/Y 16 New onset 
diabetes  
NR 936 NR Olanzapine & 
OHA 
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67181 C, F, 79 







IGT/NR 6 New onset 
diabetes  
NR 496 NR Resolved on DC 








Schizophrenia  N/N 72 New onset 
diabetes  
13.5 NR + 6.4 Risperidone & 
OHA 
69183 AA, M, 27 





Schizophrenia N/N 124 DKA NR 1240 NR Olanzapine & 
OHA 
70184 C, F, 64 







Y/NR 18 Decreased 
glycemic 
control 
NR 1240 +8.9 Ongoing DM 
(insulin) despite 
DC but with 
improved 
glycemic control 
71185 NR, F, 19 






N/NR 12 New onset 
diabetes  
NR 338 NR Resolved on DC 
72185 NR, M, 24 









NR >500 NR Died 
73186 C, M, 49 
BMI = 34.2 
Olanzapine 
20mg 
NR Schizophrenia N/NR 50 DKA 6.5 766 +15.5 Resolved despite 
ongoing 
olanzapine 
74187 NR, M, 42 
BMI = 28 
Olanzapine 
20mg 
NR Schizophrenia N/NR NR New onset 
diabetes  
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SAD N/N 2.6 New onset 
diabetes  
18.2 603 NR Thioridazine & 
OHA 
77190 C, F, 51 





SAD Y/NR 3 Decreased 
glycemic 
control 
NR 360 0 Control regained 











and on exposure 
to clozapine 
79192 NR, M, 31 
BMI = 29 
Olanzapine 
20mg 
NR Schizophrenia N/N 4 Hyperosmolar, 
nonketonic 
diabetic coma 
NR 954 +0.9 Death 
80193 C F, 39 









Schizophrenia N/N 156 New onset 
diabetes  
NR 328 0 Resolved on DC 
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82195 NR, M, 49 
BMI = 26.4 
Olanzapine 
20mg 
NR Schizophrenia N/N 20 New onset 
diabetes  
NR 275 +10 Resolved on DC 




NR Schizophrenia N/Y 20 New onset 
diabetes  
11.5 268 +21.4 Resolved on DC 
84197 Asian, M, 




NR Schizophrenia NR/Y 4 DKA 13.7 1080 -9.1 Resolved on DC 












NR 600 0 Resolved on DC 




86199 Asian, M, 








NR N/Y 45 New onset 
diabetes  






87199 Asian, M, 






NR N/N 48 New onset 
diabetes  
NR 160 BMI 
↓4.9 
No resolution on 
DC 
88199 Asian, F, 25 Olanzapine 
15 mg 
 NR N/N 47 Transient 
hyperglycemia 
NR 220 NR Resolved 
without DC 
89199 Asian, M,28 





NR N/N 47 Transient 
hyperglycemia 
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90199 Asian, M, 






NR N/N 50 Transient 
hyperglycemia 




91200 NR, F, 51 Clozapine 
400mg 
HTCZ Schizophrenia IGT/NR 1.4 New onset 
diabetes  
NR 476 3.0 Pimozide & 
OHA 





 Schizophrenia N/NR 11 New onset 
diabetes  
NR 151 0 Resolved 
without DC 
(diet) 
93200 C, M, 35 Olanzapine 
10mg 
 Schizophrenia IGT/NR 9 New onset 
diabetes  
NR 342 +8.0 Olanzapine & 
OHA 





 Schizophrenia N/NR 32 New onset 
diabetes  
NR 264 +10.0 Risperidone & 
OHA 
95200 NR, M, 48, 





SAD N/Y 182 Hyperosmolar 
nonketonic 
coma 




96200 NR, F, 65 Clozapine 
75mg 
Fluphenazine Schizophrenia Y/NR 4 Decreased 
glycemic 
control 
NR 445 NR Clozapine & 
OHA 








Y/NR 0.6 Decreased 
glycemic 
control 
NR 252 4 Resolved on DC 








Y/NR 6 Decreased 
glycemic 
control 
NR 230 NR Resolved on DC 
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99200 NR, F, 38 
BMI = 28.5 
Olanzapine 
20mg 
 Schizophrenia Y/NR 3.5 Decreased 
glycemic 
control 





Abbreviations   
AA – African-American HCTZ – Hydrochlorothiazide OCD- Obsessive Compulsive Disorder 
BMI – Body Mass Index (Kg/m2) IBW – Ideal Body Weight OHA – Oral Hypoglycemic Agent 
C – Caucasian M – Male SAD – Schizoaffective Disorder 
CBZ - Carbamazepine MDD - Major Depressive Disorder SGA – Second-Generation Antipsychotic 
DC – Discontinued MI – Myocardial Infarction Wks. – Weeks 
DKA - Diabetic Ketoacidosis MPA – Medroxyprogesterone Y – Yes 
DM – Diabetes Mellitus Mo. – Month Yr – Year 
F – Female N – No  
FGA – First Generation Antipsychotic NR – Not Reported  
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Generation Antipsychotic Therapy in Adults (continued) 
 
1. Clozapine added to a stable regimen of risperidone 6mg daily with new emergence of diabetes mellitus with poor glycemic control. 
2. Clozapine discontinued four days prior to the myocardial infarction. 
3. ‘Black’ race includes: Afro-Caribbean, African and Aboriginal races. 
4. Patient developed diabetes between 68 and 156 weeks after commencing clozapine therapy. 
5. Patient developed diabetes between 12 and 260 weeks after commencing clozapine therapy.  
6. Hyperglycemia first documented 6 days after adding quetiapine to a stable regimen of olanzapine 20mg daily. Patient was stabilized, with 
reducing doses of insulin after discontinuation of olanzapine (patient maintained on quetiapine and haloperidol). Re-emergence of poor 
glycemic control on switching therapy back to olanzapine. Patient switched to risperidone with subsequent resolution of diabetes. 
7. Not a baseline value. 
8. Patient stabilized and asymptomatic for years on clozapine and risperidone.. Two weeks after switching risperidone to ziprasidone patient 
developed rhabdomyolysis, pancreatitis and hyperglycemia. Clozapine and ziprasidone discontinued; however clozapine subsequently 
successfully restarted without re-emergence of symptoms. 
9. Hyperglycemia resolved on discontinuation of quetiapine with no re-emergence when ziprasidone started. Risperidone use preceded quetiapine 
and was co-prescribed throughout. 
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Appendix B: Comparison of Database Studies Examining the Association between Antipsychotic Use and New-Onset Diabetes 
Author 
(Year) 





Cohort Central Texas 
Veterans Affairs 
database 
09/95-11/02 Any patient ≥ 18 years treated with an FGA or 
SGA with continuous enrollment for 12 mo. 
Exclude if: use of an AP in 6 mo. pre-







defined as: new Rx 
for OHA /insulin; an 
ICD-9 of 250.xx; or 









Age, gender, race, persistence, 
mental health, BMI, 
hypertension, hyperlipidemia.  
Buse 9 
2003 
Cohort Advance PCS 
prescription claims 
database 
12/98-08/00 Any patient ≥ 18 years treated with AP 
monotherapy compared to general population 
not on AP (no AP in 6 mo. pre- or post-
enrollment). 
Exclude if: use of an AP in 6 mo. pre-








defined as: a new Rx 





Mean age, gender, mean dose 
of AP, duration of Tx. 
Carlson 229 
2005 
Cohort UK General 
Practice Research 
database 
01/94-12/01 Any patient ≥ 18 years treated with AP 
monotherapy.  
Exclude if: Hx of DM prior to enrollment; or < 
2yrs. continuous enrollment prior to index date 
for inclusion in FGA cohort. 
New-onset DM 
defined as: a new Rx 
for OHA / insulin; or 
medical claim for 










Age, gender, obesity, duration 
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Author 
(Year) 









01/97-12/99 Any patient treated with olanzapine or 
risperidone. 
Exclude if: Rx for clozapine during study 
period; or if DM in 12 mo. pre-enrollment. 
New-onset DM 
defined as: a new Rx 
for OHA / insulin; or 










Age, gender, diagnosis of 
schizophrenia, duration of Tx, 












N/R Patients with schizophrenia aged 18-65 years.  
Exclude if: DM at baseline (clinical diagnosis 
or Rx. for DM); or two glucose levels 
≥200mg/dL at baseline; or only baseline 
glucose values.  
New-onset DM 
defined as: clinical 
diagnosis for DM; Rx 
for OHA / insulin; 2x 
casual blood glucose 









Baseline casual glucose level, 
baseline risk factors for DM, 
Tx.-emergent weight gain, 
study protocol. 
(Risk factors for DM included: 
Age ≥45; BMI≥27; non-White 
ethnicity; HTN; baseline 
casual glucose level). 
Citrome 225 
2004 
Case-Control New York State 
Psychiatric 
Inpatients 
01/00-12/02 Hospitalized for at least 60 days.  
Exclude if: Rx for DM prior to index date. 
Controls: Matched to control group on calendar 
year, length of stay, race, age group and 
diagnosis. 
 
Cases defined as: new 
Rx for DM ≥60 days 










Cohort Illinois Veterans 
Affairs database 
01/99-12/01 Schizophrenia patients (minimum 2 separate 
diagnoses) treated with AP monotherapy. 
Exclude if: prior Hx of DM; or use of AP in 3 
mo. pre-enrollment. 
New-onset DM 
defined as: 2 
diagnostic codes for 








Age, gender, race, marital 
status, concomitant 
diabetogenic drugs, measures 


















N/R Long term care residents aged ≥ 65 years 
treated with FGA or SGA, with ≥ 2 consecutive 
Rx fills (within 120% of days supply). 




defined as: a new Rx 





Age, gender, total number of 








database for inpt 
and ambulatory 
care clinics in 
Indianapolis) 
01/72-12/00 Patients aged ≥ 18 years prescribed olanzapine, 
risperidone or a FGA (phenothiazine only) for  
≥1 year. 
Exclude if: Rx for haloperidol or antiemetic 
phenothiazine; Hx. of DM (any diagnosis; DM 
Rx; > 1 blood glucose level >200mg/dL; or any 




defined as: a new 
diagnosis of DM; Rx 
for DM; > 1 blood 
glucose level 
>200mg/dL; or any 
HbA1c > 9% in first 






Age, race, gender, obesity, 
mental health diagnosis, 
alcohol/drug use, number of 
visits to primary care, 
psychiatric clinic or 
emergency room, pre-Tx 




Cohort Advance PCS Rx 
claim database for 
managed care 
health plan 
12/98-08/00 Patients aged ≥ 60 years prescribed AP 
monotherapy, enrolled for ≥ 12mo. index date 
and ≥ 6mo. post index date. 





defined as: a new Rx 









Cohort Ohio Veterans 
Affairs database 
01/97-12/00 Any patient receiving ≥ 30 days supply of 
olanzapine, risperidone, fluphenazine or 
haloperidol. 
Exclude if: female; race other than AA or 






defined as: a new Rx 
for OHA /insulin; or 






Race, age, ICD-9 of 290.xx 
(individual covariates), 
number of days supplied, 
previous or concurrent Rx for 
valproic acid, lithium, other 
FGA or quetiapine. 
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Cohort Claims databases 




01/96-12/97 Any patient with an ICD-9 for psychosis.  
Exclude if: treated with AP for < 60 contiguous 
days; or if DM in 8 mo. pre-enrollment. 
New-onset DM 
defined as: a new Rx 
for OHA; or an ICD-9 
of 250.xx during Tx 




(UOA = Tx 
episode); Two 






Concurrent AP use, age, 
gender, duration of 
observation, use of other 





Cohort Blue Cross/Blue 
Shield claims 
database 
04/97-10/00 Any patient with an ICD-9 for psychosis; ID 
first Rx for an AP based on no previous Rx for 
that AP in preceding 90 days. 
Exclude if: treated with AP for < 60 contiguous 
days; or if DM in 8 mo. pre-enrollment. 
New-onset DM 
defined as: a new Rx 
for OHA; or Rx for 
insulin if 
accompanied by ICD-
9 of 250.xx during Tx 
or in 30 days post Tx; 
or ICD-9 of 250.xx if 







(UOA = Tx 
episode) 
Age, gender, duration of 
treatment, use of other 
psychotropics ($), type of 
psychosis, health care 
coverage, prior Tx for weight 




Cohort Claims databases 





01/96-12/97 Any patient with an ICD-9 for MDD or BIP. 
ID first Rx for an AP based on no previous Rx 
for that AP in preceding 90 days. 
Exclude if: treated with AP but for <60 







defined as: a new Rx 
for OHA; or an ICD-9 
of 250.xx during Tx 




(UOA = Tx 
episode) 
Age, gender, duration of 
observation, use of other 
psychotropics, type of health 
care coverage, type of mood 















Cohort Ohio Medicaid 
 
01/99-03/03 Any patient with an ICD-9 for SCZ, manic 
D/O, BIP or MDD. 
ID first Rx for an AP based on no previous Rx 
for that AP in preceding 90 days. 
Exclude if: <2 contiguous Rx. for an AP; or if 
not enrolled for 8mo. prior to index date for 





defined as: a new Rx 
for OHA or insulin; 
or an ICD-9 of 250.xx 
during Tx (Design 1); 
and restricted to a 
new Rx. claim for 




(UOA = Tx 
episode) 
Age, gender, duration of 
treatment, use of concomitant 
diabetogenic medication, 
mental health diagnosis, dose, 
substance abuse/dependence, 
prior use of statin, Hx of 
excess weight, switching of 







from 40 private 
health plans in 
US). 
 
01/99-04/02 Any patient with an ICD-9 for SCZ, BIP or 
MDD. 
ID first Rx for an AP based on no previous Rx 
for that AP in preceding 90 days. AP 
monotherapy only (Model 2). 
Exclude if: treated <2 contiguous Rx. for an 
AP; or if not enrolled for 8mo. prior to index 
date for episode; or if ICD-9 or Rx. for DM in 




defined as: a new Rx 






(UOA = Tx 
episode) 
Age, gender, mental health 
diagnosis, duration of 
treatment, use of concomitant 
diabetogenic medication, 
substance abuse/dependence, 
AP dose, Hx of excess weight, 
switching of AP in preceding 










01/94-12/98 Adults aged 18-64 who received an AP Rx. 
Exclude if: DM pre 01/1994; diagnosis of 
hyperglycemia but not DM; comorbid condition 
increasing likelihood of DM detection; <12 mo. 
recorded visits prior to 1st DM diagnosis. 
Controls matched 4:1 on age, gender, index date 
and general practice population. 
Cases defined as new 
diagnosis in medical 
record if confirmed 
by follow-up 
information consistent 





BMI, smoking status, 
alcoholism, HTN, Hx of MI, 
stroke, angina; number of past 
AP Rxs, multiple AP use, 
primary psychiatry diagnosis, 
current use of: corticosteroid, 






















06/87-09/00 Any patient with a Dx of, and drug treatment 
for SCZ. 
Control defined as: ICD-9 for SCZ but no Dx 
of, or Rx for DM at any time. 
AP use defined as: ≥ 1 AP Rx within 3mo. of 
index date 
Exclude if: < 3 mo. follow-up; if case had Rx 
for DM in 3 mo. pre-index date. 
 
Case defined as: ICD-
9 of 250.xx; or a new 
Rx for OHA / insulin 





Age, gender, index year, 
duration of follow-up, use of α 





Cohort UK General 
Practice Research 
database 
N/R Any patient treated with an AP compared to 






Age, gender, presence or 







01/95-09/00 Adults aged ≥18 diagnosed with SCZ (ICD-9 
295.x) on ≥ 2 occasions, treated with  ≥1 AP. 
Exclude if: exposure to both FGA and SGA; 
<6mo. continuous enrollment prior to index 
date for cases, prevalent DM; or not continually 
eligible during 12wks preceding DM Dx.  
Case: Developed DM subsequent to SCZ Dx. 
Control: SCZ patient without DM diagnosis at 




defined as: new ICD-
9 of 250.xx on 2 
different days; or a 






Age, ethnicity, use of 
concomitant diabetogenic 




Cohort Protocare Sciences 
claims database 
for a managed care 
organization 
09/97-12/99 Adults aged 18-65 treated with a FGA or SGA 
(include if ≥1 AP (concomitant or consecutive) 
after index date). 
Exclude if: <12mo continuous enrollment; of if 
Rx or ICD-9 for DM in 12mo. pre-index date or 
if ≥ 1AP on index date. 
New-onset DM 
defined as: a new Rx 
for OHA or insulin; 
or 2 ICD-9 of 250.xx 
on different days 






Age, squared age, gender, 
geographic region, mental 
health diagnosis, diagnosis of 














Cohort Department of 
Veterans Affairs 
database 
06/99-09/00 Schizophrenia patients on a stable regimen of 
AP for ≥3mo. 
Exclude if: OPD claim for DM; or <2 medical 
primary care visits in previous 6mo.  
New-onset DM 











Age, gender, race, income, co-
morbid mental health 
diagnoses, level of service use 





Cohort Iowa Medicaid 
database 
01/90-12/98 N/R New-onset DM 
defined as: a new Rx 
for OHA or insulin; 
















N/R Pts ≥ 65 yrs with Alzheimer’s disease or 
vascular dementia or combination of both. 
Exclude if: axis I D/O preceding dementia 
diagnosis; MMSE > 24; or DM at baseline (Dx 
of DM, Rx for DM. or casual blood glucose 
≥200mg/dL). 
New-onset DM 
defined as: clinical 
Dx for DM; Rx for 
OHA or insulin; 2x 
casual blood glucose 







Age, gender, nonwhite 
ethnicity, BMI, weight gain 
≥7% from baseline, Hx HTN, 









01/99-10/00 Any patient with mental health D/O (ICD-9: 
290.00-312.99 or 331.00-331.99 excluding 
305.1) with ≥ 30days for the same AP within a 
3 mo. period. 
Exclude if: inpatient or OPD claim for DM 




defined as: ICD-9 for 

























01/97-08/99 Patients <65 yrs with ≥ 1 SGA Rx. 
Exclude if: Rx for an AP in 180 days pre-index 
date; ≥ 2 SGA on index date; Rx for clozapine 
or quetiapine; or not eligible for plan for 180 
days pre-index date. 
New-onset DM 
defined as: Rx for 




Age, gender, FGA use in 180 
days preceding index date, 
type of beneficiary, number if 
physician visits per day of 









from 61 health 
plans in US) 
09/96-06/01 Schizophrenia patients (≥ 1 medical claim for 
schizophrenia) treated with ≥ 1 AP Rx. 
Exclude if: > 1 AP on enrollment; if < 3 mo. 
follow-up data; if AP in 6 mo. pre-enrollment; 
or Hx DM in 12 mo. pre-enrollment. 
New-onset DM 
defined as: ≥ 1 Rx for 
OHA or insulin; or ≥ 
2 ICD-9 of 250.xx 








Age, gender, health plan, 
region, calendar year of initial 
treatment, number of DM 
screening tests/lab test overall, 
other mental health Dx, other 






Cohort Advance PCS 
database (patients 
from 1171 health 
insurance plans) 
06/00-05/02 AP group: Patients with ≥ 1 Rx for an AP. 
Control group one ≥ 1 Rx for an antidepressant 
but no AP Rx; Control group two: ≥ 1 Rx for an 
antibiotic and no AP or antidepressant Rx. 
Exclude if: Rx for other psychotropic during 





defined as: ≥ 1 Rx for 
OHA or insulin after 









Cohort Italian Health 
Search Database 
01/96-03/02 Any patient treated with haloperidol, 
olanzapine, quetiapine, or risperidone 
monotherapy. 
Exclude if: use of an AP during period prior to 
study entry; or DM at baseline. 
 
New-onset DM 
defined as: a new Rx 




Age, gender, duration of 
observation, time to 
development of DM, number 














Cohort OPD community 
health center, 
Tennessee 
     -05/02 Random sample of patients visiting OPD 
between 02/01 and 05/02 and currently taking 
clozapine, olanzapine, quetiapine or 
risperidone. Index date assigned as date current 
Tx. commenced. 


















Assistance to the 
Aged Program; 
Medicare 
01/90-06/95 Patients aged > 20 years with psychiatric 
diagnosis (recorded in 6mo pre-index date) and 
with 6mo. continuous enrollment. 
Cases: Index date= date of first Rx for DM with 
no Rx and no diagnosis of DM in 6 mo. pre-
index date. 
Control: Index date frequency matched to 




Case defined as: Rx 




Age, gender, others added in 
forward stepwise selection 
procedure p<0.2: SES, 
medication use, mental health 
diagnosis, other diagnosis, 
hospital days, OPD services, 
nursing home days. 
Zhao 250 
2003 




10/96-12/98 Schizophrenia patients 18-64 years (≥1 
inpatient or ≥2 OPD diagnoses) with Rx for 
FGA or SGA and continuous enrollment for 12 
mo. pre- and 24 mo. Post. 
Exclude if: Rx for AP in 6 mo. pre-enrollment; 
or DM in 12 mo. pre-enrollment. 
 
New-onset DM 
defined as: Rx for 
OHA or insulin; or ≥ 
2 ICD-9 of 250.xx in 





Age, gender, regional 
differences, enrollment status, 
general health comorbidities 
(hyperlipidemia, HTN), other 
mental health Dx.) 
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Appendix B: Comparison of Database Studies Examining the Association between Antipsychotic Use and New-Onset Diabetes (continued) 
Author 
(Year) 
Ethnicity (%) Gender    
(% Male) 







White        69.9 
Black        24.5 
Hispanic    5.4 





Age range (years)       %: 
18-39                        5.6 
40-49                      20.0 
50-59                      35.0 
60-69                     10.6 
≥ 70                        28.8 
 
Schizophrenia          31.5 
Bipolar Disorder     34.4 
Depression              38.9 
Substance Abuse     43.4 
PTSD                       16.1 
Organic D/O            20.1 
Other                        61.4 









N/R No AP     37 
FGA        44 
SGA        38 
No AP 52 
FGA  64 
SGA  38 
% Age distribution: 
                    18-44  45-54  ≥65 
No AP          36.5    39.3    24.2 
FGA             20.8    26.0    53.2 
SGA             30.2    23.6   46.3 
Clozapine      6.8     25.3   37.9 
Olanzapine   36.6   28.7   34.7 
Quetiapine   35.8   28.1   36.0 
Risperidone  24.6   19.2   56.2 
N/R No AP                N/A 
FGA                  7(74) 
Haloperidol     68(70) 
SGA                 90(83) 
Clozapine       137(125) 
Olanzapine      89(85) 
Quetiapine      89(79) 











Compared to no AP 
FGA 
SGA 












General Population:         50(17) 
FGA:                                58(22) 
SGA:                                60(24) 
% Age distribution all pts: 
                         <45  45-64  ≥65 
General             42.6  35.3  33.0 
FGA                  32.5  24.9  42.6 
SGA                  35.3  15.5  49.1 
 
N/R FGA              184(304) 
All SGA        264(332) 
 
Olanzapine      266(304) 
Risperidone     244(331) 





Compared to FGA 
SGA 




Appendix B: Comparison of Database Studies Examining the Association between Antipsychotic Use and New-Onset Diabetes (continued) 
Author 
(Year) 
Ethnicity (%) Gender    
(% Male) 











% Age distribution all pts: 
                      <45  45-64  ≥65 
Olanzapine    57.3  25.0  17.8 
Risperidone   41.2  19.9  38.9 
% Age distribution SCZ pts: 
Olanzapine     66.0  26.2  7.9 
Risperidone    56.0  28.2 15.8 
 




White         71.1 
Non-White 28.9 
All    63.6 % Age distribution all pts: 
New-onset DM        44.4 (10.3) 
Uncertain glucose tolerance 
42.4 (11.4) 




Schizophrenia or related D/O Olanzapine      123 
Risperidone     169 
Clozapine        121 
Placebo             32 
Haloperidol       43 





White     32 
 
Cases    71 
Controls  61 
Cases            43.7 (12.8) 
Controls        43.3 (11.4) 
Schizophrenia or 
schizoaffective D/O 
Cases                 83 
Controls             83 
SGA Tx. 
Cases       121.0(60.9) 
Control     133.7(55) 
 















Appendix B: Comparison of Database Studies Examining the Association between Antipsychotic Use and New-Onset Diabetes (continued) 
Author 
(Year) 
Ethnicity (%) Gender    
(% Male) 







N/R SGA   34.2  
FGA   33.4 
SGA         84.2(7.2) 
FGA         84.7(7.1) 
N/R N/R 
Mean number of Rx 
SGA 6.9 (5.1) 
FGA 6.5 (5.1) 
N/R Compared to BZD 
FGA 
SGA 

















Olanzapine    42.9(12.0) 
Risperidone   42.414.5) 
FGA              42.6(14.9) 
 
                      SCZ  MDD DEM Other 
Olanzapine     35.2   17.1   6.2   24.9 
Risperidone    22.6   18.5   9.3   22.4 
FGA                 0.2     5.0    1.6    8.9 
 






N/R No AP 39.2 
FGA   43.1 










No Ap          72.1(8.3) 
FGA             78.4(9.1) 
SGA             79.2(8.8) 
Clozapine     75.2(7.2) 
Olanzapine   77.4(9.1) 
Quetiapine    76.9(8.5) 
Risperidone   80.4(8.8) 
N/R FGA      70.4(73.8) 
SGA       97.6(89.8) 


































100 All                   50(14) 
Olanzapine     49(12) 
Risperidone    50(14) 
Haloperidol    51(15) 
Fluphenazine  47(10) 
Schizophrenia            61 
BIP                            26 
Depression                47 
Dementia                    8 















Appendix B: Comparison of Database Studies Examining the Association between Antipsychotic Use and New-Onset Diabetes (continued) 
Author 
(Year) 
Ethnicity (%) Gender    
(% Male) 







N/R All untx 40.4 







HPFGA    
33.8 
LPFGA    
31.5 
All untx        43(14.8) 
All Tx          44(19.3) 
Clozapine    40(14.1) 
Olanzapine  43(16.9) 
Risperidone 43.0(20.7) 
HPFGA      47.0(18.7) 
LPFGA       46(20.5) 
                    SCZ  BIP MDD DEM Other 
All untx        10.4  52.1  34.3   6.8    5.8 
All Tx          17.2  21.5  38.8   6.4   16.2 
Olanzapine  22.4  24.8  37.8   2.1   12.8 
Risperidone 14.0  19.7  42.3   6.3   17.7 
HPFGA       16.6  20.1  36.9   8.6   17.7 
LPFGA        11.3  23.5  39.4  10.2  15.6 
Clozapine      57.1 19.0  14.3     0      9.5 
All Tx        204(141) 




HPFGA      210(153) 





Olanzapine   
3.6(2.0) 
HPFGA        
1.7(1.9) 
LPFGA    
1.7(2.7) 
Clozapine     
2.5(1.9) 













N/R All untx   36 
All Tx     41 






FGA    36 
 
All untx        39.5(14.3) 
All Tx         37.5(15.1) 
Olanzapine 37.1(14.5) 
Quetiapine  35.6(14.5) 
Risperidone 33.4(16.3) 
FGA            43(12.6) 
                       SCZ  BIP  MDD  Other 
All untx             1    16       76        7     
All Tx              14    35       38      13   
Olanzapine      11    37       39      13    
Quetiapine      10    37        43     10    
Risperidone    10     36       39      15 
FGA                18     32       36      14 
All Tx         297(294) 
Olanzapine 270(267) 
Quetiapine  225(189) 
Risperidone 
282(273) 
FGA            369(360) 








N/R All untx 38.9 





HPFGA 29.0    
LPFGA 26.8 
 
All untx         41.8(14.3) 
All Tx           42.4(15.3) 
Olanzapine   42.7(15.5) 
Risperidone    40(17.0) 
HPFGA       43.9(14.4) 
LPFGA       42.7(15.5) 
                               BIP  MDD   Manic 
All untx                  48.1    39.7    12.2    
All Tx                    30.6    64.5     4.9 
Olanzapine            34.9    60.4     4.7   
Risperidone           27.1    68.2     4.7 
FGA                      32.5    62.6     4.9 
All unTx    411(147) 




HPFGA     195(141) 





Olanzapine   
3.4(1.8) 
HPFGA        
1.6(1.6) 
LPFGA    
1.6(2.3) 







Appendix B: Comparison of Database Studies Examining the Association between Antipsychotic Use and New-Onset Diabetes (continued) 
Author 
(Year) 
Ethnicity (%) Gender    
(% Male) 







White       75.0 
Black        23.5 
Hispanic    1.5 
All untx 27.3 
FGA      41.4 
SGA      41.6 
All untx       40.0(18.2) 
FGA            50.4(15.7) 
Clozapine    46.2(13.5)  
Olanzapine  46.0(17.2) 
Quetiapine   41.8(16.8) 
Risperidone  44.2(19.4) 
Ziprasidone  38.2(15.0) 
 
                             SCZ  Manic     MDD 
All untx                  7.3      20.3      72.4    
FGA                      62.6     17.9      19.5 
Clozapine              85.8      10.1       4.1   
Olanzapine           48.9       27.1      24.0       
Quetiapine            38.6       31.7      29.9    
Risperidone          44.5      27.2      28.3 
Ziprasidone           51.5      28.8      19.8  
All unTx     408(242) 
FGA           555(492) 

































N/R All untx 34.1 
FGA      35.2 
SGA      41.0 
All untx        35.7(14.0) 
FGA             41.0(13.7) 
Olanzapine   36.1(15.0) 
Quetiapine    34.7(14.6) 
Risperidone   33.1(17.2) 
                                  SCZ  BIP    MDD 
All untx                      4.2   39.5    56.3    
FGA                          33.0   27.4    39.6 
Olanzapine               18.7   38.2    43.1        
Quetiapine                14.9   36.0    49.1    
Risperidone               16.3   33.2    50.5 
 
All unTx     321(219) 
FGA            243(207) 
Olanzapine 222(189) 






Olanzapine   
3.0 (3.8) 




FGA      
3.8(7.1) 








N/R All         41 Cases            51.4 N/R N/R N/R Past use (no AP in 12 mo. 
pre-index date) v. 
Recent use (AP in 6-12 
mo. pre-index date) v. 
Current use (AP in the 6 









Gender    
(% Male) 







N/R All ~ 37.5 % Age distribution all patients: 
              <20  20-44   45-64  ≥65 
Cases       0.4   16.4    42.4   40.8 
Controls   0.5   16.3    43.0   40.2 
 
Schizophrenia Mean F/U period 
5.2(3) years 
N/R Compared to no AP 
Olanzapine 
Risperidone 














White    54.9 
Black     17.1 
Hispanic  1.4 
Other       1.0 





Cases               45.3(13.7) 
Controls           45.3(13.3) 
 
Schizophrenia N/R Low/Med/High 



















N/R All         45.1 
SGA      42.4    





All                        45.1 
SGA                     42.4 
FGA                     46.3 
Olanzapine           42.2 
Risperidone          42.7 
                         SCZ    BIP    MDD 
All                    14.7    12.3     45.3  
SGA                 15.0    15.1     52.2    
FGA                 14.3     8.6      35.9 
Olanzapine       15.8    18.3     54.8 
Risperidone      14.4    12.7     49.9 
All               118.6 
SGA            126.1 
FGA            108.3 
Olanzapine  126.8 
Risperidone  123.9 














Gender    
(% Male) 











N/R Schizophrenia N/R 
 














FGA             42.9(17.1) 
Clozapine     37.4(12.1) 
Schizophrenia FGA           735(807) 
Clozapine   765(732) 
 











Olanzapine                82.1(6.4) 
Active Comparator   80.4(7.0) 











Compared to Olanzapine 
Active comparator 




N/R All      43 All                             40.4(16.8) 
 
Adjustment Disorder            12 
Anxiety                                 25 
Alzh/DEM                               8 
BIP                                        28 
Dysthymia                            36 
MDD                                     47 
Other Psychoses                    12 
PTSD                                       4 
Schizophrenia                        13 
Substance Abuse                     8 
 
Pts developing DM 
FGA                321 
Olanzapine      242 
Quetiapine       226 
Risperidone      247 
Pts NOT developing 
DM 
FGA                   251 
Olanzapine         235 
Quetiapine         170 
Risperidone        284 
 





















Gender    
(% Male) 







N/R 51.5-51.6 % Age distribution all patients: 
0-29 years:               20.4 
30-44 years:             43.8 
45-59 years:             29.9 









N/R FGA  48.6 
SGA  48.0 
FGA               42.4(11.7) 
SGA               38.0(12.4) 
Schizophrenia 
Comorbid Dx     SGA     FGA 
BIP                     43.6     31.3 
Depression         53.2     37.6 
FGA     485.0 (285.7) 
SGA     418.8 (247.2) 
N/R Compared to FGA 
SGA 






N/R FGA  52.0 
SGA  55.4 
FGA               57.0(21.2) 
SGA              42.3(27.5) 
N/R N/R N/R Compared to FGA 
SGA 
















Haloperidol       66.5(21.0) 
Olanzapine        52.6(20.4) 
Quetiapine        65.0(21.3) 















Compared to Risperidone 
Olanzapine 
Quetiapine 
Olanzapine v. Quetiapine 
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Gender    
(% Male) 











All patients   42.9(10.6) Schizophrenia spectrum D/O  54  






N/R Compared to Olanzapine 
Clozapine 
Risperidone 












Cases      
32.0 
Controls   
31.5 
Cases         63.6 (18.3) 
Controls     61.9 (17.5) 
                               Cases   Controls 
Psychotic                    40.3       39.7 
Affective                    29.1        27.4 
Anxiety                      12.8        14.0 
Other psychotic D/O  45.4        42.9  
N/R 
Range of use divided 

















N/R SGA   55.8 







SGA              44(11) 
FGA              45(11) 
Olanzapine   44(11) 
Risperidone  44(11) 
Schizophrenia 
Comorbid/Prior Dx       SGA  FGA 
BIP                                20.1   15.9 
Non-organic psychosis  56.1  47.0 
FGA           169(145) 





9.96           
(range 2.5-25) 
Risperidone 
3.39             
(range 0.5-12) 






Appendix B: Comparison of Database Studies Examining the Association between Antipsychotic Use and New-Onset Diabetes (continued) 
Author (Year) Incidence (N) /   
Treatment (N) 
Incidence per 1000 pt-yrs 
(95% CI) 
HR / RR (adjusted )/OR 
(adjusted) (95% CI) 
Conclusions Comments Affiliation 
Barner 
2003 
FGA             147/1,973 
Clozapine        2/21 
Olanzapine    59/994 
Quetiapine    15/216 
Risperidone   51/705 
Ziprasidone    1/7 
 
N/R N/R No difference in incidence of DM 
between FGA and SGA (7.5 v. 6.6%, 
p=0.2907). 
No difference in incidence between 
SGA (Chi-squared: 2.1784, p=0.7030). 
Covariates significantly 
related to the development 
of DM were age, minority 
race and preexisting 
hyperlipidemia. 







No AP        15.7(15.5-15.8) 
FGA             84(75-94) 
Haloperidol   85(70-100) 
SGA              67(62-72) 
Clozapine      67(16-188) 
Olanzapine    58(49-66) 
Quetiapine    39(27-51) 
Risperidone   79(71-87) 
No AP      15.7(15.5-15.8) 
FGA           84(75-94) 
Haloperidol   85(70-100) 
SGA            67(62-72) 
Clozapine     67(16-188) 
Olanzapine    58(49-66) 
Quetiapine     39(27-51) 
Risperidone    79(71-87) 
Compared to No AP 
FGA           3.5 (3.1 - 1.9)   
SGA           3.1 (2.9-3.4)  
Clozapine   3.3 (1.4-8.0)  
Olanzapine 3.0 (2.6-3.5) 
Quetiapine  1.7 (1.2-2.4) 
Risperidone 3.4 (3.1-3.8) 
Compared to Haloperidol: 
Clozapine   1.31 (0.60-2.86) 
Olanzapine 1.09 (0.86-1.37) 
Quetiapine  0.67 (0.47-0.97) 
Compared to risperidone: 
Olanzapine  0.90 (0.76-1.07) 
 
Increased risk of DM with FGA and 
SGA v. no AP Tx. 
Risk of DM comparable for FGA and 
SGA. 
Among SGA, only risperidone 
associated with increased risk of DM 
v. to haloperidol. 
No difference in risk of DM between 
olanzapine and risperidone. 
Dose response relationship (per 
quartile of observed dose) observed for 
thioridazine (HR: 2.6; 2.9; 2.9; 4.3) 
and possibly quetiapine (HR: 1.8; 1.4; 
0.6; 3.1). 
Mean Tx doses low but 
wide range of doses used. 
Across all agents older 
patients prescribed lower 
doses (consistent across all 
quartiles). 
Increasing age associated 
with significant increase in 






No AP                              
33,536/1,291,548 
FGA             230/59,089 
SGA              64 /9,053 
Olanzapine    17/2,374 
Risperidone   37 /5,213 
 
 
No AP       3.31(3.27-3.35) 
FGA           7.7(6.7-8.7) 
SGA           9.8(7.4-12.2) 
Olanzapine  9.8(5.1-14.5) 
Risperidone 10.6(7.4-12.2) 
Compared to no AP: 
FGA             1.9 (1.6 – 2.3) 
SGA             2.9 (2.0-4.4) 
Olanzapine   3.9 (1.8-8.1) 
Risperidone  2.5 (1.4-4.5) 
Compared to FGA  
SGA               1.6 (1.0-2.5) 
Compared to Risperidone 
Olanzapine     1.5 (0.6-3.9) 
Increased risk of DM with FGA, any 
SGA, olanzapine or risperidone v. no 
AP Tx. 
Increased risk of DM with SGA v. 
FGA. 
 No difference in risk of DM between 
olanzapine and risperidone. 
 
Obesity and increasing age 
associated with significant 
increase in risk of DM. 
Study controlled for 




Appendix B: Comparison of Database Studies Examining the Association between Antipsychotic Use and New-Onset Diabetes (continued) 
Author (Year) Incidence (N) /   
Treatment (N) 
Incidence per 1000 pt-yrs 
(95% CI) 
HR / RR (adjusted )/OR 
(adjusted) (95% CI) 
Conclusions Comments Affiliation 
Caro 
2003 
Olanzapine  319 /19,153 
Risperidone 217 /14,793 
Olanzapine          17 
Risperidone         16 
Compared to risperidone: 
Olanzapine 1.2 (1.00-1.43) 
Stratifying by Drug 
Exposure Time Risk 
compared to risperidone: 
<3 mo.     1.90 (1.40-2.57) 
3<6 mo.   1.16 (0.75-1.78) 
6<12 mo. 1.11 (0.81-1.510 
≥12mo.     1.06 (0.86-1.31) 
Increased risk of DM with olanzapine 
v. risperidone. 
Relative risk decreased with increasing 
drug exposure time, with greatest risk 
noted for drug exposure time <3mo. 
Increased risk of DM for female 
olanzapine pts. v. female risperidone 
pts (HR 1.30(1.05-1.65)). 
Dx of schizophrenia not a significant 
predictor of DM. 
 
> 1 Rx dispensed to 89.5% 
of olanzapine pts and to 
82.9% of risperidone pts. 
Olanzapine pts. younger, 
more frequently male, 
more likely to have a Dx 
of schizophrenia (62% v 
39%) and to be co-
prescribed haloperidol 





Placebo            3/206 
Haloperidol     9/1,164 
Clozapine        33/211 
Olanzapine     71/3,068 
Risperidone     5/3646 
N/R Compared to olanzapine: 
Pooled group (haloperidol/, 
placebo, risperidone)  
1.46 (0.83-2.57) 
No difference in risk of DM between 
olanzapine and a pooled cohort of 
patients receiving haloperidol, 
risperidone or placebo. 
 
Short term studies – 
median exposure duration 
< 6mo. 
Significant increase in risk 
of DM with: elevated 
blood glucose at baseline; 
presence of multiple risk 







                 Cases Controls 
FGA             17    250  
Clozapine     24    171 
Olanzapine   43    402 
Quetiapine    24    112 
Risperidone   31    305 
>1 SGA         42    208 
N/R Compared to FGA: 
Clozapine  2.06(1.07-3.99) 
Olanzapine 1.57(0.87- 2.82) 
Quetiapine  3.09(1.59-6.03) 
Risperidone 1.50(0.81-2.79) 
>1 SGA       2.86(1.57-5.2)   
Increased risk of DM with clozapine, 
quetiapine or >1 SGA compared to an 
FGA alone. 
 
Patients not limited to 
monotherapy – could 
receive concurrent FGA 
with SGA. 
Increased monitoring 
frequency observed for 









 Total      719 /12,235  N/R Compared to FGA: 
Clozapine   1.48(0.65-3.37) 
Olanzapine  1.27(1.04-1.56) 
Quetiapine   3.34 (2.51-4.45) 
Risperidone 1.49(1.22-1.81) 
Increased risk of DM with olanzapine, 
quetiapine and risperidone v. FGA. 
 
Conducted case-control 
study also with 4:1 
matching by age, sex, year 






Appendix B: Comparison of Database Studies Examining the Association between Antipsychotic Use and New-Onset Diabetes (continued) 
Author (Year) Incidence (N) /   
Treatment (N) 
Incidence per 1000 
pt-yrs (95% CI) 
HR / RR (adjusted )/OR 
(adjusted) (95% CI) 
Conclusions Comments Affiliation 
Etminan 
2003 
SGA                3,250 
FGA                1,888 
BZD                5,326 
Olanzapine    13/615 
Quetiapine      1/101 
Risperidone   48/2,274 
SGA         31 
FGA         47 
BZD         40 
Corticosteroid 190 
Compared to BZD: 
SGA         0.89(0.66-1.21) 
FGA         1.27(1.41-3.12) 
Compared to Risperidone (unadj.): 
Olanzapine  1.00 
Quetiapine  0.68 
No increase in risk of DM with 
SGA or FGA compared to BZD. 
Comparable risks of DM for 
olanzapine, risperidone and 
quetiapine. 
Older population with expected 
under-representation of 
schizophrenic pts. 
Covariates associated with an 
increased risk of DM were: 
increasing age; antiepileptic Rx; 







Olanzapine      35/438 
Risperidone    17/482 
FGA               
70/2,195 
 Compared to FGA: 
Olanzapine  1.9(1.1-1.3) 
Risperidone   0.7(0.4-1.4) 
Increased risk of DM with 
olanzapine but not risperidone v. 
FGA even after controlling for 
weight gain. 
DM not related to weight gain 
but significant risk of DM with 
baseline obesity. 
Used ITT approach. 
Schizophrenia, dementia and 
drug/alcohol use not related to 
DM risk. 





FGA            238 
/11,546 
SGA            
515/19,407 
Clozapine      5/117 
Olanzapine 142/5,382 




N/R Compared to no AP 
FGA               3.6(3.1-4.1) 
SGA               3.5(3.2-3.8) 
Clozapine       3.1(1.0-9.5) 
Olanzapine    3.6(3.0-4.2) 
Quetiapine     1.9(1.3-2.9) 
Risperidone    3.7(3.3-4.2) 
Compared to FGA* or Haloperidol: 
SGA*                1.1(0.9-1.3) 
Clozapine         1.4(0.6-3.5) 
Olanzapine       1.2(0.9-1.5) 
Quetiapine        0.7(1.5-1.1) 
Risperidone      1.2(1.1-1.6) 
Compared to haloperidol risk of 
DM increased with risperidone 
among all patients, and those 
aged ≥75 years; and with 
quetiapine in patients aged 60-74 
years only.  
Risk of DM increased for each 
AP v. no AP. 
Short Tx. Duration (2.5-3 mo.). 





Total             386 
/5,837 
Olanzapine        3,056 
Risperidone       2,493 
Haloperidol      1,790 
Fluphenazine       428 
N/R Compared to Risperidone: 
Olanzapine         1.37(1.06-1.76) 
Haloperidol        0.89(0.67-1.17) 
Fluphenazine      1.11(0.68-1.79) 
Increased risk of DM with 
olanzapine v. risperidone. 
Median time to development of 
DM: 11mo. (1 day-52mo). 
Controlled for drug switching 
patterns: % receiving agent as 
initial Tx:                   
Risperidone                 73.7          
Olanzapine                  70.3            
Haloperidol                 86               




Appendix B: Comparison of Database Studies Examining the Association between Antipsychotic Use and New-Onset Diabetes (continued) 
Author 
(Year) 
Incidence (N) /   
Treatment (N) 
Incidence /1000 
pt-yrs (95% CI) 
HR / RR (adjusted )/OR (adjusted) 
(95% CI) 
Conclusions Comments Affiliation 
Gianfrancesco 
2002 
*At 12 mo. observation  
All unTx     34 /3,061 
All Tx         67 /4,334 
Olanzapine   25 /1,047 
Risperidone   10 /1,368 
HPFGA         20 /1,376 
LPFGA           9 /486 
Clozapine         3 /63 
 
N/R Compared to unTx at 12 mo.: 
Olanzapine   3.10(1.62-5.93) 
Risperidone  0.88(0.37-2.07) 
HPFGA        2.13(1.10-4.13) 
LPFGA        3.46(1.52-7.78) 
Clozapine     7.44(1.60-34.75) 
Compared to risperidone at 12mo.: 
Olanzapine   3.53 
Clozapine    8.45  
Increased risk of DM with 
olanzapine and clozapine, but 
not risperidone v. unTx pts. 
Increased risk of DM with 
clozapine and olanzapine v. 
risperidone. 
Dose-response for olanzapine 
(2.6mg increase in olanzapine 
≡ increased OR of DM of 
1.22) but not for risperidone 
or clozapine. 
Two logistic regression models 
developed based on dose and Tx. 
duration. Data subsequently 
extrapolated to 12 mo. duration. 
Covariates significantly 
associated with increased risk of 
DM were: increasing age and 
use of non AP psychotropics. 
Type of psychosis was not 





*At 12 mo. Observation 
All unTx        87 /10,296 
All Tx            30 /6,582 
Olanzapine    15 /2,703 
Quetiapine       3 /922 
Risperidone     5 /2,860 
FGA                7 /2,756 
 
N/R Compared to unTx at 12 mo*: 
Olanzapine 1.43 (1.05-1.96) 
Quetiapine  0.976 (0.42-2.27) 
Risperidone 0.660 (0.31-1.41) 
FGA             1.05 (0.67-1.61) 
Increased risk of DM for 
patients treated with 
olanzapine but not 
risperidone, quetiapine or 
FGA v. unTx. Pts. 
30% of patients had > 1 Tx 
episode with the same or 
different AP. 
Overlap of Tx episodes occurred 
in 27% of observations 
Covariates significantly 
associated with increased odds 
of DM were: age; β blocker Rx; 
and Tx duration. Dx of BIP or 
MDD were associated with a 






Total           66 /5,723 
All unTx        2,644 
All Tx            2,592 
Olanzapine       656 
Risperidone      849 
HPFGA            785 
LPFGA             302 
N/R Compared to unTx at 12 mo.: 
Olanzapine  4.289 (2.10-8.83) 
Risperidone 1.02 (0.35-3.01) 
HPFGA       1.94 (0.79-4.79) 
LPFGA        4.97 (1.97-12.61) 
Compared to risperidone at 12mo.: 
Olanzapine         4.19** 
HPFGA              1.90 
LPFGA               4.85** 
Increased odds of DM with 
olanzapine and LPFGA v. 
unTx patients. 
Increased odds of DM with 
olanzapine and LPFGA v. 
risperidone. 
Dose response relationship 
seen with olanzapine 2.6mg 
increase in olanzapine ≡ 
increased OR of DM of 1.31) 
but not risperidone or FGA. 
15% of patients had >1 Tx 
episode with overlapping Tx. 
episodes in 20% of observations. 
Concurrent AP use documented 
as follows: risperidone 17.1%; 
olanzapine 18.9%; HPFGA 
15.0% and LPFGA 19.5%. 
Covariates significantly 
associated with an increased 
odds or DM were: age; 







Appendix B: Comparison of Database Studies Examining the Association between Antipsychotic Use and New-Onset Diabetes (continued) 
Author 
(Year) 
Incidence (N) /   
Treatment (N) 
Incidence /1000 
pt-yrs (95% CI) 
HR / RR (adjusted )/OR (adjusted) 
(95% CI) 
Conclusions Comments Affiliation 
Gianfrancesco 
2006 
>8- ≤12 mo. observation 
All unTx         190/8,589 
FGA                  61/890 
Clozapine            4/48     
Olanzapine       92/1,567 
Quetiapine        38/965 
Risperidone      80/1,632 
Ziprasidone       4/112 
 
N/R Compared to unTx –Design 2 
FGA            0.885(0.785-0.997) 
Clozapine    1.272(1.024-1.579) 
Olanzapine  1.001(0.894-1.120) 
Risperidone  0.920(0.824-1.028) 
Ziprasidone  0.673(0.438- 1.036) 
Compared to unTx –Design 3: 
FGA               1.484(1.138-1.934) 
Clozapine       1.124(0.983-1.284) 
Olanzapine     1.149(1.001-1.319) 
Risperidone    1.124 (0.983-1.248) 
Ziprasidone    0.717 (0.415- 1.239) 
 
Increased odds of DM with 
clozapine and decreased risk 
with FGA v. unTx patients 
using Design 2 (ICD-9 or Rx. 
for DM). 
Increased odds of DM with 
olanzapine and clozapine v. 
unTx patients using Design 3 
(Rx. for DM only).  
Increased odds of DM with 
medium or high dose AP v. 
no Tx or low dose AP (10-
25%). 
Lower risk of DM with SCZ 
or BIP v. MDD.(15-20%). 
Study examined for selection 
bias-authors conclude that after 
01/01 risperidone more likely 
and olanzapine less likely to be 
prescribed to patients at risk of 
DM. 
Covariates significantly 
associated with increased odds 
of DM were: increasing age; 
non-white race, baseline excess 
weight, statin use, substance use, 







Frequency (%) of DM 
adjusted for duration 
All unTx              0.98  
FGA                    3.38  
Olanzapine          2.67 
Quetiapine          1.05 
Risperidone        1.33 
 
N/R Compared to unTx. (Model 2): 
FGA              1.755(1.381-2.221) 
Olanzapine    1.858(1.549-2.238) 
Quetiapine    1.087(0.742-1.612) 
Risperidone    1.224(0.962-1.562) 
 
Increased odds of DM with 
olanzapine and FGA (but not 
quetiapine or risperidone) v. 
unTx patients. 
Increased odds of DM with 
high dose risperidone, 
medium and high dose 
olanzapine and all doses of 
FGA v. unTx patients. 
Covariates significantly 
associate with increased odds of 
DM: age, excess weight at 
baseline, use of beta-blockers. 
Increased odds of DM with SCZ 





Total                  73,428 
Cases                     424 
Controls               1,522 
Past AP (Cases)     238 
Recent AP (Cases)   26 
Current AP 
SGA (cases)              8  
FGA(cases)           152 
N/R Compared to Past exposure (none in 
12mo.): 
Current SGA             4.7 (1.5-4.9) 
Current FGA             1.7 (1.2 to 2.3) 
Recent FGA              1.0 (0.6-1.6) 
Increased odds of DM with 
current, but not recent use of 
SGA or FGA v. no AP Tx. 
Very small N for SGA (N=8 
Case; N=8 Control). 
No mental health diagnosis 
independently associated with 
increased odds of DM. 
Covariates significantly 
associate with increased odds of 
DM: increasing BMI; Hx of 
HTN and Hx of previous MI. 







Appendix B: Comparison of Database Studies Examining the Association between Antipsychotic Use and New-Onset Diabetes (continued) 
Author 
(Year) 
Incidence (N) /   
Treatment (N) 
Incidence /1000 pt-
yrs (95% CI) 
HR / RR (adjusted )/OR 
(adjusted) (95% CI) 
Conclusions Comments Affiliation 
Koro 
2002 
Total                       19,637 
DM:    Cases              451 
        Controls           2,696 
≥ 1 Rx (DM Cases): 
FGA non depot 235/17,320 
FGA depot          48/4,421 
Olanzapine            9/970 
Risperidone         15/1,683 
Other SGA           1/578 
All treated pts    4.4 
Women              5.3 
Men                   3.5 
Within 3mo. Of Rx: 
Olanzapine   
10.0(5.2-19.2) 
Risperidone   
5.4(3.0-9.8) 
FGA               
5.1(4.5-5.8) 
Compared to no Tx at 3mo.: 
FGA                1.4 (1.1-1.7) 
Olanzapine     5.8 (2.0-16.7) 
Risperidone    2.2 (0.9-5.2) 
Other SGA     1.6 (0.2-17.1) 
Compared to FGA at 3mo.: 
Olanzapine     4.2 (1.5-12.2) 
Risperidone     1.6 (0.7-3.8) 
Other SGA      1.2 (0.1-12.4) 
Increased odds of DM within 3mo. of 
index date for patients with SCZ 
taking olanzapine or FGA v. unTx pts. 
Increased odds of DM for patients 
taking non-depot FGA or olanzapine 
v. all other Tx pts. 
Increased odds of DM with olanzapine 
but not risperidone within 3mo. of 
index date v. FGA. 
 
New SGA included: amisulpiride; 
remoxipride; sertindole. 
Pts may have taken > 1 AP in study 
period. 
Very small N when limited to pts 
Tx with monoTx AP within 3 mo. 






General              266,272 
FGA                    43,561 
SGA                     2,550 
Olanzapine             535 
Risperidone         1,811 
N/R Compared to general population: 
FGA                1.3 (1.003-1.8) 
SGA                3.3 (1.7-6.5) 
Compared to FGA:  
SGA                2.6 (1.3-5.3) 
 
Increased risk of DM with FGA and 
SGA v. general population. 
Increased risk of DM with SGA v. 
FGA. 





Cases                 3,663 
 
N/R Compared to FGA: 
Clozapine       1.3(1.2-1.5) 
Olanzapine    1.4 (1.2-1.5) 
Quetiapine     1.9(0.9-4.1) 
Risperidone   1.0(0.9-1.2) 
>1 SGA         1.6(1.3-1.9) 
Using 12, 24 or 52-week exposure 
windows, odds of DM increased with 
olanzapine, clozapine or combination 
SGA v. FGA. 
Possible dose-response relationship 
with olanzapine using 52-week 
exposure window.  
 
Did not use an AP wash-out period.  
Small Tx. numbers for quetiapine. 
Dose-strata based on empirical 
distribution and clinical judgment. 
Black or Unknown race, and use of 
certain concomitant diabetogenic 
medications associated with 






Total N within 12mo.: 
Total                71 /2,315 
FGA                 31 /981 
SGA                 40 /1,334 
Olanzapine       13 /513 
Risperidone      25 /750 
 
N/R Compared to FGA: 
SGA            1.01 (0.612-1.668) 
Olanzapine  0.864 (0.431-1.732) 
Risperidone 1.074 (0.612-1.885) 
Compared to Risperidone: 
Olanzapine   0.786 (0.384-1.610) 
No difference in odds of DM between 
SGA, olanzapine or risperidone v. 
FGA. 
No difference in odds of DM between 
olanzapine and risperidone. 
 
Did not control for dual-AP Tx or 
consecutive AP after the index drug 
(ITT methodology); however >75% 
pts exposed to only the index AP. 
Tx duration, Hx of HTN and Hx of 
CVD associated with increased risk 
of DM; decreased risk of DM with 






Appendix B: Comparison of Database Studies Examining the Association between Antipsychotic Use and New-Onset Diabetes (continued) 
Author 
(Year) 
Incidence (N) /   
Treatment (N) 
Incidence /1000 pt-
yrs (95% CI) 
HR / RR (adjusted )/OR 
(adjusted) (95% CI) 
Conclusions Comments Affiliation 
Leslie 
2004 
Total  4,132/56,849 All     4.4 Compared to FGA: 
Clozapine     1.57(1.31-1.89) 
Olanzapine    1.15(1.07-1.24) 
Quetiapine    1.20(0.99-1.44) 
Risperidone    1.01(0.93-1.10) 
  
Increased risk of DM with clozapine 
and olanzapine v. FGA. 
Increased risk of DKA with clozapine 
and olanzapine v. FGA in entire 
sample, but no difference in risk when 
sample limited to DM patients. 
ITT approach: patients followed for 
up to 25 mo. with risk assessment 
based on AP Rx in first stable 3mo. 
period. AP switch rate 17% overall 
and similar across agents. 
Increased risk of DM with 
clozapine and olanzapine apparent 














Total                      2,827 
FGA                 78 /2,296 
Clozapine          21 /531 
N/R Compared to FGA: 
Clozapine      1.16 
Compared to FGA (20-34 yr): 
Clozapine     2.5 (1.2-5.4) 
 Similar incidence of DM, HTN and 
hyperlipidemia for clozapine and 
FGA. 
Increased risk of DM and 
hyperlipidemia (but not HTN) in 
patients aged 20-34 years Tx with 
clozapine v. FGA. 
Using similar time periods, 
incidence of DM in patients aged 










All                  29/1,398 
Olanzapine     19 /835 
Risperidone/FGA         
                        4 /223 
Placebo          6 /340 
 
N/R Compared to olanzapine: 
Risperidone/FGA   p=0.76 
Placebo                   p=0.82  
No difference in risk of DM in elderly 
dementia patients between olanzapine, 
an active comparator 
(risperidone/FGA) or placebo. 
Olanzapine associated with increase in 
uncertain glucose tolerance v. placebo 
(p=0.008). 
Study also examined ‘uncertain 
glucose tolerance.’ 
Elevated casual glucose 
(≥140mg/dL) the only significant 




All                  339/7,381 
FGA              145 /1,981 
Clozapine          7 /84 
Olanzapine      93 /1,986 
Quetiapine      24 /775 
Risperidone     70 /2,555 
N/R Compared to FGA: 
Clozapine   1.222(0.563-2.652) 
Quetiapine   0.740(0.726-1.236) 
Risperidone  0.690(0.514-0.925) 
 
Decrease in risk of DM with 
risperidone v. FGA.  
No difference in risk of DM between 
other SGA v. FGA. 
Stratifying by gender, decrease in risk 
of DM for men Tx. with quetiapine or 
risperidone only v. FGA. 
Annual incidence DM: 4.7%. 
ITT approach – risk based on AP 
used during first ID stable period. 
Pt could subsequently switch Tx; 
(rate 13.3%) or use dual-Tx. 
Increased risk of DM with 
diagnosis of SCZ; BIP or PTSD. 
Risk decreased for other psychoses. 
Increased risk of DM with increase 











Appendix B: Comparison of Database Studies Examining the Association between Antipsychotic Use and New-Onset Diabetes (continued) 
Author 
(Year) 
Incidence (N) /   
Treatment (N) 
Incidence /1000 pt-
yrs (95% CI) 
HR / RR (adjusted )/OR 
(adjusted) (95% CI) 
Conclusions Comments Affiliation 
Mosian 
2005 
   ( x10 -5/days)   
Olanzapine       4.45 
Risperidone      3.14 
 
N/R Compared to risperidone: 
Olanzapine  1.33(1.03-1.73) 
 
Increase in risk of DM with 
olanzapine v. risperidone.  
 
Also examined risk of new-onset 
dyslipidemia and combined risk of 
new-onset dyslipidemia and DM – 
significant increase in risk in both 







FGA              17 /617 
SGA              45 /1,826 
Clozapine        2 /35 
Olanzapine    23 /937 
Quetiapine      4 /164 
Risperidone    16 /690 
N/R Compared to FGA: 
SGA              1.172(1.061-1.30) 
Compared to olanzapine: 
Clozapine      1.467(0.930-1.168) 
Quetiapine    1.170(0.967-1.372) 
Risperidone   1.049(0.930-1.168) 
 
Increase in risk of DM with SGA v. 
FGA. 
No difference in risk of DM between 
different SGA. 
Significant positive association 
between year of commencing AP 
and odds of DM (possibly related 





FGA             52/4,607 
SGA             77/10,265 
Clozapine       1/127 
Olanzapine    31/3,190 
Quetiapine    6/1,111 
Risperidone   29/4,859 
Ziprasidone      1/69  
FGA            11.3 
SGA             7.5 
Clozapine     7.9 
Olanzapine   9.4 
Quetiapine   5.4 
Risperidone  6.0 
Ziprasidone  6.0 
Compared to FGA: 
SGA                0.86(0.60-1.23)) 
Compared to risperidone: 
Clozapine        1.13(0.15-8.37) 
Olanzapine     1.34(0.83-2.15) 
Quetiapine      0.66(0.28-1.57) 
Ziprasidone    2.64(0.35-19.90) 
 
No difference in risk of DM between 
FGA and SGA. 
No difference in risk of DM between 
clozapine, olanzapine, quetiapine or 
ziprasidone v. risperidone. 
  
Small treatment numbers of 
clozapine and ziprasidone. 
Increasing age, male gender and 
Chronic Disease Score associated 




All unTx          8 /6,026 
Haloperidol    33 /2,071 
Olanzapine      4 /226 
Quetiapine       3 /109 
Risperidone      9 /567 
All unTx        1.5 
Haloperidol    19.6 
Olanzapine     22.8 
Quetiapine     52.7 
Risperidone    24.9 
Compared to unTx: 
Haloperidol   12.40(6.27-24.52) 
Olanzapine    20.35(6.86-60.33) 
Quetiapine    33.68(9.18-123.55) 
Risperidone  18.71(8.18-42.81) 
Between AP 
No significant comparison 
between any pair of individual 
AP agents. 
Increased odds of DM with 
haloperidol, olanzapine, quetiapine or 
risperidone v. untreated patients. 
No difference in risk of DM between 
haloperidol and any SGA, or between 
SGA. 
Lack of balance in group sizes. 
Followed patients for a maximum 









Appendix B: Comparison of Database Studies Examining the Association between Antipsychotic Use and New-Onset Diabetes (continued) 
Author 
(Year) 
Incidence (N) /   
Treatment (N) 
Incidence /1000 pt-
yrs (95% CI) 
HR / RR (adjusted )/OR 
(adjusted) (95% CI) 
Conclusions Comments Affiliation 
Sumiyoshi 
2004 
Total              14/116 
Clozapine         5/23 
Olanzapine      5/55 
Quetiapine      0/15 
Risperidone    4/23 
N/R Compared to olanzapine: 
Clozapine     0.836 (0.467-1.495) 
Risperidone  0.759 (0.346-1.668) 
Compared to clozapine: 
Risperidone  0.898 (0.135-5.994) 
 
No difference in odds of DM between 
clozapine, olanzapine and risperidone. 
No difference in time to onset of DM 
between clozapine, olanzapine and 
risperidone. 
Small study – total 116 patients. 










             Cases Controls 
All            7,227  6,780 
Clozapine      94     115 
Other AP  2,414  2,400 
N/A Compared to no AP: 
Clozapine       0.78(0.59-1.02) 
Non-clozapine AP           
0.92(0.86-0.98) 
Compared to no AP by dose 
quartile: 
17-225mg      1.67 (0.75-3.76) 
226-452mg    2.03 (0.91-4.55) 
453-572mg    0.71 (0.31-1.63) 
573-1618mg  0.85 (0.38-1.91) 
No increase in risk of DM with 
clozapine compared to no AP. 
No association between increased 
dose or duration of clozapine and odds 
of DM. 
Poor statistical power to detect an 





Overall                815 
FGA                5 /353 
SGA             13 /462 
Olanzapine    4 /258 
Risperidone    8 /187 
N/R Compared to FGA: 
SGA             2.353 (0.802-6.896) 
Olanzapine   1.059 (0.261-4.302) 
Risperidone  4.061 (1.230-13.40) 
Compared to Risperidone: 
Olanzapine   0.267 (0.072-0.988) 
Increased odds of DM with olanzapine 
v. risperidone. 
Increased odds of DM with 
risperidone, but not olanzapine or 
SGA (as a group) v. FGA. 
Covariates associated with an 






Appendix B: Comparison of Database Studies Examining the Association between Antipsychotic Use and New-Onset Diabetes (continued) 
Abbreviations:   
Adj D/O - Adjustment disorder ID - Identify Rx - Prescription 
Alzh - Alzheimer’s Disease ITT - Intention-to-treat RR - Relative risk 
AP - Antipsychotic ICD-9 - International classification of disease,9th 
edition 
SCZ - Schizophrenia 
BIP - Bipolar disorder LPFGA - Low potency first-generation antipsychotic SGA - Second-generation antipsychotic 
CVD - Cardiovascular disease MDD - Major depressive disorder SES - Socio-economic status 
DEM - Dementia Mo. - Month SD - Standard deviation 
DM - Diabetes Mellitus MI - Myocardial infarction Tx - Treatment 
D/O – Disorder N/R - Not recorded T2DM - Type 2 diabetes mellitus 
Dx - Diagnosis OBS - Organic brain syndrome UK - United Kingdom 
FGA - First-generation antipsychotic OHA - Oral hypoglycemic agent Unadj -Unadjusted  
HPFGA - High potency first-generation antipsychotic OPD - Out-patient department Untx - Untreated 
HR - Hazard ratio OR - Odds ratio UOA - Unit of Analysis 
HTN - Hypertension Pts - Patients VA - Veterans affairs 
Hx - History PTSD - Post traumatic stress disorder Yrs - Years 
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Appendix C: Detailed Description of Study Variables 




Diagnosis of diabetes based on one of the following occurring during 
the patient follow-up period: 
 Medical claim with ICD-9 for diabetes (ICD-9: 250.00-250.99) 
 Treatment with an antidiabetic medication 
Categorical variable 
0 = No diabetes 
1 = Diabetes 
Recorded as percentage of 




New diagnosis of diabetes based on one of the following occurring 
at least seven days subsequent to the index date, with no history of 
diabetes in the 180 days preceding the index date: 
 Medical claim with ICD-9 for diabetes (ICD-9: 250.00-250.99) 
 Treatment with an antidiabetic medication 
 
Categorical variable 
0 = No diabetes 
1 = Diabetes 
Any case occurring less than 
30 days subsequent to 
treatment discontinuation was 
considered an incident case 
Recorded as percentage of 




Adherence defined as mean Medication Possession Ratio (MPR) Continuous variable 
 
Excluded if patient did not 





Persistence defined as the sum of the number of persistent days  
Persistent days defined as the number of continuous days therapy, 
that is, refill within (number of days supplied x 1.5) 
Continuous variable Excluded if patient did not 
have at least one prescription 
refill 
Time to occurrence 
of diabetes 
Length of time in days between the date of the index antipsychotic 
prescription and the date of first diagnosis of diabetes 
Continuous variable 
 
Excluded if occurred within 
seven days of the index date 
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Appendix C: Detailed Description of Study Variables (continued) 
Variable Definitions Categories Comments 
INDEPENDENT VARIABLES 
Demographic variables 
Age Participant’s age in years at the index date Continuous variable  
Gender  Categorical variable 
0 = Female 
1 = Male 
 
Race / Ethnicity  Categorical variable 
1 = White 
2 = African American 
3 = Hispanic 
4 = Native American  
5 = Asian American 
6 = ‘Other’ 
 
Clinical variables  
Hypertension Diagnosis of hypertension based on a medical claim with ICD-9 for 
hypertension (ICD-9: 401.x-405.x)  
Categorical variable 
0 = No hypertension 
1 = Hypertension 
 
Dyslipidemia Diagnosis of dyslipidemia based on a medical claim with ICD-9 for 
dyslipidemia (ICD-9: 272.0-272.4). 
Categorical variable 
0 = No dyslipidemia 





Appendix C: Detailed Description of Study Variables (continued) 
Variable Definitions Categories Comments 
Clinical variables continued 
Primary Mental 
Disorder Diagnosis 
Diagnoses classified based on ICD-9 codes assigned for medical 
claims and then categorized according to the following rules. If 
patient had a diagnosis of: 
Schizophrenia or bipolar disorder then this considered the primary 
diagnosis 
Both schizophrenia and bipolar disorder then patient classified 
according to the modal diagnosis. If both diagnoses occurred with 
equal frequency then the diagnosis closest to the study endpoint used 
as the primary diagnosis. 
Both ‘other psychotic disorder’ and ‘other non-psychotic disorder’ 
then ‘other psychotic disorder’ considered the primary diagnosis. 
Both ‘other psychotic disorder’ and dementia then ‘other psychotic 
disorder’ considered to be the primary diagnosis. 
Both dementia and ‘other non-psychotic disorder’ then dementia 
considered the primary diagnosis. 
Categorical variable 
0 = Schizophrenia 
1 = Bipolar disorder 
2 = Other psychotic 
disorder 
3 = Dementia 










Index prescription classified as first-generation or second-generation 
antipsychotic 
Index prescription defined as first antipsychotic prescription with no 
prescription for an antipsychotic in the preceding 180 days 
 
Categorical variable 
0 = First-generation 
agent 
1 = Second-generation 
agent 
Excluded if: 





Index prescription classified according to the specific second-
generation antipsychotic 
Categorical variables  
1 = Clozapine 
2 = Olanzapine 
3 = Quetiapine 
4 = Risperidone 
5 = Ziprasidone 
Excluded if: 
Received more than one 
antipsychotic 
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Appendix C: Detailed Description of Study Variables (continued) 
Variable Definitions Categories Comments 
Medications continued 
Mean daily dose 
(MDD) 
Daily dose inferred from the product of the quantity and strength of 
the drug dispensed divided by the number of days supplied 
Continuous variable Included only if: 
 MDD (mg): 
12.5 ≤ Clozapine < 1600 
1.25 ≤ Olanzapine < 80 
12.5 ≤ Quetiapine < 2400 
0.125 ≤ Risperidone < 16 




Length of time (days) between the index date and a study endpoint. 
Endpoint defined as occurrence of any of the following: 
 Date of development of new-onset diabetes 
 Date of switching of antipsychotic therapy 
 Date of addition of a second antipsychotic agent 
 Date of discontinuation of therapy where discontinuation of 
therapy defined as no refill of therapy within (days supply x 1.5) of 
the last refill date 




Treatment with an agent known to increase the risk of diabetes 
defined as a redeemed prescription for : β-adrenergic blockers; 
glucocorticoids; oral contraceptive pills containing norgesterol; 
phenytoin; thiazide diuretics and valproic acid 
Categorical variable: 
0 = No concomitant 
diabetogenic therapy 
1 = Concomitant 
diabetogenic therapy 
Included only if treatment 
occurred during the interval 





Appendix D: List of Variables from the Texas Medicaid Database 
File Name Data Fields 
Eligibility ID Gender Race Start End   







Start End Primary 
Diagnosis 
  
File Name Description of Variables Contained within Each File  
Patient  
ID A unique number not based on SSN (necessary for aggregating data 
files) 
Gender Patient’s gender 
Race Patient’s race 
Min_start Date patient first enrolled in Medicaid 
Min_end Date patient discontinued Medicaid enrollment 
Medication  
ID A unique number not based on SSN (necessary for aggregating data 
files) 
NDC Code Drug class code which identifies the drug preparation and strength 
Date Date drug was dispensed 
Quantity Quantity of the drug dispensed 
Day Supply Number of days of the drug supplied (entered by the dispensing 
pharmacist) 
Age Patient’s age (in years) at date of dispensing 
Gender Patient’s gender 
Medical Claims  
ID A unique number not based on SSN (necessary for aggregating data 
files) 
ICD-9 Patient’s diagnosis based on ICD-9 code (up to 5 entries per claim) 
From Date claim started 
To Date claim ended 
Primary Diagnosis Primary diagnosis assigned for that claim 
Abbreviations:  SSN - Social Security Number; NDC – National Drug Classification 
ICD-9-International Classification of Diseases, Ninth Revision. 
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Appendix E: Summary of Mental Disorder Diagnoses and Related ICD-9 Codes Stratified by 
Category  
Diagnosis ICD-9 Code 
Schizophrenic Disorders  
   Simple type 295.0 
   Disorganized type 295.1 
   Catatonic type 295.2 
   Paranoid type 295.3 
   Acute schizophrenic episode 295.4 
   Latent schizophrenia 295.5 
   Residual schizophrenia 295.6 
   Schizo-affective type 295.7 
   Other specified types of schizophrenia 295.8 
   Unspecified schizophrenia 295.9 
  
Bipolar Affective Disorders  
   Manic disorder, single episode 296.0 
   Manic disorder, recurrent episode 296.1 
   Major depressive disorder, single episode, severe, 
   specified as with psychotic behavior 
296.24 
   Major depressive disorder, recurrent episode, severe,  
   specified as with psychotic behavior 
296.34 
   Bipolar affective disorder, manic 296.4 
   Bipolar affective disorder, depressed 296.5 
   Bipolar affective disorder, mixed 296.6 
   Bipolar affective disorder, unspecified 296.7 
   Manic-depressive psychosis, other and unspecified 296.8 
  
Dementias  
   Senile dementia, uncomplicated 290.0 
   Presenile dementia 290.1 
   Senile dementia with delusional or depressive features 290.2 
   Senile dementia with delirium 290.3 
   Arteriosclerotic dementia 290.4 
   Other specified senile psychotic conditions 290.8 





Appendix E: Summary of Mental Disorder Diagnoses and Related ICD- Codes Stratified by 
Category (Continued) 
Diagnosis ICD-9 Code 
Other Psychotic Disorders  
   Alcoholic psychoses 291.x 
   Drug psychoses 292.x 
   Transient organic psychotic conditions 293.x 
   Other organic psychotic conditions 294.x 
   Other and unspecified affective psychoses 296.9 
   Paranoid states 297.x 
   Other nonorganic psychoses 298.x 
   Psychoses with origin specific to childhood 299.x 
Other Non-Psychotic Disorders  
   Major depressive disorder, single episode, not specified as  
   with psychotic behavior 
296.20 – 296.23 
296.25 – 296.26 
   Major depressive disorder, recurrent episode, not  
   specified as with psychotic behavior 
296.30 – 296.33 
296.35 – 296.36 
   Neurotic Disorders 300.x 
   Personality Disorders 301.x 
   Sexual deviations and disorders 302.x 
   Alcohol dependence syndrome 303.x 
   Drug dependence 304.x 
   Nondependent abuse of drugs 305.x 
   Psychological malfunction arising from mental  factors 306.x 
   Special symptoms or syndromes, not otherwise classified 307.x 
   Acute reaction to stress 308.x 
   Adjustment reaction 309.x 
   Specific nonpsychotic mental disorders due to organic 
   brain damage 
310.x 
   Depressive disorder, not elsewhere classified 311.x 
   Disturbance of conduct, not elsewhere classified 312.x 
   Hyperkinetic syndrome of childhood 314.x 
   Specific delays in development 315.x 
   Psychic factors associated with diseases classified  
   elsewhere 
316.x 
Note: Exclude: ICD-9: 313 (Disturbance of emotions specific to childhood and adolescence) as 
not relevant to study; and 317-319 (Mental retardation) due to difficulty of diagnosing 
comorbid mental disorders in patients with mental retardation. 
Source: International Classification of Disease - 9th Revision - Clinical Modification (ICD-9-CM)  
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Appendix F: List of Antihyperlipidemic Agents 
Class Medication 










HMG-CoA Reductase Inhibitors 
 
Atorvastatin 





 Rosuvastatin 2 
 
Other Antilipemic Preparations 
 
Ezetimibe 2 
 Niacin (nicotinic acid) 
1 Withdrawn from the U.S. market 08/08/2001. 
2 Not available on the U.S. market during the study period (01/01/1997 – 12/31/2001). 
Source: Drug Facts and Comparisons390 
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Appendix G: Variables Included in the Logistic Regression Model Comparing the Prevalence 




X3: Race / Ethnicity 
X4: Primary mental disorder diagnosis 
X5: Hypertension 
X6: Dyslipidemia 
X7:Concomitant diabetogenic mediations 
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Appendix H: Variables Included in the Logistic Regression Models Comparing the Incidence of Diabetes by Class of Antipsychotic Agent, 
Specific Second-Generation Antipsychotic Agent, Dose of the Specific Second-Generation Antipsychotic and Primary Mental Disorder 
Diagnosis for the Specific Second-Generation Antipsychotic Agents 
Model 11 Model 22 Model 33 
X1: Age X1: Age X1: Age 
X2: Gender X2: Gender X2: Gender 
X3: Race / Ethnicity X3: Race / Ethnicity X3: Race / Ethnicity 
X4: Primary mental disorder diagnosis X4: Primary mental disorder diagnosis X4: Primary mental disorder diagnosis 
X5: Hypertension X5: Hypertension X5: Hypertension 
X6: Dyslipidemia X6: Dyslipidemia X6: Dyslipidemia 
X7: Class of antipsychotic X7: Specific antipsychotic agent X7: Mean daily dose of antipsychotic 
X8: Adherence to antipsychotic therapy X8: Mean daily dose of antipsychotic X8: Adherence to antipsychotic therapy 
X9: Persistence with antipsychotic therapy X9: Adherence to antipsychotic therapy X9: Persistence with antipsychotic therapy 
X10: Concomitant diabetogenic mediations X10: Persistence with antipsychotic therapy X10:Concomitant diabetogenic mediations 
 X11:Concomitant diabetogenic mediations  
   
1. Model 1 will be used to compare the incidence of diabetes by class of antipsychotic agent (first-generation vs. second-generation). 
2. Model 2 will be used to compare the incidence of diabetes according to the specific second-generation antipsychotic agent (clozapine, 
olanzapine, quetiapine, risperidone or ziprasidone). 
3. Model 3 will be used to compare the incidence of diabetes according to the dose of antipsychotic used and according to the primary mental 
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